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One of the major focus areas of anticancer therapy is the design of new radiotherapeutic agents that 
are able to specifically target and destroy cancer cells with minimal side effects and damage to 
healthy, normal cells. This thesis describes studies towards the synthesis of a macromolecular 
bioconjugate that was designed to: i) co-ordinate a radioisotope through a tetra-amine macrocycle 
(cyclam), ii) lead to passive tumour targeting via the EPR effect and a suitably large carrier such as 
human serum albumin and iii) induce active targeting through a glucose moiety recognised by the 
over-expressed glucose transporters on the surface of highly metabolically active cancer cells. 
 
The various cyclam functionalisation strategies explored were relatively unsuccessful, but eventually 
a bis-aminal cyclam was successfully converted, through nucleophilic substitution, into a precursor 
pro-conjugate: a di-functionalised cyclam containing a β-glycoside tether and a long chain primary 
alkylamine. The glycoside tether was synthesised via glycosylation of a glycosyl iodide with 
decandiol followed by oxidation of the terminal hydroxyl group to an acid chloride for cyclam 
acylation. The second linker attached to cyclam was synthesised by conversion of decanediol to a 
brominated alkyl amine. This amine would then be converted into a maleimide functionality suitable 
for Michael addition with a free thiol group contained within the proposed bio-carrier to form the 
desired bioconjugate. 
 
Further studies described towards the synthetic construction of the bioconjugate include: 
1) The construction of a maleimide group  
2) The attachment of an  imaging radioisotope, 99mTc, or therapeutic isotope, 103Pd, to the pro-
conjugate and other glucose-cyclam precursors  
3) The determination of the potential uptake of the bioconjugate through glucose transporters by 
using a fluorescent dansyl-glucose compound as a model and monitoring its uptake into 
WHCO1 oesophageal cancer cells.  
4) The HPLC analysis of the coupling of a glucose-maleimide model compound to bovine serum 
albumin to investigate the Michael addition of the free thiol in HSA to a maleimide 
5) The development of a potentially alternative nanoparticle carrier by synthesis of palladium 
and magnetic nanoparticles with commercially available thioglucose or glucuronic acid 
moieties as the surface targeting and stabilising agent.  
 
In summary, this thesis outlines a number of synthetic, radiological and biological aspects towards the 
development of a fully functioning radiolabelled macromolecular bioconjugate that could be tested for 
improved targeted cancer radiotherapy. 
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CHAPTER 1 – INTRODUCTION 
1.1 Cancer – A General Overview 
1.1.1 Etiology of Cancer 
 
Cancer is defined as a neoplastic (new growth) disease in which there is uncontrolled growth of 
abnormal cells resulting in the formation of a cellular mass known as a tumour.1 In most cases, if left 
untreated, the growth of the tumour eventually leads to the organism’s death. Cancer cells are often 
malignant which results in the dissemination of the altered cells through the lymphatic and vascular 
system producing tumours in other parts of the body. Worldwide, the estimated number of new cancer 
cases in 2012 reached 14.1 million with the number of deaths in the same year totalling at 8.2 
million.2 Cancer is therefore the second highest cause of death in the world after heart disease.3 
However, analysis of the data between developed and developing countries indicate that while in 
developed countries cancer is the leading cause of death overall (25 %), developing countries have a 
much higher mortality rate of those diagnosed with cancer (60%) due to poor facilities for diagnosis 
and treatment.1,2 The high incidence in developed countries is partly attributed to a number of cancer 
risk factors associated with a more “western lifestyle” such as smoking, lack of exercise and 
unhealthy eating habits. It was also noted that the percentage of new cancer cases in developing 
countries is increasing, possibly due to their adoption of more of these western behaviours amongst 
other things.3 Africa, as a developing continent, should not overlook the seriousness of this disease. It 
was estimated by the International Agency for Research on Cancer that in Africa in 2008 there were 
about 681 000 new cancer cases and about 512 400 cancer deaths.4 The challenge in Africa however, 
especially Sub-Saharan and South Africa, is that cancer is often disregarded in the face of the heavy 
burden of communicable diseases such as HIV, tuberculosis and malaria. Despite being side-lined, 




Once cancer has been diagnosed, the general forms of treatment include surgery, chemotherapy or 
radiation therapy. Very often a combination of the three is applied.  
1.1.2.1 Surgery 
 
Surgery is an invasive procedure whereby physical intervention on tissues is performed by cutting 
into the patient’s body. In cancer treatment, surgery can be employed in two ways: 1) a curative form 
for cancer that is localised to a specific area and in which the tumour can be easily and completely 




removed, or in 2) a cytoreductive form in which as much of the cancer is removed as possible without 
severely damaging nearby tissue.5 The surgery is then followed up with chemotherapy or radiation; in 
all cases for cytoreductive surgery and often for curative surgery.   
1.1.2.2 Chemotherapy  
 
Chemotherapy is the administration of synthetic anti-cancer drugs to patients in order to kill 
cancerous cells. A large number of chemotherapeutic drugs exist (Table 1.1) with a variety of 
mechanisms of action that generally result in the inhibition of DNA synthesis and replication or 
inhibition of cellular mitosis which then leads to induction of cellular apoptosis.6  
 
Table 1.1: Some chemotherapeutic drugs and their mechanism of action 




            








                 

























While these chemotherapeutic drugs are relatively effective in treating a number of different types of 
cancer, the major challenge with using them more consistently and for a longer period is the large 
number of side effects that occur during treatment. The side effects range from nausea, vomiting, hair 
loss, loss of appetite, mouth ulcers, decrease in blood cell count and many other more serious effects. 
These effects are as a result of the administered drug not only affecting the cancer cells but being 
spread throughout the body and also damaging or killing normal, healthy cells.6  
1.1.2.3 Radiation therapy 
 
Radiation therapy is the use of high-energy radiation such as X-rays, gamma rays and charged 
particles to kill tumour cells.7 The cells are destroyed when the radiation irreversibly damages DNA 
either directly or by generating charged particles such as reactive oxygen species. Irradiation of the 
tumour site is done by means of a machine for external-beam radiation therapy or by means of a 
radioactive seed placed within or near the tumour for internal radiation therapy. A number of 
advances have been made in recent years in the field of external-beam radiation therapy.8, 9, 10 At the 
outset, external-beam radiation was delivered quite generally and much less specifically by means of a 
linear accelerator that generated a beam of photons. More recently, this technique has been refined to 
include the use of computed tomography (CT) scans in 3D-conformal radiation therapy (3D-CRT) to 
get a better 3 dimensional view of the tumour site to be irradiated. Other advances include intensity-
modulated (IMRT) and image-guided radiation therapy (IGRT).8 IMRT makes use of many tiny 
radiation beams that deliver a single radiation dose and so allows for optimization of irradiation of 
irregular volumes by varying the dose and intensity of radiation delivered. IGRT incorporates 
repeated image scanning of the radiation site during treatment thereby increasing the accuracy of the 
treatment and decreasing the radiation exposure of surrounding normal tissue. Stereotactic radiation 
therapy uses multiple highly focused beams that accurately deliver radiation from multiple directions 
thereby also minimising damage to healthy tissue. 
Internal radiation therapy (brachytherapy) originates from a radioisotope sealed inside very small 
pellets which are then implanted within the tumour or in very close proximity to it.10, 11 For certain 
types of cancer, brachytherapy is able to deliver a more constant, higher dose of radiation with less 
damage to normal tissue. The pellets are then left in place for an extended period to allow the 
radiation to kill the cancer cells.  
Radiation therapy is a viable source of cancer treatment, especially in combination with surgery and 
chemotherapy and in cases where tumour metastases can no longer be surgically removed, but it is 
also not without its challenges. Besides the fact that radiation also damages the surrounding healthy 
tissue, another challenge is that radiation is not very effective in low oxygen (hypoxic) conditions 
found in solid tumour environments.12 Decreased radiosensitivity will then lead to local recurrence of 
the tumour and lower rates of overall patient survival. 




The current treatment strategies for cancer have had success in putting a large percentage of patients 
into remission. However, a great percentage of people diagnosed with cancer unfortunately do not 
survive and all patients receiving treatment have varying degrees of very unpleasant, adverse side 
effects. These facts have spurred on many researchers to invest in the development of new cancer 
therapies. Around 100 yrs ago, Nobel Laureate, Paul Erlich postulated the idea of a ‘magic bullet’ 
which rationalised that if a compound could selectively target a disease-causing organism then a toxin 
towards that organism could be delivered along with that selectively targeting agent and kill the 
organism without doing any other harm.13 It has been this idea of a ‘magic bullet’ that has influenced 
and directed the ideas for new chemo and radiotherapeutic agents. 
1.2 Selective Targeting of Tumours 
 
The principle of targeted cancer therapies is the use of more efficient and accurate delivery systems in 
order to increase the efficacy of the cancer drug by improving the pharmacokinetics and 
bioavailability of the drugs and thereby decrease the drugs side effects.14 In order to design a 
selectively targeting anti-cancer agent it is necessary therefore, to understand cancer cells, 
tumourigenesis and the tumour micro-environment.  
1.2.1 Tumour cell properties and micro-environment 
 
The cell-intrinsic hallmarks of cancer15 can be summarised by three main abnormalities afforded by 
oncogenic mutations, namely de-regulated mitogenesis, suppression of apoptosis and the cell’s 
invasive ability.16 These alterations lead to cells that are fast growing, highly proliferative, often 
aggressive and do not senesce.  The acceleration of growth and division requires an adequate supply 
of energy to sustain these processes and as such, cancer cells have an increased metabolic rate that 
maintains the high levels of ATP and other cellular metabolites required.17 Tumour cells have adapted 
to provide the necessary requirements by firstly, over expressing certain cell surface receptors 
associated with cell growth and division that leads to an up-regulation of certain metabolic pathways 
within the cell.18 The second adaptation is employing certain metabolic pathways in conditions that 
are not conducive to their use and would be harmful to most normal cells.17 An example of such a 
pathway is the application of aerobic glycolysis rather than oxidative phosphorylation even in the 
presence of oxygen, an effect termed the ‘Warburg effect’.17, 19, 20 
While increased cell proliferation and decreased apoptosis are the drivers of tumourigenesis, the 
major factor that sustains tumour development and influences drug uptake is the tumour 
microenvironment.16 The micro environmental factors influencing drug uptake include interstitial 
hypertension, hypoxia, low extracellular pH, decreased lymphatics and angiogenesis. The stromal 
cells and extra cellular matrix (ECM) comprising the tumour microenvironment are a unique 
combination that support cell proliferation and help generate barriers to the access of therapeutic 




agents. The ECM consists of a collagen scaffold, interstitial fluid, proteoglycans and hyaluronate.21, 22 
Certain physicochemical properties of the ECM and the surrounding dysfunctional lymphatics and 
vasculature influence the movement of compounds from the blood to the cells. This results in an 
accumulation of vascular contents and a build up of interstitial pressure. The interstitial hypertension 
then favours the movement of interstitial fluid out of the tumour carrying along with it therapeutic 
agents. As tumour cells proliferate, they rapidly outgrow the blood supply leading to a demand for 
oxygen that is not met. The cells adaptation to this is the activation of hypoxia inducible factor-1 
alpha (HIF-1α), leading to the activation of glycolysis over oxidative phosphorylation, the regulation 
of various glycolytic enzymes and an increase in the expression of glucose transporters for the 
maintenance of energy homeostasis in the low oxygen concentrations.20 HIF-1 is also known to 
regulate the transcription of some anti-apoptotic genes and cell transporters that leads to drug 
resistance.23 The follow on effect of an oxygen deficient tumour environment is the acidification of 
the extracellular environment.20, 21 Glucose within the cells is metabolised to lactate which is then 
pumped out of the cells into the surrounding environment. The decreased pH helps protect the tumour 
cells from the immune system.20 The stromal cells, of which the most abundant cells include 
fibroblasts, immune (macrophages, neutrophils and lymphocytes) and vascular cells, also contribute 
greatly to the tumour environment and aid in cell proliferation through the production and secretion of 
cytokines and growth factors. Fibroblasts produce matrix metalloproteases and growth factors while 
immune cells contribute a number of pro-angiogenic factors (vascular epithelial growth factor 
(VEGF) and interleukin 8 (IL-8)) to promote angiogenesis.21, 22 Angiogenesis or the formation of new 
blood vessels within the tumour, results in hypervasculature to meet the high energy demands 
required for growth and metastasis.24, 25 The imbalance of angiogenic regulators and the rapid 
development of the blood vessels in a chaotic, disorganised manner produces vasculature that is 
irregular with a discontinuous epithelium containing wide fenestrations (200-2000 nm) and lacking in 
the normal basement membrane structure.24- 26 The large gap junctions between endothelial cells lead 
to vascular hyperpermeability.27,28 VEGF not only stimulates angiogenesis but also 
lymphangiogenesis,21 but despite the development of lymph ducts, the lymphatic drainage system is 
defective and clearance of fluid and particles from the interstitial space is poor.21, 24-26 The ‘gaps’ in 
the endothelium of blood vessels and the poor lymphatic drainage were noted by Matsamura and 
Maeda29 to result in the accumulation of certain macromolecular drugs preferentially within the 
tumour and was termed the “enhanced permeability and retention (EPR) effect”.24  
The development and use of drugs that are designed to exploit the tumour microenvironment and EPR 
effect to accumulate within the tumour is known as ‘Passive’ targeting24, 27 while drugs that are 
developed to have a high affinity for one of the upregulated cell receptors and so increase their 
accumulation within the tumour cell is known as ‘Active’ targeting.18 




1.2.2 Passive Targeting and the Enhanced Permeability and Retention Effect  
 
Passive targeting, as described above, is the selective accumulation of certain therapeutic 
macromolecules within the tumour due to unique anatomical and pathophysiological abnormalities of 
the tumour vasculature.28 These abnormalities include hypervasculature with defective blood vessel 
architecture and poor lymphatic drainage and together they have become known as the EPR effect 
(Figure 1.1). Generally, it is known that plasma proteins or other macromolecules, around 50 kDa and 
greater, do not extravasate from the blood into normal tissue.30 However, this was found not to be true 
for tumour tissues when the EPR effect was discovered in 1986.29 The therapeutic polymer-conjugate 
poly(Styrene-co-Maleic acid)-Neocarzinostatin (SMANCS) bound internally to serum albumin to 
form a macromolecular bioconjugate of 80kDa which was found to accumulate within the tumour. 
Upon validation of the EPR effect, using biomolecules such as albumin (66.5 kDa), transferrin (90 
kDa) and immunoglobulin (150 kDa), it was concluded that in order for a drug to exploit the EPR 
effect it should have a molecular weight greater than 40kDa which is the renal excretion threshold.25,26 
This size allows for prolonged circulation and slow clearance of the drug from the body and provides 
time for the drug to move through the vasculature and accumulate in the tumour.26 Since the 
description of the EPR effect, it has been the focus of much research for improving cancer targeting 
and has been used for the delivery of drugs conjugated to polymers, liposomes and other nanoparticle 
carriers (Table 1.2).  
 
 
Figure 1.1: Description of the Enhanced Permeability and Retention (EPR) effect: A) Normal, healthy tissue 
where small molecules diffuse in and out of blood and larger molecules remain in circulation or if they make it 
into the tissue, are cleared by the lymphatic system. B) Tumour tissue where small molecules have normal 
diffusion but the vasculature abnormalities allows permeation of macromolecules into the interstitial space 
where they accumulate due to poor lymphatic clearance and can then be taken up by the cells.31 
 
Polymers used for drug delivery are biodegradable macromolecules that are biocompatible and can be 
either synthetic or natural.27, 32 Polymer-drug conjugates are formed either by covalently bonding the 




drug to the polymer backbone or by encapsulating the aqueous phase drug within polymer 
nanoparticles.32 In order to obtain an efficient polymer-drug delivery system, the polymer needs to be 
non-toxic, have a decent drug loading capability and be stable in transit through the body but also able 
to release the drug at the desired location.21 The most commonly used synthetic polymers that are 
biodegradable include polyglutamate (PG), polylactide (PLA) and poly(D,L-lactide-co-
glycolide)(PLGA) and these have all been used to conjugate a variety of chemotherapeutic drugs 
(Table 1.2).28, 33  Polyethylene glycol (PEG) and N-(2-hydroxypropyl)methylacrylamide (HMPA) 
copolymer have also been extensively used but although being biocompatible they are not 
biodegradable.27 One of the most promising polymer drug conjugates is a PG-paclitaxel construct 
known as Xyotax33, 34 which is currently in phase III clinical trials.35 Natural polymers that are used to 
bind drugs are albumin, chitosan and heparin.27 Albumin is a 66.5 kDa protein that occurs naturally in 
serum and has been conjugated covalently to drugs as well as being formulated into a nanoparticle 
that encapsulates the drug.27, 32, 36, 37 Abraxane, also known as nab-paclitaxel, is a formulation of 
albumin that binds paclitaxel. It is approved for use in the treatment of metastatic breast cancer as it 
increases the circulation time of the drug and replaces the need to use the hypersensitivity inducing 
Cremophor EL solvent.38 Other polymer based drug-conjugates include polymeric micelles and 
dendrimers.27 Polymeric micelles are formed by amphiphilic block copolymers and result in a 
hydrophobic core encapsulating the drug and a hydrophilic shell which renders the micelles water 
soluble. Dendrimers are polymers formed from branched monomers radiating out from a central core 
and are able to conjugate a number of different molecules or drugs simultaneously. Liposomes of 
around 400 nm are formed spontaneously by the self-association of phospholipids into bilayers in an 
aqueous environment which allow drugs to be loaded into these liposomes in a drug saturated aqueous 
environment or by means of an organic solvent exchange mechanism.32 A liposomal formulation of 
doxorubicin, known as Doxil, is an approved drug for the treatment of certain cancers and has a great 
efficacy and lower cardiotoxicity than free doxorubicin.32 Viral nanoparticles that form a protein cage 
and carbon nanotubes with surface modifications to improve solubility and bind drugs are other 
nanoparticles that have been used for passive targeting and drug delivery.27  
Since the EPR effect is based on extravasation of compounds from blood vessels into the tumour 
environment, there are a number of vascular mediators that can affect this phenomenon and can so be 
used in one way or another to enhance the uptake or targeting of the drug to the tumour site. These 
vascular mediators include vascular endothelial growth factor (VEGF), bradykinin, nitric oxide and 
peroxynitrite, prostaglandins, matrix metalloproteinases and angiotensin converting enzyme (ACE) 
inhibitors .25, 26 VEGF is an upregulated angiogenesis factor involved in blood vessel formation and 
tumour growth and a number of inhibitors of VEGF have been developed. Bradykinin (a vascular 
dilating peptide), nitric oxide, peroxynitrite and prostaglandins all play an important role in vascular 
permeability and extravasation and it was noted that addition of these mediators upon administration 
of a dye/albumin complex resulted in increased uptake of the dye into the tumour. Matrix 




metalloproteinases are involved in tumour invasion, metastasis and angiogenesis, and their activation 
by peroxynitrite facilitates the EPR effect by disintegration of the extracellular matrix as well as 
leading to the production of kinin.26 ACE (angiotensin converting enzyme) inhibitors prevent the 
conversion of angiotensin-I (AT-I) to AT-II which then inhibits the degradation of bradykinin leading 
to increased vascular permeability.  
The EPR effect forms the basis of macromolecular passive targeting and any new drugs developed 
should aim to exploit this means of more selective drug delivery.   
 
Table 1.2: Types of carriers used for passive targeting and examples of chemotherapeutic drugs to 
which they have been conjugated 






















HMPA Doxorubicin (47) 














Liposomes Doxorubicin (Doxil) (54) 
Viral nanoparticles CPMV Doxorubicin (55) 
Carbon nanotubes Methotrexate (56) 
[polyglutamate(PG); poly(D,L-lactide-co-glycolide)(PLGA); polyethylene glycol(PEG); N-(2-hydroxy 
propyl)methylacrylamide (HMPA); polylactide (PLA); poly(L- aspartate)(PAA); cowpea mosaic virus(CPMV)] 
 
1.2.3 Active (receptor-mediated) Targeting 
 
Active targeting, as previously described, is the site-specific targeting of cell-surface molecules and 
receptors on cancer cells57 in which the efficiency of the active targeting agent will depend on the 
receptor being targeted. Ideally, the cell receptors or surface antigens that are targeted should be 
exclusively and homogenously expressed on the cancer cells and should not be released into the blood 
stream. It is also necessary to ensure that the targeting agent selected, once bound to the surface, will 
be internalised into the cell, generally through receptor-mediated endocytosis.27 The choice of 
targeting ligand is therefore very important for the type of cancer being treated and the effectiveness 
of the treatment.  




The first and most common type of targeting ligand used for their high specificity and wide 
availability is monoclonal antibodies (mAbs).24 The expansion of the research following on from 
mAbs has then led to the use of antibody fragments, proteins, peptides and small molecules to target a 
number of different antigens and receptors (Table 1.3).24, 58 These targeting ligands and their target 
antigens/receptors will be discussed briefly.  
Antibodies are Y-shaped glycoproteins of high molecular weight that bind to a foreign target on the 
cell and inhibit pathways which result in cell death. A number of mAbs have been approved for 
clinical use (Table 1.3).59 Trastuzumab is a mAb against HER-2/neu receptors found to be over 
expressed in a percentage of breast cancer patients.60 VEGF and epidermal growth factor (EGF) are 
both involved with tumour growth and angiogenesis, and their receptors (VEGFR and EGFR) are the 
focus of a number of mAb therapies.59 Cetuximab acts against EGFR whilst Bevacizumab binds to 
VEGFR. Despite the abundance of mAbs, their successful use has been limited owing to a less than 
0.01% specific cancer targeting efficiency61 as well as cross reactivity and slow blood clearance.58 
The initial direct conjugation of a drug to a mAb met with limited success owing to the potential of 
only a limited number of drug molecules being attached to the mAb simultaneously. This challenge 
was then addressed by attaching the mAbs to the surface of a nanoparticle and loading the drug within 
the nanoparticle.27 
Proteins and peptides provide an alternative targeting strategy. A naturally occurring protein widely 
used as a targeting ligand is transferrin (Tf). Transferrin binds iron in the blood and transports it into 
the cells by attachment to the transferrin-receptor.62 Transferrin has been directly linked to drugs such 
as doxorubicin63 or has been used as a surface ligand on nanoparticles loaded with paclitaxel.62 
Peptides have improved stability and resistance to degradation due to their smaller molecular size.24 
The most widely used peptide is the arginine, glycine, aspartic acid (RGD) motif which binds to the 
over expressed, pro-angiogenic receptor αvβ3 integrin.14, 24, 60 Other peptides that have been used 
include octreotide which is a synthetic analogue of the naturally occurring neuropeptide somatostatin 
(SST) and has a high affinity for the SST receptor.58 Bombesin is a peptide analogue of gastrin-
releasing hormone peptide (GRP) that binds to GRP receptors on a number of cancers64, while 
vasoactive intestinal peptide (VIP) binds to VIP receptors over expressed on breast cancer.65 
Small molecules are proving to be more advantageous as targeting ligands due their affordability, 
improved stability and small size that allows for easier synthesis and conjugation.24 The most 
common small molecule attached to a chemotherapeutic drug for active targeting is folate.24, 36, 66 
Folate binds to surface folate receptors (FR) with very high affinity (KD ~ 10-9M) and is easily 
internalised through receptor-mediated endocytosis. Other advantages of folic acid as a targeting 
ligand are that it is stable, non-immunogenic, inexpensive and soluble in organic solvents used for 
synthesis.36 Folate has been attached to a number of chemotherapeutic drugs, either directly or to 
nanoparticles containing the drugs. These drugs include methotrexate67, doxorubicin68, paclitaxel69 
and taxol70 among others. Other small molecules used for targeting are carbohydrates such as 




mannose, glucose and galactose that are recognised by membrane proteins. An example of this was 
the targeting to cancer cells of galactosamine conjugated to a doxorubicin bound polymer.71 More on 
carbohydrate targeting will be discussed at a later stage. 
 
Table 1.3: List of some active targeting agents and their receptors as well as passive targeting agents 
(carriers) to which they might be linked and the drugs they deliver 























-Rituximab - CD20 -nanoparticle  (59) 
-Trastuzumab - HER-2/neu -  
-Cetuximab - EGFR -  
-Bevacizumab - VEGFR -  
-Pertuzumab - HER-2 - -docitaxel 




















-RGD peptides - αvβ3 integrin Liposome/ 
nanoparticle 
 (14) 
-Octreotide -somatostatin-R -  (58) 
-Bombesin -GRPr -  (64) 



























[prostate specific membrane antigen (PSMA)] 
 
Chemotherapy as a method of treating cancer has been greatly improved by the development of active 
and passive targeting chemotherapeutic conjugates. As can be noted from Table 1.3, active and 
passive targeting are also often used in combination to improve the efficacy of drug delivery as both 
techniques complement each other to increase localisation of the therapeutic agent at the tumour site. 
However, despite the advances in chemotherapy, new possibilities for treatment are continuously 
being explored. The most common and rewarding new field of exploration is that of nuclear medicine 
and radiopharmaceuticals for both the diagnosis and treatment of cancer. 






Radiopharmaceuticals are radioactive compounds or drugs containing radioisotopes emitting α and β 
particles or γ rays74 used in the diagnosis and/or treatment of diseases, particularly cancer, by 
delivering small ionizing radiation doses to the site of disease with high specificity.75 
Radiopharmaceuticals fall under the category of nuclear medicine which became a discipline in 1936 
when artificially produced radioisotopes were first reported, and then in 1946 when 131I was used to 
treat thyroid cancer.76 Diagnostic radiopharmaceuticals produce radiation emissions which are 
recorded externally to image the localisation site. The use of radiopharmaceuticals for treatment can 
therefore be classified as a form of endoradiotherapy as they deliver a radiation dose internally to the 
site of the affected tissue and the emissions destroy the surrounding cells.77 Endoradiotherapy is 
considered more efficient than chemotherapy as it requires a much lower mass dose of the targeting 
compound. Tumour imaging agents are used in the range of 10-6- 10-8M and should not have any 
pharmacological effect78 while therapeutic agents, although used in a slightly higher concentration, 
have an effect based on the damage done by the ionizing radiation and are therefore still administered 
in much smaller amounts than a chemotherapeutic agent. In contrast to chemotherapy, it is also not 
always necessary for the radionuclide to be internalised by the cell to exert its effect. 
Radiopharmaceuticals are generally made up of two components, a radionuclide and a carrier, and it is 
these two aspects that determine the function and efficiency of the radiopharmaceutical for imaging or 
therapy.65 The aim of a radiopharmaceutical is to deliver the radionuclide quantitatively to the tumour 
site without any radiation damage to healthy tissue. As such, the design of a radiopharmaceutical 
requires careful consideration of the physical decay properties of the radioisotope used, the specific in 
vivo targeting of the tumour and the clearance of the compound from other tissues.79 The original 
isotopes used for nuclear medicinal agents were ‘organic’ isotopes such as 18F, 15O, 13N, 11C and 131I 
but their shortcomings include limited availability and lengthy synthetic routes required for their 
incorporation into the compounds through covalent bonds.58 The drive is therefore towards the use of 
metallic radioisotopes which are much more easily derived from various production methods and are 
more easily attached to the desired carrier.  The choice of the isotope will depend on its half-life, type 
of radiation and emission properties, cost and its availability in high chemical purity and with a high 
specific activity.14, 58, 75, 78, 79 The carriers used for the isotopes are generally small organic or inorganic 
compounds but can also be larger macromolecules such as antibodies or nanoparticles.14, 75, 78 
Radiopharmaceutical localisation through receptor binding is described as active targeting where as 
localisation though tumour inherent properties and the EPR-effect are described as passive targeting 
as previously discussed. Active and passive targeted radionuclide delivery systems have helped to 
improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the 
diagnosis and therapy of cancer.14 




1.3.1 Radionuclides for Imaging  
 
The ideal diagnostic radiopharmaceutical should produce a detailed image and description of the 
functionality and some morphology of the organs and tissues, especially those of tumours, through the 
accumulation of the radiopharmaceutical. This provides a non-invasive technique for assessing both 
the cancer and the efficiency of any treatment to be used.78 The two imaging modalities used most 
extensively in nuclear medicine are single photon emission computed tomography (SPECT) or 
positron computed tomography (PET). Diagnostic radiopharmaceuticals contain any radioisotope that 
can be used for either of these imaging options. Once the diagnostic agent is administered, the 
radiation emissions are detected and converted into an image that indicates the localization of the 
compound at the tumour site.58 
1.3.1.1 Single Photon Emission Computed Tomography (SPECT) 
 
SPECT functions on the principle of the detection of γ-emissions from the radionuclide attached to the 
pharmaceutical (Figure 1.2).58 γ-Emissions are high-energy electromagnetic radiation or photons that 
are produced when an excited nucleus decays to a more stable state. These γ-emissions are highly 
penetrating, travel in straight lines, have no mass or charge and generally have an energy range of 75 - 
360 keV.14, 65 SPECT detectors are designed to detect γ-rays within specific energy windows (100-250 
keV), and the best images will be obtained from radionuclides that have γ-decay energies within this 
range. Modern SPECT instruments have been improved to detect radiopharmaceuticals down to the 
nanomolar level, which minimises the dose needed for sufficient tumour imaging. 
The most common SPECT isotope used is 99mTc due to its favourable properties of 140 keV γ-
emissions and a 6 hour half-life which allows enough time for compound labelling but minimises 
radiation exposure to the patient (Table 1.4).75  
 
Table 1.4: Radionuclides used for SPECT imaging and their decay properties 
Radionuclide Half-life (hrs) γ-energy (keV) Source 
99mTc 6.02 140 99Mo/99mTc generator 
67Ga 78.3 93, 184, 300, 393 68Zn(p,2n)67Ga cyclotron 
201Tl 72.9 135, 167 203Tl(p, 3n)201Pb/201Tl cyclotron 
111In 67.2 171, 245 111Cd(p,n) 111In cyclotron 
123I 13.2 159 121Sn (α,2n)123I 
131I 8.0 (days) 365 130Te(n, γ)131Te(β)131I cyclotron 
 
99mTc is easily available in a pure form from a 99Mo/99mTc generator at low cost. Currently, the 99mTc 
used in 16 FDA-approved radiopharmaceuticals comprises around 80% of all diagnostic applications. 
Other isotopes for SPECT include 67Ga, 111In, 201Tl, 123I and 131I. 67Ga, with a half life of 78.3 hrs and 
γ-rays ranging from around 90 keV to 400 keV, has been used to identify and image inflammatory 
areas and soft tissue tumours.78 The isotope 111In (t1/2 = 67 hrs) has mostly been used for the labelling 




of anti-body based radiopharmaceuticals. Its decay releases two γ-rays of 171 keV and 245 keV. The 
first peptide radiopharmaceutical that was FDA-approved incorporated 111In into a somatostatin 
analogue and was named OctreoScan.75  
1.3.1.2 Positron emission tomography (PET) 
 
Radioimaging conducted with the use of a PET scanner relies on the emission of a positron (β+) from 
the incorporated radioisotope.80 Positrons are emitted from a nucleus during a decay process known as 
a β+ transition when a proton is converted to a neutron. Positrons are like positive electrons in that 
they have the same properties and mass as an electron but are of opposite charge and are therefore 
also considered as anti-matter. The β+ ejected from the nucleus during the decay process travels a 
short distance through the surrounding tissue and when it collides with a free or loosely bound 
electron, the two destroy each other releasing two opposed gamma rays of 511 keV in the process. 
The photons continue through the tissue and are then simultaneously detected by the PET scanner 
(Figure 1.2).58, 65 The traditional isotopes used for PET have been the short half-life isotopes 18F, 15O, 
13N, 11C (Table 1.5). The challenge with these isotopes is that their short half lives only allow for short 
time scale biological imaging as well as necessitating the need for their on-site production. The most 
favourable isotope of those mentioned is 18F which has a manageable half-life of 1.83 hrs and is 
readily available from commercial sources. 18F has found its niche in PET imaging with the 
production of [2-18F]-2-fluoro-2-deoxyglucose (18FDG) that allows for the visualisation of glucose 
consumption which is up-regulated in tumours.81 Despite the success of 18F, attempts are still being 
made to develop a metal based PET radiopharmaceutical.  These radioisotopes include 62Cu, 64Cu, 
68Ga, 86Y and 89Zr (Table 1.5). 58 
Two radionuclides of copper that are used as radiopharmaceuticals have relatively different decay 
properties. 62Cu has a half life of 9.7 min and decays with a 98% abundance of 2.9 MeV positrons. 
62Cu is eluted from a 62Zn-62Cu generator, which only lasts 1-2 days and therefore increases the cost of 
PET imaging using this isotope. The more investigated PET isotope is 64Cu which has a half-life of 
12.7 hrs and β+ emissions of 653 keV. Despite the low rate of β+ emissions (18 %), this isotope has 
been popular in the development of new imaging agents as it can be used coupled to small molecules, 
peptides or antibodies.82  64Cu could potentially also be useful as a dual imaging/therapy agent 
because it emits therapeutic β- particles (39 %) with 579 keV of energy. 
68Ga is produced in a 68Ge/68Ga generator that is commercially available and lasts for 1-2 yrs due to 
the long half life (270 days) of the parent isotope. 68Ga has an 89 % abundance of β+ decays with 
energy of 1.9 MeV. The isotope is linked to small molecules, peptides and antibody fragments that 
can localise quickly to the tumour site. The ease of obtaining 68Ga lowers the cost of production and 
therefore makes this isotope an attractive option as a PET imaging agent. 86Y has a half-life of 14.7 
hrs during which the decay process releases β+ particles of 1.22 MeV in 32 % abundance. The 
advantage of 86Y is that it has the same chemistry as therapeutic 90Y and can so be utilised as an 




imaging surrogate isotope to determine the biological properties of the therapeutic ytrium agent.  89Zr 
has found application in the labelling of antibodies and three such compounds are undergoing clinical 
trials. 89Zr, with a half-life of 78.5 hrs, emits 23 % of 902 keV positrons.  
 
Table 1.5: Radionuclides used for PET imaging and their decay properties 
Radionuclide Half-life (hrs) β-energy (keV) Source 
18F 1.83 640 18O (p,n) 18F 
11C 20.4 min 960 14N (p,α) 11C 
13N 9.96 min 1190 16O (p,α) 13N 
15O 2.07 min 1720 14N (d,n) 15O 
62Cu 9.7 min 2910 62Zn/62Cu generator 
64Cu 12.7 656 64Ni(p, n)/64Cu, cyclotron 
68Ga 67.7 min 1899 68Ge/68Ga generator 
86Y 14.7 1221 86Sr(p,n)86Y cyclotron 




Figure 1.2: Depiction of the principles of SPECT (top) and PET (bottom) imaging (adapted from (58)). SPECT 
detects γ-emissions given off directly by the radionuclide attached to the pharmaceutical while PET detects γ-








1.3.2 Radionuclides for Therapy 
 
A therapeutic radiopharmaceutical, similar to an imaging agent, contains a radionuclide emitting a 
high dose of ionizing radiation. Once the radiopharmaceutical is localised at the tumour site, the 
radiation is emitted within the surrounding tissue and the cells are destroyed by non-repairable 
damage to the DNA.58 The ionising radiation of the therapeutic radionuclide breaks covalent bonds 
within cellular biomolecules and induces free radical formation that results in fragmentation.77 Cells, 
however, contain a mechanism by which the damaged DNA can be repaired and it is therefore 
necessary, for permanent cell damage, to have a highly localised or concentrated radiation dose. The 
emissions should be non-penetrating in order to minimise the damage to the healthy tissue 
surrounding the tumour site. The amount of energy that is transferred to the soft tissue by ionising 
radiation is quantified as a linear energy transfer (LET) value that is measured in kiloelectron volts 
per micrometer of tissue penetrated (keV.μm-1).58 High LET values have a short penetration due to a 
large amount of energy dissipated per micrometer whereas a low LET value dissipates energy slowly 
and so is able to penetrate over a longer distance. The selection of an appropriate radionuclide for 
therapy depends on its emission properties, half-life and decay properties as well as the tumour 
uptake, retention and body clearance of the radiopharmaceutical.78, 79 Knowledge of the coordination 
and aqueous chemistry of the proposed radioisotope should also be taken into account in order make 
an informative decision regarding an appropriate complexing agent for the formation of stable, 
kinetically inert radiometal complexes. Radionuclides used for therapeutic purposes are alpha (α), 
beta (β-) and Auger electron emitters (Figure 1.3). These radionuclides may also have γ-emissions 
which will not have any therapeutic effects but may rather be useful for combined tumour imaging if 
the energy of the emissions is in a diagnostically useful range. 
 
1.3.2.1 Alpha Particles 
 
The radioactive emissions with the highest energy that are released from a decaying nucleus are alpha 
(α) particles. These particles are in effect helium nuclei as they consist of two protons and two 
neutrons tightly bound together resulting in a single particle with a mass of 4 a.m.u and a charge of 
+2. The α particles have a very high LET of around 100 keV.μm-1, which results in very high densities 
of ionisation and cell damaging efficiency but a very short path length and tissue penetration (40-100 
μm).83 Because of their high LET and short penetration range, α particles hold great potential for 
treating small cancer lesions and micro metastases. Despite the favourable energy properties of α-
emitting radionuclides, only a few of these isotopes (225Ac, 211At, 213Bi)(Table 1.6) have been 
investigated for radiotherapeutic applications. The reason for this is that most α-emitters have very 
long half-lives that are not suitable for in vivo applications, and it is difficult to obtain sufficient 
quantities of the isotopes with acceptable radio-purity.79 Actinium-225 has a half-life of 10 days and 




decays through a cascade of 6 daughter isotopes, including 213Bi, until it reaches stable 209Bi. In the 
process it emits 4 α particles (5.83 MeV, 5.792 MeV, 5.790 MeV, 5.73 MeV) along with 3 β- and 2 
useful γ-emissions (86 and 440 keV). The application of 225Ac in radiopharmaceuticals has been the 
labelling of antibodies, such as Lintuzumab, to deliver the radioisotope to the tumour site.84     
Bismuth-213 decays by the emission of one α particle (5.87 MeV) followed by two β- emissions or by 
the emission of a β- particle, an α particle (8.4 MeV) and another β- particle to form stable 209Bi. A γ-
ray of 440 keV is also emitted that can be used for imaging. The half-life of 213Bi is 45.6 min, which is 
a bit short for significant therapeutic applications, but a trial using 213Bi linked to an antibody has been 
completed with promising results.85 213Bi is produced from a 225Ac/213Bi generator or the in vivo decay 
of 225Ac. Astatine-211 is obtained from a particle accelerator and has a half life of 7.2 hrs and an α-
emission of 6.8 MeV.  
 
Table 1.6: Properties of radionuclides with α particle emissions used for radiotherapy  
Radionuclide Half-life Energy  Source 
Alpha (MeV) Gamma (keV) 
225Ac 10 days 5.83, 5.79, 5.79, 5.73 86, 440 n-Capture of 232Th-233U-
225Ac  
213Bi 45.6 min 5.87 or 8.4 440 225Ac/213Bi generator 
211At 17.0 hrs 6.8 - accelerator 
 
1.3.2.2 Beta particles (β-) 
 
β- particles are high energy electrons with a charge of -1 and a mass of 1/1823 a.m.u that are emitted 
by the decay of an unstable nucleus. β- emitters constitute the bulk of radiotherapeutic isotopes used 
and have a decay energy of around 0.1-2.2 MeV and a low LET value of 0.2 keV.μm-1.78 β- emitting 
nuclides are most commonly used for the treatment of larger tumours or tumours that are poorly 
vascularised since their low LET results in a penetration range of 1-12 mm,86 which therefore does not 
require the isotope to be in extremely close proximity to all the tumour cells to achieve DNA damage. 
If high-energy β--emitters are used to irradiate small tumours however, there is a much higher 
percentage of damage to surrounding healthy cells as opposed to lower energy emitters with less 
penetration. The energy of the particular β- emitter used for therapy therefore needs to be matched to 
the size and location of the tumour. 
A number of therapeutic radionuclides have been used in FDA-approved drugs of which the most 
common include yttrium-90, rhenium-186/188, lutetium-177, samarium-153, strontium-89, holmium-
166 and copper-67 (Table 1.7).58, 65, 78, 79 Isotope 90Yt is obtained from the decay of 90Sr and itself 
decays with a 100% abundance of β- particles that have an energy of 2.28 MeV. Its half life of 64 hrs 
makes it an attractive radiopharmaceutical for therapy as the longer rate of decay allows enough time 
for transport, coupling to a targeting agent and clinical use. 90Yt has been used in the FDA-approved 




monoclonal antibody drug, Zevalin™, for the treatment of non-Hodgkins’s lymphoma.87 The two 
radioactive isotopes of rhenium have slightly different decay properties. 186Re has a half-life of 3.7 
days and emits β- particles of moderate energy (Emax = 1.02 MeV, 91% abundance), while 188Re 
decays by 50 % over 17.0 hrs with 85 % emissions of 2.12 MeV β- particles. Both isotopes emit a 
percentage of γ-rays that are in the diagnostically useful energy range and can so be used for 
combined tumour imaging. 186Re is produced in a reactor by 185Re (n, γ)186Re and 188Re from 187Re(n, 
γ)188Re. 188Re has the added advantage that it can be obtained from a 188W/188Re generator, which is 
inexpensive and readily available, and so this isotope has been the most used for 
radiopharmaceuticals. Re, as a group 7 element, shares parallel chemistry with Tc in the complexes it 
forms, and so some Tc radiopharmaceutical techniques have been adapted for Re. Re has also 
therefore been used as a non-radioactive isotope to model 99mTc complex formation. 177Lu is a low 
energy β--emitter with a longer half-life (6.75 days) that is useful in labelling biological molecules 
with long half-lives and in treating smaller metastases. The three β- emissions have energies of 176 
(12 %), 384 (9 %) and 497 keV (79 %) whilst the other emissions include two SPECT useful γ-rays of 
113 and 208 keV. Two metal isotopes used for the palliation of bone cancer include 153Sm and 89Sr.  
153Sm emits three β--particles (640 keV (30 %), 710 keV (50 %), 810 keV (20%)) and decays by half 
over 1.95 days where as 89Sr has a very long half-life of 52.7 days and decays with a β- emission of 
1.46 MeV.79 Isotope 67Cu emits three β--particles (400 keV, 480 keV and 580 keV) as well as 2 γ-rays 
(93 keV and 185 keV) which can be used for diagnostics and it decays by 50 % over 62 hours. 67Cu 
has been linked to a number of monoclonal antibodies or peptide bioconjugates for cancer treatment. 
166Ho has a half-life of 26.78 hrs and an emission energy of 1.85 MeV. 
 
Table 1.7: Properties of radionuclides with β- particle emissions used for radiotherapy  
Radionuclide Half-life Energy  Source 
Beta (MeV) Gamma 
(keV) 
90Yt 64.0 hrs 2.27 - 90Sr/90Y generator 
186Re 3.7 days 1.02 137 185Re(n, γ)186Re 
188Re 17.0 hrs 2.12 155 188W/188Re generator 
177Lu 6.75 days 0.497;0.384;0.176 113; 208 176Lu(n, γ)177Lu 
153Sm 1.95 days 0.64; 0.71; 0.81 103 Reactor -152Sm  
166Ho 26.78 hrs 1.85 80.6; 1380 165Ho (n, γ) 166Ho 
212Pb 10.2 hrs 0.570 - 224Ra/212Pb generator 
32P 14.3 days 1.71 - 32S (n,p) 32P; 31P (n, γ) 
32P 
89Sr 52.7 days 1.46 - 88Sr (n, γ) 89Sr 
67Cu 62 hrs 0.40, 0.48, 0.58 93, 185 Accelerator 68Zn(p, 2p) 
1.3.2.3 Auger electrons   
 
Auger electrons, named after the French physicist Pierre Victor Auger, are emitted from a decaying 
atom during the rearrangement of the electron shells due to electron capture or internal conversion 




electron processes.88 When a vacancy is created within the inner electron shell due to the loss of an 
electron, the vacancy is filled by another electron from the outer shell. The excess energy results in 
the release of an X-ray photon or the expulsion of an Auger electron from the outer shell. Auger 
electrons and X-rays will be continued to be emitted until all subsequent vacancies within the electron 
shells are filled or no more transitions are possible and the atom is stable. These electrons are very 
low in energy (< 500 eV) and as such have a very short, nanometer path length. An average cell 
diameter can be around 10-30 μm and so the short path length of the electrons necessitates the 
internalisation of the isotope into the cell to have any therapeutic effect. The toxicity of the Auger 
electrons when the radioisotope is localised within the cytoplasm is effectively that of a low LET 
particle while if the isotope gets covalently bound to nucleic DNA, the damage approximates that of a 
high LET. Therefore, when a radiotherapeutic agent is designed for delivery of an Auger electron 
emitting radionuclide, it needs to be taken into consideration that the isotope should be able to be 
localised within the cell nucleus for the most effective energy deposition. The challenge of the 
localisation requirements of Auger electron emitters have led to the fact that there are no FDA-
approved drugs or current clinical trials that utilise these radioisotopes. There are however, a number 
of Auger electron-emitting radionuclides that have been investigated for use as potential 
radiotherapeutic pharmaceuticals (Table 1.8).   
A radioisotope generally used for its SPECT applications but one that also emits Auger electrons 
(average 14.7 electrons/decay, 6.75 keV, t1/2 = 2.8 days) and has been researched for this purpose is 
111In. However, the radionuclide that shows the most potential as a therapeutic isotope is 125I. Iodine-
125 has a half life of 60.1 days and emits on average 20 electrons per decay with an energy of 15 keV. 
125I has been chemically linked to a uracil nucleotide for cell nucleus targeting by replacing thymidine 
and intercalating into DNA.89 Other more common Auger emitting isotopes include 67Ga, 203Pb and 
201Tl, whilst some lesser know isotopes are 119Sb, 58mCo, 161Ho, 161Tb and 103mRh. 67Ga is also an 
isotope used for imaging with a half-life of 3.3 days but its average Auger electron emission is around 
4.7 and the electrons have energy of around 6.26 keV. 203Pb (t1/2 = 2.16 days) decays with an electron 
energy of 11.6 keV while 201Tl decays by half over 3 days and emits on average 36.9 Auger electrons 
with an energy of 15.27 keV.  
             
Table 1.8: Properties of radionuclides with Auger electron emissions used for radiotherapy  
Radionuclide Half-life 
(days) 




111In 2.8  6.75 171, 245 111Cd(p,n)111m,g In 
125I 60.1  15    
67Ga 3.3  6.26 93, 185, 300 68Zn(p,2n)67Ga 
203Pb 2.16  11.63 279, 401 203Tl(p,n)203Pb 
201Tl 3.02  15.27 167, 135 203Tl(p,3n)201Pb201Tl 
103Pd 16.99 0.78  103Rh(p,n)103Pd 






Figure 1.3: Illustration of the process of atom excitation by neutron bombardment and subsequent nucleus 
decay leading to the generation of various types of radiation both for imaging (gamma) and therapy (α, β- and 
Auger electrons) 
1.3.3 Labelling Methods 
 
The development of a radiopharmaceutical requires the attachment of the desired radioisotope to a 
synthetic or natural carrier compound. The therapeutic compound that is administered to the patient 
needs to have a very high radiochemical purity and specific activity. The radioisotope therefore needs 
to be well matched with the carrier in order to form a very thermodynamically stable, kinetically inert 
therapeutic agent that does not undergo any structural changes during the labelling process, and that 
retains all inherent biological and physiological functions. 
The labelling of compounds has been classified into two main categories: direct labelling methods and 
chelate methods (Figure 1.4).58, 75 The principle of direct labelling is that of direct attachment of the 
isotope to the targeting agent through covalent bonding to a thiol group within the compound. This 
technique is however difficult to control since there are many unknown factors. The amount of thiol 
or disulfide groups, if any, available for bonding as well as the amount of radioisotope bound to the 
biomolecules is often unknown and the effect of the bound nuclide on the properties and functioning 
of the biomolecules is unpredictable. This technique is therefore used very seldom. 
The chelate method uses a bifunctional chelating agent (BFCA) to serve a dual purpose of binding the 
radioisotope as well as introducing a point of derivatisation which can be used for the attachment of a 
targeting agent or biomolecule. The chelate method can again be divided into two different 
approaches, pre-labelling and post labelling. The pre-labelling technique is based on the formation of 
the metal-chelate complex in the synthesis prior to attachment to any biomolecule or targeting agent. 




This method is better defined and controlled and has been used in labelling some antibodies. The 
challenges of this method however is that pre-labelling may complicate the purification of the radio-
compound and this method is generally too long to be used with short-lived isotopes. The post-
labelling method is based on the attachment of the chelating agent to the biomolecules before any 
complexation of the radioisotope occurs. This approach is characterised by well-defined chemistry 
and is the most popular and practical approach for labelling of radiopharmaceuticals. The only pitfall 
with this method is that the harsh conditions required for complex formation can often do damage to 




Figure 1.4: Methods of radiolabelling: A) Direct labelling of a protein through reduction of disulfide bonds B) 
Pre-labelling of a chelating agent followed by attachment to the carrier and C) Post-labelling of the chelating 
agent after it has been linked to the carrier 
1.3.4 Construction of a radiopharmaceutical 
 
A radiopharmaceutical based on a bifunctional chelator concept will, in general, consist of four 
aspects: a targeting molecule, a linker, a bifunctional chelating agent (BFCA) and a radionuclide 
(Figure 1.5). All of the properties of the components need to be understood and carefully selected to 
align suitably with each other to produce an appropriate radiopharmaceutical. The targeting agent is 
generally a biomolecule that has some sort of localisation affinity for the tumour site, be it from a high 
binding affinity for over-expressed receptors on the tumour cell surface or from exploiting the tumour 
microenvironment properties. The targeting vector therefore acts as a carrier that will institute the site-
specific delivery of the radionuclide to the tumour site. The radionuclide chosen will depend on the 
intended function of the radiopharmaceutical for imaging or for therapy. Isotopes that are intended to 
be used for imaging will be γ or β+ emitting while those used for therapy are α, β- or Auger electron 
emitters. The BFCA coordinates the radionuclide. The choice of the chelator is determined by the 




nature and oxidation state of the radioisotope such that the coordination chemistry and donor-ability 
of the chelator matches the radioisotope properties to form the most stable and inert metal complex. 
The linker is used to connect the targeting molecule to the BFCA and separates the radionuclide from 
the portion of the radiopharmaceutical that targets the cells. As such, the linker should not interfere 
with either the ability of the chelate to complex the metal or the binding affinity and specificity of the 
targeting agent. The linker can be used to improve the pharmacokinetic properties of the 
radiopharmaceutical by increasing the lipo or hydrophilicity of the bioconjugate or by containing a 
metabolisable bond which can be cleaved within the cell.78 The BFCA method of designing a 
radiopharmaceutical is most often used as it allows for the synthesis and manipulation of all the 




Figure 1.5: A schematic illustration of the bifunctional chelator concept for the design of radiopharmaceuticals. 
A bifunctional chelator is used to dually complex the radioisotope as well as connect to a targeting agent. 
1.3.4.1 Chelators 
 
BFCA are most important in the development of radiopharmaceuticals as they coordinate the 
radionuclides to form stable complexes. The stable coordination of metals depends on a number of 
factors such as the radioisotope’s oxidation state as well as the donor atoms of the chelate. Chelators 
used as a BFCA form stable complexes via oxygen, nitrogen and sulphur donor ligands.77 The 
stability and pharmacokinetics of the BFCA can also be improved by the modification of the basic 
alkyl backbone with various functional groups in order to better coordinate the metal. Commonly used 
BFCA can be classified into two groups: acyclic chelators and macrocyclic chelators. Acyclic (open 
chain) chelators generally have faster metal-complexing kinetics than their macrocyclic counterparts, 
but are generally more kinetically labile.78 However, a few acyclic chelators with specific 
radioisotopes show high thermodynamic stability and kinetic inertness in vitro.90 The most commonly 
used acyclic chelator is N-diethylenetriaminepentaacetic acid (DTPA) and its analogues (Figure 1.6). 
DTPA is a strong chelating agent in the polyaminocarboxy group that has a large binding sphere and 
three nitrogen donors as well as five oxygen donor atoms. The hard donor characteristic of the oxygen 
atoms lends itself to forming stable complexes with larger hard acidic cations.58 DTPA has been 
successfully coupled to a number of different antibodies,91-93 peptides such as octreotide94 and small 
molecules such as folate.95 Three FDA-approved radiopharmaceuticals: Octreoscan™, ProstaScint™ 
and Zevalin™ contain the DTPA chelator functionality. Analogues of DTPA incorporate modification 




via the carboxylic acid arms such as bianhydride DTPA and monoreactive DTPA.96 These DTPA 
compounds have been altered to develop more efficient, simpler, single covalent couplings to peptides 
and other targeting agents.  
 
 
Figure 1.6: The most commonly used acyclic chelator DTPA (top left), and a selection of some of its analogues 
which have also been used for isotope chelation  
 
A number of radioisotopes have been used for the labelling of DTPA and the most common of these 
which has great in vivo stability with DTPA is 111In.95, 97 One of the first peptide targeting imaging 
agents developed was 111In-DTPA-Octreotide.72, 86 Indium-111 in its 3+ state with a coordination 
number of 7 forms an eight coordinated chelate structure with DTPA, using four of the carboxylate 
ions, one carbonyl oxygen lone pair and three nitrogen lone pairs. 111In’s stability constant (log KML) 
with DTPA is 29.5.98 Other isotopes that form more stable complexes with DTPA are 67/68Ga(II) (CN 
6, log KML = 25.5), 90Y(III) (CN 8, log KML = 22.0) and Cu(II) (CN 6, log KML = 21.4). 
The ongoing drive in the synthesis of bifunctional chelating agents is to obtain more inert and stable 
complexes. With this aim, the alkyl frame of DTPA has been modified with various moieties (Figure 
1.6). These backbone substitutions pre-organise the geometry of the donor atoms as well as sterically 
hinder the opening of the formed chelate ring to reduce radionuclide dissociation. The first type of 
modification is the substitution of one of the ethylene groups of DTPA with a more rigid, chiral 
cyclohexyl (CHX-A’’) group to form CHX-A’’-DTPA, which has undergone clinical trials with 111In, 
90Y and 213Bi.85 The next form of modification to DTPA was the incorporation of an 




isothiocyanatobenzyl group (p-NCS-Bz-DTPA) along with the attachment of a methyl (IB4M-DTPA) 
or cyclohexyl (p-NCS-CHX-DTPA) moiety to the other ethylene bridge.  
A radioisotope that is not particularly suited for attachment to DTPA is 99mTc. Even at high 
concentrations, this metal has a low affinity and poor selectivity for the chelating agent. When it 
comes to chelating 99mTc, a combination that has been shown to work well is nitrogen and sulphur 
donor atoms. Diaminedithiol (N2S2) compounds (Figure 1.7) have proven to be efficient acyclic 
chelators for 99mTc through the formation of stable technetium (V) oxide complexes.78  
 
 
Figure 1.7: Structures of selected aminothiol acyclic chelators that have been used in the design of bifunctional 
chelating agents 
 
N2S2 chelators have been used in the labelling of proteins, peptides and oligonucleotides with 99mTc 
and 186Re.  The simplest of these chelators is N,N’-ethane-bis(aminoethanethiol) (DADT), which is 
used as the building block for development of further N2S2 chelators such as N,N’-ethane-bis(1,1-
dimethylaminoethanethiol) (BAT-TM), monoamide-monoaminedithiols (MAMA) and  N,N’-ethane-
bis(mercaptoacetamide) (DADS). The most recent development of N2S2 chelators is the use of 
ethylenedicysteine (EC) to chelate 99mTc efficiently and stably.99 N3S BFCA such as triamidethiols 
(TAT) are used to complex 186Re and 188Re.100 Commonly used BFCA in the N3S series are 
mercaptoacetyl-glycylglycylglycine (MAG3) and mercaptoacetyl-glycylglycyl-γ-butyric acid (MAG2-
GABA).  




Another acyclic chelator, most specifically for binding Ga(III), is (1,2-bis{[[6-(carboxy)pyridine-2-
yl]methyl]- amino}-ethane) (H2dedpa)(Figure 1.8). H2dedpa is a N4O2 chelator that binds Ga with a 
stability constant of 28.1.58      
 
Figure 1.8: The acyclic chelator, H2dedpa, that has been used for Ga(III) coordination. 
 
Bone cancer is an aggressive tumour that causes much pain and for which there is no definitive 
therapy. The only ‘treatment’ of bone cancer is palliation for the pain experienced as a result of the 
tumour. Palliative care for patients with bone cancer is accomplished through acyclic chelators 
radiolabelled with 153Sm and 117mSn. The first of these chelators comprise nitrogen-containing 
structures but instead of carboxylic acids as pendant arms, they have phosphonic acid substituents 
(Figure 1.9). The FDA-approved radiopharmaceutical for this type is 153Sm-EDTMP 
(ethylenediaminetetramethylenephophonic acid) (Quadramet). 153Sm-EDTMP shows very good 
pharmacokinetics and in vivo clearance, and was approved for the treatment of painful bone 
metastases in 1997.79 The second potential bone therapeutic agent is 117mSn-DTPA. 117mSn has two 
conversion electron emissions of 127 and 129 keV which present shorter penetration ranges and so 




Figure 1.9: The structures of some selected bone palliation chelating agents: nitrilomethylenephosphinic acid 
(NTMP), ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriamine-pentamethylene 
phosphonic acid (DTPMP). 
 
Macrocyclic chelating agents form metal complexes that are thermodynamically stable and kinetically 
inert. The stereochemistry and coordination of the isotope within the macrocycle together with 
resultant complex stability is dependent on a number of factors: 1) the size of the ring; 2) the number 
of substitutions occurring at the N-atoms; 3) the properties of the substituents on the N-atoms; 4) the 
coordination number of the radioisotope; 5) the metal to ligand ratio used during complexation and 




the nature of the counter ions used; and 6) the pH of the complexation reaction which will affect the 
protonation state of the free macrocyclic chelator.101 The gold standards of BFCA for radioimaging 
and therapy are tri- and tetraaza-based amino macrocycles which are then derivatised with carboxyl 
pendant arms and other moieties for bifunctionality and to increase the stability of the chelators. The 
most popular of these macrocyclic BFCA are NOTA ((1,4,7-triazacyclononane-1,4,7-triacetic 
acid)(Figure 1.10), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)(Figure 1.11) and 
TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid)(Figure 1.11).  
The smallest of these carboxy macrocyclic compounds is the tri-aza chelator NOTA. NOTA is used 
most often to label peptide conjugates with gallium (log KML of 31.0) and indium (log KML of 26.2)94 
as it forms very stable complexes with these isotopes in high yield.102 Both these isotopes are small 
enough to fit tightly into the small binding pocket of the macrocycle and they are hard donors which 
complex with the amine nitrogen and carboxylate oxygen atoms to form hexadentate structures.  
 
 
Figure 1.10: The structures of some selected NOTA based macrocyclic chelators derived from the macrocycle, 
1,4,7-triazacyclononane 
 
68Ga(NOTA) complexes have gained a lot of attention since these complexes can be formed fast and 
efficiently at room temperature and are stable under acidic conditions and in vivo.  The rapid 
radiolabelling of the desired bioconjugate with 68Ga is crucial due to the short half-life (t1/2 = 68 min) 
of the isotope. A challenge of using 68Ga and 111In in biological systems is that ligand exchange can 
occur with transferrin which has a high affinity for these metals.78 In the development of more stable 
NOTA complexes, the macrocycle has been modified at its carboxylic pendant arms as well as along 
its alkyl backbone. Although the carboxylic acid arms of NOTA can be used to attach a linker or 
targeting agent, these connections can possibly alter the binding ability of the chelator. The first 
modification of NOTA is therefore to attach another, alternative carboxyl group to the structure. 
These analogues are NOTASA (1,4,7-triazacyclononane-N-succinic acid-N′,N″-diacetic acid) and 




NODAGA (1,4,7- triazacyclononane-N-glutamic acid-N′,N″-diacetic acid (Figure 1.10).102 NODAGA 
contains an extra carbon which extends the coupling chain slightly and so helps to increase the space 
between chelator and targeting agent for less interference and better receptor binding.75 The second 
type of modification to increase stability is functionalisation of NOTA with a separate conjugation 
moiety such as a para-isothiocyanato benzyl group (p-NCS-NOTA). NOTA has also been changed to 
some phosphonate analogues such as NOTP (1,4,7-triazacyclononane-N,N′,N′′-tris 
(methylenephosphonic) acid) which was tested for chelation of 68Ga (log KML = 26.2)102 and 111In103 
Other radioisotopes being investigated are those of Cu(II) (log KML = 21.6). An investigation of 64Cu 
labelling of a peptide-NOTA compound showed high labelling efficiency and almost no in vivo 
dissociation of the metal from its macrocycle cage.104 
The macrocyclic chelators DOTA and TETA are based on the macrocycles cyclen and cyclam 
respectively (Figure 1.11).58, 75, 78 Both these chelators have been used to form stable complexes with a 
number of different radioisotopes and have been derivatised in various ways to improve metal 
coordination. The only challenge however with these chelators is that complexation often occurs very 
slowly and requires elevated temperatures to achieve decent labelled compound yields.105  
 
 
Figure 1.11: The structures of the tetraaza macrocycles, cyclen and cyclam, and their tetra-carboxylic acid 
derivatives, DOTA and TETA 
 
DOTA, with its four pendant carboxylic acid groups, and various derivatives of DOTA form very 
stable complexes with trivalent radioisotopes such as 67/68Ga (log KML = 21.3), 90Y (log KML = 24.3), 
111In (log KML = 23.9), 117Lu (log KML = 25.5) and divalent radionuclides such as 64Cu (log KML = 
22.3).94, 98 DOTA has four nitrogen and four oxygen donors to complex the isotopes and so forms 
octa-coordinated structures with metals in the +3 oxidation state.106 Some studies however identified a 
Ga-DOTA complex that was hexa-coordinated through four nitrogen atoms and only two opposite 
carboxy oxygen atoms. This led to the assumption that two carboxylic groups could be used for 
coupling to targeting agents and other moieties without significant loss in the stability of the metal 
chelate complex in vivo. Despite favourable stability of DOTA-metal complexes in vivo, the 
formation kinetics associated with these complexes are most often less than optimal and require long 
radiolabelling synthesis or much higher temperatures (around 80 ˚C) to obtain any significant yield of 
coordinated isotopes with high specific activities.105, 107 The increased temperature conditions are a 
drawback to any potential radiolabelling of antibodies or other biological molecules as they could be 




destroyed in the process. To circumvent this challenge, the pre-labelling approach of coordinating the 
radioisotope to the chelator before attachment to the biological compound is often used. This strategy 
was investigated by the radiolabelling of DOTA compounds with 90Y, 177Lu and 225Ac before reaction 
with various peptides and oligonucleotides.107 
The desire to improve on the slow radiolabelling kinetics of DOTA, as well as the desire to attach 
various targeting agents in the development of a BFCA has spurred on the synthesis of many 
derivatives of DOTA. The approach for derivatisation of the complexes includes various strategies:  
1) amide bond formation of a substituent to one of the carboxylic acid groups; 2) alteration of the 
chain length and substituents of the carboxylate arms; 3) substitution of one or more of the carboxyl 
pendant arms; and 4) substitution onto the alkyl backbone of DOTA with various groups. Selected 
analogues of DOTA are illustrated in Figure 1.12. PA-DOTA (R-[2-(4-aminophenyl)-ethyl]-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTASA (1,4,7, 10-tetraazacyclodecane-1-succinic 
acid-4,7,10-triacetic acid) and DOTAGA  (1,4,7,10-tetraazacyclo -decane-1-glutamic acid-4,7,10-
triacetic acid) have altered carboxylate pendant arms.  DO3A and DO2A are analogues in which one 
or two of the carboxylic acid groups have been removed to attach other functionalities to the nitrogen 
atoms. CB-DO2A includes an ethylene cross bridge between two opposite nitrogens. This cross 
bridge was introduced to improve the stability of 64Cu DOTA complexes, as copper isotopes 
coordinated to DOTA only show moderate in vivo stability and undergo demetallation relatively 
easily.58 Derivatives of DOTA in which a substituent is attached to the alkyl backbone include p-
NCS-Bz-DOTA (2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic 
acid) and the derivatives 1B4M-DOTA  (2-methyl-6-(p-isothiocyanato- benzyl)-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) and CHX-DOTA (2-(p-isothiocyanatobenzyl)-5, 6-
cyclo- hexano-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetra- acetate) which include an extra 
substituent onto the p-NCS-Bz-DOTA ring.105 These extra substituents were introduced in an attempt 
to pre-organise the macrocyclic ring geometry thereby lowering the complexation energy barrier and 
increasing the rate of complex formation. P-NO2-Bz-PCTA (PCTA = 3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15), 11,13-triene-3,6,9-triacetic acid) showed very favourable 
stability properties for gallium and copper isotopes108 as well as much faster complexation and 
labelling efficiency with 68Ga.109 
TETA, similar to DOTA, is a macrocyclic ring with four nitrogen atoms that each have an acetate 
group attached to them, however, TETA is a 14-membered ring as opposed to DOTA’s 12-membered 
ring. The extra two carbons in the TETA cyclam ring make for a slightly larger cavity that can offer a 
slight increase in the stability of some metal coordination.79 Owing to the high stabilities of 
radionuclide complexes and the ease at which substitution occurs at the nitrogen atoms, cyclam is one 
of the macrocycles used most often in the formation of bifunctional chelators. TETA has been used to 
form complexes with Ga(III)(log KML = 19.7), In (III)( log KML = 21.9), Y (III)( log KML = 14.8) and 
Lu (III)(log KML = 15.3) but it is one of the most extensively used chelating agents for the therapeutic 




copper (II) radioisotopes, 64Cu and 67Cu.110 Copper TETA (log KML = 21.9) has a similar 
thermodynamic stability to Cu-DOTA (log KML = 22.9) but the TETA complexes are much more 
kinetically inert in vivo.58 The increased copper stability with TETA was proven by lower dissociation 
of the metal into the blood as measured by decreased metal binding to blood plasma proteins and 




Figure 1.12: The structures of some selected DOTA analogues that have been used as bifunctional cheltors 
 
A number of cyclam and TETA derivatives have been evaluated as BFCA labelled with 64/67Cu. The 
same derivatisation techniques of substitution onto the alkyl backbone or alteration of the acetate arms 
and moieties attached to the nitrogen atoms that have been applied to DOTA can be used for TETA. 
The functionalisation of the alkyl backbone of TETA has produced the commonly used BFCA, 
bromoacetamidobenzyl-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N‴-tetraacetic acid (BAT)110 as 
well as p-NCS-Bz-TETA (3-(4-isothiocyanatobenzyl)-1,4,8,11-tetraazacyclotetradecane-N,N′,N′′,N′′′-
tetraacetic acid) (Figure 1.13).58 The 64/67Cu-BAT complexes have an overall negative charge which is 
most likely the cause of improved in vivo clearance properties relative to some other TETA 
derivatives.79 TETA derivatives, TE3A and TE2A (Figure 1.13), have been produced by the removal 
of one or more of the carboxy pendant arms. Various functionalities can then be attached through 




amine or amide bonds to the free nitrogen atoms to develop new BFCA’s such as TE2A-Bn-NCS.111 
CPTA (4-[(1,4,8,11-tetraazacyclotetradecane-1-yl)methyl]benzoic acid) is a cyclam derivative with 
one carboxylic acid group that can be used for conjugation. The overall charge of the CPTA chelate is 
negative which helps to improve the tumour accumulation but also often results in higher level of 
uptake into the liver and the kidneys.79, 110  
The complex stability of the cyclam ring has further been improved by structural modifications to the 
backbone. The freedom of movement of the ring is limited by the addition of a carbon bridge between 
two nitrogen atoms across the cavity.112 These bridged macrocycles are known as cross-bridged (CB) 
analogues of TETA and form extremely stable complexes that have high kinetic inertness to 
dissociation with copper isotopes. The analogue used most often is the distally linked CB-TE2A 
(4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane). Copper-CB-TETA complexes 
exhibit very low transchelation of the metal from the complex to the blood as well as very little uptake 
of the metal into the liver. Although these complexes are very favourable for labelled BFCA, the 
negative aspects of the cross-bridged cyclam macrocycles is that it is not possible to use these ligands 
with short lived radioisotopes80, 112 and that the reaction conditions required for labelling are elevated 
temperatures of around 80-90˚C and reaction times of 1-2 hrs. These conditions make the CB-TE2A 
ligand unsuitable for labelling protein, peptides or other thermo-sensitive biomolecules unless the pre-
labelling approach is used. This approach is not always possible but some modifications to CB-TE2A, 
which includes reaction of the acetate groups and C-functionalisation of the cyclam (CB-TE2A-
EtOH)113 have allowed for points of derivation in order to attach different targeting groups.  
In the further investigation into developing a copper-based cyclam complex which is very inert yet 
has fast coordination properties has led to a N-dimethyl structural analogue of CB-TE2A, which is 
DM-TE2A.114 It was demonstrated that DM-TE2A has complexation stability similar to CB-TE2A 
and is suitable as a BFCA. Other copper coordinating cyclam based macrocycles include a relatively 
new range of sarcophagine (Sar) ligands (Figure 1.13). Sar (3,6,10,13,16,19-
hexaazabicyclo[6.6.6]icosane) can complex micromolar amounts of 64Cu within a few minutes at 
room temperature and therefore shows promise for their use in labelling thermally sensitive 
biomolecules.58 
Some cyclam TETA based ligands have also been used to coordinate 99mTc (Figure 1.13). These 
macrocycles include a porphyrin based tetra-TE3A structure (CAP), a tetraacetamide compound (N-
2A-methoxyethyl-2-(3A-nitro-1A-triazole) acetamide)(cyclam AK-2123) and a CPTA complex 
linked to a peptide.110 All of these complexes exhibit good tumour-to-muscle ratios as well as efficient 
and relatively fast labelling. In the further development of a bone cancer palliative agent, a cyclam 
phosphonate macrocycle, similar to TETA, has been synthesised. The tetra-(amino 
methylphosphonate) (TEPA) structure was used to complex 186Re and in vivo studies indicated 
significant skeletal targeting of the complex.110 
 






Figure 1.13: The structures of some selected TETA analogues that have been used for BFCA’s 
1.3.4.2 Linkers 
 
Linkers within a bioconjugate are used to attach the chosen BFCA to the desired biomolecule and 
play a central part in bioconjugate stability during circulation and favourable pharmacokinetics.72 In 
order for the linker to be functional within the radiopharmaceutical conjugate it cannot interfere with 
the ability of the chelate to complex radioisotopes or the affinity and binding of the targeting 




biomolecule to its specific receptor. It is also necessary, if possible, to attach the linker rapidly and at 
mild temperatures in order to prevent any degradation of thermally sensitive biomolecules. 
Conjugation strategies in radiopharmaceutical design can be divided into two main categories as 
involving non-cleavable (Figure 1.14) and cleavable linkers (Figure 1.15). Non-cleavable linkers 
maintain their integrity within the biological systems, keeping the bioconjugate together all the way 
into the cell. Cleavable linkers are designed to be degraded within the cell or in very close proximity 
to the cell. After cleavage the cytotoxic radionuclide chelator is released from the possibly 
cumbersome biomolecule to allow the radiation source to localise within the cell where it can do the 
most damage. Non-cleavable linkers comprise of predominantly four types: peptide, thiourea, 
thioether and click chemistry triazole bonds.58 The inherent functionalities of the biomolecules 
generally include amine or thiol groups which can then be used to couple to an appropriate moiety on 
the chelator. 
Peptide or amide bonds are formed between a carboxylic acid, most often as a pendant arm of a 
chelator, and a primary amine. Efficient coupling is facilitated by the activation of the carboxylic acid 
to a better electrophile with the aid of a coupling reagent. These coupling reagents are generally EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DCC (dicyclohexylcarbodiimide), HOBt (hydroxy 
benzotriazole) and HATU (O-(7-azabenzotriazol-1-yl)-N,N,N0,N0-tetramethyluronium-hexafluoro- 
phosphate), but can also include mixed-anhydride activation methods. One of the amide bond 
formation techniques most often used is activation of the carboxylic acid with N-hydroxysuccinimide 
(NHS) to form a succinimidyl ester that can be reacted with amines without any additional coupling 
reagents. The NHS-activated acids have a high selectivity for aliphatic amines and react optimally at a 
pH 8-9 in an aqueous environment.78 Peptide bond formation is a highly favourable coupling 
technique, but a chelator will often have multiple carboxylic acid groups and the biomolecule multiple 
amines, and so protection/deprotection strategies or the control of molar ratios is required to limit the 
amount of couplings that occur onto the biomolecule.  
Another type of linker conjugation strategy is the reaction of a primary amine with an isothiocyanate 
functionality to form a thiourea bond.  Isothiocyanates are used to link chelators and targeting agents 
under slightly basic conditions of pH 8.0-9.5, since a deprotonated amine is required for the 
nucleophilic addition reaction.78 Isothiocyanates are more stable in aqueous conditions than the NHS 
esters, and aromatic derivatives are often used to couple biomolecules to DTPA and DOTA. 
Thioether bonds are formed by the Michael addition of a nucleophilic thiol group to an electrophilic 
Michael acceptor such as acrylates, acrylamides, vinyl sulfones and maleimides.115 The high 
nucleophilicity of the thiol group allows for this thiol-ene coupling to occur under mild physiological 
conditions without the need for a catalyst or heating.107 The thioether bond that forms is very stable 
even under strong basic, acidic or reducing conditions but can react with oxidising agents.115 A 
maleimide Michael acceptor is used most often in the formation of radiopharmaceuticals, as acrylates 
and acrylamides are more reactive and tend to undergo polymerisation. Maleimides react best with 




thiols at a pH 7.0-7.4. Care needs to be taken with reaction above a pH of 8 as the probability of 
hydrolysis of the maleimide group to non-reactive maleamic acid increases.24 The labelling of 
biomolecules is generally directed at the amino groups of lysine residues, which are abundant within 
the structure. This increases the chance of labelling but also decreases the control of the labelling 
percentage.80 Free thiol groups originate from cysteine residues which are not found in many 
biomolecules and so it is often required to introduce this functionality by reduction of disulfide bonds. 
The use of a limited amount of thiol groups for conjugation allows for a greater control of the molar 
ratios of the compounds reacting thereby obtaining more specific, uniform labelling. Biomolecules 
that contain thiol groups count amongst a few proteins and antibodies. The most exploited and 
promising protein in this respect is human serum albumin (HSA) which has a free thiol group at the 
cysteine-34 position.116 The thiol groups in antibodies are present as disulfide bonds and so need to be 




Figure 1.14: Non-cleavable linker strategies for coupling the chelating agent to the biomolecule/targeting agent 
in bioconjugate formation: a) and b) coupling through an amide bond strategy c) thiourea bond formation via 
amine addition to isothiocyanate d) thioether bond formation via maleimide reaction with a thiol and e) triazole 
linker coupling via copper-catalysed alkyne reaction with an azide (adapted from (58)). 
 




The ‘click’ reaction is a non-concerted reaction that owes its inspiration to the pericyclic 1,3-dipolar 
cycloaddition reaction pioneered by Rolf Huisgen in the 1960s. It is so termed for its very fast 
reaction rate and involves reaction between an alkyne and an azide to form a 1,4-substituted triazole 
in a regioselective manner. Both alkyne and azide can easily be introduced into either the chelator or 
the biomolecule leading to the selective and rapid formation of a linked complex in good yields24, 58 
The challenge with this reaction is the purification to remove the copper catalyst which can become 
complexed to the chelator, and so a non-copper catalysed click-chemistry reaction has been 
developed.117 
Cleavable linkers (Figure 1.15) are most often used in chemotherapeutic drugs but still find 
application in radiopharmaceuticals. These linkers are designed for the efficient release of the 
cytotoxic payload within the tumour cells or within close proximity to them. Small hydrophobic drugs 
can easily cross the plasma membrane of cells through passive diffusion but large macromolecules are 
not easily able to permeate into the cytosolic space.118 These large bioconjugates are therefore 
endocytosed and need to be degraded into smaller components that can cross membrane barriers. The 
chelator complex is therefore cleaved from the bulky targeting agent to allow for increased 
localisation of the radioisotope within the cell. Cleavage of linkers is based on a difference in 
properties between the blood and plasma and internal cellular compartments.72 
Some types of linkers are cleaved by chemical means and these include acid-labile hydrazone bonds 
which are sensitive to changes in pH, and disulfide bonds, which are sensitive to glutathione 
reduction. Hydrazone links are stable within the blood stream and normal interstitial tissue at a pH 
7.4-7.6 but will be hydrolysed once the conjugate is internalised into the cell through endocytosis into 
endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-5.0).72,119 The tumour micro-environment surrounding 
the tumour cells also has a slightly acidic pH of 6.5-6.9, which has been found to cleave the 
hydrazone bond. Studies have shown that extracellular cleavage will still allow the chelator-
radioisotope complex to be taken into the cell but less specifically.119 Hydrazones have been used to 
connect antibodies and their fragments as well as polymers47, 119 to chemotherapeutic drugs such as 
doxorubicin but have also connected some complexes with 211At and 125I to these carriers.120 
Disulfide bonds are readily reversible and stable covalent linkages formed by the oxidation of two 
cysteine thiol groups that are found in proteins and antibodies.118 Disulfides are cleaved by high levels 
of intracellular glutathione, a thiol containing tri-peptide. Disulfide bonds used in linker strategies are 
formed by the oxidation of a free thiol group, within a biomolecule, with a sulfhydryl containing 
BFCA or chemotherapeutic drug. Tumour cells induce a hypoxic, decreased oxygen environment as a 
result of poor blood flow to the tumour which then leads to an increase in glutathione and reductive 
enzymes. Glutathione is found at high millimolar intracellular concentration levels but only in 
micromolar quantities in the blood. The reducing intracellular space thereby results in rapid cleavage 
of the linker once the compound has been internalised.  




Linkers that degrade by chemical means often have limited plasma stability. To improve stability 
within the blood, linkers that are based on peptides and cleaved by enzymatic means were 
established.72 These linkers are susceptible to different enzymes depending on which amino acids are 
used in the chain. Up-regulation of proteases, both intra and extracellular, have been found in many 
types of cancers and have been seen to play an important role in tumour progression, invasion and 
metastases.121 The intracellular cysteine cathepsin enzymes B and S are lysosomal proteases that are 
associated with protein degradation.122 These proteases are specific to lysosomes and generally never 
found in the extracellular environment except in metastatic tumours, and are highly specific for 
cleaving certain peptide sequences. Cathepsin labile linkers are therefore favourable for radioisotope 
and drug-delivery strategies, since the bioconjugates are highly stable within the serum but rapidly 
cleaved within the lysosomes. A number of cleavable peptide sequences for cathepsin B and S have 
been investigated.72, 122, 123 Cathepsin B will cleave dipeptide linkers Phe-Lys and Phe-Arg and the 
more hydrophilic Val-Lys, Val-Citrulline (Cit) and Phe-Cit. Citrulline is isoteric and isoelectric to Arg 




Figure 1.15: Cleavable linker strategies designed for release of the cytotoxic moiety of the bioconjugate at the 
tumour site or within the tumour cells: a) acid sensitive hydrazone bond, b) Glutatione (GSH) sensitive disulfide 
bond; peptide sequences cleaved by c) Cathepsin B and d) Cathepsin S, e) MMP-2/9 sensitive octapeptide    
 




Some tertapeptide linkers that have been used for cleavage by cathepsin B are Gly-Gly-Gly-Phe, Gly-
Phe-Leu-Gly and Ala-Leu-Ala-Leu. Cathepsin S cleaves the sequence Pro-Met-Gly-Leu-Pro.122 A 
number of other proteases are also found within the cell and its environment and peptide linkers have 
been developed that target these enzymes for cleavage. Thermolysin is used to cleave an Ala-Val 
dipeptide while proline endopeptidase releases cytotoxic moieties linked with Ala-Pro or Gly-Pro.124 
These linkers have connected drugs such as doxorubicin123 and radioisotopic chelators such as 177Lu-
DOTA122 and 90Y-DOTA125 to the polymers HMPA and PEG and monoclonal antibodies for cancer 
therapy. 
Matrix metalloproteases (MMP) are endopeptidases that are important for the degradation of the 
extracellular matrix and basement membranes. Within tumour cells, the increase of MMP’s plays a 
critical role in tumour progression and cell invasion leading to tumour metastases.126, 127 MMP can 
cleave peptide sequences, and an octapeptide linker was developed, Gly-Pro-Leu-Gly-Ile-Ala-Gly-
Gln, which is targeted by over expressed MMP-2 and MMP-9 in certain cancer types.127 This peptide 
was used to link doxorubicin to an albumin macromolecule for release and accumulation of the drug 
within the tumour cells. 
 
1.3.4.3 Targeting agents (Carriers) for Active and Passive Targeting 
 
Targeting agents contained within a bioconjugate serve as a carrier for the BFCA-radioisotope 
complex and help deliver the radionuclide more specifically to the tumour site. Based on the same 
principal as targeting chemotherapeutic drug bioconjugates reviewed in section 1.2, 
radiopharmaceuticals can actively and passively localise within the tumour. Active targeting agents 
recognise over-expressed surface receptors on tumour cells with high affinity and specificity resulting 
in the selective uptake of the radiopharmaceutical. Passive targeting and localisation of the 
radiopharmaceutical occurs due to the hypoxic tumour microenvironment and the EPR effect. In 
contrast to chemotherapeutic bioconjugates, the design of radiolabelled bioconjugates requires the 
careful matching of the radioisotope with the targeting agent in terms of the half-life of the 
radionuclide and the biological half-life of the targeting vector.58 In turn, the biological half-life of the 
targeting agent is determined by its clearance rate and in vivo stability.77 The most common 
biomolecule targeting agents for radiopharmaceuticals are antibodies and antibody fragments, 
proteins, peptides, small molecules, oligonucletides and nanoparticles. Nanoparticles are useful for 
passive targeting and can be derivatised with other biological agents that actively target the tumour 
cells. The different types of targeting agents will again be briefly discussed as applicable to 
radiopharmaceuticals. In the development of a radiopharmaceutical, all the targeting agents mentioned 
are radiolabelled by their attachment to a BFCA. 
Antibodies have long biological half-lives and must therefore be matched with radioisotopes that have 
similar-length half-lives to allow enough time for the antibody-radioisotope complex to accumulate 




within the tumour before the isotope has completely decayed and will no longer be effective. Despite 
the limited uses of antibodies as a result of their reduced accumulation in tumours and slow clearance 
from the blood (3-4 wks), some radiolabelled mAbs have been FDA-approved.78 These 
radiopharmaceuticals include Bexxar, Zevalin, ProstaScint and CEA-Scan. Bexxar is the antibody 
tositomomab which is labelled with 131I while Zevalin is a 90Y anti-CD20 antibody, ibitumomab 
tiuxetan, both of which are used to treat Non-Hodgkins lymphoma. ProstaScint is used for the 
imaging of prostate cancer and is capromab pendetide labelled with 111In. Another imaging mAb, 
99mTc-Arcitumomab, known CEA-Scan is used to image colorectal cancer. A mAb that is FDA 
approved but which the radiolabelled version is currently undergoing clinical trials is Trastuzumab. 
This mAb targets the HER-2/neu receptor which is over expressed in 25-30% of human breast 
cancers.98 Radioisotopes that have been used to label Trastuzumab are 111In, 64Cu, 89Zr and 212Pb.85 
The antibody against VEGF, bevacixumab, has been labelled with 90Y 128 and 64Cu.129 The recent 
trend in antibody targeting is rather to use mAb fragments. Such fragments still retain the specificity 
and affinity of the intac antibody but are of a smaller size (6-110 kDa).58 The smaller size of the 
fragments increases their blood clearance (< 10 hrs) and so allows for the use of shorter-lived isotopes 
with lower non-specific radiotoxicity. An antibody fragment currently undergoing clinical trials, 
F(ab’)2-trastuzumab, has been radiolabelled with 68Ga for PET imaging of solid tumours with HER-
2/neu receptors. Other antibody fragments include anti-EGF affibodies which have been labelled with 
177Lu and 68Ga.  
Small peptides that have been used for targeting are diverse and have very favourable biological 
properties. These properties include low immunogenicity, good affinity and uptake in the target tissue 
as well as good pharmacokinetics and clearance from the blood.58, 75 Peptides are therefore suitable for 
short lived radioisotopes due to their fast localisation and clearance. Small peptides can be more 
easily chemically modified and radiolabelled than larger molecules and are less susceptible to a loss 
of integrity and receptor affinity due to labelling conditions.75 However, also due to their size, they 
can be more influenced by the larger sized radionuclide-BFCA complex and linker properties. Often a 
spacer is also included between the BFCA and the peptide in order to minimise any interference 
between the two moieties.  
Natural peptides tend to undergo rapid enzymatic degradation and so synthetic peptides with similar 
affinity for the receptors have been designed. An example of this is targeting of the somatostatin 
receptor, which is over expressed on a variety of tumours. Natural somatostatin is a cyclic 
tetradecapeptide that is rapidly degraded in vivo and so a synthetic cyclic octapeptide analogue, 
octreotide (Figure 1.16) was developed. Octreotide is more stable in vivo and was the basis for one of 
the first imaging agents, a 111In-DOTA bioconjugate, Octreoscan.86 Subsequently octreotide has also 
been labelled with 64Cu and 99mTc.75 Analogues of octreotide have modifications to the amino acid 
chain and include octreotate, Tyr3-octreotide (TOC) and Tyr3-octreotate (TATE).75, 86 These analogues 
have been labelled with 111In, 177Lu, 68Ga, 90Y and 99mTc.75, 86 




Cyclic peptide RGD (Arg-Gly-Asp) (Figure 1.16) is used to target the αvβ3 integrin receptor. RGD has 
a relatively short circulation half-life and has been modified with the addition of a D-amino acid to 
increase its bioavailability.86 RGD has been attached to a number of BFCA’s complexing the 
radioisotopes 111In, 177Lu, 64Cu, 68Ga, 90Y and 99mTc.58, 75 Gastrin-releasing peptide receptor is 
expressed on many lung, prostate and breast cancers and is targeted by the 14 amino acid peptide, 
bombesin. Bombesin has been investigated as a targeting agent for radiopharmaceuticals labelled with 
111In, 117Lu, 64Cu and 99mTc.58, 75, 86 Another peptide that is frequently used for targeting is the linear 
tridecapeptide α-melanocyte stimulating hormone (α-MSH). α-MSH targets malignant melanoma 
tumour cells which over express the melanomacortin-1 receptor (MC-1). A dicysteine analogue of α-
MSH cyclised with Re (ReCCMSH) was directly labelled with 188Re.86 ReCCMSH attached to a 




Figure 1.16: Examples of two peptides commonly used as targeting agents: octreotide, targeting the 
somatostatin receptor, and RGD that targets αvβ3 integrin receptor. 
 
The most commonly used small molecules for targeting are folate and glucose (Figure 1.17). Highly 
proliferating cells such as tumour cells have an increased demand for folate which is a dietary vitamin 
required for nucleotide and DNA synthesis.130 As such, folate is used to target the folate receptor 
which is over expressed in many tumour types but has only limited expression in normal cell types. A 
number of folate based radiopharmaceuticals for imaging have been developed. The isotopes that 
have been attached to these radiopharmaceuticals through BFCA are 99mTc, 66/67Ga, 111In, 64/67Cu95, 131 
while 18F has been incorporated directly into the folate structure.130 Fast growing cells also have a 
high energy requirement which is generally satisfied by glucose metabolism. Glucose is taken up into 
cells through glucose transporters (GLUT) on the cell surface. Owing to the high energy demand and 
amount of glucose required by the cancer cells, a number of GLUT’s are up regulated in tumours.132 
Radiopharmaceuticals that incorporate glucose as the targeting agent have been developed for tumour 
imaging.81, 129, 133 The most successful and widely used of these imaging agents has been [18F]-2-
fluoro-2-deoxy-d-glucose (18FDG) for PET. 18FDG is taken up into the cell through the glucose 




transporters and is then metabolised to 18FDG-6-phosphate, which cannot be metabolised further and 
is so trapped inside the cell. Glucose has also been labelled directly with 11C and labelled with 99mTc 
through attachment to various chelators.81 Glucose as a targeting agent will be reviewed further in 
Section 1.4.3.1. A third type of small molecule that is used for targeting but less frequently is 
radiolabelled nucleosides. Nucleosides are the building blocks of DNA and RNA and the uptake and 
incorporation of radiolabelled nucleosides results in the imaging of tumour cell proliferation. The 
most commonly labelled nucleosides are thymidine-derivatives with 18F, 11C, 125I and 76Br.81 
 
Figure 1.17: Examples of some 18F-radiolabelled small molecules that have been used as tumour targeting 
agents 
 
Nanoparticles used for radiopharmaceuticals include liposomes, quantum dots, polymers, carbon 
nanotubes and dendrimers. Liposomes are self-assembling vesicles that encapsulate hydrophilic 
components within their inner cavity or hydrophobic agents within the lipid membrane.65 Liposomes 
can be directly loaded with radioisotopes or the isotopes can be complexed to BFCA on the liposome 
surface. Radiolabelled liposomes for passive targeting have used radioisotopes such as 99mTc, 111In, 
67Ga, 18F, 177Lu, 64Cu, 131I, 90Y, 188Re and 225Ac.14 A number of the different biomolecules mentioned 
that are used as targeting agents and have been radiolabelled, have also been attached to nanoparticles 
for dual active and passive targeting and better delivery of the conjugate (Table 1.9) Examples of 
some of these nanoparticles are liposomes derivatised with monoclonal antibodies that have been 
labelled with 111In, 90Y, 225Ac; quantum dots that link peptide targeting agents with 64Cu complexes; 
iron oxide nanoparticles that contain 64Cu and 18F; and polymers and dendrimers that have been 
labelled with 99mTc and 76Br respectively.14 
 
All the different aspects, targeting agent, linker, bifunctional chelator and radioisotope, to be 
considered when designing and synthesising a radiopharmaceutical, have been discussed. Table 1.9 










Table 1.9: Some selected radiopharmaceuticals and the targeting agents, radioisotopes, chelating 
agents and linkers used in their composition 
 
Active Targeting agent Receptor Radio-
isotope 















CD20 131I - - - 
Ibritumomab 
tiuxetan (Zevalin) 
CD20 90Y DTPA thiourea - 
Capromab 
(ProstaScint) 
PSMA 111In pendetide -  
Arcitumomab  
(CEA-Scan) 
CEA 99mTc - - - 
Trastuzumab 
(Herceptin) 













 F(ab’)Trastuzumab HER-2/neu 68Ga DOTA thiourea - 
Anti-EGF EGFR 68Ga, 177Lu DOTA thioether HSA 




























































































1.4 Design of a therapeutic radiopharmaceutical bioconjugate 
 
In the design of a therapeutic radiopharmaceutical, all of the properties must be assessed to be 
compatible with each other. The radionuclide should have a favourable half-life and decay properties 
and if possible, be easy to obtain and affordable. The chelator should match the radioisotope in terms 
of half-life and form a thermodynamically stable and kinetically inert complex with the chosen 
radionuclide. Ideally, the radiolabelling of the chelator should occur under low concentrations in 
minimal time and at minimal temperatures to preserve any biological molecules present. The targeting 
agent should be attached to the chelator through a suitable linker and the agents’ affinity for its 
specific receptor should not be influenced by the chelator. The targeting agent should ideally only 
accumulate the radiopharmaceutical at the tumour site, and any other free radiobioconjugate should be 
rapidly excreted from the system to reduce damage to healthy cells.    
 1.4.1 Selection of a radioisotope 
 
The selection pool for choice of a therapeutic radioisotope consists of a few α-emitters, β-emitters and 
those radioisotopes that emit Auger electrons (section 1.3.2). While a few β-emitting 
radiopharmaceuticals have been approved, there are currently no FDA-approved α- or Auger electron 
emitters for tumour therapy.58 A radiopharmaceutical labelled with an Auger-emitting radioisotope 
would be more desirable than an α-emitter due to its highly localised, low energy emissions and very 
small, nanometer penetration range thereby decreasing toxicity to healthy tissue. The challenge with 
using an Auger electron emitter though, is that the conjugate is required to localise within the cell 
nucleus to do the most irreversible damage.  The most commonly used Auger emitters are 111In (6.75 
keV), 125I (15.0 keV) and 67Ga (6.26 keV). Another Auger-emitting radioisotope that shows great 
potential is 103Pd. 103Pd decays via electron capture to 103mRh which then also releases gamma rays to 
form stable 103Rh (Figure 1.18).134 Palladium-103 has a half-life of 17 days, while 103mRh decays by 
half in 56.1 min. The process of electron capture results in an inner-shell vacancy which initiates an 
electron cascade to fill the subsequent vacancies and in the process releases a number of low-energy 
Auger electrons. Upon the radioactive decay of 103Pd, Auger electrons are given off at five distinct 
energies: 16.5, 17.0, 23.9, 36.3, 39.1 keV. Although these energies are low, a large amount of 
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Figure 1.18: The electron capture (EC) decay process of 103Pd to the stable isotope 103Rh through the transition 
isotope 103mRh 
 
103Pd is a synthesised radionuclide obtained by either neutron activation of 102Pd or proton activation 
of 103Rh. Conversion of 102Pd to 103Pd by absorption of a neutron is a difficult, costly method 




considering that the natural relative abundance of 102Pd is 0.9 % and that the product is not obtained 
with high specific activity or high radiopurity.135 Proton activation is cheaper and easier to perform. 
103Rh is present in 100% natural abundance and is therefore easy to obtain. 103Pd is obtained when 
103Rh is bombarded by a high-energy charged proton beam from an accelerator and undergoes a 
transmutation process. During the transmutation ‘p,n reaction’ (103Rh(p,n) 103Pd), a proton enters the 
nucleus of 103Rh and a neutron gets emitted to form 103Pd. 
The development of a radiopharmaceutical requires that the radioisotope be complexed to the chelator 
through covalent bonds. A concern in the choice of chelator-radioisotope complex is that the recoil 
energy experienced by the daughter isotope in the decay process is large enough to break the metal 
complex bonds and release the radioisotope. When a radioisotope decays and releases a particle with 
certain energy in one direction, the principle of conservation of momentum dictates that the linear 
moment of the daughter nucleus will be equal to the ejected particle but in the opposite direction. This 
energy is known as the recoil energy and can result in a lot of damage if the radioisotope is released 
into healthy surrounding tissue. The exact energy of bonds in the covalent complex will depend on the 
type of radioisotope was well as the chelator used. A chelate-complex such as DOTA has an average 
covalent bond strength of at least 3 eV. The recoil energies following the decay of 103Pd are around 
2.8 x 10-3 eV to 2.17 x 10-1 eV134 which is well below the energy required to break the complex bonds. 
The most common use for 103Pd is in prostate and vascular brachytherapy. 103Pd is encapsulated in a 
metal seed which is then implanted within, or in very close proximity to, the desired tumour site.136 
Prostate brachytherapy is used to treat prostate cancer when the tumour is in the early stages of 
growth and is localised. The radioactive seeds are placed permanently within the prostate gland. 
Vascular therapy is the placing of the seed within a blood vessel to help prevent restenosis or the 
rethickening of the blood vessels due to neointimal hyperplasia that can occur after some sort of 
vascular surgery.137 
The use of ‘cold’ palladium isotope is well documented, and a number of compounds exist that are 
anti-viral, anti-fungal, anti-microbial and anti-cancer.138 Pd (II) is a soft Lewis acid and so forms 
stronger bonds and more stable complexes with nitrogen and sulphur donors. These chelators include 
thiosemicarbazones and organopalladates among others. Although these compounds are non-
radioactive, their complexes still display numerous favourable properties for treating diseases. The 
technology developed for cold palladium can be adapted for the use of 103Pd since the chemistry of the 
metal for binding and complex formation remains the same.  
The use of radioisotopic Pd (II) is not very widespread for therapeutic applications except for 
brachytherapy and therefore a lot of potential exists for the incorporation of this isotope into other 
radiopharmaceuticals. The challenge remains, however, that in order to have any effect, the 103Pd 
needs to be localised in close proximity to DNA and this will depend on the bioconjugate to which it 
is attached. 




1.4.2 Selection of a chelating agent 
 
Cyclam, the functionalisation of which has been briefly reviewed in Section 1.3.4.1, has proven to be 
a very effective metal chelator. It is relatively inexpensive and readily available and has been widely 
used in synthesising a number of compounds for medicinal applications.110 These medical 
applications are predominantly the use of a bicyclam compound and its analogues for anti-HIV 
treatment and the use of 64Cu labelled cross bridged cyclam and its analogues for tumour imaging.   
The anti-HIV cyclam compounds that have been the most effective in limiting the replication of the 
HIV virus are based on the template of benzyl-linked bicyclam compound, AMD3100 (Figure 
1.19).139 This structure has been derivatised with AZT140 or galactosylceramide141 in attempts to 
improve on its inhibitory capabilities. Further attempts at improving efficacy are the complexation of 




Figure 1.19: Structure of the bicyclam anti-HIV drug, AMD3100 that acts as a chemokine receptor antagonist  
 
The development and synthesis of cyclam analogues with side and cross-bridges and their use to 
complex 64Cu has been well documented.113, 114, 142-147 Some of these cyclam derivatives also contain 
receptor targeting agents to improve tumour delivery. A cyclam analogue that uses the peptide 
Bombesin, targets GRP receptors,148 Tyr3-Octreotate cyclam selectively binds to somatostatin 
receptors,149 folate-cyclam binds to folate receptors,95 and RGD-cyclam conjugate delivers 64Cu 
selectively to tumours through binding integrins.150 Another targeting cyclam analogue which has 
been synthesised that has the potential to bind radioisotopes is a biotinylated cyclam that binds 
streptavidin.151  
A cyclam chelator that is to be used as a BFCA for a radiopharmaceutical needs to form a highly 
stable complex with the metal. Formation of a metal cyclam complex can result in a variety of 
configurations related to the relative positioning of hydrogen atoms on nitrogen, and the structure 
pertaining to a particular metal complex can potentially have a major effect on the biological activity 
of the conjugate. The configuration and relative energy of any metal cyclam complex is affected by 
the substituents on the cyclam ring, the size of the metal ion, the specific interaction between the 
cyclam ring and the metal, any additional ligands or counter ions and the pH.110 Metal cyclam 
complexes can be found in five different configurational isomers (Figure 1.20). These are designated 
trans-I (RSRS), trans-II (RSRR), trans-III (RRSS), trans-IV (RSSR) and trans-V (RRRR). It has 




been noted that the most stable isomer is the trans-III form especially for octahedral metal complexes 




Figure 1.20: The five different configurational isomers possible for metal-cyclam complexes due to the chirality 
invoked by the coordinated N-atoms as illustrated by a tetramethylated, metal-cyclam complex (adapted from 
Barefield et. al.152) 
 
Although no 103Pd-cyclam complexes have been reported, cyclam has been used to coordinate ‘cold’ 
palladium in the investigation of metal complexes for useful applications139, 152, 153 and the favourable 
binding characteristics of palladium to cyclam shows great potential for a radiopharmaceutical cyclam 
conjugate that binds 103Pd.  
However, in the development of a BFCA using cyclam, the substituents that are attached to cyclam 
need to be evaluated as these might affect the overall structure and configuration of the complex and 
the metal binding stability. The N-functionalisation of cyclam with a combination of substituents can 
pose a significant synthetic challenge due to the presence of four equivalent nucleophilic nitrogen 
donor atoms. In alkylation or acylation strategies four different (mono, di, tri or tetra) substituted 
configurations can be obtained (Figure 1.21). The C2-symmetry of cyclam leads to three possible di-
substituted alternatives: N1-N4, N1-N8 and N1-N11.  
1.4.3 Selection of a targeting agent 
 
The specificity of a radiopharmaceutical for tumour localisation requires that the radioisotope-chelator 
complex be attached to a targeting agent that improves and increases the affinity of the 
radiopharmaceutical. The targeting agent needs to have a sufficient biological half-life in order to 
accumulate within the tumour before being metabolised and excreted. Both active and passive 
targeting methods (Section 1.2 and 1.3.4.3) have been used to develop a number of diagnostic and 
therapeutic radiopharmaceuticals. Two specific tumour targeting agents, glucose for active targeting 
and albumin for passive targeting, will be discussed.  
 






Figure 1.21: The mono, di, tri and tetra substitution patterns that could possibly be obtained during 
functionalisation of cyclam  
1.4.3.1 Glucose active targeting agent 
 
Tumour cells have a higher demand for energy to support the abnormal functioning, growth, 
migration and the invasion of normal cells. A very good indicator or ‘hallmark’ of cancer is enhanced 
glycolysis by the tumour cells for ATP production, rather than ATP generation through oxidative 
phosphorylation.20, 154 This phenomenon was discovered in 1924 and termed the “Warburg effect” 
after Otto Warburg. Glycolysis is less efficient than oxidative phosphorylation for generating ATP but 
the rate of ATP production through glycolysis is faster thereby giving cancer cells a competitive edge 
for energy resources.20 Glycolysis is also the pathway by which many essential carbon precursors for 
biosynthetic pathways are produced. These precursors are needed for the synthesis of nucleic acids, 
phospholipids, cholesterol, porphyrins and fatty acids.155 The use of glycolysis, despite oxygen 
availability, therefore assists the survival and proliferation of tumour cells.  
One of the mechanisms responsible for the switch to glycolysis is the tumour microenvironment. As 
the tumour cells grow there is no longer a sufficient supply of blood and oxygen and they become 
hypoxic. The cells adapt to hypoxia by stimulating the transcription factor, HIF-1 which then activates 
glycolysis by regulating a number of glycolytic enzymes. Glycolysis metabolises glucose to lactate 
which is then released into the extracellular environment leading to acidosis. Tumour cells have 
adapted to survive in a low pH but the acidic conditions are toxic to normal cells, which protects the 
tumour against attack from the immune system.155 Since the use of glycolysis requires a greater 
consumption of glucose to provide all the energy and metabolite requirements of highly proliferative 
tumour cells, HIF-1 also increases the efficiency of glycolysis by increasing the expression of GLUTs 
on the cell surface.20 Glucose uptake is the rate limiting step in its metabolism and so the increase of 
GLUTs increases the uptake and translocation of glucose into the cell to improve the energy supply.156 
GLUTs are facilitative sugar transporters and move glucose across the cell membrane down a 




concentration gradient without any energy being consumed. GLUTs occur in two conformations that 
expose a glucose binding site to either the extra or intra cellular environment. As glucose binds to the 
transporter at either position, a conformational change from the one conformation to the other is 
triggered thereby carrying the glucose across the membrane. The GLUTS that have a high affinity for 
glucose and been found to be over-expressed in a number of tumours are mainly GLUT1 followed by 
GLUT3 and GLUT4.20, 132, 156 
The altered energy metabolism by increased expression of GLUTs and enhanced glycolysis within 
tumours represents a hallmark of tumour progression. Compounds that can be acted on by glycolytic 
enzymes or compounds that are glucose analogues and taken up by GLUTS, are promising targets for 
the development of new anti-cancer agents for the diagnosis or treatment of cancer. The most widely 
used radiopharmaceutical that exploits these properties is 18FDG.  18FDG is a neutral glucose analogue 
taken up though GLUTs and then metabolised to the anionic 18FDG-6-phosphate, which cannot be 
further metabolised and so accumulates in the cell thereby allowing imaging of the tumour with 
PET.154 The 18FDG has been functionalised in various ways to attach to a variety of groups within the 




Figure 1.22: Examples of 18F labelled glucose functionalised with various reactive substituents for attachment 
of the glucose to another linker or chelating agent 
 
Based on the same principle of GLUT and glycolysis targeting, a few other radioisotopic-glucose 
analogue targeting agents have been developed. A 11C glucose compound labelled in the carbon-6 
position was used to determine the percentage of glucose used for energy production and of that used 
for biosynthesis.81 The short half life of 18F (T1/2 = 109.8 min), its high cost and limited availability 
has led to the investigation of 99mTc (T1/2 = 6.01 h) for 99mTc-glucose imaging agents which is cheaper 
and more readily available. Glucose itself is a weak complexing agent for 99mTc and so the use of a 
BFCA to bind the metal is crucial.157 Glucose functionalisation at the hydroxyl groups of positions C-
1, C-2, C-3 and C-6 with various chelating systems has been based on glycosylation reactions and 
nucleophilic substitutions.81, 133, 157, 158 Other glucose bioconjugates are based on peptide coupling with 




the 2-deoxyglucose compound, glucosamine.81, 99, 129, 154 Schibli et al.158 functionalised glucose at the 




Figure 1.23: Examples of glucose functionalised at various ring positions with an amino-diacid chelator 
 
The 99mTc-complexes of these compounds were then used to investigate their uptake through GLUT1. 
The results however seemed to indicate that uptake was unspecific via passive diffusion rather than 
active transport through GLUT1. The hypothesis was that the 99mTc-glucose complexes were too 
sterically hindered to be recognised by the extracellular binding site of GLUT1. Despite this 
conclusion, Zhang et al154 reported the specific uptake of a larger pyropheophorbide 2-
deoxyglucosamide compound (PP-DG) (Figure 1.24) through glucose transporters and a number of 
other groups reported the specific localisation of 99mTc-glucose conjugates within tumours through the 




Figure 1.24:  Examples of glucose-chelator compounds that have been used to complex 99mTc 




De Barros et al157 and Chen et al129 reported mercaptoacetyl- glycylglycylglycine (MAG3) glucose 
analogues that are 99mTc labelled. Chen also reported the synthesis of a 99mTc-MAMA-BA-DG 
complex but this was not as effective as the MAG3 complex. Yang et al99, 159 synthesised a 
diglycosylated compound, ethylenediscysteine-deoxyglucose (ECDG) through the peptide coupling of 
glucosamine to ethylenedicysteine. The 99mTc-ECDG complex was then evaluated for tumour 
localisation and was found to have a good tumour-to-muscle ratio and be taken up through the 
GLUTs. A recent approach by Benoist et al for coupling glucose derivatives to a chelator is the 
“click-to-chelate” approach.133 Glucose was derivatised with an azide at the C-1 position and coupled 
to an alkyne through a copper-catalysed 1,3-dipolar cycloaddition. The alkyne fragment was 
functionalised with various pyridine analogues in order to chelate the 99mTc. The 99mTc-glucose click 
complexes are under investigation for their biodistribution and tumour targeting properties. 
The potential drawback for any glucose targeting agent not being taken up through the GLUTs, 
remains a concern. However, the use of glucose still poses an attractive idea as a hydrophilic, 
biocompatible targeting agent that could possibly also be recognised by surface carbohydrate binding 
proteins (lectins). Indeed, a tetra-glycosylated cyclam that was synthesised to complex radioisotopes 
has been shown to bind to surface lectins (Figure 1.25).160  
Another structurally similar di- and tetra-glycosylated cyclam has been synthesised, not as a targeting 





Figure 1.25: The structure of the tetra-glycosylated cyclam that has been used to bind to surface carbohydrate 
binding proteins 
 
1.4.3.2 Albumin passive targeting agent 
 
Albumin is a macromolecular plasma protein that has become the focus of many drug-delivery 
strategies. Its favourable biological properties have made it an attractive carrier for both 




chemotherapeutic drugs and diagnostic or therapeutic radioisotopes. Human serum albumin (HSA) is 
one of the smallest proteins in plasma with a molecular weight of 66.5 kDa but it is the most abundant 
(35-50 g/L).36, 37 HSA is synthesised in the liver and has a half-life of around 19 days. It is responsible 
for a number of biological functions within the blood such as solubilisation of long chain fatty acids, 
the binding and carrying of some endogenous hydrophobic molecules and the transport of Cu(II), 
Ni(II), Ca(II) and Zn(II).37 Albumin is a slightly acidic, extremely robust protein that is very stable 
under stressing conditions of pH (between pH 4-9), temperature (heated up to 60˚C for 10 hrs) and 
organic solvents (soluble in 40 % ethanol).36, 37 Albumin as a drug carrier has been shown to be non-
toxic, biodegradable, non-immunogenic, easy to purify, soluble in water and is metabolised to 
harmless amino acids. Along with all of these properties, albumin is also readily available and 
affordable and so is an ideal candidate for drug delivery. 
Albumin as a drug carrier helps localise the compound to the tumour site through passive targeting 
and the EPR effect. The pore size of defective blood vessels ranges from 100 – 1200 nm and so 
macromolecules with a size typically between 2 – 10 nm (HSA size is 7.2 nm) can penetrate into the 
tumour environment and experience reduced clearance if the molecular weight is greater than 40 
kDA.37 The accumulation of albumin in a tumour though passive targeting was demonstrated by an 
Evans blue-albumin complex which localised at a tumour site.26 A secondary mechanism for the 
enhanced tumour uptake of albumin is related to transcytosis and a gp60 receptor.36, 38 Albumin binds 
to a cell surface gp60-glycoprotein receptor that in turn binds to caveolin-1, which initiates 
invagination of the cell membrane and transcytosis. Once the albumin is in the extracellular matrix it 
can bind to SPARC (secreted protein acid rich in cysteine) which then further assists in tumour 
accumulation of the drug.36, 38    
Two main principles for drug delivery using albumin are pertinent. The first is the coupling of the 
drug or BFCA to commercially available, isolated albumin (exogenous) or albumin circulating in the 
blood (endogenous) and the second is the encapsulation of the drug into an albumin nanoparticle. The 
first principle of attachment to albumin is based on the reaction of a thiol-binding pro-drug/BFCA to 
the cysteine-34 position of albumin. Around 70 % of circulating, endogenous HSA contains a free 
cysteine-34 thiol group that is not blocked by other sufhydryl compounds.116 HSA is one of only four 
serum proteins that contains a free cysteine residue and these other proteins do not react readily under 
physiological conditions while the free thiol group of HSA is quite reactive due to the low pKa of 
Cys-34 (pKa = 7.0) which makes HSA a unique protein that can be exploited. Coupling a cytotoxic 
moiety to the free thiol group is most often done through the Michael acceptor group, maleimide.37 
For the coupling of a drug or complex to commercial, isolated albumin, a number of different linkers 
(Section 1.3.4.2) can be used apart from the thiol specific maleimide group that is required for 
coupling to circulating albumin. These linkers include isocyanates, N-hydroxysuccinimide esters or 
other activated carboxylic acids which react with amino groups of albumin lysine residues. The 
chemotherapeutic drug, methotrexate was modified to attach to isolated, exogenous HSA though the 




lysine residues,37 whereas another drug, doxorubicin was modified with a terminal maleimide group 
to link to circulating, endogenous HSA116 (Figure 1.26 A). The use of circulating HSA as a drug 
carrier has a number of advantages over the synthesis of ex-vivo drug-HSA complexes, namely; 1) 
avoiding the use of potentially immunogenic commercial HSA and 2) the characterisation and 
purification of the drug is easier to do rather than trying to purify a drug-protein complex.37 The 
incorporation of a cleavable bond (Section 1.3.4.2) between the drug and the albumin can allow for 
the specific release of the drug at the tumour site such as doxorubicin linked to albumin via a matrix 
metalloprotease cleavable linker.127  
 
 
Figure 1.26: Illustration of the two methods of drug delivery using albumin: A) Functionalisation of the 
chemotherapeutic drug, doxorubicin, with a maleimide moiety to bind to the free thiol within HSA, B) 
Encapsulation of the chemotherapeutic drug within albumin nanoparticles  
 
The second drug-delivery method is the use of albumin nanoparticles (Figure 1.26). These 
nanoparticles offer some advantages over other nanoparticles in that they are biodegradable, easy to 
prepare, well tolerated and offer surface functional groups such as amines or carboxylic acids for 
derivatisation of the nanoparticle.36 Attachment of a receptor targeting agent to the surface of the 
albumin nanoparticle can help with localisation of the conjugate by dual targeting methods. The 
method for encapsulating drugs within an albumin nanoparticle (nab-technology) was developed by 
American Biosciences Inc. HSA and the drug is mixed together in an aqueous environment and 
passed through a jet under high pressure to form nanoparticles of between 100-200 nm.37 An albumin-
based nanoparticle that is FDA approved for the treatment of metastatic breast cancer is Abraxane™. 
Abraxane encapsulates the drug, paclitaxel, and is around 130 nm in size.  
Despite the success of albumin as a chemotherapeutic drug delivering agent, the use of radiolabelled 
albumin has not been that widespread. The most common radiolabelled albumin application is the 
measurement of liver function through the use of 99mTc and SPECT imaging.162 The surface of the 
albumin was first modified using iminothiolane to contain a number of surface thiol groups followed 
by addition of a maleimide functionalised DTPA chelating agent to which the 99mTc was then 
complexed (Figure 1.27 A). Galactose or lactose modified with a maleimide moiety was also attached 
to the albumin as a targeting agent. These carbohydrates are used for their selectivity towards the 
asialoglycoprotein receptor which is expressed in hepatocytes. Another HSA-bioconjugate, 




radiolabelled with 177Lu or 64Cu, has been investigated as a radiotherapeutic agent for cancer (Figure 
1.27 B).163 This albumin conjugate was functionalised through amino acid amino groups with a 
DOTA derivative that was subsequently used to complex the radioisotope. The targeting capability of 
the albumin bioconjugate was improved by the attachment of antibody fragments (affibodies) (ZEGFR) 
targeted towards the EGFR, especially of head and neck carcinomas. After conjugation of the albumin 
with, on average, three DOTA derivatives, the ZEGFR was attached in a ratio of 1-5 affibodies per 
albumin. The 177Lu labelled compound showed the most potential as a radiopharmaceutical for cancer 
therapy. The challenge with conjugating to albumin lysine residues, is that the degree of 
radiolabelling can be uncertain in that the results are not always uniform between experiments. 
 
 
Figure 1.27: Examples of albumin that has been modified for radiolabelling A) Albumin modified with 
iminothiolane to provide a number of surface thiol groups to which derivatised lactose was attached as a 
targeting agent as well as a DTPA as a chelating agent for 99mTC, B) Albumin modified through its amino 
groups with EGF affibodies as targeting agents and DOTA macrocylces to chelate 177Lu 
1.5 Hypothesis and Aim of a proposed radiopharmaceutical 
bioconjugate 
 
The hypothesis of the project was that a bifunctional chelator, modified to form a bioconjugate for 
dual active and passive targeting of tumours, would complex a radioisotope to affect tumour therapy. 
The bioconjugate would consist of the chelator connected to a ligand for the active targeting of a 




specific tumour receptor as well as to another molecule that is sufficiently large to be used for passive 
targeting through the EPR effect. The bioconjugate would then be complexed with an Auger electron-
emitting radioisotope and after administration, localisation of the bioconjugate within the tumour 
environment would occur. The destruction of the cells would result from the radiation emitted by the 
isotope but the small radiation penetration range would lead to minimal damage to surrounding 
healthy tissue. With this hypothesis in mind, the general aim of the project was to synthesise a new 
Auger emitting therapeutic radiopharmaceutical greater than 40 kDa in size and one with an increased 
specificity for tumours in order to carry out preliminary in vitro tests of the bioconjugate. 
The proposed radiopharmaceutical bioconjugate is illustrated in Figure 1.28. The BFCA chosen was 
cyclam, and the Auger emitter, 103Pd. Cyclam and Pd(II) form complexes with good stability and the 
recoil energy of Pd was not considered to be large enough to overcome the metal-cyclam bonds. 
Cyclam would be di-functionalised through the nitrogen atoms to attach the tumour targeting agents, 
glucose and albumin. Glucose, which is taken up by over-expressed GLUTs in cancer cells, was 
chosen as the active targeting agent, and modified through the anomeric C-1 position for attachment 
to the cyclam. The passive targeting agent chosen was albumin, with a mass of 66.5 kDa. The final 
task in the synthesis envisaged attaching the conjugate to circulating HSA, and therefore a pre-
labelling approach was adopted. Preliminary studies on the conjugate addition to albumin would, 
however, be conducted using commercial Bovine Serum Albumin (BSA). In order to bind the 
glucose-cyclam conjugate to HSA, the conjugate would be functionalised with a maleimide linker for 
reaction with the free thiol group of Cys-34 in albumin. 103Pd and HSA have similar half-lives of 17 
and 19 days respectively. These two components of the radiopharmaceutical are therefore well suited 
to each other as there is sufficient time for localisation of the bioconjugate to occur before degradation 
begins. Owing to the size of the bioconjugate, entry into the tumour cells and into the cell nucleus 
might pose a problem. A disulfide bond, which will be cleaved by increased glutathione levels in the 
tumour, can therefore be inserted into the albumin linker.  The viable routes to synthesise cyclam with 
different substitution patterns of the attached moieties as well as glucose functionalisation and 
maleimide-linker synthesis will be further reviewed in Chapter 2. 
As far as can be seen from review of these components and radiopharmaceuticals, there seems to be 
no complex of cyclam and 103Pd or cyclam and albumin, and very limited compounds of glucose 
linked to cyclam or albumin. Therefore, the combination of cyclam acting as a bifunctional chelating 
agent for 103Pd, functionalised with glucose and attached to albumin appears to be novel. The 
development of this bioconjugate, which will be discussed in the subsequent chapters, would therefore 
provide a new radiopharmaceutical that can be tested for cancer therapy.  






Figure 1.28: Illustration of A) the structures of the two constitutional isomers of the proposed synthetic glucose-
cyclam-maleimide pro-conjugate with various linker alternatives that is radiolabelled with 103Pd, and B) Michael 
addition of the free thiol in albumin to the maleimide of the pro-conjugates to form the proposed 
radiopharmaceutical bioconjugate    
 




CHAPTER 2 – SYNTHESIS  
2.1 Introduction 
 
The envisaged radiopharmaceutical involved joining three synthetic components to form a pro-
conjugate before linking to a biomolecule (Figure 2.1). These components were: 1) a glucose 
containing linker derivatised in the anomeric position for active targeting, 2) a cyclam functionalised 
through N-linkages for radioisotope chelation and 3) a maleimide linker for attachment to albumin. 
The synthesis of the pro-conjugate would require the careful manipulation of a variety of different 
functional groups to connect all the required components. The various methods by which these 
components could be functionalised will be briefly discussed. 
 
 
Figure 2.1: Illustration of the principal synthetic components comprising the pro-conjugate: Glucose for active 
targeting, cyclam to coordinate the radioisotope and maleimide as a Michael acceptor for attachment to albumin  
2.1.1 Functionalisation of Glucose 
 
Carbohydrates play an integral part in biological systems, offering chiral pool starting materials for 
synthesis. Their stereoselective synthesis, which focuses on the formation of integral glycosidic 
linkages, has been a challenge in the field for some time. Carbohydrate chemistry has been a point of 
research for well over a century in which the most generally applicable and useful reaction for the 
synthesis of glycosides was developed by Koenigs and Knorr164 in 1901 (Scheme 2.1). This method 
employs the conversion of a peracetylated D-glucose (2.1) into a peracetylated glycosyl bromide (2.2) 
through reaction with hydrogen bromide. The glycoside (2.5) is then formed by the reaction of the 
halide with an alcohol in the presence of silver or mercury salts as Lewis acid promoters. A powerful 
stereoselective aspect of this reaction is that an anomeric mixture in this reaction produces 
predominantly only the β-glycoside via a neighbouring group participation of the 2-acetyl group onto 
the oxocarbenium ion(2.3) from the α-face to form an orthoester intermediate (2.4).165 Thereafter, the 
poorly nucleophilic alcohol attacks the anomeric carbon from above to give the β-glycoside (2.5).  
 






Scheme 2.1: The mechanism of the Koenigs-Knorr glycosylation reaction in which a glycosyl halide becomes a 
glycosyl ether 
 
Subsequent research into this reaction and its mechanism yielded the observation that the glycosyl-
halide is in the α-configuration166, 167 due to an anomeric effect. The latter was described in 1955 by 
J.T. Edward168 and is defined as the preference of electronegative substituents at the C-1 anomeric 
position of monosaccharides to occupy the axial (α) position instead of the sterically less hindered 
equatorial (β) position169(Figure 2.2). The most widely accepted explanation of this phenomenon is 
given as due to antiperiplanar hyperconjugative stabilisation between one of the non-bonding lone 
pairs of the oxygen (nO) in the ring and the anti-bonding orbital of the anomeric carbon-oxygen bond 
(σ*CO) involving the α-electronegative substituent. This orbital stabilisation does not occur with 




Figure 2.2: Illustration of the anomeric effect which favours the synthesis of α-glycosides and its formation due 
to antiperiplanar hyperconjugation  
 
The other proposed explanations for this effect invoke dipole stabilisation and electrostatic 
repulsion169 (Figure 2.3). Dipole considerations predict that the net dipole from lone pairs on the 




oxygen ring and the C-OR bond is more severe, and hence destabilising, when the OR substituent is in 
the β-equatorial configuration, while electrostatic repulsion considers the repulsion between ring-
oxygen lone pairs and electron density in the C-O bond to be greater also for the β-anomer – these 




Figure 2.3: The alternative dipole stabilisation and electrostatic repulsion explanations for the anomeric effect 
 
The rate limiting step for both the formation of the glycosyl halide and the alkyl-glycoside in the 
Koenigs-Knorr reaction shown in Scheme 2.1 is formation of the oxocarbenium ion intermediate.170 
The electronic effects of the ring substituents can therefore greatly influence the reactivity of the 
glycosyl donor. Electron-withdrawing protecting groups like acetyl destabilise the oxocarbenium ion 
relatively more than ether protecting groups like benzyl. This chemoselectivity can be exploited when 
synthesising disaccharides, in which the less destabilising groups impart a connotation of “armed” to 
the sugar in question. The acetyl or benzoyl protected, disarmed glycosyl-halides are thus more stable 
towards elimination. 
The search for improved glycosylation techniques has led to the development of a wide range of 
glycosyl donors to include, thioglycosides, sulfoxides, trichloroacetimidates and pentenyl glycosides 
(Scheme 2.2). Thioglycosides (2.6) were first reported in 1909 by Fischer171 and are formed by the 
reaction of a peracetylated sugar (2.1) with the appropriate thiol and BF3.OEt2. They are readily 
synthesised and are very stable under a wide range of reaction conditions. Donor thioglycosides are 
generally activated for glycosylation using N-iodosuccinimide(NIS)/silver triflate(AgOTf), and are 
also easily oxidised to sulfoxides (2.7), which can act as an alternative, more reactive glycosyl donor 
source.170 Trichloroacetimidate (2.8) donors are formed by addition of trichloroacetonitrile to a free 
anomeric hydroxyl group (2.1a) under basic conditions (172), and are easily formed and activated for 
glycosylation with BF3.OEt2 or TMSOTf. Pentenyl glycosides (2.9) are formed by the reaction of 
pentenol with peracetylated sugars using BF3.OEt2, and are activated through reaction with a 
brominating reagent to form a bromonium ion which then undergoes a 5-exo cyclisation via a lone 
pair of the glycosidic oxygen to form a cyclic oxonium ion intermediate (2.10).173 
O-glycosylations are most often used for anomeric linking but there are one or two alternatives that 
include substitution of the anomeric hydroxyl group with an azide133 or a thiol.174 A glycosyl azide is 
formed by the direct substitution of peracetylated glucose with TMSN3 using a Lewis acid promoter 
and can then be reduced to an amine for peptide coupling157 or undergo a copper catalysed ‘click’ 




reaction with an alkyne derivative.133 Similarly, thioglucose can be formed by the reaction of a 
glycosyl halide with thiourea followed by hydrolysis.174  
 
 
Scheme 2.2: Illustration of the synthesis of selected glycosyl donors – thioglycosides (2.6), sulfoxides (2.7), 
trichloroacetimidates (2.8) and pentenyl glycosides (2.9) – and their activation with various reagents for reaction 
 
Despite the number of alternatives available for forming glycosidic linkages, the anomeric halides are 
still most commonly employed. While glycosyl chlorides are less reactive than glycosyl bromides, 
both can be activated with silver or mercury salts.175 Glycosyl-fluorides have not been extensively 
investigated owing to their decreased reactivity but have been found to have high thermal and 
chemical stability and are being more readily applied. Glycosyl iodides, first prepared in 1929 by the 
reaction of glycosyl bromide with sodium iodide,176 were for a long time considered to be impractical 
reagents for glycosylation reactions owing to their instability, although methods for their generation 
have improved in recent years. For instance, Thiem showed that reaction of glycosyl acetates with 
iodotrimethylsilane (Me3SiI) produces the α-anomer glycosyl iodide (2.11),177 the formation of which 
was studied mechanistically by Gervay et al.178 - the mechanism is shown in Scheme 2.3. The 
preparation of these iodides and their use in glycosylation is generally carried out in situ to prevent 
degradation during purification. Further improvement on glycosylations, using glycosyl iodide, led to 
a method developed by Kartha et al. in which hexamethyldisilane (HMDS)-I2 is used to generate the 
expensive and unstable Me3SiI in situ.179  





Scheme 2.3: Illustration of the formation and intermediates of α and β glycosyl iodides using Me3SiI 
 
Glycosylation reactions using glycosyl iodides have generally been performed using heavy metal 
promoters such as AgOTf and Hg(CN)2 and so iodonium reagents and other Lewis acid activators 
have been introduced. These include NIS and I2 as well as TMSOTf, CuOTf and ZnCl2. Van Well et 
al175 investigated the use of acetylated glycosyl iodides for glycosylation and found that a mixture of α 
and β-glycoside products were obtained while the benzoyl protected sugar only produced the β-
glycoside. Murakami et al.180synthesised glycosides from glycosyl iodides by the method illustrated in 
Scheme 2.4 using N-bromosuccinimide (NBS) and zinc halides (ZnCl2, ZnI2 and ZnBr2) as 
glycosylation promoters. Benzoylated glucose also proved to be more efficient in forming the β-
glycoside than acetylated glucose, as less of the orthoester and benzoylated β-glucose product was 
formed.   
The different glycosylation reactions that are available for functionalising glucose provide a number 
of viable alternatives for attachment of glucose as a targeting agent to a cyclam chelator. 
 
 
Scheme 2.4: The one pot glycosylation method as devised by Murakami et al.180 for the synthesis of a β-
glycoside from a glycosyl iodide with some ortho-ester and benzolyated glucose as the by-products 
 




2.1.2 Functionalisation of a linker with maleimide 
 
Maleimide, the imide (denoting carbonyl-nitrogen-carbonyl functionality) from (Z)-2-butenedioic acid 
(maleic acid) is an α,β-unsaturated carbonyl system and its role in the pre-conjugate was seen to be as 
a Michael acceptor in a 1,4 conjugate Michael addition involving the free thiol group (Cys-34) of 
albumin.  Such an addition would then link the synthesised glucose-cyclam-maleimide conjugate to 
albumin. The synthesis of an N-substituted maleimide can be achieved in two main ways: 1) via a 
RNH2 condensation with a suitable maleic electrophile and 2) via N-alkylation of maleimide (easily 
prepared from maleic anhydride and ammonia). 
2.1.2.1 Condensation of a maleic electrophile with an amine 
 
The first and most common method to synthesise N-substituted maleimides was established in 1948 
by Searle181 (Scheme 2.5) who reported the formation of N-substituted maleamic acid (2.12) from the 
nucleophilic attack of an amine on maleic anhydride in diethyl ether. The maleamic acid then 
underwent dehydration and cyclisation in the presence of acetic anhydride and sodium acetate at 
elevated temperatures to form the N-substituted maleimide (2.13) in yields of 50-70%.182 The 
proposed mechanism for the synthesis of maleimide 2.13 via mixed anhydride formation and SNAc 




Scheme 2.5: Maleimide (2.13) synthesis from a maleamic acid intermediate (2.12) using acetic anhydride and 
sodium acetate to induce cyclisation 
 
The synthesis of N-functionalised maleimide has competing side reactions which are the formation of 
the isomaleimide (2.15), by cyclisation of 2.14 occurring through the amide oxygen rather than the 
nitrogen (Scheme 2.6), as well as isomerisation of the cis-double bond of maleamic acid to an 
unreactive trans configuration. The formation of isomaleimides, first reported by Piutti183 in 1910, 
was investigated by Cotter et al.184 in 1961 and have been synthesised by the dehydration of maleamic 
acid with N,N’-dicyclohexylcarbodiimide (DCC), ethyl chloroformate/triethylamine or trifluoroacetic 
anhydride/triethylamine as well as acetyl chloride/triethylamine and acetic anhydride/triethylamine.185 
Studies have revealed that N-substituted isomaleimides are the kinetic products, and these can be 
isolated in higher yields at lower temperatures. However, they readily isomerise to the 
thermodynamically more stable N-substituted maleimides in the presence of sodium acetate or another 




base (Scheme 2.7) or they slowly hydrolyse back to maleamic acids in the presence of water or 
acid.184 The dehydration of maleamic acid requires elevated temperatures but exceeding the optimal 
temperature range results in degradation of the product and isomerisation of the cis-olefin to trans-
fumaric acid186 whose configuration does not allow for cyclisation. 
The maleamic acid, maleimide and isomaleimide products are characterised and distinguished from 
each other by their olefinic proton 1H NMR coupling patterns187 in which the olefinic protons for 
maleimide resonate as a singlet around 6.7-7.0 ppm whereas the maleamic acid (6.3-6.5 ppm) and 
isomaleimide (7.3 and 6.5 ppm) show a typical non-equivalent JAB coupling system with coupling 








Scheme 2.7: Mechanism showing the isomerisation of isomaleimide (2.15) under basic conditions back to 
maleimide (2.13)  




Another method for N-substituted maleimide synthesis via a maleic electrophile is activation with 
methyl chloroformate and N-methyl morpholine to form N-acylmaleimide 2.16.188 Maleimide 2.16 
then reacts with an amine to form intermediate 2.17 which cyclises under slightly basic conditions 




Scheme 2.8: Functionalised maleimide formation through activation of nitrogen with methylchloroformate to 
form the intermediate methoxy carbonylmaleimide (2.16)  
2.1.2.2 Maleimide substitution using the Mitsunobu reaction 
 
The second way in which an N-substituted maleimide can be obtained is through direct N-alkylation 
using the Mitsunobu reaction in which an alcohol provides the electrophilic partner.189 The 
mechanism of the reaction is illustrated in Scheme 2.9. This method was investigated by Walker et 
al.189 who improved the low to moderate yields afforded by the traditional Mitsunobu methodology by 
establishing that it was necessary to pre-form intermediate 2.19 and 2.20 from 2.18, before the 
addition of maleimide. This method proves useful for substrates that are sensitive to the dehydration 
conditions of the acetic anhydride cyclisation method but gives low yields for substrates with alcohols 
that are prone to elimination. 
    
 








2.1.2.3 Peptide coupling for attachment of a carboxylic acid maleimide to an amine 
 
In the development of conjugates that link chelating agents, such as DTPA, DOTA, chemotherapeutic 
drugs, as well as a number of targeting agents to monoclonal antibodies and proteins,162, 190, 191 the N-
substitution of a maleimide by the methods described above is not always possible. Therefore, peptide 
coupling of a bi-functional maleimido-carboxylic acid (2.23) with a nitrogen centre has been 
developed (Scheme 2.10). The maleimido-carboxylic acid reagents can be synthesised using the acetic 
anhydride-sodium acetate method192 or alternatively, according to Song et al, through refluxing of a 
maleamic acid in water (Scheme 2.10).191 Once a maleimido-acid such as 2.23 is obtained, standard 
peptide coupling techniques such as activation of the carboxylic acid with N-hydroxysuccinimide 
(NHS)162, 191 or reaction with EDCl, HOBt and triethylamine190 are used to form the amide (2.25).  
The use of maleimide for bioconjugation with thiolated compounds is not without its pitfalls in that 
Michael addition often presents a problem of cross reactivity during their synthesis, and hydrolysis of 
the succinimidyl thioether product easily occurs under basic conditions.193, 194 These challenges need 
to be taken into consideration during the synthesis of any compounds containing maleimide. 
 
 
Scheme 2.10: Illustration of the formation of maleimide-carboxylic acids (2.23) and their activation with NHS 
and DCC through the intermediate (2.24) or with EDCl and HoBt for peptide coupling to form 2.25  
 
2.1.3 Functionalisation of cyclam 
 
The tetraaza-macrocycle, Cyclam, has four nitrogen donor atoms available for functionalisation, 
which presents challenging selectivity issues. The possible substitution patterns are illustrated in 
Chapter 1, Figure 1.21. Not surprisingly, synthetic chemists have devised a number of strategies 
which exploit the nucleophilicity of the various nitrogen atoms. Such strategies are broadly 
categorised as direct alkylation, protecting group manipulation and nitrogen bridging strategies.  
2.1.3.1 Functionalisation of cyclam via direct alkylation 
 
Although the regioselective alkylation of cyclam is difficult, improvements in reaction procedures in 
recent years have made this methodology possible to access mono- or tri-alkylated derivatives in high 
yield without the formation of other isomers, but di-alkylated derivatives are invariably formed as a 




mixture of regioisomers that are difficult to separate. The most common method of alkylation is via 
SN2 substitution with an alkyl halide, although Michael addition to acrylamide reagents,195 as well as 
reductive amination with aldehydes and borohydride reagents151 is known.   
A summary of selective alkylation techniques for tetra-azamacrocycles is given in Table 2.1 and these 
methods are briefly discussed. Monoalkylation generally uses an excess of the cyclam free base, 
which makes the approach costly in view of the expense of the macrocycle. However, Kruper et al.196 
has reported the formation of monoalkylated product using equimolar ratios of cyclam and alkyl 
halide by conducting the reaction in chloroform, a nonpolar, aprotic solvent. His studies concluded 
that selectivity for monoalkylation depends on solvent polarity, the steric nature of the electrophile, 
and the degree of proton exchange of the macrocyclic amines in solution. The best solvent for 
achieving selectivity was found to be nonpolar, aprotic solvents as these do not promote proton 
transfer within the reaction. Furthermore, a more sterically hindered electrophile was found to favour 
monoalkylation as well as favouring trans over cis isomers in disubstituted products. Monoalkylation 
was also proposed to be favoured as a result of amine protonation. Each amine within cyclam has a 
different pKa (pKa = 11.6, 10.6, 1.6, 2.4)195 and protonation of the most basic amine, diminishes the 
nucleophilicity of the remaining amines thereby promoting selective alkylation. Similar 
monoalkylation results were obtained by Massue et al.197 using an alkyl halide in the presence of 
triethylamine in which the recovery of unreacted cyclam was demonstrated. Wardle et al.198, after 
obtaining the monoalkylated macrocycle, achieved a second, single alkylation in DMF at room 
temperature. Owing to steric hindrances around the ring, the trans N1,N7-alkylated product was 
formed. 
Alkylation with tertiary butyl bromoacetate (BrCH2CO2t-Bu) leads to TETA bifunctional chelating 
agents (Section 1.3.4.1) such as di-alkylated TE2A, which are difficult to obtain as pure isomers. Tri-
alkylated TE3A is also readily formed in this reaction. The di-alkylation of macrocycles with the 
bromoacetate generally produces the N1,N7 substituted product, although Li et al. has described the 
synthesis of a N1,N4 di-alkylated macrocycle.199 A number of literature procedures report the 
synthesis of tri-alkylated products using BrCH2CO2t-Bu which is then followed by alkylation of the 4th 
nitrogen with a different component.200-202  Here, it was noted that the fourth alkylation doesn’t readily 
take place, requiring extended heating in the presence of a base. In general, the aza-ring systems have 
a strong propensity towards intramolecular hydrogen bonding and therefore a base is added to insure 
that nucleophilic N-function is maintained.198 
The nucleophilic addition of tetraazamacrocycles to acrylamide derivatives is another method that has 
been employed. Selectivity for mono-derivatisation has been obtained by the addition of p-TsOH 
which results in protonation of the most basic nitrogen (pKa 11.6) thereby leaving only the second 
basic nitrogen (pKa 10.6) readily available for Michael addition.195, 203 Tetraalkylation and di-
alkylation of cyclam using an acrylamide compound has also been carried out with the preference for 
regioselectivity determined by the solvent.161 





Table 2.1: Selected examples of direct alkylation methods for tetraazamacrocycles 
    






Solvent Additive Temp 
(˚C) 
Kruper196 mono cyclen Alkyl-Br 1:1 CHCl3 - RT 
Massue197 mono cyclen Alkyl-halide 4:1 CHCl3 Et3N reflux 
Wardle198 Mono (1st) cyclen Alkyl-Br 2:1 CH3CN K2CO3 reflux 
mono (2nd)  mono-cyclen Alkyl-Br 1:1 DMF K2CO3 RT 
di (3rd & 4th)  di-cyclen BrCH2CO2t-Bu Excess  DMF K2CO3 RT 
Li 2003199 di cyclen BrCH2CO2t-Bu 1:2 CHCl3 Et3N RT 
mono (3rd)  di-cyclen Alkyl-Br 1:1 CH3CN K2CO3 60 
Machitani201 tri cyclam BrCH2CO2t-Bu 1:3.3 CH3CN NaHCO3 RT 
mono (4th)  tri-cyclam Alkyl-Br 1:1 CH3CN Na2CO3 60 
Li 2009200 mono (4th) tri-cyclam Alkyl-Br 1:1 CH3CN K2CO3 70 
Aime202 Mono (4th) tri-cyclam Alkyl-Br 1:1 CH3CN K2CO3 RT 
Gaudinet203 mono cyclam Alkyl-
acrylamide 
1:1 CHCl3 pTsOH RT 
Fensterbank195 mono cyclam Alkyl-
acrylamide 
1:1 CHCl3 pTsOH RT 











2.1.3.2 Protecting group manipulation strategy  
 
Protection-functionalisation-deprotection has been another important strategy for the selective 
derivatisation of tetraazamacrocycles in which the most common protecting groups include tert-
butyloxycarbonyl (Boc), p-toluenesulfonyl (Tosyl), benzyloxycarbonyl (CBz) and benzyl (Bn) 
groups. Despite the disadvantages of this method, which includes regioselectivity challenges as well 
as low to moderate yields of the final product in view often of harsh deprotection conditions, this 
method has been effectively used to obtain the tri- and di-protected macrocycles which lead to mono- 
and di-derivatised products respectively. 
Dessolin et al.140 used Boc anhydride in dichloromethane to obtain tri-Boc cyclam (2.26) and a 
mixture of inseparable di-Boc cyclam (2.27a/b/c) as shown in Scheme 2.11. The chemical shifts of 
the macrocycle methylene protons, influenced by the nitrogen substituents, were used to identify the 
different isomers. The chemical shifts between 1.40-1.90 ppm were assigned as due to β-methylene 
protons, while α-methylene protons next to alkylated nitrogens were assigned to resonate between 
2.35-2.60 ppm, with 2.60-2.90 ppm for α-methylene protons next to unalkylated nitrogens and 3.00-
3.60 ppm for α-methylene protons next to Boc nitrogens (carbamate). Subsequently Krivickas et al.151 
derivatised the remaining nitrogen of the tri-Boc cyclam (2.26) using SN2 alkylation or reductive 




amination techniques to form the tertiary amine, or using traditional peptide coupling conditions with 
DCC and DMAP or an acid chloride to form the amide (Scheme 2.11). Although amide formation 
occurs more rapidly than alkylation, the amine products are very stable to a wide range of reaction 
conditions, whereas the amide products are known to undergo Lewis acid-catalysed hydrolysis. 
Deprotection of the Boc-groups was accomplished using acidic conditions of either 1 M HCl in 
diethylether or 20% TFA in dichloromethane to effect monoderivatisation overall.  
Other protection-deprotection sequences that have been followed include the use of Bn and 2,2,2-
trichloroethoxycarbonyl (Troc) protection204 as well as trifluoroacetate (TFA) protection205 with 
selective deprotection being accomplished through hydrogenolysis, reductive conditions with 












2.1.3.3 Nitrogen bridging (bis-aminal) strategies 
 
The nitrogen bridged or bis-aminal tetraazamacrocycles (2.28 in Scheme 2.12), formed by 
condensation of cyclam with the dialdehyde, glyoxal, in methanol or acetonitrile at room 
temperature206-208 or by the condensation of a linear tetraamine with glyoxal followed by cyclisation 
with a biselectrophile,209 allows for a better control of mono and trans di-alkylation through mono- 
(2.29) or di-quaternary (2.30) ammonium salts (Scheme 2.12). The choice of solvent and the 
solubility of the quaternary ammonium salt in the solvent is an essential element for selective 
alkylation.  The mono-salt 2.29, synthesised with a range of alkyl halides, is best obtained in toluene, 
since further alkylation to 2.30 is prevented by its precipitation out of solution,207, 210, 211 while 
acetonitrile, in which the mono-alkylated salt is soluble, has been found to be best for obtaining the 
di-alkylated salt 2.30. Di-alkylation of the bis-aminal results in a N1,N8 di-alkylated cyclam as the 
only isomer 207, 210, 211 due to the cis-conformation of the ethylene bridge, which governs the nitrogen 
reactivity by virtue of the folded geometry of the cyclam.207, 208 The geometry of 2.28 directs two 
nitrogen lone pairs inwards towards the concave side while the other two nitrogen lone pairs face 
outwards on the convex side, and these are hence the more nucleophilic of the quartet and their 
substitution results in the trans di-quaternary ammonium salt.210 
Hydrolysis of 2.29 and 2.30 under basic conditions of 20 % KOH,211 aq. NaOH, hydrazine 
monohydrate, or ethanolic hydroxylamine210 yields the mono (2.31) or di-alkylated (2.32) macrocycle, 
while reductive cleavage of 2.29 and 2.30 using sodium borohydride produces the ethylene side-
bridged cyclam 2.33 or cross-bridged cyclam 2.34.144 Bridged cyclams 2.33 and 2.34   were found to 
have greatly increased complex stability with 64Cu because of their reduced flexibility and have been 
used in the synthesis of a number of copper chelating radiopharmaceuticals.144, 149 
A second bis-aminal strategy for the synthesis of alkylated cyclam is that involving intermediacy of a 
tricyclic bis-aminal (2.35, Scheme 2.13), which has been synthesised by the reaction of cyclam with 
formaldehyde in water212 or by refluxing cyclam with 30 % NaOH in dichloromethane.213 
Crystallographic analysis of 2.35 indicated that the methylene bridge occupied a trans orientation and 
NMR analysis showed a diagnostic 1H resonance at 5.40 ppm and a 13C resonance at 69 ppm.213 
Similarly to the glyoxal bis-aminal 2.28, alkylation of 2.35 in acetonitrile resulted in a distal N1,N8 
di-alkylated quaternary ammonium salt (2.36), whose hydrolysis with 3 M NaOH yielded the N1,N8 
di-alkylated cyclam while reduction with NaBH4 gave a di-alkylated, di-methylated cyclam (2.37). In 
search of more stable copper-cyclam complexes, Pandya142,143 and Dale et al.114 used this 
methodology for synthesising TE2A-bridged and non-bridged cyclam as shown in Scheme 2.14. 
 






Scheme 2.12: Bis-aminal strategy for synthesis of alkylated cyclam: bis-aminal cyclam (2.28) is synthesised 




Scheme 2.13: An alternative bis-aminal strategy via synthesis of tri-cyclic cyclam (2.35) for regioselective 
cyclam alkylation  
 






Scheme 2.14:  The synthesis described by Pandya142,143 and Dale et al.114 for the functionalisation of cyclam 
with two carboxylic acid groups and a cross bridge 
2.2 Retrosynthetic analysis 
 
As discussed in Section 1.5, the first aim of the project, was synthesis of the proposed glucose-
cyclam-maleimide pro-conjugate 2.41 or 2.42. Analysis of the literature methods as described in 
Section 2.1 for the synthesis of similar compounds provided insight into how to go about this. The 
retrosynthetic analysis of 2.42 is given in Scheme 2.1 but both conjugates 2.41 and 2.42 can be 
synthesised by the same methods. Thus, the conjugate 2.42 was envisaged to be formed from 2.43 
after removal of all of the protecting groups. A disconnection of 2.43 at the N1, N8 alkyl positions 
suggested the three key intermediates 3, 35 and 12, which in turn could be traced back to the starting 
materials as glycosyl iodide 1a (obtained from 1), cyclam and tert-butyl bromoacetate, and maleimide 
or succinimide respectively as depicted in Scheme 2.15. 





Scheme 2.15: Retrosynthetic analysis of the pro-conjugate target molecules (2.41 and 2.42) to show the three 
principal required components glycoside 3, cyclam 34 and maleimide linker 12 
 
 




2.3 Results and Discussion 
2.3.1 Synthesis of a glucose functionalised linker 
 
The synthesis of C-1, O-alkylated glucose 3 containing a bromide at the alkyl terminus, using the 
glycosylation method described by Murakami et al.180 is outlined in Scheme 2.16. Compound 3 is the 
key intermediate for attaching a glucose moiety to cyclam through an SN2 N-alkylation. As with all 
carbohydrate synthesis, the first step was protection of the hydroxyl groups and since it was noted by 
Murakami that the use of O-acyl protecting groups led to higher yields of an ortho-ester by-product, 





Scheme 2.16: Synthesis of bromo-glucoside: i) BzCl, pyridine, 0˚C – RT, (89 %) ii) I2, (Me3Si)2, ZnCl2, DCM, 
16 h, RT iii) 10-bromodecanol (2), ZnCl2, Molecular sieves 4 Ǻ, DCM (59 % over 2 steps) 
 
For anomeric iodo exchange, Me3SiI was generated in situ from HMDS-I2 and reacted with 
perbenzoylated glucose 1 at room temperature to form the α-glycosyl iodide 1a as the only isomer. 
Murakami reported that it is possible to do a one-pot iodination-glycosylation reaction, however, in 
our case, an extractive work up of 1a using aqueous NaHCO3-Na2S2O3 to remove the trimethylsilyl 
benzoate by-product, was found to be preferable. The unpurified iodide (1a) was activated using 1 eq. 
of ZnCl2 and reacted with an equivalent amount of 10-bromodecanol (2), the synthesis of which is 
shown in Scheme 2.17 using standard functional group conversion chemistry, to yield alkyl-glycoside 
3 in 59% over the two steps (Scheme 2.16). A C-10 alkyl chain was used for the linker to allow 
enough space between the targeting agent and chelator so as to prevent interference between the two 




Scheme 2.17: Synthesis of 10-bromodecanol: i) 48% HBr, toluene, reflux, 48 hrs (86 %) 




The glycoside 3 was isolated as only the β-anomer, which is explained by the mechanism shown in 
Scheme 2.1, in which the anomeric orientation (stereoselectivity) was determined by NMR analysis. 
The doublet signal of an α-anomeric proton is shifted slightly more downfield as compared to that of a 
β-anomer and has a much smaller coupling constant between H1 and H2 due to a much smaller 
dihedral angle (60˚ as gauche for α; 180˚ as anti-periplanar for β) in the Karplus equation. 1, which is 
in the α-configuration, exhibited a doublet at 6.85 ppm with a coupling constant of 3JH1,H2 = 4.0 Hz, 
while 3, in a β-configuration, had a doublet at 4.81 ppm with a coupling constant of 3JH1,H2 = 7.8 Hz. 
The difference between these anomeric signals allowed for continuous evaluation of the reaction 
products to determine if any isomerisation had occurred.  
Owing to literature reports on the slow SN2 N-alkylation of cyclam with larger halogenated 
compounds, the rate of alkylation with 3 was expected to be slow and so in order to circumvent this 
potential problem, an acylation strategy was adopted using the reactive acid chloride glycoside 10a to 
form an amide bond. The methodology for the oxidation of a primary alcohol to its acid chloride was 
devised in a model study (Scheme 2.18) and this chemistry was then used to synthesise 10a (Scheme 
2.19). An important difference between this strategy, to synthesis 10a, and that of the alkylation one, 
to synthesise 3, involved installing the acid chloride functionality on an already derivatised glucose 





Scheme 2.18: Oxidation strategy for converting an alcohol to its acid chloride i) TBDPSCl, Imidazole, THF, 24 
hrs (56 %) ii) PCC, DCM (27 %) iii) NaClO2, NaH2PO4, 2-methyl-2-butene, t-BuOH, 2.5 hrs, (98 %), iv) 
Oxalyl-Cl, DMF, DCM, 1 hr, 0˚C – RT. 
 
Thus, glycosyl iodide 1a was first reacted with mono-protected alcohol 4 to produce 7 (76 % yield) 
which was followed by deprotection with tetrabutyl ammonium floride (TBAF) to yield the desired 
glycoside 8 (90 %). PCC as an oxidising agent, for alcohol conversion to an aldehyde, was found to 
be inefficient and so oxidation of 8 to 9 was completed in good yields (79%) with the use of Dess-
Martin periodinane (DMP). Thereafter aldehyde 9 was converted to carboxylic acid 10 in 89 % 
through a Pinnick oxidation214 which uses sodium chlorite (NaClO2) and sodium dihydrogen 
phosphate (NaH2PO4) in tert-butanol. The by-product of this reaction, hypochlorous acid (HOCl), is 
very reactive and so a HOCl scavenger, 2-methyl-2-butene was added to the system.215 The final step 




in the oxidation procedure was a Vilsmeier-Haak type reaction216 that converted the carboxylic acid 
10 to its acid chloride 10a, through a chloroiminium ion, by reaction with oxalyl chloride in the 
presence of DMF. 
Glycoside 10 presented characteristic 1H signals of a doublet for the glucose anomeric proton at 4.83 
ppm with a coupling constant of J = 7.8 Hz that confirmed the β-anomer. The difference between the 
1H NMR for 3 and 10 is that the methylene protons next to the bromide in 3 resonated as a triplet at 
3.37 ppm while those next to the more inductively shielding carboxylic acid in 10 were found as a 
triplet at 2.32 ppm.     
 
 
Scheme 2.19: Glycosylation reaction to form acid chloride: i) I2, (Me3Si)2, ZnCl2, DCM, 16 h, RT ii) 10-(tert-
butyl diphenyl- silyloxy)decan-1-ol (4), ZnCl2, Molecular sieves 4 Ǻ, DCM (76 %), iii) TBAF, AcOH, THF, 36 
hrs (90 %), iv) DMP, DCM, 1.5 hrs (79 %), v) NaClO2, NaH2PO4, 2-methyl-2-butene, t-BuOH, 2.5 hrs, (89 %), 
vi) Oxalyl-Cl, DMF, DCM, 1 hr, 0˚C – RT.  
 
The fully characterised glycosides 3 and 10 were synthesised with generally high yielding reactions 
and could now be used for attachment of the glucose moiety to the bifunctional chelator, cyclam. 
 
2.3.2 Synthesis of a maleimide functionalised linker 
2.3.2.1 Maleimide insertion using the Mitsunobu reaction 
 
Maleimide intermediate 12, the second key component in the synthesis of the pro-conjugate for 
attachment to albumin, was perceived as being available in two ways, as illustrated by the 
retrosynthesis (shown in Scheme 2.15), the first via a Mitsunobu reaction between an alcohol and 
maleimide, and the second via condensation between an amine and succinimide (Section 2.1.2). The 
Mitsunobu option involving PPh3, DIAD and maleimide was attempted first using mono-protected 
alcohol 4 as the substrate, but no product was obtained (Scheme 2.20). The reaction was then repeated 




using 1,10-decanediol, which successfully yielded maleimide 11 in 51 % after chromatography. An 
Appel reaction, using PPh3 and CBr4,217 was then used to convert 11 into 12 in a 75 % yield.  
 
 
Scheme 2.20: Synthesis of a brominated maleimide linker (12) via a Mitsunobu reaction, i) TBDPSCl, 
imidazole, THF, RT, 24 hrs (56 %), ii) PPh3, DIAD, maleimide, THF, 40˚C, 48 hrs (11 = 51 %), iii) PPh3, CBr4, 
DCM, 32 hrs (75 %)  
 
Maleimide 12 was however found to be quite sensitive and unstable to bases and was therefore 
unsuitable as the cyclam alkylating agent proposed in the retrosynthetic analysis. 
2.3.2.2 Cyclisation of maleamic acid for formation of maleimide 
 
An alternative method for formation of a maleimide, via condensation of a maleic electrophile with an 
amine, as described in Section 2.1.2.1, was then investigated for application as one of the last 
conversions in the pro-conjugate synthesis rather than via the proposed early insertion of 12. Firstly, a 
model reaction between hexylamine and maleic anhydride in diethyl ether was carried out, which 
formed the intermediate N-hexyl maleamic acid (13) as a white solid in a good yield of 78% (Scheme 
2.21). However, the further conversion of 13 to maleimide 14, through mixed anhydride activation in 
acetic anhydride with sodium acetate, gave only a low yield of product (48 %) as well as a Michael 
addition product of acetate ion with 14. 
 
 
Scheme 2.21: Synthesis of N-hexyl-maleimide using a common literature procedure: i) maleic anhydride, Et2O, 
3 hr (78 %) ii) Acetic anhydride, sodium acetate, 80˚C, 1 hr (48 %) 
 
Moreover, reaction of 14 with sodium methoxide, as a model for the removal of the glucose 
protecting groups in the pro-conjugate later on, also resulted in 1,4 conjugate addition of methoxy to 
the double bond. Therefore, it was realised that removal of the benzoyl ester protecting groups of 




glucose in the pro-conjugate would not be possible in the presence of the maleimide. The problem, 
however, of maleimide insertion using the acetic anhydride/sodium acetate method (Scheme 2.21), 
after glucose deprotection, was that these reaction conditions would also result in the acetylation of 
the free glucose hydroxyl groups, so an alternative method for the cyclisation of a maleamic acid 
intermediate therefore needed to be devised. In this regard, the amide coupling techniques involving 
carboxyl activation for SNAc that were applied to the maleamic acid intermediate 13 are summarised 
in Table 2.2.  
 
Table 2.2: Cyclisation methods attempted for the formation of the model N-alkylated maleimide (14) 








Entry 1 is the procedure as discussed above while entry 2 involved a method using p-Tosic acid and 
refluxing in toluene,218 which did afford the maleimide but in a low yield of only 31 % yield. 
Similarly, no product could be isolated from the reaction of maleamic acid in DMF with POCl3 (entry 
3). The peptide coupling techniques (entries 4 and 5) making use of DCC or ethyl chloroformate with 
Et3N, yielded not the desired maleimide 14, but rather the isomaleimide 15 in moderate yields (48 – 
55 %), as discussed in Section 2.1.2 and illustrated in Scheme 2.9. 
The 1H NMR spectroscopic comparison of 13, 14 and 15 clearly indicated a difference in coupling in 
the vinyl signals based on symmetry (Figure 2.4), in which the unsymmetrical products, maleamic 
acid 13 and isomaleimide 15, presented a double doublet at 6.58/6.27 ppm and 7.19/6.58 ppm 
respectively with a coupling constant of JH1H2 = 12.9 Hz and JH1H2 = 5.4 Hz. By comparison, as 




Figure 2.4: 1H NMR comparison of olefinic protons of A) hexyl-maleamic acid (13) B) hexyl-maleimide (14) 
and C) hexyl-isomaleimide (15) 
 




Cotter et al.184 noted that isomaleimides could be isomerised to their maleimide isomers in the 
presence of acetate at higher temperatures and so 15 was heated at 100˚C with DCC and sodium 
acetate in DMF for 1.5 hrs but no significant conversion to the desired product could be detected. The 
isomaleimides also proved to be unstable over prolonged periods at room temperature in air, 
hydrolysing back to the maleamic acid. 
The next coupling methodology attempted (entry 6) involved using another standard peptide coupling 
involving the carbodiimide, EDCl, with 1-hydroxybenzotriazole (HOBt) both as catalyst and to 
prevent isomerisation of the activated O-acyl intermediate into an unreactive N-acylurea. However, 
only a 10% yield of the desired product was obtained owing to the low conversion of starting material 
as well as the formation of a number of by-products. A mechanistic interpretation of these events is 
shown in Scheme 2.22.219  
 
 
Scheme 2.22: Mechanism of amide formation with HOBt and EDCl to afford a N-hexyl maleimide  
 
The final attempt (entry 7) involved activation of the carboxyl group with 1-chlorobenzotriazole 
(BtCl) using PPh3, through the initial formation of a chlorophosphonium salt followed by an 
acylbenzotriazole (acyl-Bt) intermediate.220 TLC monitoring of this reaction proved to be invaluable, 
suggesting the formation of the acyl-Bt intermediate. Thereafter, the formation of BtH as by-product 
indicated that some cyclisation was occurring, either to the desired maleimide or isomaleimide. 
However, after 24 hours at room temperature, a large amount of the acyl-Bt was still present, as well 
as another UV-active product that had formed, but with little increase in the amount of the desired 
maleimide product. Refluxing the solution reduced the amount of acyl-Bt but only served to increase 
the unknown product. Chromatographic separation of products from the reaction mixture produced a 
5 % yield of maleimide 14 together with a 52 % yield of the unknown compound which proved to be 




succinimide-Bt derivative 16 (Table 2.2, Reaction 7), formed once again via a Michael addition 
process.  
Observations from the attempts at cyclisation of a maleamic acid can be summarised as follows: 
1) Maleimide formation occurs under thermodynamic conditions in which the product is more 
stable in acidic media.  
2) Isomaleimide is the kinetic product.  
3) The maleimides, once formed, tended to undergo 1,4 conjugate addition with nucleophilic 
bases.  
4) As a consequence of the above, the yield of maleimide was generally moderate to very low 
and at low conversion. Water also needs to be excluded from the reaction to avoid the 
hydrolysis of the maleimide back to maleamic acid.  
These observations led to the conclusion that SNAc methodology was not suitable for introduction of a 
maleimide moiety into the pro-conjugate and so an alternative strategy was necessary. 
2.3.2.3 Alternative maleimide derivatisation strategies  
 
An alternative strategy for maleimide introduction, as discussed in Section 2.1.2.3, was considered to 
be via a bifunctional reagent using an amide bond coupling between an amine and a maleimide-
carboxylic acid synthon. A simple and efficient bifunctional synthon to utilise, according to Song et 
al.,191 is 4-maleimido-butyric acid (17), shown in Scheme 2.23. Song et al. described the synthesis of 
17 from maleic anhydride and 4-amino butyric acid in acetic acid to form the maleamic acid 
intermediate, followed by refluxing in water for 1 hr to effect ring closure. Using these conditions a 
white solid was isolated that matched the characterisation details of the product obtained by Song; 
however, following numerous failed peptide coupling techniques, this product was re-examined and 
determined not to be 17, but instead the maleic acid-ammonium salt 18. The desired 17 was then 
successfully synthesised in a 51 % yield by omitting the water and refluxing the corresponding 
maleamic acid in acetic acid alone.221 
 
 
Scheme 2.23: Synthesis of 4-maleimido-butyric acid (17) from maleic acid anhydride and 4-amino butyric acid: 
i) AcOH, RT, 14 hrs; reflux, 5hrs (51 %). An alternative ammonium salt product (18) was obtained following 
reflux of the intermediate in water. 
 
The mixed anhydride peptide coupling method with ethyl chloroformate and Et3N, and hexylamine as 
a simple model amine was then used to convert 17 into the desired model amide compound 19 in a 
77% yield (Scheme 2.24). Acylation methodology for this conversion, using catalytic DMAP, was 




also attempted but decomposition of the maleimide occurred. The stability of the maleimide was then 
further investigated and while the maleimide is stable under acid conditions, it was found that heating 
in a neutral or basic solution in the presence of DMAP, resulted in rapid reaction of the maleimide 




Scheme 2.24: Amide coupling of 4-maleimido-butyric acid through mixed anhydride methodology i) a. ethyl 
chloroformate, Et3N, THF, b. hexylamine, -15˚C to RT (77 %) 
 
In spite of the success with the bifunctional strategy just described, it was decided to double check 
this method by synthesising a more representative amine model compound. Towards this end, 
alcohols 20 and 22, varying the N-protecting group, were synthesised and used for glycosylation 
reactions employing the same anomeric coupling methodology described previously (Scheme 2.25). 
This allowed access to 23 and 24, which following Zemplen deprotection and amine unmasking of 25 




Scheme2.25: Glycosylation of an aliphatic amine to form a model glycosyl-amine(27) i) Potassium phthalimide, 
DMF, 100 ˚C, 20 hrs, (97 %) ii) Hydrazine hydrate, EtOH, reflux, 24 hrs (88 %), iii) CBzCl, PPh3, Na2CO3, 
DCM:H2O 1:1, 20 hrs, (22 91%) iv) a) I2, (Me3Si)2, ZnI2, DCM, b) 20/22, molecular sieves 4A, ZnCl2, (23 = 70 
%, 24 = 83 %), v) NaOMe, MeOH, (25 = 82%, 26 = 47 %) vi) H2, Pd/C, MeOH, (87 %) vii) H2N.NH2.H2O  




With 27 in hand, the bifunctional strategy described above using 4-maleimido butyric acid (17) was 
applied (Scheme 2.26). Unfortunately, SNAc regioselectivity challenges were encountered with this 
method, as the unoptimised reaction yielded an approximately 50:50 mixture of two compounds 
which were identified as the desired maleimide 28 and carbamate 28a. 
 
 
Scheme 2.26: Formation of the activated carboxylic acid of 4-maleimido butyric acid (17) followed by amide 
coupling with amino-glycoside 27 to form maleimide 28 and some carbamate 28a by-product i) ethyl 
chloroformate, Et3N, THF, -15˚C to RT 
 
In view of this disappointing result, it was decided to resort back to direct amine to maleimide 
conversion, similar to the method discussed in Section 2.3.2.2 but with a carbamate rather than a 
carbonate leaving group, and therefore an activated maleic electrophile was first explored with a 
model amine. To this end, maleimide was reacted with Boc-anhydride to produce activated maleimide 
29 followed by reaction with hexylamine under basic conditions. However, only 29a could be isolated 
without the desired ring closure (Scheme 2.27). Believing the latter to be due to a steric problem 
around the SNAc centre due to the bulky t-butyl group, the same sequence was repeated applying the 
sterically less demanding methoxy group, using methyl chloroformate in the activation step. 
Gratifyingly, the reaction of methoxy carbonyl maleimide 30 with hexylamine, carried out using basic 
conditions reported by Lerchen et al.188 of sat. NaHCO3: 1,4-dioxane (2:1) at 0˚C, produced N-hexyl 
maleimide in a good yield of 78 %.  
This method was then applied to the model glycosyl-amine compound 27 (Scheme 2.28), which 
joyously furnished maleimide-functionalised alkyl glucoside 31 in a 60 % isolated yield. The method 
indicated compatibility with the free glucose hydroxyl groups and therefore suggested the bonus of 
being able to introduce the maleimide after deprotecting the glucose in the hot synthesis of the pro-
conjugate. 
In summary, following a lot of screening, confidence had now been raised that a methodology was 
available for proceeding to the functionalisation of a glucose-cyclam-amino pro-conjugate with 
maleimide. 
 






Scheme 2.27: Synthesis of activated maleimide-carbamates (29 and  30) and their subsequent reaction with the 
nucleophile, hexylamine i) (Boc)2O, DMAP, THF, 16 hrs (68 %), ii) methyl chloroformate, NMM, EtOAc, 0˚C, 
1 hr (67 %), iii) hexylamine, NaHCO3, DCM, 20˚C (64 %), iv) hexylamine, sat. NaHCO3: 1,4-dioxane (2:1), 
0˚C (78 %) 
 
 
Scheme 2.28: Application of the Lerchen et al.188 method (reaction of an amine with methoxy-
carbonylmaleimide) for functionalisation of the model glucose compound with maleimide: i) methoxy-
carbonylmaleimide (30), sat. NaHCO3: 1,4-dioxane (2:1), 0˚C (60 %) 
2.3.3 Functionalisation of Cyclam and synthesis of the pro-conjugate 
 
The third and central key component of the proposed radiopharmaceutical pro-conjugate (Figure 2.5) 




Figure 2.5: Illustration of the desired pro-conjugate with all its components: Glucose for active targeting, 
cyclam for radioisotope coordination and maleimide for attachment to albumin 
 
The synthesis of the pro-conjugate required that cyclam be derivatised with the glycosyl linkers 3 or 
10a (for active targeting), a maleimide linker (for attachment of albumin) and two carboxymethylene 




groups (to assist in metal chelation), which posed a regioselectivity challenge due to four equivalent 
nitrogens being available for functionalisation (Chapter 1, Figure 21; Chapter 2, Section 2.1.3). The 
different methods discussed in Section 2.1.3 by which cyclam could be N-functionalised with non-
equivalent groups included alkylation of the free-base form of cyclam or alkylation of a nitrogen 
bridged bis-aminal cyclam, and these two methods were applied to functionalise cyclam to form the 
desired pro-conjugates. 
2.3.3.1 Alkylation of cyclam 
 
The first functionalisation method explored was the alkylation of the free-base form of cyclam, which 
was carried out with tert-butyl bromoacetate using the literature conditions for alkylation of 
tetraazamacrocycles, as reviewed in Scheme 2.29 and Table 2.1. Tert-butyl bromoacetate was selected 
as the electrophile in order to dialkylate with alkoxycarbonylmethylene groups to form 34 
(Retrosynthesis Scheme 2.15), thereby leaving the other two nitrogens available for alkylation with 
the glucose and maleimide linkers. The conditions selected for alkylation not only had to minimise the 
formation of both tri- and mono-alkylated products, but were also considered unlikely to avoid 
formation of all three regioisomeric di-alkylated cyclam products. In the event, following a method 
described by Li et.al.,199 various reactions were performed in the polar, aprotic solvent chloroform or 
acetonitrile, in which cyclam proved to be only mildly soluble, together with triethylamine as base 
and two equivalents of acetate electrophile (Table 2.3, entry 1-4). These reactions however, only 
resulted in a complex mixture of regioisomers, unreacted cyclam and a polar compound which was 
found to be the quaternary ammonium salt formed between Et3N and BrCH2CO2t-Bu. Et3N was 
therefore deemed not to be a suitable base for the reaction. As a control, alkylation was attempted 
without a base present (entry 5) but no great difference in product distribution was seen compared to 
the other reactions. Other literature methods using NaHCO3 and K2CO3 as the base were then 
investigated (Reaction 6-11), but the major product obtained was still mainly tri-alkylated 32 and a 
mixture of the other regioisomers. The isomers were not easily purified using column chromatography 
and a very polar mobile phase system of varying ratios of dichloromethane and methanol with added 
Et3N or NH4OH was required which failed to separate the di-alkylated products (33/34). The major 
influence on the outcome of the reaction was attributed to the poor solubility of cyclam in chloroform 
and acetonitrile, which led to the preferential formation of the tri-alkylated product as a result of 
improved solubility and reactivity of the cyclam with successive alkylation. Initial reactions had been 
conducted at room temperature and so in an attempt to improve solubility, the reaction was refluxed 
(entry 8 and 11), but this only led to a greater production of the tri-alkylated, as well as some tetra-
alkylated, cyclam. The reaction was then repeated with 5% water added to the solution to help 
dissolve the starting materials (entry 12/13) which successfully led to an increase in the amount of the 
di-alkylated compounds but still with an equivalent percentage of tri-alkylated product.  
 






Scheme 2.29: A generalised reaction for alkylation of cyclam with tert-butyl bromoacetate using a base and the 
solvents acetonitrile or chloroform to produce six possible alkylated cyclam products  
 
Table 2.3:  Alkylation of cyclam with tert-butyl bromoacetate under varying conditions 
 
Entry Equiv. of 
bromide 
Base (Eq) Solvent Time 
(hrs) 
Temp Major products 
isolated 
1 2 Et3N (10) CHCl3 2 RT Tri -22 % 






Tri – 23% 
Di – 17% 









5 2 - CH3CN 5 RT Tri – 33% 
Di – 14% 
6 0.5-1-1.25-
1.5-1.75 
NaHCO3 (2) CH3CN 5 RT Tri – 37 % 
7 0.5-1-1.5-2 NaHCO3 (2) CHCl3 9 RT Tri – 46% 
Di – 3% 
8 2 NaHCO3 (2) CH3CN 15 reflux Tri – 59% 
9 2 K2CO3 (2) CH3CN 3 RT Tri – 23% 
Di – 17% 
10 0.5-1-1.5 K2CO3 (2.5) CH3CN 6 RT Tri – 16% 
Di – 16% 
11 2 K2CO3 (2) CH3CN 48 Reflux 
 
Tetra- 10 % 
Tri – 43 % 
12 2  K2CO3 (2.5) CH3CN 
(5% H2O) 
8 RT Tri – 32 % 
Di – 41 % 
13 2 K2CO3 (2.5) CH3CN 
(5% H2O) 
18 RT Tri – 33 % 
Di – 36 % 
 
As mentioned, although the di-alkylated product mixture was generally inseparable, a very small 
amount of the first and last di-alkylated product to elute off the column in the chromatography could 
be isolated. The NMR analysis and comparison of the chemical shifts and coupling patterns of these 
two purified products allowed for an educated guess to be made regarding regioisomer structure in 
which the first product was identified as the N1,N4-isomer (33) (Figure 2.6), while the last di-
alkylated product was assigned as the N1,N8 isomer (34) (Figure 2.7).  
 






Figure 2.6: 1H and 13C NMR of N1,N4 alkylated cyclam 33  
 
The signals between 2.6 and 2.8 ppm in the 1H spectrum, which integrated for 16 protons in each 
case, and between 45 and 55 ppm in the 13C spectrum of 33 and 34 corresponded to the ring 
methylene groups bonded to the nitrogens. Compound 33, as shown in Figure 2.6, was concluded to 
have the tBu-acetate groups attached in the N1, N4 position of cyclam, as the horizontal line of 
symmetry makes the H-2 and H-3 methylene groups as well as H-9 and H-10  protons, equivalent and 
therefore resonate as two singlets just above 2.7 ppm with no splitting. The resonance signals of the 
remaining α-methylene groups (5, 7, 12, 14) were seen as overlapping multiplets in the same region 
with the two amine protons resonating as a very broad singlet between 2.4 and 2.5 ppm. The 
formation of isomer 33 is contrary to the N1,N11 derivatised cyclam that was obtained by Dessolin et 
al.140(Scheme 2.11), but the 1H and 13C NMR spectra for 33 clearly indicates a symmetry in the 
structure in which the two β-methylene groups (6 and 13) are equivalent that give a single resonance 
at about 25 ppm, while in the N1,N11 isomer, the two β-methylene groups (6 and 13) are unequal and 
would give rise to two carbon singlets therefore, it was concluded from the NMR spectrum of 34 




(Figure 2.7) that the tBu-acetate groups were attached in the N1, N8 position because of a more 
symmetrical set of resonance signals as a result of C2 rotational symmetry that results in the 
methylene groups α- to the inductively electron-withdrawing substituents (H-2/9; H-7/14) resonating 
with similar chemical shifts (the 4 of the 2:4:2 where numbers refer to those of methylene groups). 
Conversely, the other two clumps (the 2’s of the 2:4:2) presumably correspond to H-3/10. And H-




Figure 2.7: 1H and 13C NMR of N1,N8 alkylated cyclam 34 
 
Following alkylation with t-butyl bromoacetate, the mixture of di-alkylated cyclam (33/34) was 
carried through to subsequent steps in the hope that purification would be easier at a later stage but 
only very low yields of any product was obtained and always as a mixture. Thus, despite involving a 
slightly longer synthesis, it was therefore decided to investigate the second method for cyclam 
functionalisation for pro-conjugate formation. 
 




2.3.3.2 Bis-aminal method  
 
The second cyclam functionalisation method explored was the bis-aminal strategy (section 2.1.3.3). 
To this end, tetracyclic bis-aminal 2.40 was synthesised in good yield using glyoxal in methanol 
(Scheme 2.30) and was then reacted with the three electrophiles shown in Scheme 2.30, in the hope of 
obtaining alkylated cyclam products. However, no conclusive products from these reactions could be 




Scheme 2.30: The formation of cyclam bis-aminal (2.40) using glyoxal and its unsuccessful attempted reaction 
with three different electrophiles 
 
The second nitrogen-bridging strategy focused around the alkylation of tri-cyclic bis-aminal cyclam 
36. This bridged cyclam was obtained as a colourless solid in very good yield, either by refluxing 
cyclam with NaOH in DCM (88 % yield) or by reacting cyclam with formaldehyde in water (94 % 
yield) (Scheme 2.31).  
 
Scheme 2.31: Synthesis of tri-cyclic bis-aminal 36 i) NaOH, DCM, reflux, 24 hrs, (88 %), ii) formaldehyde (37 
% in H2O), H2O, 0-5 ˚C to RT˚, 2.5 hrs, (94 %) 
 
Cyclam 36 was recrystallised from water/THF, and a single crystal X-Ray structure determination 
was obtained (Figure 2.8). The X-Ray picture revealed two six-membered rings each in stable chair 




conformations, with the two bridges orientated opposite to each other in order to minimise steric 
strain, resulting in two of the nitrogen lone pairs directed inwards and two outwards. The crystal 




Figure 2.8: The crystal structure of bridged cyclam 36 and a line structure representation of it to show the 
orientation of the nitrogen lone pairs either in or out of the ring 
 
The alkylation of 36 with four equivalents of BrCH2CO2t-Bu in acetonitrile according to Pandya et 
al.143 was thought would result in the formation and precipitation of a regioselectively N1,N8 di-
alkylated quaternary ammonium salt product because of the two opposite outward facing lone pairs 
being more available for alkylation. It was also expected that the two aminal bridges of this product 
would be retained but could then be removed by base hydrolysis. However, in the event only the 
mono-alkylated cyclam 37 was formed (65 % yield) in which the aminal bridge at the site of 
alkylation was deprotected in situ by a mechanism proposed below in Scheme 2.32, which involves 
water in the reaction originating from the recrystalisation of 36. The 1H NMR spectrum of 37 also 
suggested that the secondary amine of the cyclam neutralised the HBr liberated. This reaction was 
repeated numerous times varying the temperature, solvent and equivalents of BrCH2CO2t-Bu in search 
of the di-alkylated product but in all cases the major compound isolated was the mono-alkylated 
bridged cyclam 37, which deprotonated to 37a on treatment with 3M NaOH with retention of the 
other aminal bridge. This result then prompted an approach involving the mono-alkylation of 36 using 
10-bromodecanol (2) (1 equivalent) to obtain an N-alkylated cyclam containing a hydroxyl group for 
conversion to an amine or maleimide. This alkylation reaction (Scheme 2.33) successfully yielded the 
desired mono-alkylated 38 as the major product (61 %) but together with a significant amount of the 
di-alkylated ammonium salt 39 (15 %). As expected, based on the result from Scheme 2.32 for 37, 
product 38 did not retain the aminal bridge at the site of alkylation, but unexpectedly the di-alkylated 




product 39 retained both bridges. This unexpected turn of events allowed formation of 38a and 40 on 
treatment with NaOH, retaining one and no aminal bridges respectively. 
 
 
Scheme 2.32: The proposed mechanism of alkylation of bridged cyclam 36 with tBu-bromoacetate which leads 
to the formation of mono-alkylated 37a i) BrCH2CO2t-Bu (4 eq), MeCN, 48hrs (65 %), ii) 3 M NaOH, DCM, 16 





Scheme 2.33: Alkylation of bridged cyclam 36 with 10-bromo-decanol i) 2, MeCN, RT˚, 48 hrs (38 61 %, 39 
15 %) ii) 3M NaOH, DCM, (38a 90 %, 40 95 %)  
 
The overall yield of 38a from 36 of 58 % was only modest but nevertheless sufficient to proceed to 
the next step, which involved di-alkylation with two equivalents of BrCH2CO2t-Bu to obtain a mixture 
of regioisomers that couldn’t be separated chromatographically (Scheme 2.34). This mixture of tri-
alkylated cyclam was then reacted with glycosyl bromide 3 in the hope of obtaining a fully alkylated 
cyclam containing a glucose moiety. Cyclam 41 successfully formed, but the yield was extremely low 
(14 %) even after heating the reaction at 60˚C for five days. The regiochemistry of 41 was deduced 




from the coupling patterns and chemical shifts of the cyclam methylene groups in the 1H and 13C 
NMR spectra, and the poor yield of the reaction was probably due to steric factors retarding the SN2 
alkylation, although electronic deactivation of the secondary amino nucleophilicity by adjacent 
tertiary nitrogens containing electron-withdrawing groups couldn’t be discounted. In the event, it was 
decided to pursue another method for accessing the tetra-alkylated cyclam. 
 
 
Scheme 2.34: Functionalisation of mono-alkylated cyclam with tBu-bromoacetate and glycoside 3 to form tetra-
alkylated cyclam: i) BrCH2CO2t-Bu (2.5 eq), K2CO3, MeCN, ii) 3, K2CO3, MeCN, 60˚C, 5 days (14 %) 
 
Exchanging bromide for the more reactive iodide in the sugar electrophile 3 using a Finkelstein 
reaction with catalytic tetrabutylammonium iodide (TBAI) in an in situ generation of the iodide 3a 
(Scheme 2.35) resulted in isolation problems with unreacted TBAI. Thus, iodide 3a was synthesised 
from reaction of stoichiometric amounts of sodium iodide with 3, which presented fewer problems in 
its isolation but unfortunately reaction of it with the tri-alkylated cyclam mixture similarly failed to 




Scheme 2.35: Improving the electrophilicity of glycoside 3 by bromide substitution with iodide i) TBAI or 
NaH, DCM 
 
The second method considered for improving on the functionalisation of the fourth nitrogen was to 
use an acylation rather than an alkylation. An appropriate model compound for testing this strategy 
out was tri-alkylated 34, which had been formed from di-alkylation of cyclam with BrCH2CO2t-Bu 
(Scheme 2.29). Reaction of 34 independently with three acid chlorides of different sizes successfully 
formed acylated cyclams 42, 43 and 44 (Scheme 2.36) in very good yield (> 80%), one of them (44) 




incorporating the desired tethered glucose fragment. Thus acylation was considered to be an effective 
method for achieving a fully functionalised cyclam product. 
 
 
Scheme 2.36: Acylation of tri-tBuOAc-cyclam (34) with different acid chlorides i) CH3COCl, DMAP, Et3N, 
THF, 2 hrs (87 %), ii) 6a, DMAP, Et3N, THF, 2 hrs (82 %), iii) 10a, DMAP, Et3N, THF, 2 hrs (87 %)  
 
The knowledge gained in the preceding reactions then directed a change in the pro-conjugate 
synthesis strategy. Instead of mono-alkylating 36 with bromodecanol to obtain a linker with a 
hydroxyl group, it was proposed that alkylation using a linker that already containing a protected 
amine for conversion to a maleimide would be more suitable. Thus, carbamate 45 was synthesised 
from alcohols 22 and used to mono-functionalise 36 into cyclam 46 (Scheme 2.37) in an acceptable 
yield (~ 65 %). As before (Scheme 2.33) product 46 retained one bridge only, as supported by the 1H 
and 13C spectra as illustrated in Figure 2.9. 
 
 
Scheme 2.37: Mono-functionalisation of cyclam with a synthesised CBz-protected amine linker, i) CBr4, PPh3, 
DCM, (45 92%), ii) 36, MeCN, 3 days, RT˚ (46 69%) 







Figure 2.9: A) 1H NMR and B) 13C NMR analysis (selected portion) of 46 to indicate the presence of the single 
nitrogen bridge 
 
The subsequent reaction of 46 with 3M NaOH once again only served to deprotonate the cyclam to 
form 46a (Scheme 2.38), in which retention of the bridge was confirmed by acetylation of cyclam 46a 
with excess acetic anhydride to form monoacetylated 47. 
 
 
Scheme 2.38: Alkylation of cyclam with the CBz-protected amine linker followed by acetylation to confirm the 
presence of the nitrogen bridge: i) 3M NaOH, DCM, ii) acetic anhydride, Et3N, DMAP, DCM, 3 hrs (31 %)  
 
Once the presence of the bridge was established, it was decided to acylate the available secondary 
amine with the glycosyl fragment at this point rather than use it as the final cyclam functionalisation 
since this would result in an unambiguous regiochemistry in the final product. To this end glycoside 
10a, prepared by chlorination of the corresponding acid with oxalyl chloride and DMF (Scheme 2.19), 
was reacted independently with cyclam 46a to form the desired functionalised cyclam 50 in good (65 
%) yield (Scheme 2.39).  






Scheme 2.39: Acylation of alkylated cyclam (46a) with an acid chloride glucose moiety i) DMAP, Et3N, THF, 
2 hrs (48 65 %) 
 
The 1H and 13C NMR spectra of 48 clearly indicated the presence of the glucose linker, the protected-
amine linker and the central cyclam structure with the aminal bridge. The spectrum of 48 is shown in 
Figure 2.10 with key diagnostics assigned. While the glucose protons resonated as sharp peaks with 
defined coupling patterns and were easily assigned the assignment of the cyclam methylene protons 
was made difficult by the slow inter-conversion of the cyclam ring between conformations which 
resulted in very broad undefined peaks. The 13C data was therefore more informative for analysis of 
the cyclam unit but was also complicated by the presence of two rotational conformations (rotamers) 
around the amide bond as indicated by two carbon resonances seen at around 33.2 ppm for the 
methylene carbons alpha to the carbonyl group of the amide. The two N-CO rotamers also affected 
the cyclam ring resonances, and in the region of 45-55 ppm, 16 carbon signals instead of 8 were seen 
for the methylene groups alpha to nitrogen which did not all have the same intensity, preventing a 
specific assignment of these signals. It was also noted from the carbon signal at 70.7 ppm that the bis-
aminal bridge was still present.  
In the further pursuit of the envisaged pro-conjugate (Scheme 2.15), subsequent alkylation of 48 with 
two equivalents of BrCH2CO2t-Bu gave tetra-alkylated cyclam 49 (73 %) (Scheme 2.40), in which 
both amines had been alkylated and the bridge removed. The structure of this tetra-alkylated cyclam 
was ascertained on the basis of the presence of two tertiary butyl groups as well as the absence of the 
aminal bridge in both the 1H and 13C NMR spectra. Despite the success of this reaction in yielding the 
desired cyclam 49, in the interest of time and to minimise the length of the synthesis, it was deemed at 
this point, following literature evaluation, that alkylation (with bromoacetate) might not be essential in 
order for the pro-conjugate to chelate a radioisotope and so the subsequent synthetic work focused on 
the reaction of cyclam 48 with the aim to remove the bridge in the final stages.  
Having settled on this decision, deprotection of the benzoate groups of CBz-carbamate 48 using 
sodium methoxide under Zemplen conditions resulted in a good yield of 50 (92 %) (Scheme 2.41) and 




deprotection of its CBz protecting group was carried out using hydrogenolysis with H2 (g) and 
activated Pd/C.  
 
 
Figure 2.10: NMR analysis of 48 containing glucose, cyclam and amine linker components 
 
The products of this reaction were very polar and once again TLC and column chromatography 
required the use of DCM: MeOH: NH4OH 7:2.5:0.5 as the eluent, which in this case afforded an 
inseparable mixture of two products (89 % yield). Laborious purification and successful isolation of a 




small amount of each product in a pure form identified them as 50a and 51 in an approximately equal 
ratio, indicating that hydrogenolysis had removed not only the CBz protecting groups in both cases, 
but fortuitously also the bis-aminal bridge in 51, thereby yielding a cyclam compound that was 
region-functionalised with both a glucose moiety and an amine linker. 
 
 




Scheme 2.41: Final method for functionalisation of cyclam with glucose and a terminal amine linker, i) 
NaOMe, MeOH, 1 hr, (92 %), ii) H2, Pd/C, MeOH, 24 hrs (89 % mixed isomers) 
 




2.3.3.3 Maleimide insertion 
 
The synthesis of cyclam 51 was the penultimate step in obtaining a pro-conjugate for radiolabelling 
and albumin attachment. The final step would involve converting the terminal amino group to its 
maleimide by the methods investigated and discussed in Section 2.3.2 and so with 51 in hand this 
conversion was attempted (Scheme 2.42). The first reaction of 51 with maleic anhydride formed the 
desired maleamic acid intermediate in very small amounts but no subsequent ring closure to the 
maleimide could be induced. The peptide coupling of maleimido-butyric acid to 51 was then 
attempted as well as the reaction of 51 with methoxy-carbonyl maleimide but while both these 
reactions seemed promising on TLC, no product could be isolated during the work up. The conversion 
of the amine of 51 into a maleimide derivative was therefore not successful and the project was 
stopped at this point. 
 
 
Scheme 2.42: Attempted conversion of the terminal amine of 51 to a maleimide using: a) succinic anhydride, b) 
ethyl chloroformate and maleimido-butyric acid, and c) methoxy-carbonyl maleimide 
 
2. 4 Summary of synthesis 
 
In summary, the focus of this synthesis was to develop a cyclam bifunctional chelating pro-conjugate 
containing glucose as a targeting agent and a second linker functionalised with maleimide to bind to 
the protein carrier, albumin. The synthesis of the glucose component was successfully achieved along 
with the synthesis of an amine linker and a method for its conversion to a maleimide group. Upon 
investigation of the functionalisation of cyclam it was found that while alkylation of the cyclam to 
form a di-alkylated product is possible, this is not favourable due to the number of regioisomers that 
can form. The synthesis was therefore changed to a bis-aminal cyclam strategy, which after a number 




of modifications to the synthetic route employed, led to the eventual successful formation of cyclam 
51 that is a pre-cursor to the desired pro-conjugate. This regio-functionalised cyclam 51 was then 
subjected to the various strategies identified to incorporate a maleimide moiety into the structure to 
form the desired pro-conjugate but all with unsuccess. Despite the failure thus far to attain the 
glucose-cyclam-maleimide pro-conjugate, the precursor 51 that contains all the necessary glucose, 
cyclam and amine components but not the Michael acceptor for the albumin, presented an opportunity 
for its use as a model compound in radiolabelling and biological studies towards the development of a 
radiolabelled bioconjugate. These results are discussed in the subsequent three chapters. 
  




CHAPTER 3 - RADIOLABELLING STUDIES 
3.1 Introduction 
 
Radiopharmaceuticals, as discussed in Section 1.3, comprise a number of different compounds that 
are labelled with a range of different isotopes depending on the application of the 
radiopharmaceutical. The aim of this project was to synthesise a pro-conjugate that could be 
radiolabelled with 103Pd. However, this isotope is costly and difficult to obtain and so investigation 
into the radiolabelling of cyclam compounds was first done using the readily available radioisotope 
99mTc before attempting 103Pd labelling. 
3.1.1 99mTc radiolabelling 
3.1.1.1 General properties and chemistry of 99mTc 
 
99mTc, used in approximately 80% of all imaging radiopharmaceuticals, is obtained from a 99Mo-99mTc 
generator as sodium pertechnetate (Na99mTcO4) and has extremely favourable physical and radiation 
characteristics222 of 6 hr half life and a 140 keV γ-ray. Technetium, a group VIIB transition metal, can 
exist in eight oxidation states, -1 to +7, with the most stable of these states + 7 and +4, depending on 
the chemical environment and stabilising ligands. 
3.1.1.2 General considerations and principles for 99mTc radiolabelling222 
 
The anion 99mTcO4-, which has an oxidation state of +7, is quite non-reactive and needs to be reduced 
before any labelling can occur. The most common reducing agent used is stannous chloride 
(SnCl2.2H2O) while others include stannous citrate, stannous tartrate and sodium borohydride. A 
small amount of SnCl2 in an acidic medium reduces 99mTc from the +7 to the +4 state. Once 99mTc is 
reduced, it is able to bind the chelating agent through co-ordinate covalent bonds with lone pairs from 
heteroatoms such as oxygen, nitrogen and sulphur to form various oxo-technetium complexes.  
Technetium reduction can be represented by the equation below: 
 
99mTcO4- + 16H+ + 3Sn2+ + chelate →  299mTc4+ (chelate) + 3Sn4+ + 8H2O 
 
Two concerns exist when using SnCl2 for reduction of 99mTc: firstly, any oxygen present in the vial 
can lead to oxidation of the stannous ion to stannic ion thereby decreasing the amount of tin(II) 
available as a reducing agent;223 secondly, SnCl2 can also hydrolyse in basic aqueous solutions to 
form insoluble Sn(OH)2 colloids that bind reduced 99mTc and also decrease the labelling efficiency. It 
is therefore common practice to flush all vials and solutions with N2 gas before use to maintain an 
inert environment, and to dissolve the SnCl2 in HCl to prevent hydrolysis by having a high 




concentration of chloride ion. Another challenge during radiolabelling with technetium is that reduced 
99mTc may react with water, depending on the pH and other compounds present in solution, to form 
hydrolysed 99mTcO2.2H2O224 complexed with other species such as SnO or Al.  
Three major 99mTc species will therefore be present in the labelling process: “free” or unreduced 99mTc 
as 99mTcO4-, reduced/hydrolysed 99mTcO2.2H2O complexes and a reduced chelated species as 
99mTc(O)n(chelate) which is “bound” to a chelating agent. It is also possible that some reduced, 
unbound 99mTc ions are present.  Efficient labelling techniques seek to reduce the amount of free and 
reduced-hydrolysed 99mTc thereby increasing the amount of reduced-chelated 99mTc. Here the 
challenge is that the chelating agent often is poorly soluble in the aqueous reaction medium resulting 
in heating being required together with longer reaction times for dissolution that result in an increase 
in 99mTc-colloid formation. In such circumstances, a weaker but water soluble chelating agent such as 
tartrate and gluconate can be added to the reaction to stabilise the reduced 99mTc before ligand 
exchange (transchelation) with a stronger chelating ligand is applied to the solubilised species. 
3.1.1.3 Radiochemical purity analysis of 99mTc-chelates222 
 
A labelled compound needs to be evaluated in terms of its radiochemical purity which is defined as 
the amount of total radioactivity that is attached to the radiopharmaceutical in the desired form. From 
this, the level of radiochemical impurity needs to be determined and removed if possible before 
administration to the patient. A general technique for determining radiochemical purity is paper 
(Whatman No 1 or 3) or instant thin-layer (glass-fibre impregnated with silica gel) chromatography 
(ITLC-SG) run in polar mobile phases. The different components of the radiolabelling mixture are 
determined by segmentation of the plate and measuring the radioactivity of each segment. This data 
can be plotted as a histogram and the percentage of impurity present can be determined by the ratio of 
the activity of the undesired compound to the total activity applied on the base line. For 99mTc-labelled 
compounds, this TLC technique is simplified as there should only be three radioactive components 
within the solution: unreduced (U), reduced-hydrolysed (R-H) and reduced-chelated (R-C) 99mTc 
(Figure 3.1). The mobile phase used for the paper strip is acetone and indicates the amount of 
unreduced 99mTc as this moves with the solvent front, while R-H and R-C 99mTc remain at the origin. 
ITLC is run in 0.9 % NaCl (saline) solution and indicates the amount of R-H 99mTc that forms as these 
colloids remain at the origin. The percentage of R-C 99mTc can then be calculated by the equations 
given in Figure 3.1.  
While TLC can provide useful information on radiolabelling, a more suitable technique for analysis of 
radiolabelled compounds is high performance liquid chromatography (HPLC) coupled to a radiation 
detector. Generally for polar compounds, the column used for separation is a C18 reverse phase 
column with varying compositions of solvents, such as water, acetonitrile or methanol, used as the 
mobile phase. Since the column is coupled to a radioactivity detector such as an NaI crystal, the UV 
chromatogram of the components can be compared with the radio-chromatogram to confirm 




radiolabelling of the desired compound. The challenge with HPLC is that compound behaviour on 
different columns varies, and it is often difficult to choose a mobile phase and a suitable column from 
the numerous columns available that will give good compound separation.  
TLC and HPLC are used to determine the impurities present in the labelling solution which is then 
followed by ion-exchange chromatography to purify the radiolabelled compound. Ion exchange 
resins, based on the species charge and affinity for the stationary phase, can be cation or anion 
exchange resins that separate different species by exchange of the counter ions on the resin for the 
compound ions in solution. The desired compound bound to the column can then be eluted by 
changing the solvent conditions.  
 
 
𝑈 (%) =  
𝑈 𝑥 100
𝑅𝐻 + 𝑅𝐶 + 𝑈
             𝑅𝐻 (%) =  
𝑅𝐻 𝑥 100
𝑅𝐻 + 𝑅𝐶 + 𝑈
           𝑅𝐶 (%) = 100 − 𝑈(%) −  𝑅𝐻(%)   
 
Figure 3.1: ITLC analysis method for determining the percentage of unreduced, reduced-chelated and reduced-
hydrolysed 99mTc in a solution 
3.1.1.4 99mTc radiolabelled cyclam 
 
Cyclam binding to 99mTc has been documented225 since 1979 when it was found to form a positively 
charged 99mTc(V)dioxo-cyclam complex (Figure 3.2) following reduction of the 99mTc7+ by Sn2+ to 
99mTc5+ in which the highest yields of the 99mTc-cyclam complex were obtained between a pH of 7-12. 
The complex comprised 99mTc as a dioxo species with the four cyclam nitrogens as coordinate donors 
in a hexacoordinate [99mTcO2(cyc)]+ structure.226 Since then, numerous 99mTc-cyclam complexes and 
labelling conditions have been investigated which include the use of alternative tin reducing agents 
such as stannous tartrate, the formation of technetium(I)-tricarbonyl complexes such as  99mTc(CO)3-
cyclam227 and derivatisation of the cyclam nitrogens with a range of different functional groups. The 
range of these derivatised complexes include the simple methylated 99mTcO2(tetra-N-methyl 
cyclam)228 (Figure 3.3A) to the more complex octapeptide functionalised cyclam as a CD4/T4 receptor 
marker229 (Figure 3.3B) and a tetra N-acetamide cyclam derivative as a marker for tumour hypoxia230 
(Figure 3.3C).  





Figure 3.2: The structure of the first 99mTc(V)dioxo-cyclam complex obtained following the reduction of the 
99mTc7+ by Sn2+ and reaction with cyclam  
 
Reaction to form these 99mTc-complexes proved to require longer reaction times at elevated 
temperatures (80-100 ˚C) and higher pH (9-11) to promote efficient labelling. Monitoring of these 
reactions to determine the labelling efficiency was done using TLC and HPLC. 
 
 
Figure 3.3: Structures of selected 99mTc-cyclam complexes 
3.1.2 103Pd radiolabelling  
3.1.2.1 Irradiation and dissolution of a Rh target for acquiring 103Pd  
 
103Pd is used as a suitable isotope for brachytherapy seeds (Section 1.4.1) and has other potential 
nuclear medical applications owing to its seventeen day half-life and low energy Auger electron and 
X-ray (20-22 keV) emissions. 103Pd is produced by irradiation of a rhodium (103Rh(p,n)103Pd)target but 
this is limited by issues encountered in separating the rhodium carrier from the 103Pd by dissolution. 
In this regard rhodium metal targets (plated layers, foils and wires) have been dissolved by sodium 
bisulphate fusion and gold tetrachloroaurate oxidation, both of which are time consuming and 
expensive, and by the static AC electrodissolution in HCl which is used for Rh foils but is not suitable 
for wires or powder.231 Electrodissolution, whilst being simple to carry out, has a number of 
challenges which Lagunas-Solar et al.232 tried to improve on by developing a method to increase 
dissolution by minimising fragmentation of the foil, controlling the dissolution time and decreasing 
the large volume of HCl required.  
3.1.2.2 Separation of carrier free 103Pd 
 
Once the irradiated foil has been dissolved, the next step is separation of the 103Pd from the 103Rh 
either by solvent extraction or ion exchange chromatography. Solvent extraction of the 103Pd from a 
HCl solution obtained after the dissolution process is carried out using a furyldioxime-chloroform or 
dimethylglyoxime-chloroform system which complexes with the 103Pd(II) and removes it from the 




water phase.231 Once separated, the organic phase can be evaporated and the organic material 
destroyed with 15M HNO3 and 12M HCl to leave behind the 103Pd(II) salts. A more common method 
for separation is anion or cation exchange chromatography. A cation exchange resin, AG50WX8 
(H+/100-200 mesh), which comprises a matrix of a styrene divinylbenzene copolymer with sulfonic 
acid functional groups, is used to bind the Rh3+ and Pd2+ ions. c.HCl is then used to elute, first 
rhodium and then the palladium, from the column.231 For anion exchange columns, the resin used is 
Dowex1X8 (Cl-/100-200 mesh) which is also a styrene divinylbenzene copolymer lattice but has 
quaternary ammonium functional groups. This column was used by Chunfu et al.233 to trap RhCl63- 
and 103PdCl42- ions obtained from electrodissolution of the Rh target. The rhodium ions were eluted 
from the column with 6M HCl while palladium was recovered by elution with a 1:1 mixture of 0.5 M 
NH3/NH4Cl which converted the 103PdCl42- ion to 103Pd(NH3)42+. The NH4Cl was added to the 
ammonia eluent to improve removal of the 103Pd(NH3)42+ from the column as it was found that use of 
NH3 solution only,  resulted in the palladium salt sticking to the column and tailing in its elution 
distribution. 
 3.1.2.3 Radionuclide purity analysis of 103Pd 
 
Radionuclide purity is defined as the amount of the total radioactivity that is present in the form of the 
desired radionuclide.222 Impurities can occur from unwanted nuclear reactions within the target or 
from the production of unexpected target isotopes during the irradiation process. The radionuclide 
purity is determined by measuring the characteristic radiation emissions in conjunction with the half-
life of the isotope. γ-Rays, measured with a NaI(T1) crystal or a lithium-drifted germanium [Ge(Li)] 
detector coupled to a multichannel analyser, are the most easily distinguished of emissions and most 
useful for identifying isotopes. Irradiation of a Rh target should lead mainly to the production of 103Pd 
which then decays to 103mRh but, depending on the energy of the irradiating beam, other Pd, Rh 
isotopes or even other elemental isotopes such as silver (Ag) could be formed from which 
purification, using the techniques mentioned above, should separate out the desired 103Pd. The 
characteristic X-ray and γ-emissions of 103Pd and 103mRh that can easily be detected and used to 
determine the radionuclidic purity of the sample of 103Pd, are given in Table 3.1.234,235 The isotope 
103mRh, the short-lived daughter radionuclide from 103Pd, however, has the same X-ray emissions as 
103Pd but at a much lower percentage and so can only be distinguished from 103Pd by the absence of 
the gamma emissions in the 300 – 500 keV region. Note that 103Pd is always in the presence of 103mRh 
(56 min half-life) and so after 56 min a full equilibrium between the two is reached in which and they 










Table 3.1: Characteristic radiation emissions for 103Pd and 103mRh 
 
Palladium-103 Rhodium-103m 
Radiation Type Energy (keV) % Radiation Type Energy (keV) % 
X 20.07 22.06 X 20.07 2.2 
X 20.21 41.93 X 20.21 4.2 
X 22.7 13.05 X 22.7 1.3 
gamma 39.75 0.07 gamma 39.75 0.07 
gamma 62.41 0.001    
gamma 294.98 0.03    
gamma 357.45 0.02    
gamma 497.08 0.004    
 
3.1.2.4 103Pd radiolabelled cyclam  
 
Although no 103Pd-cyclam complexes have been reported, cyclam has been used to coordinate ‘cold’ 
palladium in the investigation of metal complexes for useful applications. Palladium (II) has been 
coordinated to cyclam with counter ions of PF6 and ClO4152 but the most well studied is 
[Pd(cyclam)]Cl2.153, 236 Pd(II) forms four-coordinate, square planar complexes that favour  a trans-III 
configurational form (Section 1.4.2). A [Pd(cyclam)]Cl2 complex153 that was included into 
cucurbit[8]uril was formed by ligand exchange with [Pd(NH3)4]Cl2 based on the greater stability  of 
the cyclam complex (Pd(II) binding with cyclam pK = 56.9; Pd(II) binding ammonia pKa = 25.7). 
3.2 Results and discussion 
3.2.1 99mTc labelling of cyclam pro-conjugate intermediates 
 
The investigation in this thesis into radiolabelling cyclam compounds with 99mTc was envisaged 
would provide information on the methodology required and on the capability of these cyclam 
compounds to complex radioisotopes. To this end, the glucose-cyclam intermediate 51 described in 
Chapter 2 was reacted with 99mTcO4- in different buffers with varying pH’s and with stannous chloride 
as reductant (Scheme 3.1, Table 3.2). 
 
Scheme 3.1: Proposed synthesis of 99mTc-complexed 51 
 




Table 3.2: Conditions used for attempted labelling of 51 with 99mTc 
Entry Ligand 
(51) 










1 1 mg 
(300uL) 
- - - 100 uL 20  RT 0.5  
2 - Phos/Cit 
(100 uL) 
5-6 200  100 uL 500  80 0.5  




5-6 - 100 uL 80  80 0.5  
4 - Phos/Cit 
(100 uL) 
7-8 200  100 uL 150  80 0.5  




7-8 - 100 uL 150  80 0.5  




7-8 - 100 uL 500  80 0.5  
7 - NaH2PO4/ 
Na2HPO4 
(100 uL) 
7-8 500  100 uL 500  80 0.5  





7-8 - 100 uL 500  80 0.5  





7-8 - 100 uL 500  80 0.5  





9-10 - 100 uL 500  80 0.5  
11 - - 7-8 200  Sn(II)Tartrate  
6 x 10-4M  
(150 uL) 
150  RT 0.5  
12 1 mg 
(200uL) 
- 7-8 - Sn(II)Tartrate  
6 x 10-4M  
(150 uL) 
150  RT 1.5  




9-10 - Sn(II)Tartrate  
6 x 10-4M  
(100 uL) 
150  80 0.5  
 
The reducing agent used for 99mTcO4- reduction was SnCl2 dissolved in a 0.1 M HCl solution to 
prevent hydrolysis to Sn(OH)2 and all the vials and solutions were degassed before use in order 
minimise any unwanted stannous oxidation (Section 3.1.1.2). HPLC analysis of these reactions 
involved using a Phenomenex Luna 5 uM C-18(2) 100 Ǻ, 4.6 x 250 mm column attached to a gamma 
detector with a gradient elution using water containing 0.1 % TFA, and acetonitrile as the base solvent 
(method adapted from Boschi et al.229). Starting material 51 in this system was seen to elute with a 
retention time of about 13.4 min. Radiolabelling with 99mTcO4- was first attempted in an aqueous 




solution containing only cyclam 51 and SnCl2 at room temperature for 0.5 hrs (Table 3.2, Entry 1) but 
HPLC analysis indicated that no reaction occurred since no radiopeak corresponding to the retention 
time of 51 was detected. The next method applied, following a procedure developed by the Necsa 
Radiochemistry group for 99mTc labelling, was the use of a Na2HPO4 (Phos)/citrate (Citr) buffer at pH 
5.5 with heating. Both a control (entry 2) reaction and labelling reaction (entry 3) of 51 was 
performed. Radio-HPLC analysis of unreduced 99mTcO4- indicated a retention time of 4.8 min while 
the reduced 99mTc peak for the control solution (phos/citr pH 5.5) eluted at 2.9 min (Figure 3.4 A) 
owing to the stabilising complex formed between reduced 99mTc and citrate  from the buffer237, 238 
(Figure 3.5).  
 
A) B)  
 
Figure 3.4: A) Radio-HPLC spectra for control solutions: ‘free’ 99mTcO4- in saline and 99mTcO4- in a Na2HPO4 
/citrate buffer at pH 5.5, B) UV and Radio-HPLC spectra for reaction of 51 with 99mTcO4- in a Na2HPO4 /citrate 
buffer at pH 5-6 
 
Analysis of the reaction mixture (Figure 3.4 B) showed some small impurities around 3-4 min and a 
peak at 12.5 min in the UV spectrum corresponding to 51, however, in the radio-spectrum only a 
broader, small peak at 3-4 min that would most likely be the 99mTc bound to citrate was seen. TLC 
analysis of these mixtures (Table 3.3) firstly using Whatmann TLC in acetone showed that for the 
control there was no unreduced 99mTcO4- present as indicated by 0% activity measured at the solvent 




front, while in the reaction mixture only 2 % was unreduced. ITLC in saline then indicted that 99 % of 
the reduced 99mTc in the control and 90 % in the reaction was labelled in some form. The 10 % 




Figure 3.5: Illustration of the complex that could form between 99mTc and citrate 
 
Table 3.3: TLC analysis of control and labelling reaction mixtures in Phos/Citr buffer pH 5-6 
 
Entry ITLC (Saline) Whatmann No 3 (Acetone) 
 Origin Front Origin Front 
Control - 2 1 % 99 % 100 % 0 % 
Reaction - 3 10 % 90 % 98 % 2 % 
 
Literature methodology for labelling of cyclam compounds has generally been most successful at 
higher pH’s where the cyclam is in its free amine form. The pH of the Phos/Citr buffer was therefore 
increased to pH 7-8 in the labelling experiment in an attempt to keep the cyclam deprotonated whilst 
still trying to minimise the hydrolysis of SnCl2 that occurs at higher pH’s. The radio-HPLC spectra for 
a control (Table 3.2 Entry 4) and reaction mixture (Table 3.2 Entry 5) in this buffer at different times 
are shown in Figure 3.6. For both the control and reaction, immediately after addition of the 99mTcO4- 
(T = 0 min), only one radio-peak was seen that corresponded to the proposed 99mTc-citrate complex, 
while after heating for 30 min both spectra showed some new radioactive peaks. The control spectrum 
had a new, unknown peak at 5.9 min which could possibly have been some form of the citrate 
complex. The reaction spectrum also showed a very slight amount of this peak (5.9 min) but more 
interesting was a very broad band of radioactivity between 12-15 min. However, despite the fact that 
this band corresponded to the approximate retention time of 51 no distinct peak was seen that could be 
concluded as labelled compound.  
TLC analysis of these two mixtures (Table 3.4) confirmed that, by 0% activity at the solvent front in 
the acetone/Whatmann LC, no unreduced 99mTcO4- was present. The difference between this reaction 
at pH = 7-8 and the previous reaction at pH = 5-6, as indicated by the ITLC done in saline, was that 
80-90 % of the reduced 99mTc was present as colloids. The lack of any significant radioactive peaks in 
the HPLC spectra would have been as a result of these colloids that are filtered out before injection of 
the solution onto the column. The change in pH therefore did possibly assist labelling of 51 but had a 
much greater negative effect on the SnCl2 and 99mTcO4-. Repetition of this reaction with a greater 
amount of 99mTcO4- (Table 3.2, Entry 6), did not yield any other results. 





Figure 3.6: Radio-HPLC spectra for 99mTc labelling in a Na2HPO4/citrate buffer at pH 7-8: A and B) Control 
solution at T = 0 and T = 30 min; C and D) Reaction solution at T = 0 and T = 30 min 
 
Table 3.4: TLC analysis (% radioactivity at origin and front) of the control and labelling reaction 
mixtures of attempted 99mTc complexation with cyclam 51 in Phos/Citr Buffer pH 7-8 
 
Entry ITLC (Saline) Whatmann No 3 (Acetone) 
 Origin Front Origin Front 
Control - 4 84 % 16 % 100 % 0 % 
Reaction - 5 91 % 9 % 100 % 0 % 
 
Different buffer systems, which did not contain citrate, were then investigated as NaH2PO4/Na2HPO4 
(pH 7-8), KH2PO4/NaOH (pH 7-8) and NaHCO3/Na2CO3 (pH 9-10) (Table 3.2, Entries 8-10). The di-
phosphate buffer reaction showed no radioactively labelled ligand and TLC analysis (Table 3.5) of 
this mixture indicated that most of the radioactivity was present in the colloidal form. The reaction in 
the phosphate/hydroxide buffer was not analysed by HPLC since the solution became very cloudy 
from colloidal precipitation, and once filtered, practically no radioactivity remained in solution. The 
carbonate buffer produced similar results to the phosphate/hydroxide buffer in that a very large 
amount of colloids were seen to form, both in the solution and on ITLC (Table 3.6). HPLC of this 
filtered solution showed the presence 99mTcO4- at 4 min as well as the small broad band at 13-15 min.  
 
Table 3.5: TLC analysis (% radioactivity at origin and front) of the control and labelling reaction 
mixtures of attempted 99mTc complexation with cyclam 51 in NaH2PO4/Na2HPO4 buffer pH 7-8 
 
Entry ITLC (Saline) Whatmann No 3 (Acetone) 
 Origin Front Origin Front 
Control - 7 86 % 14 % 100 % 0 % 
Reaction - 8 100 % 0 % 100 % 0 % 




Table 3.6: TLC analysis (% radioactivity at origin and front) of the labelling reaction mixture of 
attempted 99mTc complexation with cyclam 51 in NaHCO3/Na2CO3 buffer pH 9-10 
 
Entry ITLC (Saline) Whatmann No 3 (Acetone) 
 Origin Front Origin Front 
Reaction - 10 77 % 33 % 70 % 30 % 
 
Stannous tartrate is often used to reduce 99mTcO4- at higher pH’s since it forms a stabilising complex 
with the reduced 99mTc to prevent further hydrolysis. Therefore, labelling of 51 was attempted using 
Sn(II) tartrate instead of SnCl2 (Table 3.2, Entry 11-13) as the reducing agent but with unsuccessful 
results as the only radioactive-peaks seen from HPLC were those corresponding to a reduced  99mTc-
tartrate complex.  
 
The observations and suppositions made from these labelling experiments were the following: 
1) The stannous chloride requires an acidic environment to prevent its hydrolysis and the formation of 
colloids. 
2) Labelling of cyclam 51 should be done at a high pH but this then increases hydrolysis of stannous 
chloride and colloid formation.  
3) Hydroxide and carbonate buffers are not suitable for use with SnCl2 as hydrolysis occurs very 
rapidly. 
4) Citrate and tartrate stabilises 99mTc but it is possible that the cyclam moiety in 51 is not a strong 
enough chelating agent for 99mTc to allow for trans-chelation.  
 
The conclusion drawn from these labelling experiments was that 99mTc complexation with 51 is not a 
simple procedure and requires further optimisation of these conditions. This method was therefore not 
the best model for determining general isotope labelling conditions so further attempts at labelling 
were rather focused on the desired isotope, 103Pd. 
3.2.2 Dissolution of Rh target foil and separation of carrier-free 103Pd 
 
The production of 103Pd from a Rh target foil (mass = 156 mg) requires irradiation at an energy of 
between 10 keV and 15 keV for the maximum amount of this isotope to form without significant 
formation of the contaminants, 102m,102g Rh and 101Pd.239 This irradiation was performed at the 
Hungarian Academy of Sciences, Institute for Nuclear Research (Atomki) in Debrecen, Hungary. The 
dissolution of the rhodium metal by oxidation to acquire the 103Pd was then carried out using the 
Lagunas –Solar method 232 of electrodissolution as shown in Figure 7.1. Initially the current was set 
very high at 7-8 A, which resulted in vigorous gas evolution and heating of the solution that led to a 
less effective, erratic current flow owing to the formation of gas bubbles on the graphite electrode that 
varied the wetted surface area.  The HCl was also rapidly consumed resulting in the liquid level 
dropping below the required mark for contact with the electrode and so shortening the available 




reaction time to around 15 min. This process was not efficient enough to solubilise all the 103Pd, and 
after five repetitions 100mg of the foil remained (approximately 11mg of rhodium dissolved per 
fraction). The RhCl63- salt that formed had a distinct pinkish colour, and the intensity of the colour of 
the HCl solution obtained after a dissolution run gave a good indication of the amount of the rhodium 
that was dissolved. The voltage was then set to keep the current between 2.0-2.5 A. This current was 
much more effective as it resulted in slower reaction of the HCl and much less gas evolution, which 
extended the reaction time and allowed for better oxidation and solubilisation of the metal. Most of 
the remaining 100 mg of foil was dissolved in three runs at which time the last bit of foil had 
fragmented and could no longer be used.  
The HCl fractions of dissolved foil were then passed through an anion-exchange column of AG1X8 
(Cl-/100-200 mesh) that was equilibrated with 6 M HCl according to Chunfu et.al.233 As the HCl 
fractions were loaded onto the column, the red RhCl63- passed straight through and eluted with a slight 
amount of radioactivity which was due to 103mRh. The remaining rhodium on the column was then 
washed off with 6M HCl followed by a 1:1 mixture of 0.5 M NH3/NH4Cl which converted the 
103PdCl42- salt to a 103Pd(NH3)42+ salt which then eluted from the column. The first two fractions of the 
NH3/NH4Cl elution were very radioactive, and these were followed by a long tailed distribution of the 
eluting radioactive compound. However, a large amount of radioactivity still remained on the column 
as measured by a radioactivity detector and so the column was again washed with 6M HCl, water and 
NH3/NH4Cl, which eluted slightly more material, but not in any significant amount. A possible reason 
for failing to elute all of the activity was that electron emissions from the palladium may have altered 
the resin structure resulting in a tighter binding of the metal. Alternatively, the Pd(II) could have been 
reduced back to Pd(0) which would have been retained on the column. 
All the fractions eluted from the column were then analysed with a Canberra Germanium Detector – 
GC2518 (24 % deficiency) to confirm the presence of 103Pd and to determine the radionuclide purity 
and amount of radioactivity. The emission spectrum obtained (Figure 3.7), when compared to 
reference emissions (Table 3.1), indicated that 103Pd was present as the isotope. The activity 
measured, with respect to the 39.75 and 357.18 keV 103Pd gamma rays, for the fractions obtained from 
elution with NH3/NH4Cl are given in Table 3.7. No other radionuclides seemed to be present in the 
solution but the radionuclide purity was not 100 % accurate as some 103mRh would have been present, 
and this cannot be distinguished from the palladium.  
The total amount of 103Pd radioactivity recovered from ion-exchange chromatography of the solutions 
obtained from Rh foil dissolution was determined to be almost 93 % (Table 3.8) despite the large 
amount of radioactivity that seemed to remain on the column based on the measurements from the 
radioactivity detector. This could be interpreted to indicate that the radioactive material on the column 
was actually minimal or that in the initial measurement of the Rh foil activity, the Rh metal atoms 
shielded the low energy emissions of the 103Pd and that the activity was in effect larger than the 
measured 50 MBq. 







Figure 3.7: Gamma analysis emission spectrum of a fraction, obtained from anion exchange column 
chromatography, containing 103Pd. 
 
Table 3.7: Radioactivities of the NH3:NH4Cl fractions obtained from the anion exchange column for 
purification of 103Pd as measured by a Gamma Detector 
 
NH3 Fractions 39.75 keV emission (MBq) 357.18 keV emission (MBq) Average activity 
(MBq) 
1 2.55 2.55 2.55 
2 10.00 9.52 9.76 
3 0.40 0.47 0.435 
4 0.09 0.09 0.09 
5 0.06 0.06 0.06 
6 0.06 0.06 0.06 
7 0.05 0.06 0.055 
Second wash 1 0.23 0.25 0.24 
Second wash 2 0.09 0.09 0.09 
resin 0.92 1.15 1.035 
 
Table 3.8: Calculation of the percentage 103Pd recovered from the Rh foil 
 
Measured radioactivity after irradiation ±50 MBq 
Time from irradiation to dissolution approx. 25 days    ±1.5 half lives 
Therefore approximate activity remaining     18.75 MBq 
First column fractions 1-3  2.55 + 9.76 + 0.44 = 12.75 
Second column fractions       0.6 + 4.1 = 4.7 MBq 
Approximate total 103Pd activity obtained     17.45 Mbq 
 
The use of a 103Pd solution for labelling of a cyclam compound requires a concentrated solution of the 
active metal and so the volume was reduced by evaporating off the water from each 103Pd-containing 
fraction. A large amount of NH4Cl from the column elution was present in each fraction, which was 
thought would affect the labelling process, and so this had to be removed. In order to accomplish this, 




a dried 103Pd fraction was dissolved in a minimal amount of water, again passed through a mini 
AG1X8 (Cl-/100-200 mesh) column (0.4 x 1.5 cm) and eluted with 6M HCl, followed by water and 
then 0.1M NH3. The radioactivity was measured by determining the counts per second with a 
handheld detector and this determined that while most of the activity had eluted with the ammonia 
solution (46 %), some (25 %) was not retained on the column at all and had washed out in the initial 
HCl wash. The column once again retained a percentage of the activity and so it was again eluted with 
0.5 M NH3 /NH4Cl, although only approximately 6 % more radioactivity was obtained while a further 
21% remained on the column. The ammonia fractions containing 103Pd with minimal NH4Cl were 
concentrated again under a stream of nitrogen before being used for labelling of the cyclam 
compound. 
3.2.3 103Pd labelling of cyclam conjugate model compounds 
3.2.3.1 Synthesis of cyclam model compounds  
 
The unsuccessful labelling of cyclam 51 with 99mTcO4- prompted the development of a method for 
103Pd labelling using two cyclam model compounds, 55 and 57, which were synthesised as shown in 




Scheme 3.2: Synthesis of glucose-cyclam model compound 55: i) 10a, Et3N, DMAP, THF, 0˚C to rt, 2.5 hr, 
63% ii) 20 % TFA in DCM, 3 hr, rt, 89%, iii) NaOMe, anh. MeOH, 1 hr, rt, 69%  
Cyclam 55 was chosen as a model compound in order to determine the effect of both an amide 
linkage and the absence of other co-ordinating functional groups on radioisotope coordination. It was 
synthesised by acylation of tri-Boc protected cyclam 52 with 10a to produce 53 which was then 
followed by removal of the t-butyl groups and decarboxylation to form 54. Benzoate ester 




deprotection was then accomplished with NaOMe to give the desired cyclam 55. Cyclam 57, selected 
for its four amine connections and three pendant carboxyl groups, was synthesised from alkylation of 
32 with glucose 3 to form 56 followed by deprotection with NaOMe and TFA.   
 
Scheme 3.3: Synthesis of glucose-cyclam model compound 57: i) Bromide 3, MeCN, reflux, 48 hrs, 48% ii) 
NaOMe, MeOH, rt, 67% iii) DCM: TFA (1:1), 16 hrs, rt, 43%  
3.2.3.2 Formation of cold Pd-cyclam complexes 
 
In the development of new radiolabelled compounds, it is essential that complexation of the metal to 
the chelating agent first be tested with the use of the stable “cold” isotope and that any of these metal 
complexes formed should be fully characterised. This will then allow for transfer of the metal 
chelation methodology to the more certain formation of the radioisotope complex.  Therefore, for 
radiolabelling with 103Pd, the initial complexation reactions were carried out using non-radioactive 
palladium. Cyclam was reacted with dichloro(1,5-cyclooctadiene)-palladium(II) (PdCl2(COD)) to 
form the PdCl2cyclam complex 58 in a moderate yield (63%) with easy displacement of the bidentate 




Scheme 3.4: Cyclam-palladium complex formation i) PdCl2(COD), DCM, 1 hr, RT (63 %) 




However, despite the success of obtaining complex 58, the synthesis of a radioactive 103PdCl2(COD) 
source was considered to be challenging. Therefore, since the 103Pd would be purified on an anion 
exchange column (Section 3.2.2) and eluted as 103Pd(NH3)4Cl2, complex formation with cyclam-55 
was attempted using non-radioactive Pd(NH3)4Cl2 that was obtained from a solution of H2PdCl4 
neutralised with NH4OH. This reaction was done by refluxing in water,153 and although the 
consumption of all starting material seemed to indicate complex formation, two spots were seen on 
TLC, one of which was identified as glucose-C10-carboxylic acid. This result indicated that 
complexation of the Pd with the cyclam somehow activated the amide bond and assisted in its 




Scheme 3.5: Attempted palladium complex formation with glucose-cyclam 55, i) Pd(NH3)4Cl2, H2O, 2.5 hrs,  
reflux 
 
3.2.3.3 103Pd labelling of cyclam conjugate model compounds 
 
The lability of the amide bond under the conditions used for Pd complexation made cyclam 57 
containing an alkyl amine linker to the glucose, preferable for labelling. LC-MS with a Phenomenex 
Luna® 5 µm C18(2) 100 Å, 250 x 4.6 mm column at a wavelength of 210 nm was used to analyse 57 
in order to determine its elution profile for comparison with a potentially labelled product.  The mass 
of 57 was confirmed ([M + H] = 963.3) at a retention time of 2.3-2.4 min which indicated that the 
column did not retain 57 effectively, but this was the only column at hand and was used for further 
HPLC analysis. Due to time constraints, an exploratory investigation into radiolabelling with 103Pd 
was carried out by the reaction of cyclam 57 with 103Pd(NH3)4Cl2 that had been eluted from the anion 
exchange column with 0.5 M NH3/NH4Cl. The reaction was carried out at elevated temperatures 
(80°C) and at a high pH of 9-11 to ensure that the cyclam amino groups were not protonated. The 
high pH of the reaction also resulted in deprotonation of the three carboxyl groups which were 
envisaged as providing stabilising coordination towards the positively charged 103Pd. The 
103Pd(NH3)4Cl2 solution was first analysed as a control sample  by HPLC fitted with a Raytest Gabi 
Star Gamma detector and although 103Pd is not a very strong gamma emitter, a very small radio-peak 
at 2.45 min indicated 103Pd(NH3)4Cl2 elution. Since 103Pd(NH3)4Cl2 is not UV active, no peak was 
expected in the UV spectrum however, a very broad peak with high absorbance was seen to elute 
between 2.4 and 3.0 min. The origin of this peak is unknown but as no other components were present 




in the control solution except for the 103Pd(NH3)4Cl2  and a large amount of NH4Cl, it might be 
possible that this peak comes from some sort of salt complex (Figure 3.8A).   
The reaction mixture of 103Pd(NH3)4Cl2 and cyclam 57 was then analysed by UV-HPLC spectrum to 
detect any potential cyclam 57-complex but again only one large, broad peak with a similar retention 
time (2.88 min) to the control was seen, which masked any cyclam compound present and provided 
no information on the radiolabelling reaction (Figure 3.8B). The radio-HPLC spectrum did not yield 
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Figure 3.8: UV-HPLC and radio-HPLC chromatograms for A) the control solution (103Pd(NH3)4Cl2 in water 
with NaOH, pH 10-11) UV peak = 2.73 min, Radio peak = 2.45 min, and B) the reaction mixture 
(103Pd(NH3)4Cl2 and cyclam 57 in water with NaOH, pH 10-11) UV peak = 2.88 min, Radio peak = 2.50 min 
using the Phenomenex Luna® 5 µm C18 column at a wavelength of 210 nm with water: acetonitrile (50:50)(1.0 
mL/min)  
 
The labelling experiment was then repeated using 103Pd(NH3)4Cl2 that had been eluted through 
another small anion exchange column to remove most of the NH4Cl that could be influencing the 
analysis of the mixture. The UV-HPLC analysis (Figure 3.9)  of the two starting component solutions 
(cyclam 57 and 103Pd(NH3)4Cl2) as well as the reaction between 103Pd(NH3)4Cl2 and 57 now showed a 
slight distinction between the two components which would be cyclam-57 eluting at 2.3 min and the 
unknown impurity peak eluting at 2.5 min. However, the radio-HPLC analysis (Figure 3.10) indicated 




only one small radioactive peak at 2.3 and 2.4 min for the control and reaction mixtures respectively. 
The rapid elution of these compounds from the column did therefore not allow any conclusions to be 




Figure 3.9: HPLC-UV analysis of A) cyclam 57, B) 103Pd(NH3)4Cl2 control with less NH4Cl and C) labelling 
reaction of 103Pd(NH3)4Cl2-cyclam 57 using the Phenomenex Luna® 5 µm C18 column at a wavelength of 210 
nm with water: acetonitrile (50:50)(1.0 mL/min)    
 
          A)                                                                     B) 
          
 
Figure 3.10: Radio-HPLC chromatogram of: A) 103Pd(NH3)4Cl2 control solution containing less NH4Cl 
(retention time = 2.40 min) and B) the labelling reaction mixture of 103Pd(NH3)4Cl2 and cyclam 57 (retention 
time = 2.30 min) analysed with the Phenomenex Luna® 5 µm C18 column at a wavelength of 210 nm with 
water: acetonitrile (50:50)(1.0 mL/min) 





ITLC analysis was then performed on the control 103Pd(NH3)4Cl2 solution and the radiolabelled 
reaction mixture using different solvent combinations (Figure 3.11). In the water based solvent 
systems such as 0.9 % saline and water: MeCN (50:50), the radioactivity mostly moved with the 
solvent front while in the more organic solvent systems of acetone, methanol and water: MeCN 
(20:80), the radioactive material mostly remained at the origin. None of these analyses gave any 
indication of the amount of 103Pd-labelled compound compared to the free 103Pd present in the mixture 




Figure 3.11: ITLC analyses of the 103Pd(NH3)4Cl2 control and radiolabelled reaction mixture 103Pd(NH3)4Cl2-
cyclam 62 that was done using different solvent systems  
 
Since neither the Luna C-18 column nor the ITLC techniques were efficient for reaction analysis an 
alternative column, the Agilent Zorbax Extend C-18 5um, 4.6 x 250mm column with a pH range of 2 
- 11.5, which is more suitable for basic compounds, was obtained for investigation. Cyclam 62 was 
re-analysed using LCMS fitted with the alternative column and was found to be successfully retained 
for longer, only eluting at 6.6 min ([M - H]+ = 691.4) (Figure 3.12).  The 103Pd(NH3)4Cl2 control 
solution containing a small amount of NH4Cl eluted at 1.35 min as indicated by the radioactive HPLC 
trace (Figure 3.13) but again the UV trace showed the unknown peak at 1.6 min.  
The labelling reaction mixture of 103Pd(NH3)4Cl2 with cyclam 57 was re-analysed using this 
alternative column and while some decomposition had occurred, the UV-HPLC trace still showed the 
presence of the unknown peak at 1.6 min but more importantly, the compound peak at 6.6 min. The 
radio-HPLC analysis of the reaction mixture showed that while a small radioactive peak at 1.35 min 




indicated some 103Pd(NH3)4Cl2 remaining in solution (40%), another split radio-peak at 6.45 min (60 
%) (Figure 3.14) indicated that a 103Pd-57 complex had successfully formed despite the labelling 
efficiency only being a moderate 60%.  
       
                                              UV chromatogram                                                     Mass spectrum 
 
Figure 3.12: UV-HPLC and MS spectrum of cyclam 57 (pH 10) analysed using the Agilent Zorbax Extend C-
18 5um column (mobile phase: A- 0.01 M ammonium acetate pH 9.5, B- methanol; gradient elution (0 min A:B 
= 95:5; 2 min A:B = 80:20; 4 min A:B = 50:50; 10 min A:B = 0:100) flow rate of 0.8 mL/min) (retention time 






Figure 3.13: UV and Radio-HPLC chromatograms of the 103Pd(NH3)4Cl2 control solution containing less NH4Cl 
analysed using the Zorbax Extend C-18 5um column (A: 0.01 M ammonium acetate pH 9.5, B: methanol; 
gradient elution (0 min A:B = 95:5; 2 min A:B = 80:20; 4 min A:B = 50:50; 10 min A:B = 0:100) with a flow 
rate of 0.8 mL/min) (UV peak of unknown complex = 1.6 min, Radio peak of 103Pd(NH3)4Cl2 = 1.35 min) 
 






Table 3.14: UV and Radio-HPLC chromatogram of  the labelling reaction mixture of 103Pd(NH3)4Cl2 and 
cyclam 57  analysed using the Zorbax Extend C-18 5um column (A: 0.01 M ammonium acetate pH 9.5, B: 
methanol; gradient elution (0 min A:B = 95:5; 2 min A:B = 80:20; 4 min A:B = 50:50; 10 min A:B = 0:100) 
with a flow rate of 0.8 mL/min) (UV peak retention time of compound = 6.6 min, Radio peak retention time = 
1.35 for unreacted 103Pd(NH3)4Cl2 and 6.5 min for 103Pd(NH3)4Cl2-cyclam 57 complex) 
3.3 Summary of radiolabelling studies 
 
In summary, with regards to labelling of the glucose-cyclam compound 51 with 99mTc, it was found 
that the conditions used for labelling were not suitable owing to the incompatibility between the acidic 
environment best suited for technetium reduction and the basic environment optimally required for 
cyclam coordination. Therefore, further investigations into the structure of the ligand and optimisation 
of the labelling conditions are required in order to use 99mTc as the complexed radioisotope. 
The use of 103Pd for radiolabelling presented a few more challenges as the 103Pd first had to be isolated 
from a Rh foil target and a method developed for HPLC analysis of the reaction solutions to 
determine the percentage labelling. The purification of 103Pd was successfully achieved using a cation 
exchange column and for HPLC analysis it was found that the Phenomenex Luna® C18 column was 
not adequate for separation of the components of the reaction mixture and that a more basic Agilent 
Zorbax Extend C-18 column was required in order to distinguish any labelled compound. Using this 
analysis method to analyse the reaction of cyclam 57 with 103Pd(NH3)4Cl2 under basic conditions, it was 
found that the labelling of cyclam 57 with 103Pd was accomplished with a 60 % labelling efficiency. 
This result therefore gave some confidence to proceed with the future work of labelling cyclam 51 
and the proposed cyclam bioconjugate with 103Pd.  
  




CHAPTER 4 – NANOPARTICLE STUDIES 
4.1 Introduction 
 
Nanotechnology (molecular and synthetic material components that are between 1 and 100 nm), has 
generated several nanocarriers for radiopharmaceuticals (Section 1.3.4.3). These nanocarriers are 
organic compounds such as liposomes, hydrogels and natural or synthetic polymers27, 240 or inorganic 
nanoparticles such as carbon nanotubes, metal nanoparticles, magnetic (Fe3O2) nanoparticles, and 
semiconducting quantum dots composed of CdSe/CdS/CdTe nanocrystals.241 Nanoparticles have 
certain advantages over conventional drug or radioisotope delivery, namely: i) the size of the 
nanoparticle can be tailored to be small enough to escape the reticuloendothelial system but large 
enough to prevent leakage from healthy capillaries and allow for their prolonged accumulation in the 
tumour tissue due to the enhanced permeability and retention (EPR) effect, and ii) the surface of the 
nanoparticle can be designed to be hydrophilic to avoid recognition by the immune system and can be 
modified to contain various targeting agents designed to recognise cell-surface receptors and actively 
target the tumour site.27, 61, 240   
Inorganic nanoparticles also have unique material and size-dependent physicochemical properties 
such as optical and magnetic properties and well as inertness and stability which make them an 
attractive alternative to organic nanoparticles.241 Quantum dots are used for biological, fluorescent 
imaging as they emit light of a tunable wavelength depending on the size of the nanocrystals. In 
cancer therapy, metallic gold nanoparticles have been modified for drug or radioisotope delivery 
while magnetic iron oxide nanoparticles that can be directed through an external magnetic field to the 
tumour site, are used for thermal ablation. Both of these nanoparticles have also found application as 
contrast agents for magnetic resonance imaging (MRI). Inorganic nanoparticles can be prepared both 
in solution and in the vapour phase by methods that include metal evaporation, pyrolysis, liquid-solid-
solution and vapour-solid solution growth, plasma-chemical reduction and wet chemistry242 and the 
aim of these techniques is to optimise the synthesis of uniform, monodisperse particles with defined 
sizes. Metallic and magnetic nanoparticles provide interesting possibilities for biological applications 
and the next section will focus more specifically on palladium and magnetic iron oxide nanoparticles. 
4.1.1 Palladium nanoparticles 
 
Palladium nanoparticles (PdNP) are very often used as catalysts in various reactions such as the 
hydrogenation of olefins 243 and Suzuki reactions,244 but have also been applied in biomedicine for 
immunolabelling245 by functionalising their surface with antibodies. Their synthesis is carried out in 
an aqueous solution, usually in the presence of a capping agent such as linear polymers, ligands, 
surfactants and tetraalkylammonium salts, for stabilisation,246 and involves reduction of a few metal 




ions which then agglomerate to form small metal clusters that act as nucleation sites for further 
reduction of the metal atoms leading to nanoparticle growth.247 This nucleation and growth occur 
simultaneously and so control of the particle size is difficult making for a broad size distribution. The 
stronger the reducing agent, the less of a control there is over the formation of new nucleation sites 
and so the more varied the sizes are that are obtained. A capping agent present during synthesis helps 
to stabilise the growth of the nanoparticles and prevent metal cluster aggregation, leading to a more 
monodispersed, limited sized nanoparticle solution. Despite the many studies that have been carried 
out to improve methods for size-controlled nanoparticle synthesis by changing the reducing and 
capping agent, as well as the concentration of these agents and the temperature of the reaction, a 
significant challenge still exists for obtaining nanoparticles of a narrow size distribution.  
The reducing agents generally used are NaBH4, sodium citrate or ascorbic acid in organic solvents 
such as ethanol, while stabilising capping agents include sodium carboxymethylcellulose (CMC), 
alkanethiols, thioethers, β-D-glucose, starch, tetraoctylammonium bromide (TOAB), poly(N-2-vinyl-
pyrrolidone)(PVP). Examples of reaction conditions used for palladium nanoparticle synthesis and the 
sizes of particles obtained are reported in Table 4.1 
 
Table 4.1: Summary of selected literature conditions for the synthesis of palladium nanoparticles and 





agent Stabiliser Solvent 
PdNP size 
(nm) Reference 





polyacrylate water 12-47  




sodium citrate water 5 - 10  
H2PdCl2 ethanol PVP water/ EtOH 1.7-3  (246) 
H2PdCl2 ethanol PVP water/ EtOH 3/3.9/5.2/6.6  (244) 
H2PdCl2 ethanol PVP water/ EtOH 2.4/3.8 (248) 
Na2PdCl4 NaBH4 - DMSO 3-4 (249) 
Na2PdCl4 NaBH4 TOAB water/toluene 0.9 - 3.5 (242) 
Na2PdCl4 ascorbic acid PVP water 7 – 8 (250) 
Na2PdCl4 ascorbic acid CMC water 3.4 - 7.6  (247) 
Na2PdCl4 
NaBH4 CMC water 2 -3  (251) 
NaBH4 B-glucose water 3 - 5   
Pd(OAc)2 PEG - - 5 (252) 
 
 




4.1.2 Magnetic Nanoparticles 
 
Magnetic nanoparticles are composed of ferri- or ferro- materials which at a nanoscale, above a 
certain temperature, exhibit superparamagnetic properties that allow them to maintain one large 
magnetic moment but with a net loss of magnetisation and lack of any residual magnetisation when 
the external magnetic field is removed, which therefore reduces agglomeration.253, 254 The most 
common magnetic nanoparticles are composed of iron oxide nanocrystals, magnetite (Fe3O4) or 
maghemite (γ- Fe2O3), which are relatively easy to synthesise and have very good biocompatibility as 
they can be degraded to iron ions which are incorporated in normal biological functioning systems.  
These iron oxide nanoparticles have been produced by a number of different methods which include 
co-precipitation, thermal decomposition, microemulsion and hydrothermal synthesis but a challenge 
with these magnetic nanoparticles however is that, left uncoated, they tend to aggregate and oxidise 
easily in air which results in loss of magnetisation and dispersability.254 The solution to these 
challenges has been to develop strategies to chemically protect and stabilise the nanoparticle by 
coating the surface, during or after synthesis, with organic compounds such as polymers or 
surfactants, or inorganic materials such as silica, metal or metal oxides.254, 255 The most actively 
investigated applications for magnetic nanoparticles are as MRI contrast agents, in cancer, 
cardiovascular disease and molecular imaging, and as carriers for targeted drug delivery, since the 
protective shells can easily be functionalised with various drugs, and their placement controlled by 
means of an external magnetic field.  Specific active targeting agents can also be attached to the 
nanoparticle surface, thereby adding a second targeting and localisation method for drug delivery.  
A less common application of magnetic nanoparticles is their use for thermal ablation (hyperthermia) 
as a supplement to cancer chemotherapy.256 The principle of hyperthermia is that when magnetic 
nanoparticles are subjected to an alternating magnetic field they produce heat and when placed within 
a tumour, this heat will destroy the cancer cells.  
4.1.3 Characterisation of nanoparticles  
 
Nanoparticles that are intended for medicinal applications need to be carefully characterised due to 
the complex nature of the nanoparticle composition. The characterisation includes assessment of the 
individual parts, such as stoichiometry and connectivity between the components, as well as 
characterisation of the particle as a whole with respect to physicochemical properties, sterility, 
pyrogenicity, biodistribution and toxicity.257 
Physicochemical properties, which include the size, shape, surface chemistry and aggregation can 
drastically affect nanoparticle behaviour in vivo. Size and aggregation characterisation is determined 
by transmission-electron microscopy (TEM), which is also used for shape analysis, and dynamic light 
scattering (DLS). Nanoparticle characterisation by multiple methods, such as TEM and DLS, helps to 
resolve ambiguities that would arise from the use of each method in isolation. 




4.1.3.1 Transmission Electron Microscopy 
 
Electron microscopy is useful for obtaining information on the size, size distribution and shape of 
nanoparticles. TEM provides a high resolution image, especially for electron-dense material such as 
metal nanoparticles, but often is not able to distinguish organic or biological material, such as 
components attached to a nanoparticle surface, owing to the insufficient electron beam deflection by 
these materials. Therefore TEM would only be a measure of the core-particle size rather than the 
actual size as a result of the functionalised surface layer. Another challenge with TEM is that image 
analysis requires a very thin sample in a high-vacuum state and sample preparation for these 
conditions could alter the physicochemical properties of the nanoparticle.257 
4.1.3.2 Dynamic light scattering  
 
Dynamic light scattering (DLS), also referred to as photon correlation spectroscopy (PCS), is used to 
determine the hydrodynamic size – the effective size of the nanoparticle with its functionalised 
surface – of nanoparticles in solution but does not provide any information on the shape of the 
particle. DLS works on the principle of analysing the way light is scattered, with small, time-
dependent fluctuations in intensity due to Brownian motion, by particles in a suspension. The changes 
in light intensity are measured by a photon detector and then, taking into account the viscosity of the 
solution and the temperature, converted into a measurement of the diameter of the particle using the 
Stokes-Einstein equation.257, 258 The optical configuration for DLS is illustrated in Figure 4.1. The 
analysis using DLS also generates a polydispersity index that gives an indication of the size 




Figure 4.1: Optical configuration for DLS measurements: A laser emits a beam of light that passes through the 
sample and gets scattered according to the particles in the sample. The scattered light is measured by a photon 
detector which correlates the data into a measurement of the particle diameter 
 
Considerations for DLS, when determining the nanoparticle size, is that the diameter is calculated 
from how the particle diffuses within a fluid and this can be influenced by the viscosity, temperature 




and ionic strength  of the solution and surface structure and shape of the particles. Changes in these 
variables can therefore result in slightly skewed size measurements. Another factor that could 
influence measurements is the presence of agglomerates or dust in the solution since the intensity of 
scattered light is proportional to the particle diameter x 106, larger particles scatter light more 
efficiently than smaller particles and therefore the smaller particles become “negligible”. It is 
therefore important to use multiple analysis techniques when determining the size of particles.   
4.1.4 Aim 
 
Based on the overall aim of the project - the synthesis of a new Auger-emitting therapeutic 
radiopharmaceutical, consisting of cyclam, glucose, albumin and 103Pd, which is greater than 40 kDa 
(± 7-10 nm) in size and with an increased specificity for tumours through active and passive targeting 
- the aim of this investigation was to expand on the possibilities of a therapeutic radiopharmaceutical 
by development of a nanoconjugate. This intended to be based on Pd or magnetic iron oxide 
nanoparticles of an appropriate size (± 7-10 nm) for passive targeting, and functionalised with a 
glucose-cyclam active targeting agent to which 103Pd could be complexed. Palladium nanoparticles 
(PdNP) were selected since 103Pd could possibly be incorporated into the nanoparticle thereby 
eliminating the need for cyclam, while magnetic nanoparticles (MNP) were investigated due to the 
possibility to direct them to a specific location using an external magnetic field to provide an 
additional means of cancer targeting. 
4.2 Results and discussion 
4.2.1 Synthesis of glucose derivatives for nanoparticle stabilisation and surface 
functionalisation  
 
The glucose-cyclam pro-conjugate 51, synthesised in Chapter 2 for complexing of 103Pd and 
conjugation to albumin, was the desired target for attachment to nanoparticles. However, as an 
alternative to using cyclam as a chelating agent it was proposed that 103Pd could be incorporated 
directly into the PdNP during their synthesis. Therefore glucose derivatives 27, 62 and 64 were 
synthesised (Scheme 4.1), using previously described glycosylation methods (Section 2.3.1), for 
attachment to the nanoparticle surface as alternative glucose targeting agents. The terminal functional 
group was varied between an amine (27 and 62) and a thiol (64) group since the sulphur should bind 
slightly more strongly to, and stabilise the PdNP better than the amine nitrogen. The alkyl chain 
length was varied to determine the effect that the distance between the glucose and nanoparticle 
would have on nanoparticle synthesis and recognition by cell receptors. The intermediates to these 
compounds were synthesised with relative ease, barring the last deprotection in each case, at which 
point the challenge was the purification of the extremely hydrophilic products. Another problem 




occurring was the formation of disulfide bonds during the synthesis of thiol 64, although these 
disulfides were thought not to affect the synthesis of the nanoparticles, as both the free thiol and 
disulfide sulphur atoms are able to form bonds to the palladium and functionalise the nanoparticle 
surface.   
 
 
Scheme 4.1: Synthetic scheme for the synthesis of glucose derivatives (27, 62, and 64) to be used for 
nanoparticle surface functionalisation i) I2, (Me3Si)2, ZnCl2, DCM, 16 h, RT ii) 22/59/S-3-hydroxypropyl 
thioacetate, ZnCl2, Mol. sieves 4 Ǻ, DCM, 16 h, RT (23 70%, 60 63%, 63 80%), iii) NaOMe, MeOH, 1 hr, RT 
(25 82%, 61 70%, 64 68%), iv) H2(g), Pd/C(10%), EtOH, 20 h (27 87%, 62 73 %) 
 




The method for synthesis of palladium nanoparticles, using 51, 27, 62 and 64 was unknown and so 
thioglucose (Figure 4.2) was first used as a readily available, cheaper model compound for method 
development.  
 
Figure 4.2: Structure of thioglucose 
4.2.2 Palladium nanoparticle synthesis 
4.2.2.1 Thioglucose-Pd nanoparticles 
 
The approximate size of an albumin bioconjugate is around 7-10 nm and so the desired size for the 
synthesised nanoparticles was in this range. The first attempt at synthesising the glucose-Pd 
nanoparticles was made using the solution phase technique and a number of experiments were carried 
out in which the ratio of the thioglucose and reducing agent added to the Na2PdCl4.3H2O solution was 
varied, along with the temperature of the reaction and the reaction time. Ascorbic acid was used as the 
preferred reducing agent as it is much milder than NaBH4 and the use of NaBH4 as the reducing agent 
led to much larger particles that were unstable and which agglomerated and precipitated out of 
solution. The hydrodynamic sizes of the particles were measured in water at 25˚C using DLS and 
reported as the sizes obtained from the Z-average intensity values that were measured before and after 
dialysis to remove the excess reagents from the solution and purify the nanoparticles. The results of 
these experiments in terms of the sizes of the obtained nanoparticles are summarized in Table 4.2.  
Analysis of the sizes of nanoparticles obtained under the different reaction conditions and before 
dialysis, led to a number of observations being made. It was found that the greater the equivalents of 
thioglucose used, the smaller the size of the particles up to a point. At a thioglucose ratio of 1 (not 
shown in table), the palladium failed to achieve adequate stabilisation as evidenced by the particles 
precipitating whereas with two equivalents of thioglucose, the particles were stabilised enough to 
remain in solution but the particle sizes were very large and poly-dispersed. Thioglucose equivalents 
of 2.5-3 seemed to be the most adequate for stabilised particles while at 4 and 5 eq, the nanoparticle 
nucleation sites were not given a chance to grow in size with the amount of stabilising agent present, 
and appeared as very small (3-5 nm) particles. The temperature of the reaction affected the particle 
size by resulting in larger, more aggregated particles at higher temperatures while a longer reaction 
time also increased the nanoparticle size. Another observation noted was that if the reducing agent 
was added first, the particles would either precipitate or that the sizes would be very large. The reason 
for this could have been that the reduction of the metal began as soon as the reducing agent was added 
while if no stabilising agent was present, the particles immediately started to aggregate.  
 




Table 4.2: Summary of the conditions applied for the synthesis of thioglucose-PdNP and the size of 












Size (nm) – 
Before Dial. 
Size (nm) – 
After Dial. 
1 2 2 RT 22 17.03 18.62 
1 2 2  
(Add 1st) 







RT 22 10.99 Not measured 
36 13.06 Not measured 





3 RT 22 43.79 19.49 
44 44.35 17.83 
1 2.5 2 RT 22 8.79 7.38 
1 2.5 2  
(Add 1st)  
RT 0.5 187.1 ppt 
22 85.16 ppt 
30 73.31 ppt 
1 2.5 2.5 RT 22 7.22 7.60 
1 2.5 3 RT 22 8.63 7.86 
44 10.52 9.47 
1 3 2 RT 22 7.43 8.87 
1 3 3 RT 22 6.72 6.88 
1 5 3 RT 22 4.18 6.10 
58 22 15.28 9.07 
95 22 19.73 9.70 
*ppt = precipitate/aggregation of nanoparticles 
 
The colour of the reaction solution was generally an indication of the size of the nanoparticles that had 
formed and varied from a yellow colour (very small particles) to darker, orange-brown colour (Figure 
4.3) as the particles became larger and then to a very dark, almost black colour when the particles 




Figure 4.3: Picture of palladium nanoparticle synthesis solutions containing various ratios of thioglucose. The 
darker the colour of the solution, the larger the nanoparticles obtained. 
 




The nanoparticle solutions were purified by dialysis over 2 days with repeated water changes to 
restore the concentration gradient and after each water change, a sample of the water was analysed by 
HPLC for the presence of ascorbic acid and thioglucose. After four days practically no ascorbic acid 
or thioglucose remained and so it was assumed that the nanoparticle solution was purified. The 
challenge however, with the dialysis step, especially for solutions containing fewer equivalents of 
thioglucose was that during dialysis, since all the excess thioglucose was removed, many of the 
particles were no longer sufficiently functionalised and stabilised and so a large amount of the 
particles precipitated. These particles were then filtered off before size analysis was done and the 
measurements only reflected those particles that were stabilised enough to remain in solution (Table 
4.2). The most favourable conditions that resulted in nanoparticles with hydrodynamic diameters that 
were stable both before and after dialysis in the 7-10 nm range, were thioglucose ratios of 2.5 or 3 
equivalents with 2 or 3 equivalents of ascorbic acid at room temperature for 22 hrs.   
The transfer of this methodology to synthesising palladium nanoparticles incorporating 103Pd would 
require the adaptation to a basic solution as the radioisotope is acquired in a NH4OH solution.  The 
synthesis of the Pd nanoparticles was therefore attempted in a solution of NH4OH(aq) and fortunately 
very similar results to the initial experiments using water were obtained (Table 4.3), thereby 
indicating that the synthesis to incorporate 103Pd into the nanoparticles should be possible in basic 
solution too.  
 
Table 4.3: Summary of conditions applied for thioglucose-Pd NP synthesis in a NH4OH solution (pH 













Size – Before 
dialysis 






RT 15 min 51.9 14.76 
95 15 min ppt* ppt 
RT 44 h 44.35 17.83 
95 44 h ppt ppt 
1 2.5 3 RT 1.5 h 8.01 Not measured 





RT 15 min 4.46 9.04 
95 15 min 6.78 5.81 
RT 44 h 4.48 7.16 







2 13.42 Not measured 
13.72 Not measured 
13.59 Not measured 
58 
 
22 30.73 58.00 
17.04 60.94 
33.01 38.69 
*ppt = precipitate/aggregation of nanoparticles 
 




The Pd-nanoparticles were characterised by NMR and FTIR techniques to confirm the presence of the 
thioglucose within the compound. The FTIR spectra for thioglucose and thioglucose-palladium 




Figure 4.4: FTIR spectra of A) pure thioglucose and B) three thioglucose-PdNP solutions synthesised under 
different conditions 
 
While the presence of the thioglucose is clear, it was attempted to confirm the Pd-S bond through far 
infrared analysis of the samples using CsI instead of KBr but a large amount of interference from 
atmospheric water and carbon dioxide hindered the measurement of the small vibration frequency of 
this bond (300-400 cm-1)259, 260 and no signal was obtained. The TG-PdNP were then analysed by 
Raman spectroscopy and compared to pure thioglucose and H2PdCl4 (Figure 4.5). Using these spectra, 
the Pd-S bond was confirmed by the shoulder on the peak between 350-400 cm-1. 
 







Figure 4.5: Raman spectra of thioglucose-Pd-NPs for their comparison with pure thioglucose and dihydrogen 
tetrachloropalladate  
 
Following the DLS measurements on particle size, it was decided to resort to TEM to confirm the 
values. Examples of TEM images obtained from various nanoparticle solutions are shown in Figure 
4.6. Images A and B are of nanoparticles before dialysis, formed under conditions of two equivalents 
of thioglucose. The nanoparticles are less stabilised and so much larger (20-40 nm) or form 
aggregates. Images C and D are also solutions before dialysis but these contain a very large amount (5 
eq) of the thioglucose and so the nanoparticles formed are very small (2-5 nm). The nanoparticles in 
E, formed under the favourable conditions of 3 eq. thioglucose with 2 eq. ascorbic acid at room 
temperature for 22 hrs, are obtained after dialysis and filtration and measure 5-7 nm. The diameters 
determined from DLS for these particles are around 8-10 nm. 
The discrepancy between the values obtained from TEM and those from DLS could have been due to 
TEM only distinguishing the metal core of the nanoparticle while DLS measured the size of the 
nanoparticle including the surface shell. Although the core size of the TG-PdNP is slightly smaller 
than desired, the general hydrodynamic size of the nanoparticles obtained using the above mentioned 
methods, is in the desired 7-10 nm range, and so this method could be transferred to the synthesis of 
Pd-NPs functionalised with the synthesised glucose targets 51, 27, 62 and 64 (Scheme 4.1). 








Figure 4.6: TEM images (different magnifications) of various thioglucose-PdNP solutions formed under 
conditions of: A and B) 2 eq. thioglucose, RT, 22 hrs, before dialysis, C and D) 5 eq. thioglucose, RT, 22 hrs, 
before dialysis, E) 3 eq. thioglucose, 2 eq, ascorbic acid, RT, 22 hrs, after dialysis 




4.2.2.2 The Glucose Pd-nanoparticles 
 
Three equivalents each of synthesised glucose derivatives 51, 27, 62 and 64 (Scheme 4.1) and 2 eq. of 
ascorbic acid in each case were reacted independently with 1 eq. of 0.05M Na2PdCl4 at room 
temperature for 24 hrs in a slightly basic solution. The results of the experiments are summarised in 
Table 4.4. Reaction with glucose derivatives 27 and 62 containing a terminal amino group 
immediately resulted in aggregation of palladium as inferred by the observation of a precipitate, and 
so these compounds were assumed not able to bind and stabilise the reduced metal. By comparison, 
the glucose-cyclam derivative 51, also containing a terminal amino group did not result in 
precipitation, although the particles that formed were very large (170-190 nm)(Figure 4.7 A). 
However, once again, after dialysis, a large quantity of precipitate was formed and the particles that 
remained in solution were very polydisperse (Figure 4.7 B). It is therefore proposed that the 
stabilisation of the Pd-NP with 51 is not as a result of the terminal amino group but rather due to 
binding and stabilisation of the Pd by the cyclam group. However it appears that the binding is fairly 
weak and the excess compound is removed by dialysis which then exposes more of the small core 
particles leading to aggregation and a range of particle sizes. It is necessary to note that 51 required 
the addition of a small amount of methanol in order to improve solubility, during nanoparticle 
formation and it is possible that this methanol also helped stabilise the nanoparticles before dialysis. 
Glucose derivative 64, containing a terminal thiol group, was able to stabilise the reduced metal 
nucleation sites much better and 75 % of the nanoparticles were in the range of 3-6 nm, although, 
there were still very large particles and aggregates present (Figure 4.8 A). After dialysis, the 
percentage of larger particles, which formed from further growth and aggregation of the 3-6 nm 
particles, had increased to 69 % while the remaining particles were still very small (2-4 nm) and did 
not have a chance to grow in size (Figure 4.8 B). TEM analysis of this dialysed solution confirmed the 
two different particle sizes (Figure 4.9)  
 
Table 4.4: Summary of the conditions used for synthesis of PdNP using the synthesised glucose 
ligands as surface functionalising agents and the sizes of the PdNP obtained 
Ligand Ratio (M:L:R) Time size (nm) Notes 
27-GlucoseC10NH2 1:3:2 - ppt Pd ppts 
62-GlucoseC3NH2 1:3:2 - ppt Pd ppts 
51-Glucosecyclam 1:3:2 24 181.4 Before dialysis 
64-GlucoseC3SH 1:3:2 24 
4.5 (75%) 
>100 (25%) Before dialysis 
160 (69%) 
2.7 (31%) After dialysis 
M:L:R = metal: ligand: reducing agent 





Figure 4.7: Intensity plots obtained from DLS measurements on a Malvern Zetasizer of glucose-cyclam 51-
PdNP synthesis A) before dialysis and B) after dialysis. Pd-NP refractive index = 4.1; Absorption = 0.01 
Dispersant = Water at 25 ˚C; RI = 1.330; viscosity = 0.8872; Equilibration time = 2 min; Number of runs = 5  
 
           A) 
 
           B) 
 
Figure 4.8: Intensity plots obtained from DLS measurements on a Malvern Zetasizer of glucose-64-Pd-NP 
synthesis: A) before dialysis and B) after dialysis. Pd-NP refractive index = 4.1; Absorption = 0.01 Dispersant = 
Water at 25 ˚C; RI = 1.330; viscosity = 0.8872; Equilibration time = 2 min; Number of runs = 5 







Figure 4.9: TEM images of glucose-64-Pd-NP synthesis after dialysis showing small (< 5 nm) and large 
particles (> 200 nm) 
 
The conclusion reached from the attempted synthesis of Pd-NP using the synthesised glucose 
compounds is that amino functional groups do not form strong enough bonds with palladium probably 
because of their hardness, and that any further development of Pd-NP will require the use of a softer 
thiol-functionalised ligand. 
4.2.3 Fe2O3 magnetic nanoparticle synthesis 
4.2.3.1 Thioglucose- Fe2O3 nanoparticles 
 
The magnetic nanoparticles intended for functionalising the surface with a synthesised glucose-
cyclam compound on order to complex 103Pd was maghemite (γ-Fe2O3). A sample of such γ-Fe2O3 
particles, with a core size of around 4 nm (hydrodynamic diameter = 7-8 nm) in diethylene glycol 
(DEG) and ethyl acetate, was received from Xavier University of Louisiana. The challenge with 
magnetic nanoparticles is that they are synthesised in organic media but for their use in biological 
systems, they need to be transferred to an aqueous solvent in which they are not stable unless covered 
by surface protecting groups. Thioglucose was then again used as the model compound to develop the 
methodology for attaching a ligand to the nanoparticle surface to stabilise these particles in an 
aqueous environment.  
The best method devised to transfer the particles from the organic to aqueous phase was by reacting 
thioglucose with the Fe2O3 particles in DEG, followed by washing and precipitation with ethyl acetate 
and then redissolving the precipitate in water. Owing to the results obtained from the PdNP synthesis, 
the amount of thioglucose added was to the tune of either 2.5 or 3.5 equivalents. Polyethylene glycol 
was also investigated as an alternative solvent for the synthesis. The sizes of the particles were again 
measured using DLS techniques and the results of the experiments are summarised in Table 4.4. 




 Table 4.4: Summary of the conditions used for synthesis of thioglucose-Fe2O3 nanoparticles  
 
Fe2O3 (eq) Thioglucose (eq) Solvent Size (nm) Notes 







1.PEG/H2O 139 Very polydisperse 
2.PEG/H2O 365 Very polydisperse 





H2O 7.59 EtOAc precip 
21.42 MeOH wash 
 
All the nanoparticles were very stable in DEG and not much difference was seen between 2.5 or 3.5 
equivalents of thioglucose in which the hydrodynamic diameter increased to 9-12 nm in size. Once 
the particles were precipitated with ethyl acetate and redissolved in water, some instability was seen 
as judged by the formation of larger particles, but these were filtered out and the majority of the 
particles then appeared to be stable in the aqueous environment at similar sizes to the particles in DEG 
indicating that the surface is sufficiently covered with thioglucose. In an attempt to increase the 
contact between thioglucose and the Fe2O3, the reaction solution was sonicated for a few minutes at a 
low frequency. The result was that the particles in the DEG went from 9.76 to 7.25 nm and retained 
their size (7.59 nm) following precipitation and dissolution in water which suggests that the surface 
was well stabilised by the thioglucose. The thioglucose- Fe2O3 nanoparticles were then analysed by 




Figure 4.10: FTIR spectra comparisons of pure thioglucose and thioglucose- Fe2O3 nanoparticles 




4.2.3.2 Synthesised glucose ligands- Fe2O3 nanoparticles 
 
Synthesised glucose derivatives 51, 27, 62 and 64 were reacted with Fe2O3 nanoparticles in the same 
manner as described above for the synthesis of thioglucose-Fe2O3 nanoparticles except that 3 eq. of 
the ligands were used. A summary of the reaction conditions and size measurements obtained by DLS 
is given in Table 4.5. The results indicate that none of the glucose compounds (51, 27, 62) containing 
a terminal amino group were able to functionalise the surface of the magnetic nanoparticles as 
inferred from aggregation of the Fe2O3 nanoparticles within minutes of addition of the compounds in 
DEG. The only compound that assisted in stabilisation of the nanoparticles was 64 with its terminal 
thiol group, and even then the surface coverage was not optimal as a great number of large particles 
and some aggregates were still formed. The reaction of 64 in DEG resulted in a particles with average 
diameters of 7.4 nm and 200 nm in a ratio of about 73:27 (Figure 4.11 A).   
 





Size (nm) Notes 
27-GlucoseC10NH2 1:3 DEG 5 ppt Fe2O3 aggregates 
62-GlucoseC3NH2 1:3 DEG 5 ppt Fe2O3 aggregates 
51-Glucosecyclam 1:3 DEG 5 ppt Fe2O3 aggregates 







Figure 4.11: Intensity plots obtained from DLS measurements of glucose-64- Fe2O3-NP synthesis: A) before 
dialysis and B) after dialysis: Fe2O3 NP refractive index = 2.42; Absorption = 0.01; Dispersant = Water at 25 ˚C; 
RI = 1.330; viscosity = 0.8872; Dispersant = DEG at 25 ˚C; RI = 1.447; viscosity = 35.7; Equilibration time = 2 
min; Number of runs = 5  




These particles were then washed and precipitated with ethyl acetate followed by redissolving in 
water. The process of washing, precipitation and dissolution of the nanoparticles resulted in a size 
increase and the particles that aggregated were filtered out to leave a solution containing glucose-
Fe2O3 nanoparticles in the order of 70-90 nm (Figure 4.11 B).  
The conclusion drawn from the attempted synthesis of the magnetic Fe2O3 nanoparticles is that a 
primary amino group is not a suitable functional group for binding with the particles, whereas the 
softer thiol group showed a lot more potential to achieve the objective. Functionalising the surface of 
these particles therefore, with a glucose-cyclam pro-conjugate was not considered to be a viable 
option without converting terminal amino to thiol in the pro-conjugate.  
4.3 Summary of nanoparticle studies 
 
Thioglucose-palladium nanoparticles and thioglucose-Fe2O3 magnetic nanoparticles were synthesised 
under various conditions to obtain an optimal hydrodynamic size of 7-10nm and were characterised 
using DLS, TEM and FTIR. The methodology developed for the nanoparticle synthesis using 
thioglucose was adapted for the attempted synthesis of the nanoparticles with synthesised glucose 
derivatives (51, 27, 62 and 64). While the thiolated glucose derivative (64) proved to work marginally 
for both types of nanoparticles, the glucose compounds containing a terminal amine group (51, 27 and 
62) were found not to be suitable for use with these nanoparticles.  
The overall conclusion is that for developing a radiotherapeutic nanoparticle with a glucose surface 
targeting agent, 103Pd will need to be incorporated directly into the Pd-nanoparticles rather than 
complexing to an external chelating agent. Such a task requires a great deal more work regarding 
optimising synthesis aspects. It was also concluded that magnetic nanoparticles are not suitable for 
delivering 103Pd to tumour sites and will only have a therapeutic effect based on thermal ablation.  
  




CHAPTER 5 – BIOLOGICAL STUDIES  
5.1 Introduction 
 
The development of a new radiotherapeutic bioconjugate was based on the principles of both active 
and passive targeting – active targeting through a glucose moiety designed to be recognised by cell 
surface glucose transporters (GLUTs) (Section 1.4.3.1) and passive targeting by attachment of a 
maleimide functionalised pro-conjugate to in vivo human serum albumin (HSA) (Section 1.4.3.2), 
thereby forming a large bioconjugate that brings into play the Enhanced Permeability and Retention 
(EPR) effect.  
The process of developing a potential therapeutic compound requires that, following synthesis, 
significant in vitro and in vivo studies be done before any clinical trials can be considered. In vitro 
studies include the determination of cellular uptake and toxicity of the compound among other tests 
while in vivo studies are required to determine the overall effects of the compound on a living system. 
Cell uptake studies determine the amount of compound taken into the cells and require a means by 
which the compound is visualised, generally through attachment of a fluorescent marker. The 
accumulation and specific location of the fluorescent compound within the cell can then be 
determined by fluorescence microscopy,261 or the general percentage of uptake can be determined by 
separation of the cells from the media and measurement of the fluorescence of each fraction.  
A number of organic fluorescent markers (fluorophores), with different functional groups for 
connectivity and specific, characteristic excitation and emission spectra, are available for labelling 
compounds and biomolecules (Figure 5.2). Depending on the application, a fluorophore has to fulfil 
certain chemical as well as photophysical requirements which include specific reactivity and pH 
stability, defined absorption (λabs) and emission (λem) wavelengths, a high extinction coefficient (ε), a 
high quantum yield (φ)(ε and φ influence the brightness of the emission) and a certain fluorescence 
lifetime (τ).262 It is also important that the fluorescent markers do not influence the characteristics of 
the compound or biomolecule that they are labelling. Dansyl chloride, first introduced in 1952 by 
G.Weber, has been widely used to label many drugs, organic compounds, proteins and other 
biomolecules with the dansyl fluorophore, as it reacts easily with amino groups.262-265 It is non-
fluorescent until it reacts with amines to form a sulphonamide, at which point, depending on the 
substrate, the maximum absorbance wavelength is around 330-340 nm and results in a strong 
fluorescence emission around 500-550 nm which is easily visible and can be used to detect labelled 
compounds in very small amounts. 
 
  





Figure 5.2: Structures of some selected fluorophores used for fluorescent labelling. The colour of the structure 
indicates the approximate maximum λem (DAPI = 4,6-Diamidino-2-phenylindole; TMR= tetramethylrhodamine) 
 
The first stage in the development of cancer is a genetic mutation which leads to the abnormal 
proliferation of the cells. The cancer cells are physiologically quite different to normal, healthy cells 
and display altered mechanisms in the way they proliferate, differentiate and survive that has been 
described as the “hallmarks” of cancer.15 These traits are reduced requirements for growth signals, 
insensitivity to contact inhibition (anti-growth signals), uncontrolled proliferative capabilities, evasion 
of apoptosis, secretion of growth factors that promote angiogenesis and secretion of extracellular 
proteases to facilitate tissue invasion. As a result of these traits, cancer cells are have a number of 
different biological components and cellular mechanisms as compared to normal cells and therefore, 
any proposed studies for investigation of a potential therapeutic cancer agent needs to be done on 
cancer cells. A range of different cell-lines, representing a number of different cancer types, are 
commercially available or have been cultured from biopsies for in vitro testing purposes. 
While in vitro studies are important for the initial investigations into a potential therapeutic agent, in 
vivo studies are essential for the development of a bioconjugate that passively targets tumours through 
the EPR effect (Section 1.2.2), as only in a living system with a growing tumour is it possible to 
evaluate the targeting potential of the compound. In order to exploit the ERP effect, the size of the 
compound is important and this is controlled by attachment of a macromolecule. One of the most 
favourable proteins to be used for the EPR effect and passive targeting is human serum albumin 
(HSA) (Section 1.4.3.2) since it is a very abundant plasma protein with favourable biological 
properties and is one of the very few plasma proteins to contain a free thiol group that can react 
specifically with maleimide groups. The challenge with a HSA-bioconjugate that is synthesised ex 
vivo is that it requires very careful purification and characterisation as commercially available HSA 
could potentially be immunogenic.266 A more recent approach is therefore, the in vivo coupling of a 




thiol binding maleimide pro-conjugate to in vivo circulating HSA.266 The utilisation of this approach 
requires that the before being administered to a live subject, the synthesised maleimide compound 
first has to be tested with HSA in a vial of blood plasma and analysed for binding by HPLC. The 
administration then of the pro-conjugate which binds HSA, to mice containing tumour xenografts, 
will allow for evaluation of the targeting and therapeutic properties of the bioconjugate by monitoring 
the size and growth of the tumour. 
The synthesis of a glucose-cyclam-albumin bioconjugate for radiotherapy will require a number of 
biological tests to prove the hypothesis of the project and so the aim of this present study was: firstly, 
to determine whether or not a glucose-cyclam compound will be recognised and taken up 
preferentially by cancer cells and whether or not this up-take is through the glucose transporters; and 
secondly, to determine if a glucose-cyclam-maleimide pro-conjugate is able to bind to the free thiol 
group in HSA to form a bioconjugate. 
5.2 Results and Discussion 
5.2.1 Uptake of fluorescently tagged glucose 
 
The aim of this study was to use a model glucose compound to determine, through fluorescence 
microscopy, whether or not the compound would be taken up by the cells and whether or not this 
uptake, if any, was through the glucose transporter, GLUT 1. Therefore, the fluorescently labelled 
dansyl-glucose 65 was synthesised from 27 and dansyl chloride as shown in Scheme 5.1.  
In South Africa, oesophageal cancer is a very prominent type of cancer, especially amongst the black 
African community. Therefore an oesophageal squamous cell carcinoma cell line (WHCO1) was used 
in this study. The WHCO1 cells were initially cultured using Dulbecco’s Modified Eagle’s Medium 
(DMEM)267 to which fetal calf serum (FCS) and a mixture of penicillin-streptomycin was added to 
provide all the essential components for cell growth and to prevent contamination of the cells by 
bacteria.  However, this DMEM contains a large amount of glucose which would interfere with the 
cells uptake of the model glucose compound 65 and so for the proposed studies of determining the 
assimilation of 65 into the cells a glucose-free DMEM was used to replace the normal media. The 
method by which the compound is then taken up would be determined by the addition of extra glucose 
into the media to provide competition for binding to the GLUTs. If compound 65 is recognised by the 
glucose transporter, the preferential uptake of glucose over the compound would decrease the 
fluorescence within the cell.  
 






Scheme 5.1: Synthesis of fluorescent dansyl-labelled glucose 65 as a model compound for cell uptake studies, i) 
dansyl-Cl, acetone: 0.25 M NaHCO3 (aq) (1:1), 1.5 hrs, RT (82 %). (Synthesis of 27 is described in Section 2.3)  
5.2.1.1 Determination of a suitable concentration of glucose 73 for uptake studies 
  
The initial focus of the study, before investigating the mechanism of uptake, was to determine a 
suitable concentration of 65 for investigating cellular uptake as measured by the amount of 
fluorescence visible inside the cell. To achieve this, 65 was dissolved in DMSO and three dilutions of 
the compound (25, 50 and 130 uM) to 0.1% DMSO was made with glucose-free DMEM. At the lower 
concentration of 25 uM, the solution seemed homogenous however, at higher concentrations, upon 
addition of 65 to the DMEM, a white precipitate formed which was only partially soluble in the 
media. The insolubility of the compound at higher concentrations was most likely due to the dansyl 
group altering the polarity and making 65 a good surfactant with a polar glucose head and non-polar 
dansyl tail to form micelles. These DMEM/compound solutions (25, 50 or 130 uM with precipitate) 
were then added to the cells in the 24 well plates and observed by fluorescence microscopy after 1 hr 
of incubation. Phase contrast and fluorescent images of the WHCO-1 cells incubated with 
concentrations of 25, 50 or 130 uM of 65 taken through a blue filter are shown in Figure 5.3 while 
Figure 5.4 indicates the control cells under the same conditions but lacking 65. At 50 and 130 uM, the 
insoluble 65 formed fluorescent spots that looked like micelles with a fluorescent hydrophobic centre 
under the microscope. It was assumed that the insoluble particles would influence the compound 
uptake but at all three concentrations after 1hr of incubation, fluorescence was visible inside the cells 
indicating there was still soluble compound within the media and that this compound was rapidly 
assimilated. Analysis of the 25 uM fluorescent images also indicated that 65 seemed to be localised in 
the cytoplasm. Further observation of the cells after the 1 hr incubation period, indicated that both the 
cells in the control and experiment wells were getting stressed and a number of cells in these wells 
had died. After 2 hours incubation, most of the cells were dead and were removed when the media in 
each well was washed out. The proposed explanation for this was that the media the cells were 
growing in contained no glucose or FCS and while the compound contained a glucose moiety, this  






Figure 5.3: The phase contrast (PH) and fluorescent images (NU) (10x magnification) of WHCO1 cells 
incubated with different concentrations of 65 for 1 hr at 37˚C / 5% CO2: A) PH and B) NU images of cell with 
25 uM 68, C) PH and D) NU images of cells with 50 uM 68, E) PH and F) NU images of cells with 130 uM 68.  




could not be further metabolised by the cells to provide the energy required for growth and the cells 
were in effect being starved. It was therefore proposed that in subsequent experiments a small amount 
of FCS be added to the media in order to provide the cells with the other nutrients required for a more 
sustainable growth whilst minimising the exposure to glucose. The conclusions drawn from the first 
investigation with 65 were that a lower concentration (< 25 uM) of the compound was better for 
solubility purposes and that the compound was internalised very rapidly and so shorter monitoring 




Figure 5.4: Phase contrast image (10 x magnification) of control WHCO1 cells grown in glucose-free, serum-
free DMEM for 1 hr at 37˚C / 5% CO2 
5.2.1.2 Competitive binding studies with exogenous glucose to investigate mechanism of 
glucose 73 uptake 
 
The subsequent study for investigation into the uptake of glucose 65 was focused on determining the 
mechanism of its uptake. The conclusions drawn from the previous study resulted in a method 
employing a concentration of 10 uM of Compound 65 in DMEM and a shorter, 30 min,cell-compound 
incubation time. The 10 uM solution of 65 was added to each well and at this low concentration no 
precipitates or solubility problems in the media was encountered. Glucose-free media with the 
addition of 1% FCS was again used in order to provide the other essential cellular requirements and 
prevent the cells from getting too stressed in the low glucose environment. A dilution series of 
exogenous glucose (0, 10, 50, 100, 500, 1000, 2000 uM) was prepared in DMEM and these were then 
added to the cells along with the 10 uM solution of 65. The cells were observed by fluorescence 
microscopy after a 30 min incubation period. All the fluorescent images were taken with a 20 ms 
exposure time in order to compare the amount of fluorescence between images and relate that to the 
amount of compound taken up by the cells. The images of the control cells, which are shown in 
Figure 5.5, indicate that the cells were relatively more stable with the 1% FCS added and that no 
fluorescence was visible anywhere as expected. The WHCO-1 cells incubated with 65 and all the 




concentrations of exogenous glucose were analysed under the fluorescent microscope but only the 
images of cells with 0, 100 and 2000 uM extra glucose are shown in Figure 5.6 in order to provide 




Figure 5.5: Phase contrast and fluorescent images of control WHCO1 cells grown in glucose-free DMEM (1% 
FCS) for 1 hr at 37˚C / 5% CO2. No fluorescence is visible in NU channel as expected for the control. 
 
Images of the cells from the wells containing glucose 65 showed that the cells were slightly stressed 
but still surviving. Since it was noted, from previous experiments, that the cells rapidly internalise 65, 
it was expected that there would be a large amount of fluorescence visible inside the cells that were 
treated with 65 only and no added glucose. It was also expected that, if internalisation is through 
GLUT 1, the addition of increasing amounts of exogenous glucose would result in a visible decrease 
in the fluorescence of the cells due to less of 65 being taken up.  
The predicted result of a large amount of fluorescence visible in the cells treated with no extra 
glucose, even after the shorter period of 30 min, was seen in Figure 5.6 B. Analysis of the cells 
incubated with 10, 50, 100, 500, 1000, 2000 uM of extra glucose however, also showed fluorescence 
inside all cells and when comparing these images in sequence there seemed to be no notable 
difference in intensity for any of the concentrations. A closer comparison though of the NU images 
from 0, 100 and 2000 uM glucose with a 20 ms exposure (Figure 5.6 B/D/F) seemed to indicate that at 
2000 uM glucose the amount of fluorescence inside the cells was less while the background 
fluorescence seemed slightly more but this could not be determined quantitatively. The results of 
these experiments are not conclusive as to the exact uptake mechanism of 65 and while it is possible 
that some compound is being internalised through GLUTs, the fluorescence inside the cells, even after 
a short incubation time, indicate that it is also likely that some of 65 is being taken up non-specifically 
by diffusion across the cell membrane.  
Therefore, in the development of the desired radiopharmaceutical, further studies would need to be 
done using an alternative method to fluorescence microscopy to determine the exact mechanism by 
which a synthesised glucose targeting compound would be internalised. 






Figure 5.6: Phase contrast (PH) and fluorescent (NU) images (10x magnification and 20ms exposure time) of 
WHCO1 cells incubated for 30 min at 37˚C / 5% CO2 with 10 uM of 65 and different concentrations of 
exogenous glucose: A and B) no glucose, C and D) 100 uM glucose, E and F) 2000 uM glucose.  




5.2.2 Studies towards attachment of a pro-conjugate to albumin (HSA) 
 
The completion of the desired macromolecular bioconjugate requires that the synthesised glucose-
cyclam-maleimide pro-conjugate be attached to HSA through reaction of the free thiol group in HSA 
with the pro-conjugate maleimide moiety and so this method was investigated. HSA is costly and 
difficult to acquire and so the cheaper and more easily available bovine serum albumin (BSA), which 
also contains a free cysteine thiol group, was used for method development. Synthesised glucose-
maleimide 31 (synthesis described in Section 2.3.2.3), similar to 65, was used as a model compound 




Figure 5.7: The model glucose-maleimide compound synthesised in Section 2.3.2 for reaction with BSA  
 
HPLC analysis on a Agilent Zorbax Eclipse Plus C-18 (4.6 x 150 mm 5 um) column was used to 
determine binding between the BSA and 31. For reference purposes however, the retention time of the 
two components separately in phosphate buffer saline (PBS) at a physiological pH of 7.3 first had to 
be determined. The wavelength of the lamp used was 230 nm as this was found to be the best for 
analysis of both 31 and BSA. The HPLC trace of 31 (Figure 5.8 A) indicates a retention time for 31 of 
16.9 min with an almost negligible peak at 15.7 min amongst other impurities but after incubation of 
the solution for two hours in PBS at 37˚C, HPLC analysis showed that the peak at 15.75 min had 
increased to an approximately 50:50 ratio (Figure 5.8 B). After 24 hrs under the same conditions, the 
peak for 31 had almost disappeared and the major peak was at 15.8 min (Figure 5.8 C). The instability 
of 31 under prolonged incubation in PBS, as shown by the increase of the peak at 15.7 min, was 
proposed to be due to the maleimide moiety that is known to be slightly unstable in aqueous 
conditions as hydrolysis occurs to form a maleamic acid. The new peak present was therefore 
proposed to be the hydrolysed maleamic acid form of 31.  
The HPLC trace for the BSA control in PBS at 37˚C is shown in Figure 5.9. BSA elutes as 3 peaks 
with retention times around 22.1 min, 22.6 min and 23.0 min. Once the reference retention times for 
31 and BSA were established, these two components were incubated together in PBS at 37˚C for 5 
min after which HPLC analysis was performed (Figure 5.10). The HPLC trace indicated that there 
was a negligible amount of 31 remaining in solution (peaks 15.7 and 16.9 min) but a large signal 
around 22 min which corresponded to the BSA. However, this signal now contained not only three 
BSA peaks (retention times = 22.1, 22.6 and 23.1 min) but a fourth peak with a retention time of 22.7 
min. It was therefore proposed that this fourth peak could be the 31-HSA bioconjugate. 







Figure 5.8: HPLC analysis of 31 (A) incubated in PBS at 37˚C after B) 2 hrs, C) 24 hrs (wavelength = 230 nm; 
Agilent Zorbax Eclipse Plus C-18 (4.6 x 150 mm 5 um) column run with a gradient elution of A: CH3CN (0.1 % 
TFA) and B: H2O (0.1 % TFA), 0 - 60 % A over 30 min) 




This result seems to indicate that the maleimide moiety of 31 reacts quickly and efficiently with BSA 
under physiological conditions but the HPLC analysis is not conclusive and binding between 31 and 
BSA needs to be confirmed by a high molecular weight mass spectrum of the sample. Other future 
work to characterise any compound-BSA bioconjugate includes analysis of the reaction mixture with 
gel-electrophoresis to separate out the components according to their masses and then purification of 




Figure 5.9: HPLC analysis of BSA in PBS at 37˚C (wavelength = 230 nm; Agilent Zorbax Eclipse Plus C-18 
(4.6 x 150 mm 5 um) column run with a gradient elution of A: CH3CN (0.1 % TFA) and B: H2O (0.1 % TFA), 0 




Figure 5.10: HPLC analysis of BSA reacted with 31 in PBS at 37˚C after 5 min (wavelength = 230 nm; Agilent 
Zorbax Eclipse Plus C-18 (4.6 x 150 mm 5 um) column run with a gradient elution of A: CH3CN (0.1 % TFA) 
and B: H2O (0.1 % TFA), 0 - 60 % A over 30 min) 




5.3 Summary of biological studies 
 
The biological studies aimed at developing a base understanding, using model compounds, of how a 
glucose targeting compound would be taken up by cells and how a maleimide pro-conjugate would 
bind to albumin. It was found that the selected model fluorescent glucose compound (65) was not 
suitable for these studies as this compound present solubility challenges and exhibited non-specific 
accumulation inside the cells. To better understand the proposed glucose targeting mechanism, a more 
suitable model compound needs to be utilised. The binding studies of a model maleimide compound 
to albumin showed more promising results as HPLC analysis of the reaction between 31 and BSA 
seemed to indicate the formation of a 31-BSA compound but this result would need to be confirmed. 
However, once this method for binding has been fully developed, it can be applied to investigating the 
reaction of the synthesised glucose-cyclam-maleimide pro-conjugate with BSA and then HSA to form 
the desired macromolecular bioconjugate which can be tested in vivo. 
  




CHAPTER 6 – CONCLUSION 
 
The aim of this project was to develop a novel radiopharmaceutical that could be used as a targeted 
cancer therapy. The three aspects of the project that were addressed were: i) the synthesis of a novel 
pro-conjugate comprising a glucose and maleimide functionalised linker attached to a central cyclam 
unit for complexation of the auger emitting radioisotope 103Pd, ii) the formation of a bioconjugate by 
attachment of the synthesised pro-conjugate to human serum albumin, and iii) performing in vitro and 
in vivo biological studies with this bioconjugate to determine its potential for cancer radiotherapy. 
While the overall aim of the project was unfortunately not absolutely realised, the study has given 
crucial insights towards achieving a new radiopharmaceutical as well as successfully realising the 
synthesis of a glucose-cyclam-amine ligand (51) (Figure 6.1) that was one step from realisation of a 
pro-conjugate compound. The work also studied several model systems, which uncovered a 
significant amount of highly useful knowledge on how to achieve the radiolabelling and albumin 




Figure 6.1: The synthesised glucose-cyclam-amine compound (51)  
 
Notably, methodology for the glucose targeting unit was developed via glycosylation of a glycosyl-
iodide followed by functional group conversion to form either a glycosidic alkyl bromide for 
alkylation (SN2) or a glycosidic acid chloride for acylation (SNAc). The maleimide linker for cyclam 
was envisaged to be attached through maleimide directly, which was found to be susceptible to 
nucleophilic attack and so an electrophilic carbamate was synthesised for late stage conversion of the 
amine to a maleimide. 
Following the synthesis of the linker components of the pro-conjugate, the first strategy for 
functionalising cyclam was based on its SN2 alkylation with a tert-butyl bromoacetate electrophile but 
this proved challenging owing to the formation of mono, di and tri-substituted cyclam compounds. 
The strategy that proved successful for attaching the synthesised groups to cyclam was to use a bis-
aminal cyclam as the starting point. A glucose-cyclam-amine ligand was then synthesised by 
nucleophilic substitution to form an amine bond followed by acylation with the glycoside acid 




chloride to form an amide bond rather than to couple via alkylation. All the protecting groups as well 
as the bis-aminal bridge were then removed by sequential deprotection steps using standard 
conditions. The synthesis of a pro-conjugate in the simplest manner prompted leaving the remaining 
two cyclam amines unfunctionalised rather than attaching the original proposed protecting groups. 
Methods in the literature on maleimide synthesis were used to attempt to incorporate maleimide into 
the pro-conjugate, which unfortunately failed.  
In the absence of the glucose-cyclam-maleimide pro-conjugate, cyclam 51, along with the synthesised 
glucose-cyclam compounds 55 and 57 (Figure 6.2), were then used as model compounds to 
investigate radiolabelling of a cyclam conjugate. It was found that these cyclam compounds did not 
complex with 99mTc under the acidic conditions required for reduction of the isotope with SnCl2. 
Therefore, in the future a more suitable reductive method needs to be devised to accomplish 99mTc 
labelling. With regards to the complexation of cyclam 55 and 57 with palladium, it was found that 
while the amide bond of 55 hydrolysed, 57 complexed 103Pd with 60 % labelling efficiency. These 
observations from the radiolabelling led to the conclusion that, while alkylation of cyclam takes 
longer than acylation, the amine bond for functionalised cyclam is more favourable than an amide for 
metal chelation. The presence of the three carboxyl groups in 57 was also proposed to assist in metal 
complex stabilisation. Therefore, rather than using 51 in the synthesis of the desired pro-conjugate, it 
might be necessary to adjust the cyclam unit to have only amine connection and to contain two 




Figure 6.2: Synthesised glucose-cyclam compounds 55 and 57 that were used as model compounds for 
radiolabelling studies.  
 
If the synthesis of the pro-conjugate can be realised, the next objective of the project would be to 
attach it to HSA by Michael addition of the free thiol group in the protein to the maleimide moiety of 
the pro-conjugate to form a bioconjugate. Towards this end, the model glucose-maleimide 31 (Figure 
6.3) was synthesised and reacted with BSA to investigate the conditions required for this addition to 




occur. Using HPLC analysis, preliminary results indicated that this binding occurs rapidly under 
physiological conditions but further investigation into this reaction would be required before the 
method can be applied to the binding of any pro-conjugate to HSA. The use of nanoparticles was also 
investigated as an alternative carrier to albumin. A method for palladium and magnetic nanoparticle 
synthesis with a glucose functionalised surface was developed using thioglucose. This method was 
then used in an attempt to functionalise the nanoparticles with cyclam 51 and other synthesised 
glucose compounds but without success. Therefore, the use of nanoparticles as a potential alternative 




Figure 6.3: The synthesised glucose-maleimide (31) and glucose-dansyl (65) model compounds that were used 
to investigate maleimide binding to albumin and the uptake of glucose into cancer cells, respectively. 
 
The use of a glucose targeted bioconjugate, such as the new proposed glucose-cyclam-albumin 
compound, required further investigation into its potential uptake into cancer cells through the glucose 
moiety via the glucose transporters. In order to investigate this, a fluorescently tagged glucose-dansyl 
compound (65) (Figure 6.3) was synthesised and incubated with WHCO1 oesophageal cancer cells 
with different concentrations of glucose added. This study indicated that the dansyl group was 
unsuitable as a fluorescent tag as it influenced the solubility of the compound. However, it could still 
be seen that some of this small glucose compound was taken up non-specifically into the cell. Owing 
to the presence of fluorescence inside all the cells regardless of the amount of glucose added, no 
conclusions could be drawn as to the possible mechanism of accumulation of a glucose-targeted 
bioconjugate inside the cell. In order to further investigate this uptake mechanism, a more suitable 
method for determining the presence of the compound within the cell needs to be used. 
In conclusion, significant progress was made towards various facets of developing a radiolabelled 
macromolecular bioconjugate crucial for realising improved targeted cancer radiotherapy.  




CHAPTER 7: EXPERIMENTAL 
7.1: General 
All commercial chemical reagents were purchased from Sigma Aldrich Chemical Co. Ltd or Merck 
(South Africa). All solvents freshly were distilled and dried by appropriate methods under argon – 
THF was dried and distilled over sodium wire and benzophenone, MeCN from calcium hydride and 
DCM from phosphorous pentoxide – except for analytical grade ethanol, anhydrous methanol and 
acetone. All organic solutions were dried over anhydrous magnesium sulfate. Thin layer 
chromatography was carried out on Silica-gel 60 F254 plates (Art. 5554; Merck) and all TLC plates 
were visualized by ultraviolet light or by staining with 2.5 % anisaldehyde (H2SO4 and EtOH)(1:1 
v/v) or acidic ethanolic solution of ninhydrin. Column chromatography was done using Silica-gel 60 
from (Merck 7734, 0.040-0.063 mm). Melting points were determined on a Reichert-Jung Thermovar 
hot-stage microscope. Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR 
Spectrometer using NaCl disks for oils or KBr/compound discs for solids. Optical rotation ([]D) was 
measured on a Perkin Elmer 141 polarimeter at 20˚C (c = g/100 mL). High-resolution mass spectra 
were obtained on a Agilent 6530 Accurate-Mass Q-TOF LC/MS with electrospray ionization (ESI) 
using an Agilent 1290 HPLC fitted with Agilent Eclipse Plus C18 RRHD 1.8 micron 2.1 x 50 mm 
column. ¹H NMR and ¹³C NMR were recorded on a Varian Mercury 300 MHz (75.5 MHz for 13C), a 
Varian Unity (400 MHz for 13C) or a Bruker Advance III with Ultra Shield 400 Plus magnet. All 
spectra were recorded in deuterated chloroform, deuterated methanol or deuterium oxide and all 
chemical shifts were recorded in ppm with reference to the resonance of the residual solvent used as 
internal standard for 1H NMR and deuterated solvent peaks as reference for 13C NMR: CDCl3 ( 7.26 
ppm 1H NMR,  77.00 13C NMR), D2O ( 4.81 ppm 1H NMR) and CD3OD ( 3.31 ppm 1H NMR,  
49.15 13C NMR). The numbering scheme for each compound is for assignment purposes only and is 
not necessarily consistent with IUPAC naming convention. Selected ¹H and 13C NMR spectra are 
attached in the appendix for reference purposes.  





2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl Benzoate (1) 
 
Benzoyl chloride (4.68 g, 33.3 mmol) was added dropwise to a solution of α-D-glucose (1.0 g, 5.6 
mmol) in pyridine (30 mL) at 0˚C. After 10 min at 0˚C, the solution was stirred for 2 hrs at room 
temperature. The reaction was quenched by addition of cold water (50 mL) and the product extracted 
with EtOAc (3 x 50 ml). The combined organic layers were washed with 1N HCl (3 x 50 mL) 
followed by brine (50 mL) and then dried, filtered and concentrated. The crude product was purified 
by recrystallisation with hot Hexane: EtOAc 2:1 to give the title compound as a white solid (3.48 g, 
89%). Rf = 0.28 (Hex: EtOAc 8:2). The 1H and 13C NMR spectra agreed with those reported in the 
literature.268  
H (CDCl3, 400 MHz): 8.16 (2H, d, J = 8.0 Hz, H-Ar), 8.02 (2H, d, J = 8.0 Hz, H-Ar), 7.94 (2H, d, J = 
8.0 Hz, H-Ar), 7.88 (4H, d, J = 8.0 Hz, H-Ar), 7.66 (1H, t, J = 8.0 Hz, H-Ar), 7.53-7.28 (14H, m, H-
Ar), 6.85 (1H, d, J = 4.0 Hz, H-1), 6.32 (1H, t, J = 8.0 Hz, H-3), 5.85 (1H, t, J = 8.0 Hz, H-4), 5.68 
(1H, dd, J = 4.0, 8.0 Hz, H-2), 4.62 (2H, m, H-6a/H-5), 4.59 (1H, dd, J = 4.0 Hz, J = 12.0 Hz, H-6b)  
C (CDCl3, 100 MHz): 166.1, 165.9, 165.3, 165.1, 164.4 (C=O), [133.9, 133.5, 133.4, 133.3, 133.1 
130.0, 129.9 (x2), 129.8 (x2), 129.6, 129.1, 128.9, 128.8, 128.6, 128.4 (x2), ArC)], 90.0 (C-1), 76.6 




Hexamethyldisilane (0.531 g, 3.63 mmol) in CH2Cl2 (10 mL) was added to a solution of α-D-glucose-
pentabenzoate (1) (4.10 g, 5.85 mmol) in CH2Cl2 (60 mL). To this solution was added ZnI2 (0.467 g, 
1.46 mmol), followed by I2 (0.921 g, 3.63 mmol) and stirred for 16 hrs. The reaction was quenched by 
addition of CH2Cl2 (40 mL) and an aqueous solution (120 mL) of NaHCO3 (1.68 g) and Na2S2O3 
(1.12 g) and then stirring for 10 min until the pinkish colour and milky solution had cleared. The 
organic phase was separated and washed with brine (50 mL) and the combined aqueous phases 
extracted with CH2Cl2 (2 x 50 mL). The combined organic extracts were dried over MgSO4, filtered 




and concentrated in vacuo to yield a crude oil of the title compound (1a) which was used directly in 
the next reaction.  
10-Bromodecan-1-ol (2) 
 
1, 10-decanediol (5.00 g, 28.7 mmol) was dissolved in toluene (60 mL) and reacted with aq. HBr (48 
% w.w)(4.9 mL, 29.1 mmol). The mixture was refluxed for 1 day with monitoring of the reaction by 
TLC. Another 0.2 eq of 48 % HBr (1.00 mL, 5.9 mmol) was added and the mixture was again 
refluxed for 24 hrs. The solution was cooled to room temperature and the toluene solvent removed in 
vacuo. The residue was dissolved in CH2Cl2 and washed with NaHCO3 (sat aq) (60 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 70 mL). The combined organic layers were dried, filtered and 
concentrated. The crude product was purified by column chromatography (Hexane: EtOAc 9:1) to 
give the mono-brominated product 2 as a pale-yellow oil (5.96 g, 86%). The 1H and 13C NMR spectra 
agreed with those reported in the literature.269 Rf = 0.42 (Hex: EtOAc 8:2)  
H (CDCl3, 300 MHz): 3.64 (2H, t, J = 6.6 Hz, H-1), 3.41 (2H, t, J = 6.8 Hz, H-10), 1.86 (2H, qn, J = 
6.8 Hz, H-2), 1.57 (2H, qn, J = 6.8 Hz, H-9), 1.44-1.30 (12H, m, Alk-CH2); C (CDCl3, 100 MHz): 
63.0 (C-1), 34.0 (C-10), 32.8 (C-2), 32.7 (C-9), 29.4, 29.3, 29.3, 28.7, 28.1, 25.7 
10-bromodecyl-tetra-O-benzoyl-β-D-glucopyranoside (3) 
 
Previously prepared iodide 1a (1.81 g, 2.57 mmol) was dissolved in CH2Cl2 (40 mL) under N2 (g) and 
4Ǻ Molecular Sieves (4.00 g) along with ZnCl2 (0.525 g, 3.85 mmol), and 10-bromodecanol (2) 
(0.914 g, 3.85 mmol) in CH2Cl2 (5 mL) was added to the solution. The reaction was stirred for 17 hrs 
after which the colour of the solution had changed to a light pink. EtOAc (60 mL) was added and the 
reaction was quenched by addition of an aqueous solution (80 mL) of NaHCO3(s) (1.80 g) and 
Na2S2O5(s) (2.40 g). The colour changed from a yellow-orange to a milky white after stirring for 10 
min. The solution was filtered through a Celite pad and the phases separated. The organic phase was 
washed with brine and the combined aqueous phases extracted with EtOAc (2 x 30 mL). The 
combined organic layers were dried, filtered and concentrated to yield a crude oil (2.99 g), which was 
purified by column chromatography (Hexane: EtOAc  8:2). The title product 3 was obtained as a clear 
oil (1.23 g, 59% over 2 steps). Rf = 0.48 (Hex: EtOAc 8:2). The 1H and 13C NMR spectra agreed with 
those obtained in the literature.270  




[α]20,D = +16.6 (c = 1.0 in CH2Cl2); H (CDCl3, 400 MHz): 8.0-7.80 (8H, m, ArH), 7.53-7.24 (12H, m, 
ArH), 5.89 (1H, t, J = 9.6 Hz, H-3’), 5.65 (1H, t, J = 9.6 Hz, H-4’), 5.49 (1H, dd, J = 7.8, 9.7 Hz, H-
2’), 4.81 (1H, d, J = 7.8 Hz, H-1’), 4.61 (1H, dd, J = 3.3, 12.0 Hz, H-6a’), 4.49 (1H, dd, J = 5.2, 12.0 
Hz, H-6b’), 4.13 (1H, m, H-5’), 3.89 (1H, dt, J = 6.3, 9.6 Hz, H-1a), 3.52 (1H, dt, J = 6.7, 9.6 Hz, H-
1b), 3.37 (2H, t, J = 6.6 Hz, H-10), 1.80 (2H, qn, J = 9.6 Hz, H-9), 1.55-1.45 (2H, m, H-2), 1.41-1.30 
(2H, m, Alk-H), 1.19-1.05 (10H, m, Alk-H); C (CDCl3, 100 MHz): [166.2, 165.8, 165.2, 165.1 
(C=O)], [133.4, 133.2, 133.1, 133.0, 129.8 (x2), 129.7 (x2), 129.6, 129.5, 128.9, 128.8, 128.4, 128.3, 
128.3, 128.2 (ArC)], 101.3 (C-1’), 73.0 (C-3’), 72.2 (C-5’), 72.0 (C-2’), 70.3 (C-1), 69.9 (C-4’), 63.3 
(C-6’), 33.9 (C-10), 32.8, 29.4, 29.3, 29.2, 29.1, 28.7, 28.1, 25.7 (C-Alk). 
 
Bromide 3 was converted to iodide 3a by reaction with sodium iodide. Bromide 3 (0.050 g, 0.06 
mmol) was dissolved in acetone (5 mL) and stirred overnight at room temperature with NaI (0.027 g, 
0.18 mmol). The solvent was removed in vacuo and the crude product redissolved in CH2Cl2 (5 mL). 
The white salt product was filtered off, the filtrate concentrated under vacuum and the product 
purified with column chromatography (Hexane: EtOAc 6:4) to yield the compound 3a as an oil 
(0.035, 66%). H (CDCl3, 400 MHz): 8.0-7.80 (8H, m, ArH), 7.53-7.24 (12H, m, ArH), 5.89 (1H, t, J 
= 9.6 Hz, H-3’), 5.65 (1H, t, J = 9.6 Hz, H-4’), 5.49 (1H, dd, J = 7.8, 9.7 Hz, H-2’), 4.81 (1H, d, J = 
7.8 Hz, H-1’), 4.61 (1H, dd, J = 3.3, 12.0 Hz, H-6a’), 4.49 (1H, dd, J = 5.2, 12.0 Hz, H-6b’), 4.13 
(1H, m, H-5’), 3.89 (1H, dt, J = 6.3, 9.6 Hz, H-1a), 3.52 (1H, dt, J = 6.7, 9.6 Hz, H-1b), 3.10 (2H, t, J 
= 6.6 Hz, H-10), 1.80 (2H, qn, J = 9.6 Hz, H-9), 1.55-1.45 (2H, m, H-2), 1.41-1.30 (2H, m, Alk-H), 




Imidazole (3.50 g, 51.7 mmol), followed by TBDPSCl (8.70 g, 31.5 mmol) was added slowly to a 
solution of 1,10-decanediol (5.00 g, 28.7 mmol) in dry THF (60 mL) under N2(g) and left stirring at 
room temperature for 24 hrs. The reaction was quenched by evaporation of THF in vacuo followed by 
addition of H2O (60 mL) and CH2Cl2 (60 mL). The organic phase was separated and extracted with 
water (2 x 50 mL) and washed with brine (50 mL). The organic phase was dried, filtered and 
concentrated. The crude product was columned [Hexane: EtOAc (9:1)] and pure alcohol 4 obtained as 
an oil (6.59 g, 56%). Rf = 0.42 (Hexane: EtOAc 8:2). The 1H and 13C NMR spectra agreed with those 
reported in the literature.271 




H (CDCl3, 400 MHz): 7.70-7.65 (4H, m, Ar), 7.45- 7.35 (6H, m, Ar), 3.63 (2H, t, J = 6.0 Hz, H-1), 
3.61 (2H, t, J = 6.0 Hz, H-10), 1.70-1.60 (4H, m, H-2; H-9), 1.35-1.45 (12H, m), 1.09 (9H, s, H-t-Bu)  
C (CDCl3, 100 MHz): [135.6, 134.5, 129.4, 127.5 (Ar-C)], 64.0 (C-10), 63.0 (C-1), 33.0, 32.8, 29.5, 




Alcohol 4 (0.50 g, 1.21 mmol) was dissolved in CH2Cl2 (30 mL) and pyridinium chlorochromate 
(PCC) (0.522 g, 2.42 mmol) was added to the solution. The suspension was stirred for 2 h at room 
temperature. A large amount of starting material remained as indicated by TLC, and so additional 
PCC (0.130 g, 0.61 mmol) was added and the reaction stirred for another hour. No significant change 
in conversion of the starting material was seen and so diethyl ether (20 mL) was added to the solution 
to precipitate the chromium salts. The solution was then filtered through a pad of silica, which was 
washed with ether (3 x 30 mL). The solvent was evaporated in vacuo to yield a crude oil which was 
purified using column chromatography (Hexane: Ethyl acetate 7:3) to obtain unreacted alcohol 4 
(0.364 g) and the product aldehyde 5 (0.135 g, 27 %), Rf = 0.66 (Hex: EtOAc 8:2). The 1H and 13C 
NMR spectra agreed with those reported in the literature.272  
H (CDCl3, 400 MHz): 9.76 (1H, t, J = 2.5 Hz, H-1), 7.68- 7.65 (4H, m, ArH), 7.45-7.34 (6H, m, 
ArH), 3.66 (2H, t, J = 8.6 Hz H-10), 2.41 (2H, dt, J = 9.8 Hz, 2.5 Hz, H-2), 1.63-1.54 (4H, m, H-3/H-
9), 1.30-1.20 (10H, m), 1.04 (9H, s, H-tBu); C (CDCl3, 100 MHz): 202.8 (C-1), [135.6 (x2), 134.2, 
129.5, 127.6 (x2) (ArC)], 64.0 (C-10), 43.9 (C-2), 32.6, 29.7, 29.4, 29.3, 29.2, 26.9, 25.7, 22.1, 19.2  
 
10-(t-butyldiphenylsilyloxy)decanoic acid (6) 
 
An aqueous solution (0.4 mL) of NaClO2 (0.043 g, 0.373 mmol) and NaH2PO4 (0.045 g, 0.373 mmol) 
was added to a solution of aldehyde 5 (0.118 g, 0.287 mmol) and 2-methyl-2-butene (0.135 g, 1.92 
mmol) in t-butanol (1 mL) and stirred for 16 hrs. The solvent was evaporated to yield a crude oil 
which was redissolved in CH2Cl2 (5 mL) and washed with H2O (10 mL). The aqueous phase was 




extracted with CH2Cl2 (4 x 5 mL) and the combined organic phase was dried over MgSO4, filtered 
and concentrated. The crude material was purified with column chromatography (Hex:EtOAc 7:3) to 
yield the title product 6 as an oil (0.120 g, 98%)  Rf = 0.40 (Hex: EtOAc 7:3). The 1H and 13C NMR 
spectra agreed with those reported in the literature.273  
H (CDCl3, 400 MHz): 7.68- 7.66 (4H, m, ArH), 7.44-7.35 (6H, m, ArH), 3.66 (2H, t, J = 8.0 Hz, H-
10), 2.35 (2H, t, J = 8.0 Hz, H-2), 1.64 (2H, qn,  J = 8.0 Hz, H-9), 1.56 (2H, qn, J = 8.0 Hz, H-3), 
1.35-1.25 (10H, m, Alk-CH2), 1.05 (9H, s, H-tBu); C (CDCl3, 100 MHz): 179.0 (C-1), [135.6 (x2), 
134.3, 129.5, 127.6 (x2)(ArC)], 64.0 (C-10), 33.9 (C-2), 32.6, 29.4, 29.3, 29.2, 29.1, 26.9, 25.7, 24.7, 
19.2 
 
10-(tert-butyldiphenylsilyloxy)decanoyl chloride (6a) 
 
A drop of DMF was added to a solution of acid 6 (0.10 g, 0.23 mmol) in CH2Cl2 (10 mL) under N2(g). 
The flask was placed at 0˚C and oxalyl chloride (0.036 g, 0.28 mmol) was added dropwise to the 
solution. The reaction was left stirring at room temperature for 2 hrs. A small amount of solution was 
removed and quenched with methanol for TLC purposes. TLC indicated that all starting material had 
been consumed. The reaction was stopped by evaporation of the solvent under vacuum. A small 
amount of toluene was added and again evaporated and dried under vacuum to remove any remaining 
oxalyl-Cl. The crude oil product 6a was then used directly in the next reaction.  
10-(tert-butyldiphenylsilyloxy)decyl-tetra-O-benzoyl-β-D-glucopyranoside (7) 
 
Molecular sieves (7.00 g), ZnCl2 (1.43 g, 10.5 mmol) and alcohol 4 (2.17 g, 5.25 mmol) in CH2Cl2 (15 
mL) was added to freshly prepared iodide 1a (3.71 g, 5.25 mmol) in CH2Cl2 (60 mL) and the reaction 
stirred for 8 hrs. CH2Cl2 (40 mL) was added to the solution and the molecular sieves were filtered off 
through a celite pad followed by the addition of an aqueous solution (100 mL) of NaHCO3 (0.960 g) 
and Na2S2O3 (1.44 g) and stirred for 10 min. The organic layer was separated and the aq. phase 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine and aq. 




phase extracted once more with CH2Cl2 (50 mL). The organic extracts were dried over MgSO4, 
filtered and concentrated in vacuo to yield a crude oil product which was dry-loaded onto a pre-
packed column and purified using column chromatography (Hex:EtOAc 9:1, 8:2, 7:3) to yield the title 
compound 7 as an oil (3.55 g, 68%). Rf = 0.51 (Hex: EtOAc 8:2) 
[α]20,D = +11.1 (c = 1.0 in CHCl3) max/ cm-1: 1735 (C=O); H (CDCl3, 400 MHz): 8.05-7.83 (8H, m, 
ArH), 7.68 (4H, m, ArH), 7.55-7.26 (18H, m, ArH), 5.91 (1H, t, J = 9.6 Hz, H-3’), 5.68 (1H, t, J = 9.6 
Hz, H-4’), 5.53 (1H, dd, J = 7.8, 9.6 Hz, H-2’), 4.85 (1H, d, J = 7.8 Hz, H-1’), 4.65 (1H, dd, J = 3.3, 
12.0 Hz, H-6a’), 4.52 (1H, dd, J = 5.2, 12.0 Hz, H-6b’), 4.17 (1H, m, H-5’), 3.92 (1H, dt, J = 6.3, 9.6 
Hz, H-1a), 3.66 (2H, t, J = 6.6 Hz, H-10), 3.55 (1H, dt, J = 6.7, 9.6 Hz, H-1b), 1.59-1.50 (4H, m, H-
2/9), 1.29 (2H, m, H-8), 1.22- 1.00 (10H, m, AlkCH2), 1.04 (9H, s, H-2’’); C (CDCl3, 100 MHz): 
[166.1, 165.8, 165.2, 165.0 (C=O)], [135.6 (x2), 134.2 (x2), 133.4, 133.2, 133.1, 133.0, 129.8, 129.7 
(x3), 129.5 (x2), 128.9 (x2), 128.4, 128.3 (x5), 127.5 (x2) (ArC)], 101.3 (C-1’), 73.0 (C-3’), 72.2 (C-
2’), 72.0 (C-5’), 70.3 (C-1), 70.0 (C-4’), 64.0 (C-10), 63.3 (C-6’), 32.6, 29.5, 29.4, 29.4, 29.3, 29.2, 
26.9 (C-2’’), 25.8, 25.7, 19.2 (C-1’’). 
HRMS (ESI MALDI-TOF): m/z Calculated for C60H66O11Si (M+ Na)+ 1013.4272; found, 1013.4224 
10-hydroxydecyl-tetra-O-benzoyl-β-D-glucopyranoside (8) 
 
Acetic acid (0.245 g, 4.09 mmol) and N-tetra butyl ammonium flouride (6.80 mL, 1.0M in THF, 6.80 
mmol) was added to a solution of glucopyranoside 7 (3.38 g, 3.40 mmol) in THF (100 mL) and stirred 
for 36 hrs. The solvent was evaporated to yield a residue to which H2O (50 mL) was added and then 
extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (50 mL), 
dried over MgSO4, filtered and concentrated. The crude material was purified with column 
chromatography (Hex:EtOAc 2:1) to yield the title alcohol 8 as a clear oil (2.30 g, 90%).  Rf = 0.16 
(Hex: EtOAc 2:1) 
[α]20,D = +14.4 (c = 1.0 in CHCl3); max/ cm-1: 3487 (OH), 1736 (C=O), 1718 (C=O); H (CDCl3, 300 
MHz): 8.02-7.81 (8H, m, ArH), 7.56-7.25 (12H, m, ArH), 5.90 (1H, t, J = 9.6 Hz, H-3’), 5.67 (1H, t, J 
= 9.6 Hz, H-4’), 5.51 (1H, dd, J = 7.8, 9.6 Hz, H-2’), 4.83 (1H, d, J = 7.8 Hz, H-1’), 4.63 (1H, dd, J = 
3.3, 12.0 Hz, H-6a’), 4.51 (1H, dd, J = 5.2, 12.0 Hz, H-6b’), 4.18- 4.12 (1H, m, H-5’), 3.90 (1H, dt, J 
= 6.3, 9.6 Hz, H-1a), 3.62 (2H, t, J = 6.6 Hz, H-10), 3.53 (1H, dt, J = 6.7, 9.6 Hz, H-1b), 1.63-1.46 
(4H, m, AlkCH2), 1.35-1.05 (12H, m, AlkCH2); C (CDCl3, 100 MHz): [166.1, 165.8, 165.2, 165.1 
(C=O)], [133.4, 133.2, 133.1, 133.0, 129.8, 129.7, 129.6, 129.4, 128.9, 128.4, 128.3, 128.2 (ArC)], 
101.3 (C-1’), 73.0 (C-3’), 72.2 (C-2’), 72.0 (C-5’), 70.3 (C-1), 69.9 (C-4’), 63.3 (C-6’), 63.1 (C-10), 




32.8, 29.4, 29.4, 29.3, 29.3, 29.1, 25.7, 25.6; HRMS (ESI MALDI-TOF): m/z Calculated for 
C44H49O11 (M + H)+ 753.3269; found, 753.3252. 
10-(tetra-O-benzoyl-β-D-glucopyranos-1-yl)-decanal (9) 
 
Dess-Martin periodinane (0.59 g, 1.4 mmol) was added to a solution of alcohol 8 (0.870 g, 1.16 
mmol) in anh. CH2Cl2 (60 mL) and stirred for 1.5 hrs. The reaction was quenched by the addition of 
sat. aq. NaHCO3 solution (60 mL) and stirred for 15 min. The aqueous phase was extracted with 
CH2Cl2 (3 x 50 mL).  The combined organic phase was washed with brine (50 mL), dried over 
MgSO4, filtered and concentrated. The crude material was purified with column chromatography 
(Hex:EtOAc 6:4) to yield the title compound 9 as a clear oil (0.693 g, 79%), Rf = 0.75 (Hex: EtOAc 
1:1).  
[α]D = +15.5 (c = 1.0 in CHCl3); max/ cm-1: 1720 (C=O); H (CDCl3, 300 MHz): 9.75 (1H, t, J = 1.5 
Hz, H-1), 8.02-7.82 (8H, m, ArH), 7.56-7.23 (12H, m, ArH), 5.90 (1H, t, J = 7.2 Hz, H-3’), 5.67 (1H, 
t, J = 7.2 Hz, H-4’), 5.51 (1H, dd, J = 7.5, 6.0 Hz, H-2’), 4.83 (1H, d, J = 6.0 Hz, H-1’), 4.63 (1H, dd, 
J = 2.4, 9.0 Hz, H-6a’), 4.51 (1H, dd, J = 4.2, 9.0 Hz, H-6b’), 4.14 (1H, m, H-5’), 3.91 (1H, dt, J = 
4.8, 7.2 Hz, H-10a), 3.54 (1H, dt, J = 4.8, 7.2 Hz, H-10b),  2.38 (2H, dt, J = 1.2, 5.4 Hz, H-2),  1.60-
1.47 (4H, m, AlkCH2), 1.27-1.05 (10H, m, AlkCH2); C (CDCl3, 100 MHz): 202.7 (C-1), [166.1, 
165.8, 165.2, 165.0 (C=O)], [133.3, 133.1, 133.1, 133.0, 129.8 (x2), 129.7 (x2), 129.4, 128.9, 128.4 
(x2), 128.3 (x2), 128.2 (x2)(ArC)], 101.3 (C-1’), 73.0 (C-3’), 72.2 (C-2’), 72.0 (C-5’), 70.2 (C-10), 
69.9 (C-4’), 63.3 (C-6’), 43.8 (C-2), 29.3, 29.1, 29.1, 29.1, 29.0, 25.7, 22.0 (C-Alk) 
10-(tetra-O-benzoyl-β-D-glucopyranos-1-yl)decanoic acid (10) 
 
An aqueous solution (4.0 mL) of NaClO2 (0.157 g, 1.7 mmol) and NaH2PO4 (0.208 g, 1.30 mmol) 
was added to a solution of aldehyde 9 (1.00 g, 1.30 mmol) and 2-methyl-2-butene (0.626 g, 8.90 
mmol) in t-butanol (40 mL) and the solution stirred for 2.5 hrs until all the yellow colour had 
disappeared. The solvent was evaporated to yield a crude oil which was redissolved in CH2Cl2 (50 
mL) and H2O (100 mL). The solution was acidified with 1M HCl (10 mL) and the aqueous phase 
extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried over MgSO4, filtered 




and concentrated. The crude material was purified with column chromatography (Hex:EtOAc 1:1) to 
yield the title compound 10 as a clear oil (0.90 g, 89%)  Rf = 0.39 (Hex: EtOAc 1:1) 
[α]20,D = +14.8 (c = 1.0 in CHCl3); max/ cm-1: 3020 (OH), 1734 (C=O); H (CDCl3, 300 MHz): 8.03-
7.81 (8H, m, ArH), 7.53-7.26 (12H, m, ArH), 5.91 (1H, t, J = 9.6 Hz, H-3’), 5.67 (1H, t, J = 9.6 Hz, 
H-4’), 5.52 (1H, dd, J = 7.8, 9.6 Hz, H-2’), 4.83 (1H, d, J = 7.8 Hz, H-1’), 4.64 (1H, dd, J = 3.4, 12.1 
Hz, H-6a’), 4.51 (1H, dd, J = 5.2, 12.1 Hz, H-6b’), 4.19-4.13 (1H, m, H-5’), 3.91 (1H, dt, J = 6.2, 9.7 
Hz, H-10a), 3.54 (1H, dt, J = 6.2, 9.7 Hz, H-10b),  2.32 (2H, t, J = 7.4 Hz, H-2),  1.62-1.46 (4H, m, 
AlkCH2), 1.27-1.02 (10H, m, AlkCH2); C (CDCl3, 100 MHz): 179.1 (C=O), [166.1, 165.8, 165.2, 
165.0 (C=O)], [133.4, 133.2, 133.0, 129.8, 129.7, 129.6, 129.4, 128.9, 128.4, 128.3, 128.2 (ArC)], 
101.3 (C-1’), 73.0 (C-3’), 72.2 (C-2’), 72.0 (C-5’), 70.3 (C-10), 69.9 (C-4’), 63.3 (C-6’), 33.9 (C-2), 
29.3, 29.1, 29.1, 29.0, 28.9, 25.7, 24.6 (C-Alk); HRMS (ESI MALDI-TOF): m/z Calculated for 
C44H48O13 (M+ H2O)+ 784.3094; found, 784.3345. 
10-(tetra-O-benzoyl-β-D-glucopyranos-1yl)decanoyl chloride (10a) 
 
A few drops of DMF were added to a solution of decanoic acid 10 (0.900 g, 1.17 mmol) in anh. 
CH2Cl2 (30 mL) under N2(g). The flask was placed at 0˚C and oxalyl chloride (0.11 mL, 1.29 mmol) 
was added dropwise to the solution. The reaction was left stirring for 1 hr after which the solvent was 
removed under vacuum. A small amount of toluene (5 mL) was added and again evaporated in vacuo 
and the residue was then dried under a vacuum pump for 10 min to remove any remaining oxalyl-Cl. 
The crude oil product 10a was not characterised but used directly in the next acylation reaction.  
N-(10-hydroxydecyl)maleimide (11) 
 
1,10-decanediol (0.200 g, 1.15 mmol) dissolved in dry THF (2 mL) was added to a stirring solution of 
PPh3 (0.331 g, 1.26 mmol) in dry THF (5 mL) followed by the addition of maleimide (0.122 g, 1.26 
mmol) and the dropwise addition of DIAD (0.255 g, 1.26 mmol). The reaction was stirred for 48 hrs 
at 40 ˚C after which the solvent was removed in vacuo. The crude product was purified using column 
chromatography (Hex: EtOAc 1:1) to give the title compound 11 as a white solid (0.112 g, 51%). The 
1H and 13C NMR spectra agreed with those reported in the literature.274 





M.P = 223-227 ˚C; max/ cm-1: 3403 (-OH), 1688 (C=O); H (CDCl3, 300 MHz): 6.67 (2H, s, H-2’, H-
3’), 3.62 (2H, t, J = 6.5 Hz, H-10), 3.49 (2H, t, J = 7.2 Hz, H-1), 1.61 – 1.50 (4H, m, H-2/9), 1.30-
1.20 (12H, m, H-3-8); C (CDCl3, 100 MHz): 170.8 (C-1’/4’), 134.0 (C-2’/3’), 63.0 (C-10), 37.9 (C-




PPh3 (0.131 g, 0.50 mmol) and CBr4 (0.133 g, 0.39 mmol) were added to a solution of maleimide 11 
(0.090 g, 0.33 mmol) in dry CH2Cl2 (13 mL) and stirred for 16 hrs. Not all the starting alcohol had 
been consumed and so extra PPh3 (0.024 g, 0.09 mmol) and CBr4 (0.022 g, 0.07 mmol) was added and 
again left reacting for 16 hrs. The solvent was evaporated under vacuum and the triphenylphosphine 
oxide was crystallised out using CH2Cl2 and hexane and filtered off. The filtrated was concentrated 
down and purified using column chromatography (Hex: EtOAc 9:1) to give a white solid which was 
recrystallised with CH2Cl2:Hexane to give the title compound 12 (0.083 g, 75 %). 
max/ cm-1: 1693 (C=O); Mp: 43-45˚C; H (CDCl3, 300 MHz): 6.67 (2H, s, CH-2’, H-3’), 3.49 (2H, t, J 
= 7.2 Hz, H-1), 3.39 (2H, t, J = 6.5 Hz, H-10), 1.83 (2H, qn, J = 6.0 Hz, H-9), 1.56 (2H, m, H-2), 1.40 
(2H, m, H-8),  1.30-1.25 (10H, m, H-3-7); C (CDCl3, 100 MHz): 170.8 (C-1’/4’), 134.0 (C-2’/3’), 
37.9 (C-1), 34.0 (C-10), 32.8 (C-9), 29.3, 29.3, 29.0, 28.7, 28.5, 28.1, 26.7 (C-2-8); HRMS (ESI 
MALDI-TOF): m/z Calculated for C14H23BrNO2+ (M + H)+ 316.0906; found, 316.2837. 
 
N-Hexylmaleamic acid (13) 
 
Hexylamine (0.516 g, 5.1 mmol) dissolved in diethyl ether (2 mL) was slowly added to a solution of 
maleic anhydride (0.50 g, 5.1 mmol) in diethyl ether (20 mL) and stirred for 3 hr after which a white 
solid had formed in solution. The solution was put on ice to cool and the white precipitate was filtered 
off and washed with ether (2 x 15 mL) to yield the title compound 13 as a white solid (0.795 g, 78 %) 




which was greater than 95% pure by 1H NMR spectroscopy. The 1H and 13C NMR spectra agreed 
with those reported in the literature.182  
M.P: 73- 78˚C (Lit = 78 ˚C); max/ cm-1:  3234 (-NH), 1701 (C=O), 1636 (C=O); H (CDCl3, 300 
MHz): 8.43 (1H, bs, NH), 6.58 (1H, d, J = 12.9 Hz, H-2), 6.27 (1H, d, J = 12.9 Hz, H-3), 3.33 (2H, q, 
J = 6.3 Hz, H-1’), 1.63-1.53 (2H, m, H-2’), 1.35-1.26 (6H, m, H-3’/4’/5’), 0.86 (3H, t, J = 6.6 Hz, H-
6’); C (CDCl3, 100 MHz): 166.7 (C-1), 166.2 (C-4), 135.3 (C-3), 132.6 (C-2), 40.6 (C-1’), 31.3 (C-




N-Hexylmaleamic acid 13 (0.795 g, 4.0 mmol) and sodium acetate (0.167 g, 2.03 mmol) were 
suspended in acetic anhydride (2 mL) and heated at 80˚C for 1 hr, whereupon all solid dissolved. The 
solution was removed from the heat and left to cool. CH2Cl2 (10 mL) and H2O (10 mL) were added 
and the organic phase was separated out. The aq. phase was extracted with CH2Cl2 (2 x 20 mL) and 
the combined organic phases were washed with NaHCO3(aq) (20 mL) followed by drying over MgSO4, 
filtration and evaporation of the solvent in vacuo. The crude product was purified using column 
chromatography (Hex: EtOAc 9:1, 8:2) to yield the title compound 14 as a yellowish oil (0.370 g, 48 
%). The 1H and 13C NMR spectra agreed with those reported in literature.275  
max/ cm-1:  1698 (C=O); H (CDCl3, 300 MHz): 6.66 (2H, s, H-2, H-3), 3.49 (2H, t, J = 7.2 Hz, H-1’), 
1.60- 1.52 (2H, qn, J = 6.7 Hz, H-2’), 1.25-1.20 (6H, m, H-3’/4’/5’), 0.88 (3H, t, J = 6.3 Hz, H-6’); C 
(CDCl3, 100 MHz): 170.8 (C-1/4), 133.9 (C-2/3), 37.8 (C-1’), 31.2 (C-4’), 28.4 (C-2’), 26.3 (C-3’), 




Triethylamine (0.110 g, 1.1 mmol) was added to a solution of N-hexylmaleamic acid 13 (0.200 g, 1.0 
mmol) in anh. THF (15 mL) under N2 (g) and cooled to -15 ˚C. Ethyl chloroformate (0.119 g, 1.1 
mmol) was slowly added to the solution upon which a white solid formed. The reaction was stirred for 




1.5 hrs at the reduced temperature after which the salts were removed via filtration through Celite. 
The solvent was evaporated in vacuo and the crude oil redissolved in EtOAc (30 mL). The organic 
phase was then extracted with H2O (3 x 20 mL), dried, filtered and dry loaded onto silica. After 
purification with column chromatography (Hex: EtOAc 9:1, 7:3), the title product 15 was obtained as 
a pure oil (0.100, 55%). Rf = 0.70 (Hex: EtOAc 7:3) 
H (CDCl3, 300 MHz): 7.19 (1H, d, J = 5.4 Hz, H-3), 6.58 (1H, d, J = 5.4 Hz, H-2), 3.59 (2H, t, J = 
7.0 Hz, H-1’), 1.64 (2H, qn, J = 7.2 Hz, H-2’), 1.40-1.20 (6H, m, H-3’/4’/5’), 0.87 (3H, t, J = 6.9 Hz, 
H-6’); C (CDCl3, 100 MHz): 167.0 (C=O-1), 151.8 (C=O-4), 142.1 (C-2), 128.3 (C-3), 49.8 (C-1’), 




1-Chlorobenzotriazole (0.277 g, 1.80 mmol) was dissolved in CH2Cl2 (2 mL) and added to a solution 
of PPh3 (0.474 g, 1.80 mmol) in CH2Cl2 (10 mL) at 0˚C and stirred for 20 min. Maleamic acid 13 
(0.300 g, 1.50 mmol) dissolved in CH2Cl2 (3 mL) was slowly added to the solution at 0˚C. The 
reaction was stirred for 4 hrs at 0-10˚ C after which it was stirred for 16 hrs at RT. A large amount of 
Bt-derivative was still present and so the solvent was evaporated in vacuo and the crude oil 
redissolved in anh. MeCN (10 mL) and refluxed for 24 hrs. The solvent was evaporated followed by 
redissolving the crude oil in CH2Cl2 and washing with sat. NaHCO3(aq) (20 mL). The aq. phase was 
extracted with CH2Cl2 (2 x 20 mL) after which the organic extracts were combined and washed with 
brine (20 mL) followed by washing with 1M HCl (6 x 20 mL). The organic phase was dried, filtered, 
concentrated and the major product isolated from column chromatography (Hex: EtOAc 6:4) was the 
title product 16 as a yellowish oil (0.141 g, 52 %).  
max/ cm-1: 1706 (C=O); H (CDCl3, 400 MHz): 8.10 (1H, dt, J = 8.4, 0.8 Hz, H-5’’), 7.58-7.51 (2H, 
m, H-7’’, H-8’’), 7.43 (1H, ddd, J = 8.0, 6.8, 1.6 Hz, H-6’’), 5.79 (1H, dd, J = 9.6, 5.2 Hz, H-3), 3.64 
(2H, t, J = 7.6 Hz, H-1’), 3.63 (1H, dd, J = 18.0, 5.2 Hz, H-4a), 3.45 (1H, dd, J = 18.0, 9.6 Hz, H-4b), 
1.66 (2H, qn, J = 7.6 Hz, H-2’), 1.37-1.27 (6H, m, H-3’/4’/5’), 0.88 (3H, m, H-6’); C (CDCl3, 100 
MHz): 172.9 (C-2), 171.7 (C-5), 146.2 (C-4’’), 133.0 (C-9’’), 128.4 (C-7’’), 124.6 (C-6’’), 120.6 (C-
5’’), 108.9 (C-8’’), 55.5 (C-3), 39.8 (C-1’), 34.8 (C-4), 31.2 (C-3’), 27.5 (C-2’), 26.4 (C-4’), 22.4 (C-




5’), 13.9 (C-6’); HRMS (ESI MALDI-TOF): m/z Calculated for C16H20N4O2 (M + H)+ 300.1586; 
found 300.2025 
 
4-N-Maleimidobutyric acid (17) 
 
Maleic anhydride (4.00 g, 40.8 mmol) and 4-aminobutyric acid (4.20 g, 40.8 mmol) were dissolved in 
glacial acetic acid (40 mL) and stirred for 14 hrs after which a white solid had formed in solution. The 
solution was refluxed for 5 hrs after which it was removed from the heat and left to cool. Around half 
of the acetic acid was distilled off under vacuum and most of the remainder azeotroped off with 
toluene. The remaining acidic residue was dissolved in EtOAc (60 mL) and any remaining 
aminobutyric acid was extracted with H2O (3 x 50 mL). The organic layer was washed with brine (60 
ml) and then dried, flitered and concentrated to yield a crude solid which was purified using column 
chromatography (Hexane: EtOAc 8:2 – 2:8). The title compound 17 was obtained as a white solid 
(3.83 g, 51%). The 1H and 13C NMR spectra agreed with those reported in literature.276  
Mp = 86-89 ˚C (Lit = 87.5- 88.5); max/ cm-1:  1688 (C=O); H (CDCl3, 300 MHz): 10.11 (1H, b.s, 
COOH) 6.70 (2H, s, H-3’/4’), 3.59 (2H, t, J = 6.9 Hz, H-4), 2.37 (2H, t, J = 7.2 Hz, H-2), 1.92 (2H, 
qn, J = 7.2 Hz, H-3); C (CDCl3, 100 MHz): 177.6 (C -1), 170.7 (C-2’/5’), 134.1 (C-3’/4’), 37.1 (C-4), 
31.1 (C-2), 23.6 (C-3) 
4-Aminobutyric acid ammonium maleate salt (18) 
 
Maleic anhydride (1.00 g; 10.9 mmol) and 4-aminobutyric acid (1.05 g; 10.9 mmol) was dissolved in 
glacial acetic acid (15 mL) and stirred for 18 hrs after which a white solid had formed in solution. The 
white precipitate was filtered off, washed with H2O (3 x 50 mL) and then dissolved in MeOH and 
filtered through celite. The filtrate was concentrated down under vacuum to yield a crude white solid 
(1.82 g) which was partially dissolved in H2O (20 mL) and refluxed for 1.5 hrs. The solution was 
cooled to room temperature and H2O evaporated in vacuo. The white solid residue was recrystallised 
with CH2Cl2: MeOH to yield the title compound 18 as a clear, flaky solid (1.30 g; 69 %). The 1H and 
13C NMR spectra agreed with those reported in literature.191 




max/ cm-1: 3154 (OH, NH), 1692 (C=O), 1639 (C=O); H (D2O, 300 MHz): 6.34 (2H, s, H-2, H-3), 
3.06 (2H, t, J = 8.0 Hz, H-1’), 2.51 (2H, t, J = 7.2 Hz, H-3’), 1.98 (2H, qn, J = 7.5 Hz, H-2’), C (D2O, 




Et3N (0.121 g, 1.20 mmol) was added to a solution of 4-maleimidobutyric acid 17 (0.200 g, 1.09 
mmol) in anh. THF (10 mL) under N2 (g) and cooled to -14˚C in an ice/salt bath. Ethyl chloroformate 
(0.130 g, 1.20 mmol) was added dropwise to the solution and stirred for 15 min after which the 
temperature had reached -12˚C. Hexylamine (0.121 g, 1.09 mmol) was added slowly to the solution 
which was then removed from the cold bath and left to stir for 2 hrs and warm to room temperature. 
The solvent was removed in vacuo, the crude solid redissolved in EtOAc (30 mL) and H2O (20 mL) 
and then extracted with EtOAc (2 x 40 mL). The combined organic extracts were washed with brine 
(30 mL), dried, filtered and concentrated to yield a crude solid which was purified with column 
chromatography (CH2Cl2: MeOH 9.6: 0.4; 9.2: 0.8) to yield the title compound 19 as a creamish solid 
(0.237 g, 77%). 
Mp = 99- 103 ˚C (recrystallised from EtOAc and Hexane); max/ cm-1: 3286 (NH), 1698 (C=O), 1631 
(C=O); H (CDCl3, 300 MHz): 6.68 (2H, s, H-3’/4’), 5.84 (1H, bs, NH), 3.54 (2H, t, J = 6.3 Hz, H-4), 
3.20 (2H, q, J = 6.9 Hz, H-1’’), 2.11 (2H, t, J = 6.9 Hz, H-2), 1.90 (2H, qn, J = 6.9 Hz, H-3), 1.47 
(2H, m, H-2’’), 1.30-1.20 (6H, m, H-3’’/4’’/5’’), 0.85 (3H, m, H-6’’); C (CDCl3, 100 MHz): 171.5 
(C-1), 170.9 (C-2’/5’), 134.1 (C-3’/4’), 39.6 (C-1’’), 37.1 (C-4), 33.7 (C-2), 31.4 (C-2’’), 29.5 (C-3’’), 
26.5 (C-4’’), 24.9 (C-3), 22.5 (C-5’’), 13.9 (C-6’’); HRMS (ESI MALDI-TOF): m/z Calculated for 




Potassium phthalimide (3.50 g, 18.9 mmol) was added to a solution of 10-bromodecanol 2 (4.48 g, 
18.9 mmol) in DMF (50 mL). The mixture was heated at 100˚C for 20 hrs after which most of the 




DMF was distilled off. The remaining product was redissolved in CH2Cl2 and then washed with H2O 
(2 x 50 mL). The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo 
to yield a crude solid which was purified using column chromatography (Hex: EtOAc 6:4). The title 
compound was obtained as a white solid (4.92 g, 97%). Rf =0.45 (Hex: EtOAc 1:1). The 1H and 13C 
NMR data agreed with those reported in literature.277 
Mp (˚C) = 74-76 ˚C; max/ cm-1: 3506 (-OH), 1697 (C=O); H (CDCl3, 300 MHz): 7.84- 7.81 (2H, m, 
ArH), 7.70- 7.68 (2H, m, ArH), 3.66 (2H, t, J = 7.2 Hz, H-1), 3.62 (2H, t, J = 6.8 Hz, H-10), 1.66 (2H, 
qn, J = 8.0 Hz, H-2), 1.55 (2H, qn, J = 8.0 Hz, H-9), 1.42 (1H, s, -OH), 1.32-1.25 (12H, m, Alk-CH2); 
C (CDCl3, 100 MHz): 168.4 (C=O), 133.8 (Ar-3’), 132.2 (ArC-2’), 123.1 (ArC-4’), 63.0 (C-10), 38.0 




Hydrazine hydrate (1.28 g, 1.24 mL, 25.3 mmol) was added to a solution of phthalimide 20 (4.50 g, 
14.8 mmol) in EtOH (180 mL) and refluxed overnight. Starting material remained and so extra 
hydrazine (0.4 ml) was added and the solution again refluxed overnight. The solvent was evaporated 
and the crude solid product redissolved in CH2Cl2 (100 mL) and basified with 2M NaOH until all 
solid had dissolved. The organic layer was separated out and the aqueous phase extracted with CH2Cl2 
(2 x 80 mL). The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
The crude white solid obtained was recrystallised (CH2Cl2: Hexane) to yield the title compound 21 as 
a white solid (2.22 g, 88%). Rf = 0.07 (CH2Cl2: MeOH 9:1) The 1H and 13C NMR agreed with those 
reported in the literature.278a  
Mp = 69 - 73˚C (Lit: 72 ˚C278b); H (CDCl3, 400 MHz): 3.60 (2H, t, J = 6.6 Hz, H-1), 2.66 (2H, t, J = 
6.9 Hz, H-10), 1.54 (2H, qn, J = 7.0 Hz, H-9), 1.41 (2H, qn, J = 6.9 Hz, H-2), 1.35-1.24 (12H, m, H-
3-8); C (CDCl3, 100 MHz): 63.0 (C-1), 42.3 (C-10), 33.9 (C-9), 32.9 (C-2), [29.5, 29.5, 29.4, 29.4, 
26.9, 25.8 (Alk-CH2)] 
 
O-Benzyl-N-(10-hydroxydecyl) carbamate (22) 
 
Na2CO3 (2.96 g, 27.9 mmol) and benzyl chloroformate (2.07 mL, 2.47 g, 14.5 mmol) was added to a 
solution of alcohol 21 (1.93 g, 11.1 mmol) in CH2Cl2:H2O (1:1, 100 mL), which was stirred for 20 




hrs. The organic layer was separated and aqueous layer extracted with CH2Cl2 (3 x 50 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo to yield a crude 
solid which was purified using column chromatography (Hex:EtOAc 6:4, 5:5) to give the title 
compound 22 as a white solid (3.13 g, 91%). Rf = 0.35 (Hex: EtOAc 1:1),  
Mp = 88-89 ˚C; max/ cm-1: 3376 (HN-C=O), 3337 (OH), 1686 (C=O); H (CDCl3, 400 MHz): 7.36-
7.26 (5H, m, ArH), 5.10 (2H, s, H-2’), 4.70 (1H, b.s, -NH), 3.63 (2H, t, J = 6.6 Hz, H-10), 3.18 (2H, 
m, H-1), 1.58- 1.47 (4H, m, H-2/9), 1.30-1.20 (12H, m, H-3-8); C (CDCl3, 100 MHz): 156.4 (C=O), 
[136.7, 128.5, 128.0 (ArC)], 66.6 (C-2’), 63.0 (C-10), 41.1 (C-1), 32.8 (C-9), 29.9 (C-2), [29.4, 29.4, 
29.3, 29.2, 26.7, 25.7 (AlkCH2)]; HRMS (ESI MALDI-TOF): m/z Calculated for C18H30NO3 (M + H)+ 
308.2220; found, 308.2217. 
10-(O-Benzyloxycarbonylamino)-N-decyl-tetra-O-benzoyl-β-D-glucopyranoside (23) 
 
Molecular sieves (3.00 g), ZnCl2 (0.266 g, 1.95 mmol) and carbamate 22 (0.300 g, 0.97 mmol) in 
CH2Cl2 (13 mL) was added to freshly prepared iodide 1a (0.690 g, 0.97 mmol) in anh. CH2Cl2 (7 mL), 
which was then reaction stirred for 19 hrs. The molecular sieves were filtered off through a Celite pad 
and the reaction was quenched with an aqueous solution (100 mL) of NaHCO3 (0.96 g) and Na2S2O3 
(1.44 g) and stirred for 10 min. The organic layer was separated and the aq. phase extracted with 
CH2Cl2 (3 x 50 mL). The organic layers were combined, dried over MgSO4, filtered and concentrated 
in vacuo to yield a crude product which was purified using automated column chromatography 
(Hex:EtOAc 9:1, 8:2) to yield the title compound 23 as a clear oil (0.60 g, 70%). Rf = 0.41 (Hex: 
EtOAc 7:3)  
[α]20,D= +15.2 (c =1.0 in CH2Cl2); max/ cm-1:  3050 (NH), 1733 (C=O); H (CDCl3, 300 MHz): 8.03-
7.82 (8H, m, ArH), 7.56-7.25 (17H, m, ArH), 5.91 (1H, t, J = 9.6 Hz, H-3’’), 5.67 (1H, t, J = 9.6 Hz, 
H-4’’), 5.52 (1H, dd, J = 7.8, 9.6 Hz, H-2’’), 5.10 (2H, s, H-2’),  4.84 (1H, d, J = 7.8 Hz, H-1’’), 4.75 
(1H, bs, -NH), 4.65 (1H, dd, J = 3.4, 12.0 Hz, H-6’’a), 4.51 (1H, dd, J = 5.1, 12.0 Hz, H-6’’b), 4.19-
4.13 (1H, m, H-5’’), 3.91 (1H, dt, J = 6.3, 9.9 Hz, H-1a), 3.54 (1H, dt, J = 6.6, 9.6 Hz, H-1b),  3.17 
(2H, q, J = 6.6 Hz, H-10), 1.57-1.41 (4H, m, H-2/9), 1.28-1.05 (12H, m, AlkCH2); C (CDCl3, 100 
MHz): [166.1, 165.8, 165.2, 165.0 (C=O)], 156.4 (C=O), [136.7, 133.3, 133.1, 133.1, 133.0, 129.8 
(x4), 129.7 (x4), 129.4, 128.9, 128.5, 128.4, 128.3 (x2), 128.2, 128.0 (ArC)], 101.3 (C-1’’), 73.0 (C-
3’’), 72.2 (C-2’’), 72.0 (C-5’’), 70.3 (C-1), 69.9 (C-4’’), 66.5 (C-2’), 63.3 (C-6’’), 41.1 (C-10), [29.9, 




29.4 (x2), 29.3, 29.2, 29.1, 26.6, 25.7 (CH2Alk)]; HRMS (ESI MALDI-TOF): m/z Calculated for 
C52H56NO12 (M+ H)+ 886.3724, found: 886.3775 
10-(Phthalimido)decyl-tetra-O-benzoyl-β-D-glucopyranoside (24) 
 
Molecular sieves (3.00 g), ZnCl2 (0.313 g, 2.29 mmol) and phthalimide 20 (0.348 g, 1.15 mmol) in 
CH2Cl2 (12 mL) was added to 1-iodo-glucose pentabenzoate (0.810 g, 1.15 mmol) in anh. CH2Cl2 (8 
mL) and the reaction stirred for 19 hrs. The molecular sieves were filtered off through a Celite pad 
and the reaction quenched with an aqueous solution (100 mL) of NaHCO3 (0.96 g) and Na2S2O3 (1.44 
g) and stirred for 10 min. The organic layer was separated and the aq. phase extracted with CH2Cl2 (3 
x 50 mL). The organic layers were combined, dried over MgSO4, filtered and concentrated in vacuo to 
yield a crude product which was purified using automated column chromatography (Hex:EtOAc 9:1, 
8:2) to yield the title compound 24 as a clear oil (0.838 g, 83%). Rf = 0.45 (Hex: EtOAc 7:3)   
[α]20,D = +15.5 (c =1.0 in CH2Cl2); max/ cm-1: 1733 (C=O), 1713 (C=O); H (CDCl3, 300 MHz): 8.05-
7.83 (8H, m, ArH), 7.86-7.83 (2H, m, 3’/4’), 7.72- 7.69 (2H, m, 3’/4’), 7.58-7.26 (12H, m, ArH), 5.92 
(1H, t, J = 9.6 Hz, H-3’’), 5.69 (1H, t, J = 9.6 Hz, H-4’’), 5.54 (1H, dd, J = 7.8, 9.6 Hz, H-2’’), 4.86 
(1H, d, J = 7.8 Hz, H-1’’), 4.65 (1H, dd, J = 3.4, 12.0 Hz, H-6’’a), 4.53 (1H, dd, J = 5.1, 12.0 Hz, H-
6’’b), 4.21-4.15 (1H, m, H-5’’), 3.92 (1H, dt, J = 6.3, 9.9 Hz, H-1a), 3.68 (2H, t, J = 7.2 Hz, H-10), 
3.55 (1H, dt, J = 6.6, 9.6 Hz, H-1b), 1.70-1.61 (2H, m, H-9), 1.58-1.47 (2H, m, H-2), 1.32-1.02 (12H, 
m, AlkCH2); C (CDCl3, 100 MHz): 168.4 (C=O), [166.1, 165.8, 165.2, 165.0 (C=O)], 133.8 (C-3’), 
[133.3, 133.1, 133.1, 133.0 (ArC)], 132.2 (C-2’), [129.8, 129.8, 129.7, 129.7, 129.5, 129.4, 128.9, 
128.3, 128.3, 128.3, 128.2, 128.2 (ArC)], 123.1 (C-4’), 101.3 (C-1’’), 73.0 (C-3’’), 72.2 (C-2’’), 71.9 
(C-5’’), 70.3 (C-1), 69.9 (C-4’’), 63.3 (C-6’’), 38.0 (C-10), [29.3, 29.3, 29.2, 29.1, 29.0, 28.5, 26.8, 















O-Benzyl N-10-(β-D-glucopyranos-1-yl) decylcarbamate (25) 
 
Sodium (0.028 g, 1.24 mmol) was reacted with anh. MeOH (2.0 mL) to form a solution of NaOMe 
that was added to a solution of carbamate 23 (0.550 g, 0.63 mmol) in anh. MeOH (10 mL) and 
CH2Cl2 (3 mL) under N2(g). The solution was stirred for 1 hr. The solvent was evaporated in vacuo and 
the crude white solid material redissolved in EtOAc with H2O and sat. aq. NH4Cl until pH 7. The 
organic phase was separated and the aqueous phase extracted with EtOAc (3 x 20 mL). The organic 
extracts were dried over MgSO4, filtered and concentrated in vacuo to yield a crude solid which was 
purified using column chromatography (CH2Cl2: MeOH 9:1) to yield the title compound 25 as a white 
waxy solid (0.240 g, 82%). Rf = 0.15 (CH2Cl2: MeOH 9:1) 
[α]20,D = -12.4 (c =1.0 in MeOH); Mp = 83-87 ˚C (recrystallised from CH2Cl2: MeOH); max/ cm-1: 
3356 (-OH, NH), 1687 (C=O); H (CD3OD, 300 MHz): 7.35-7.27 (5H, m, ArH), 5.06 (2H, s, H-2’), 
4.25 (1H, d, J = 7.8 Hz, H-1’’), 3.89 (1H, m, H-10a), 3.85 (1H, m,  H-6’’a), 3.67 (1H, m, H-6’’b), 
3.53 (1H, dt, J = 6.6, 9.6 Hz, H-10b), 3.38-3.24 (3H, m, H-3’’/4’’/5’’), 3.17 (1H, dd, J = 7.8, 8.7 Hz, 
H-2’’), 3.10 (2H, t, J = 7.2 Hz, H-1), 1.62 (2H, qn, J = 7.2 Hz, H-2), 1.48 (2H, qn, J = 6.9 Hz, H-9), 
1.41-1.28 (12H, m, AlkCH2); C (CD3OD, 100 MHz): 156.4 (C=O), [133.6, 129.4, 128.9, 128.7 
(ArC)], 104.4 (C-1’’), 78.2 (C-3’’), 77.9 (C-2’’), 75.1 (C-5’’), 71.7 (C-10), 70.9 (C-4’’), 67.3 (C-2’), 
62.8 (C-6’’), 41.8 (C-1), [30.9, 30.8, 30.6, 30.6, 30.5, 30.4, 27.8, 27.1 (CH2Alk)]; HRMS (ESI 
MALDI-TOF): m/z Calculated for C24H40NO8 (M+ H)+ 470.2748, found: 470.2745 
10-(Phthalimido)decyl β-D-glucopyranoside (26) 
 
Sodium metal (0.039 g, 1.70 mmol) was reacted with anh. MeOH (2 mL) to form a solution of 
NaOMe which was then added to a solution of glucopyranoside 24 (0.750 g, 0.85 mmol) in anh. 
MeOH (10 mL) and CH2Cl2 (3 mL) under N2(g). The solution was stirred for 45 min after which the 
solution had become slightly yellow. The solvent was evaporated in vacuo and the crude white solid 
material redissolved in EtOAc with H2O and sat. aq. NH4Cl until pH 7. The organic phase was 
separated and the aq. phase extracted with EtOAc (4 x 20 mL). The organic extracts were combined, 




dried over MgSO4, filtered and concentrated in vacuo to yield a crude solid which was purified using 
column chromatography (CH2Cl2:MeOH 9:1) to yield the title compound 26 as a white solid (0.189 g, 
47%). Rf = 0.15 (CH2Cl2: MeOH 9:1),  
[α]20,D = -22.0 (c =0.1 in MeOH); Mp = 113- 115 ˚C (recrystallised with CH2Cl2: MeOH); max/ cm-1: 
3316 (-OH), 1713 (C=O); H (CD3OD, 300 MHz): 7.86-7.77 (4H, m, 3’/4’), 4.24 (1H, d, J = 7.5 Hz, 
H-1’’), 3.92-3.84 (2H, m,  H-6’’a/H-1a), 3.69-3.63 (1H, m, H-6’’b), 3.66 (2H, t, J = 7.2 Hz, H-10), 
3.53 (1H, dt, J = 6.6, 9.6 Hz, H-1b), 3.32-3.24 (3H, m, H-3’’/4’’/5’’), 3.16 (1H, dd, J = 7.5, 9.0 Hz H-
2’’), 1.71-1.56 (4H, m, H-2/9), 1.40-1.20 (12H, m, AlkCH2); C (CD3OD, 100 MHz): 169.9 (C=O), 
135.3 (Ar-3’), 133.4 (Ar-2’), 124.0 (Ar-4’), 104.4 (C-1’’), 78.2 (C-3’’), 77.9 (C-2’’), 75.1 (C-5’’), 
71.7 (C-1), 70.9 (C-4’’), 62.8 (C-6’’), 38.8 (C-10), [30.8, 30.5, 30.5, 30.4, 30.1, 29.4, 27.8, 27.0 
(CH2Alk)]; HRMS (ESI MALDI-TOF): m/z Calculated for C24H36NO8 (M + H)+ 466.2435; found, 
466.2429 
 
(10-Aminodecyl) β-D-glucopyranoside (27) 
 
Carbamate 25 (0.220 g, 0.47 mmol) was dissolved in EtOH (10 mL) and Pd/C (0.022 g, 10% w/w) in 
EtOH (2 mL) was added to the solution. The flask was flushed with H2 (g) and the reaction stirred 
under H2 (g) for 20 hrs. The solution was filtered through a Celite pad and the EtOH removed under 
vacuum. A crude white solid was obtained which was recrystallised using MeOH to yield pure 
product 27 (0.145 g, 87 %).   
[α]20,D = -27.0 (c = 0.1 in MeOH); Mp = 133- 135 ˚C; max/ cm-1: 3353 (NH), 3217 (OH); H (CD3OD, 
300 MHz): 4.24 (1H, d, J = 7.8 Hz, H-1’), 3.89 (1H, m, H-1a), 3.86 (1H, m,  H-6’a), 3.67 (1H, m, H-
6’b), 3.53 (1H, dt, J = 6.6, 9.6 Hz, H-1b), 3.38-3.22 (3H, m, H-3’/4’/5’), 3.17 (1H, dd, J = 7.8, 8.4 Hz, 
H-2’), 2.62 (2H, t, J = 6.9 Hz, H-10), 1.62 (2H, qn, J = 6.9 Hz, H-2), 1.47 (2H, qn, J = 6.9 Hz, H-9), 
1.41-1.28 (12H, m, AlkCH2); C (CD3OD, 100 MHz): 104.4 (C-1’), 78.2 (C-3’), 77.9 (C-2’), 75.1 (C-
5’), 71.7 (C-1), 70.9 (C-4’), 62.8 (C-6’), 42.5 (C-10), 33.7 (C-9), [30.8, 30.6, 30.6, 30.5, 30.5, 28.0, 












Et3N (0.017 mL, 0.12 mmol) was added to a solution of 4-maleimidobutyric acid 17 (0.020 g, 0.11 
mmol) in anh. THF (2 mL) under N2 (g) and cooled to -14˚C in an ice/salt bath. Ethyl chloroformate 
(0.012 mL, 0.12 mmol) was added dropwise to the solution and stirred for 15 min. Amine 27 (0.040 g, 
0.11 mmol) dissolved in DMF (0.20 mL) was slowly added to the solution and left to stir for 1 hr. 
TLC (EtOAc: MeOH 9:1) indicated minimal starting material remaining but the formation of two 
products in approx. 50:50 ratio. EtOAc (20 mL) and H2O (40 mL) were added to the solution and the 
aqueous layer extracted with EtOAc (4 x 50 mL). TLC of the organic layer indicated extraction of 
both compounds whereas the aqueous layer contained only one compound as the desired product. The 
aqueous layer was concentrated down and the crude product was purified with column 
chromatography (EtOAc: MeOH 9:1) to yield the title compound 28 as an oil (0.009 g, 16%). 
max/ cm-1: 3301 (-OH), 1688 (C=O), 1631 (C=O); H (CD3OD, 300 MHz): 6.80 (2H, s, H-6), 4.24 
(1H, d, J = 7.8 Hz, H-1’’), 3.92-3.84 (2H, m,  H-6’’a/H-10’a), 3.67 (1H, m, H-6’’b), 3.57-3.50 (1H, 
m, H-10’b including 3.52 (2H, t, J = 6.9 Hz, H-4)), 3.38-3.22 (3H, m, H-3’’/4’’/5’’), 3.17 (1H, m, H-
2’’), 3.13 (2H, t, J = 6.9 Hz, H-1’), 2.17 (2H, t, J = 7.2 Hz, H-2), 1.87 (2H, qn, J = 6.9 Hz, H-3),  1.62 
(2H, qn, J = 6.9 Hz, H-2’), 1.48 (2H, qn, J = 6.6 Hz, H-9’), 1.42-1.28 (12H, m, AlkCH2); C (CD3OD, 
100 MHz): 174.8 (C-1), 172.5 (C-5), 135.4 (C-6), 104.4 (C-1’’), 78.2 (C-3’’), 77.9 (C-2’’), 75.1 (C-
5’’), 71.7 (C-10’), 70.9 (C-4’’), 62.8 (C-6’’), 40.5 (C-1’), 38.1 (C-4), 34.2 (C-2), 30.8 (C-2’), 30.6 
(x2), 30.5, 30.4 (x2), 28.0, 27.1 (CH2Alk), 25.8 (C-3); HRMS (ESI MALDI-TOF): m/z Calculated for 
C24H43N2O93+ (M + H)3+ 503.2952; found 503.2973 
N-(t-butoxycarbonyl)maleimide (29) 
 
Di-tert-butyl dicarbonate (2.25 g, 10.3 mmol) and DMAP (0.013 g, 0.10 mmol) were added to a 
solution of maleimide (1.00 g, 10.3 mmol) in anh. THF (50 mL). The reaction was stirred for 16 hrs 
after which the THF was removed in vacuo. The crude oil was redissolved in CH2Cl2 (50 mL) and 
washed with water (100 mL) and then NaHCO3 (aq) (100 mL). The aq. phase was extracted with 
CH2Cl2 (2 x 20 mL). The combined organic phases were dried, filtered and concentrated followed by 




dry loading and purification with column chromatography (Hex:EtOAc 9:1 – 6:4). A white solid 29 
was obtained which was then recrystallised with hexane/ CH2Cl2 (1.36 g, 68 %). The 1H NMR 
spectrum was similar to that reported in the literature.279  
max/ cm-1: 1754 (C=O), 1713 (C=O); H (CDCl3, 300 MHz): 6.76 (2H, s, H-3/4), 1.55 (9H, s, H-3’); 




Methyl chloroformate (0.87 mL, 11.3 mmol) was added slowly to a solution of maleimide (1.00 g, 
10.3 mmol) and N-methyl morpholine (1.24 mL, 11.3 mmol) in EtOAc (80 mL) at 0˚ C and stirred for 
1 hr. The precipitate was separated out through filtration through a celite pad and the filtrate 
concentrated in vacuo. It was attempted to recrystallise the crude oil with hexane: CH2Cl2 but no 
crystallisation occurred. The crude product was redissolved in EtOAc (100 mL), adsorbed onto silica 
and purified using column chromatography (Hex: EtOAc 6:4) to yield a white solid 30 (1.07 g, 67%). 
The 1H NMR spectrum agreed with that reported in the literature.280  
max/ cm-1: 1754 (C=O), 1708 (C=O); H (CDCl3, 300 MHz): 6.83 (2H, s, CH-3/4), 3.94 (3H, s, CH3-




Maleimide 30 (0.014 g, 0.09 mmol) was added at RT to a stirring solution of amine 27 (0.015 g, 0.04 
mmol) in dioxane (0.75 mL) and sat. NaHCO3 (aq) (1.5 mL). The reaction was stirred for 1 hr after 
which the reaction was quenched with EtOAc (10 mL) and H2O (10 mL). The organic phase was 
separated out and the aq. phase extracted with EtOAc (3 x 10 mL). The organic layers were 
combined, dried, filtered and the solvent evaporated under vacuum. The residue was adsorbed onto 
silica and purified with column chromatography (CH2Cl2: MeOH 9:1). The title compound was 
obtained as a clear oil (0.011 g, 60 %) Rf = 0.15 (CH2Cl2: MeOH 9:1) 




max/ cm-1: 3358 (-OH), 1688 (C=O); H (CD3OD, 300 MHz): 6.79 (2H, s, 3’/4’), 4.24 (1H, d, J = 7.5 
Hz, H-1’’), 3.93-3.84 (2H, m,  H-6’’a/H-10a), 3.69-3.64 (1H, m, H-6’’b), 3.57-3.50 (1H, dt, J = 6.6, 
9.6 Hz, H-10b), 3.48 (2H, t, J = 6.9 Hz, H-1), 3.38-3.22 (3H, m, H-3’’/4’’/5’’), 3.19-3.13 (1H, m, H-
2’’), 1.64-1.54 (4H, m, H-2/9), 1.42-1.28 (12H, m, AlkCH2); C (CD3OD, 100 MHz): 172.6 (C-2’/5’), 
135.3 (C-3’/4’), 104.4 (C-1’’), 78.2 (C-3’’), 77.9 (C-2’’), 75.1 (C-5’’), 71.7 (C-10), 70.9 (C-4’’), 62.8 





t-Butyl bromoacetate (0.205 g, 1.05 mmol) dissolved in MeCN (25 mL) was added to a solution of 
cyclam (0.100 g, 0.50 mmol) and NaHCO3 (0.088 g, 1.05 mmol) in MeCN (70 mL) and refluxed for 
15 hrs. The white precipitate that formed was filtered off and the solvent was removed in vacuo. The 
residue was then purified with column chromatography (CH2Cl2: MeOH: NH4OH 10:1:0.1) to give 
the title compound as a slightly yellow oil which crystallised. The solid was recrystallised with 
toluene to yield clear crystal of compound 32 (0.126 g, 46%). The 1H NMR spectrum agreed with that 
reported in the literature.201  
max/ cm-1: 1725 (C=O), 1144 (C-N); Mp = 185-186 ˚C (Lit: 188.5-189.5 ˚C) 
Protonated form: H (CDCl3, 400 MHz): 9.01 (2 H, bs, -NH), 3.42 (2H, s, H-1’), 3.38 (2H, s, H-1’),  
3.29 (2H, m, H-12), 3.17 (2H, m, H-9), 3.11 (2H, s, H-1’), 3.03 (2H, m, H-10), 2.74 (2H, t, J = 5.6 
Hz, CH2N), 2.70 (2H, m, CH2N), 2.63 (2H, t, J = 5.6 Hz, CH2N), 2.59 (4H, m, CH2N), 2.03 (2H, bm, 
H-13), 1.66 (2H, m, H-6), 1.46 (9H, s, H-4’), 1.45 (9H, s, H-4’), 1.43 (9H, s, H-4’); C (CDCl3, 100 
MHz): 171.1 (C=O), 170.8 (C=O), 170.5 (C=O), 82.3 (C-3’), 81.6 (C-3’), 81.2 (C-3’), 55.8 (C-1’), 
55.7 (C-1’), 55.3 (C-1’), 53.8 (CH2N), 52.0 (C-12), 51.2 (C-9), 50.5 (CH2N), 49.2 (CH2N), 48.5 (C-
10), 47.6 (CH2N), 46.7 (CH2N), 28.2 (C-4’), 23.3 (C-6), 22.5 (C-13) 
The free base form was obtained by washing the NMR sample (0.5 mL) with 3 M NaOH (1 mL), 
separating the organic layer and drying the sample in the oven at 55 ˚C for 2 hrs. 
Free base form: H (CDCl3, 400 MHz): 3.28 (2H, s, H-1’),  3.27 (2H, s, H-1’), 3.22 (2H, s, H-1’),  
2.78 – 2.55 (16H, m, CH2N), 2.02 (1H, bs, -NH), 1.68 (2H, m, H-6), 1.58 (2H, m, H-13), 1.43 (27H, 




s, H-4’); C (CDCl3, 100 MHz): 171.1 (C=O), 170.8 (C=O), 170.5 (C=O), 80.6 (x3)(C-3’), 56.3 (C-
1’), 54.7 (C-1’), 54.6 (C-1’), [53.8, 52.4, 51.6, 50.1, 49.9, 48.7, 47.6, 47.4 (CH2N)], 28.3 (C-4’), 26.0 




t-Butyl bromoacetate (0.146 g, 0.75 mmol) dissolved in MeCN (20 mL) was slowly added over 45 
min to a solution of potassium carbonate (0.517 g, 3.75 mmol) and cyclam (0.300 g, 1.50 mmol) in 
CH3CN (120 mL). Additional t-butyl bromoacetate (0.146 g, 0.75 mmol) was added to the solution 
after 1.5 hrs and again (0.146 g, 0.75 mmol) after another 1.5 hrs. The solution was then stirred for a 
further 1.5 hrs. The solid salts were filtered off through Celite and the filtrate concentrated down in 
vacuo to yield an oily residue which was purified using column chromatography (CH2Cl2: MeOH 5:1) 
to yield the title compound 33 (0.100 g, 16 %) as a clear oil. Tri-alkylated cyclam was also obtained 
(0.133 g, 16 %).  
Protonated form: max/ cm-1: 3380 (NH), 1726 (C=O), 1149 (C-N); H (CDCl3, 400 MHz): 3.24 (4H, 
bs, H-1’), 3.12 (4H, s, H-2/3), 3.06 (4H, t, J = 6.0 Hz, H-5/14), 2.60 (4H, t, J = 7.0 Hz, H-7/12), 2.47 
(4H, m, H-9/10), 1.94 (4H, m, H-6/13), 1.44 (18H, s, H-4’); C (101 MHz) (CDCl3): 171.6 (C=O), 82.3 
(C-3’), 55.6 (C-1’), 55.0 (C-2/3), 53.8 (C-5/14), 47.6 (C-7/12), 45.0 (C-9/10), 28.2 (C-4’), 23.2 (C-
6/13) 
Free base form: max/ cm-1: 3409 (NH), 1726 (C=O), 1150 (C-N); H (CDCl3, 400 MHz): 3.26 (4H, s, 
H-1’), 2.72 – 2.62 (16H, m, H-2/3/5/7/9/10/12/14), 2.45 (2H, bs, -NH), 1.71 (4H, m, H-6/13), 1.41 
(18H, s, H-4’); C (CDCl3, 100 MHz): 170.6 (C=O), 80.7 (C-3’), 54.0 (C-1’), [52.3, 50.6, 47.0, 46.5 
(C-2/3/5/7/9/10/12/14)], 28.2 (C-4’), 25.9 (C-6/13); HRMS (ESI MALDI-TOF): m/z Calculated for 












t-Butyl bromoacetate (0.098 g, 0.50 mmol) dissolved in MeCN (5 mL) was slowly added over 30 min 
to a solution of potassium carbonate (0.345 g, 2.50 mmol) and cyclam (0.200 g, 1.00 mmol) in MeCN 
(80 mL) and H2O (4 mL). Additional t-butyl bromoacetate (0.098 g, 0.50 mmol) was added to the 
solution after 2hrs and again after another 5 hrs. The solution was then stirred for 16 hrs. The solution 
was dried over MgSO4, filtered, and the solvent evaporated in vacuo. The oily residue was purified 
using column chromatography (CH2Cl2: MeOH 5:1) to yield a yellowish oil to which was added 3 M 
NaOH (1 mL) and extracted with CH2Cl2 (3 x 1 mL). The extracts were combined, the solvent 
removed under vacuum and the residue dried in an oven at 55 ˚C for 2 hrs to yield the title compound 
34 (0.174 g, 41 %) as a clear oil. The 1H and 13C NMR spectral data agreed with those reported in the 
literature.111 
 
max/ cm-1: 3301 (-NH), 1726 (C=O), 1137 (C-N) 
Free base form: H (CDCl3, 400 MHz): 3.27 (4H, s, H-1’), 2.73 – 2.57 (16H, m, H-
2/3/5/7/9/10/12/14), 1.72 – 1.67 (4H, m, H-6/13), 1.39 (18H, s, H-4’); C (CDCl3, 100 MHz): 170.5 





The title compound 35 was isolated as a clear oil (0.065 g, 21 %) from the reaction to synthesise 
compound 34. 
max/ cm-1: 3372 (NH), 1730 (C=O), 1148 (C-N); H (CDCl3, 400 MHz): 3.26 (2H, s, H-1’), 2.79 – 
2.60 (19H, m, H-2/3/5/7/9/10/12/14 + 3xNH), 1.77 – 1.68 (4H, m, H-6/13), 1.42 (9H, s, H-4’); C 
(CDCl3, 100 MHz): 170.5 (C=O), 80.7 (C-3’), 55.2 (C-1’), [53.9, 52.4, 50.5, 49.2, 48.9, 48.9, 47.8, 




47.4 (C-N)], 28.8 (C-13), 28.2 (C-4’), 26.2 (C-6); HRMS (ESI MALDI-TOF): m/z Calculated for 
C16H34N4O2 (M+ H) 314.2681, found: 314.2299 
1,4,8,11-Tetraazatricyclo[9.3.1.1]hexadecane (36) 
 
Method 1: An aqueous solution of NaOH (6.00 g in 20 mL) was added to a solution of cyclam (0.210 
g, 1.05 mmol) in CH2Cl2 (25 mL) and refluxed for 24 hrs. The two phases were separated and the aq. 
phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried, filtered and 
concentrated to yield a crude white solid product which was purified by recrystallisation with hot 
THF: H2O 1:1 to give product 36 as a white solid (0.21 g, 88%). Rf = 0.28 (Hex: EtOAc 8:2).  
Method 2: Formaldehyde (37% in H2O) (0.75 mL, 10.0 mmol) was added to a solution of cyclam 
(1.00 g, 5.0 mmol) dissolved in H2O (20 mL) and cooled in an ice bath to 0-5 ˚C. The solution was 
stirred for 5 min at that temperature after which it was allowed to warm to room temperature and 
stirred for 2.5 hrs. The reaction was cooled again to 0-5 ˚C and stirred for 5 min to maximise the 
precipitation of white solid which had formed which was then filtered off and washed with ice water 
(3 x 20 mL). The solid was dissolved in CH2Cl2 (25 mL) and MeOH (5 mL) and the solution dried 
over MgSO4. The MgSO4 was filtered of and the solvent removed in vacuo to yield the title product 
36 as a white solid (1.05 g, 94 %). The 1H and 13C NMR agreed with those reported in the literature.213 
H (CDCl3, 400 MHz): 5.40 (2H, dt, J = 3.0 Hz, 13.5 Hz, H-1’a), 3.14 (4H, m, H-2/3/9/10), 2.90 (2H, 
d, J = 13.5 Hz, H-1’b), 2.85 - 2.80 (4H, m, H- 5/7/12/14), 2.62 (4H, td, J = 4.5 Hz, 15.5 Hz, H- 
5/7/12/14), 2.38 (4H, m, H-2/3/9/10), 2.28 – 2.18 (2H, m, H- 6/13), 1.21 – 1.16 (2H, dqn, J = 2 Hz, J 













ammonium bromide salt (37) 
 
t-Butyl bromoacetate (0.175 g, 0.90 mmol) was added to a solution of cyclam 36 (0.100 g, 0.45 
mmol) in CH3CN (15 mL). After 1 hr, extra t-butyl bromoacetate (0.175 g, 0.90 mmol) was added and 
the reaction was stirred for another 47 hrs. The reaction was quenched by removal of solvent in vacuo 
to yield a crude clear oil product. The crude product was then purified with column chromatography 
(CH2Cl2: MeOH 5:1) to give the pure mono-alkylated product 37 as a clear oil (0.095 g, 65 %), Rf = 
0.65 (CH2Cl2: MeOH 5:1) 
max/ cm-1: 1723 (C=O), 1147 (C-N); H (CDCl3, 400 MHz): 4.16 (1H, d, J = 15.0 Hz, H-15a), 3.71 
(1H, m, CH2N), 3.39 (1H, m, CH2N), 3.35 (1H, d, J = 15.0 Hz, H-15b), 3.18 (2H, s, H-1’), 3.14 – 2.85 
(9H, m, CH2N), 2.81 – 2.70 (2H, m, CH2N), 2.60 (1H, m, CH2N), 2.29 (1H, m, CH2N), 2.14 (2H, m, 
H-13a + CH2N), 1.96 - 1.70 (3H, m, H-13b/6a + NH), 1.58 (1H, m, H-6b), 1.44 (9H, m, H-4’); C 
(CDCl3, 100 MHz): 170.3 (C-2’), 81.4 (C-3’), 72.8 (C-15), 55.6 (C-1’), [52.8, 50.0, 49.8, 49.1, 47.9, 
47.9, 46.3, 45.2(CH2N)], 28.1 (C-4’), 25.1 (C-6), 22.7 (C-13); HRMS (ESI MALDI-TOF): m/z 
Calculated for C17H35N4O2 (M+ H)+ 327.2754, found 327.2783 
 
1-(10-hydroxydecyl)-1,4,8,11-tetraaza-4,8-methano-cyclopentadecane-11-ammonium 
bromide salt (38) 
 
10-bromodecanediol (0.529 g, 2.20 mmol) in MeCN (5 mL) was added to a solution of bridged 
cyclam 36 (0.500 g, 2.20 mmol) in CH2Cl2 (50 mL) and left stirring for 48 hrs with TLC monitoring. 
A small amount of white solid was seen to form. The solvent was removed under vacuum and the 
crude product was redissolved in CH2Cl2 (15 mL) upon which some white solid precipitated out. 
Extra CH2Cl2   (10 mL) and diethyl ether (3 mL) was added which resulted in more precipitate 
forming. The white solid was filtered off and the filtrate concentrated down to a crude oil which was 




purified with column chromatography (CH2Cl2: MeOH 6:1). The title compound 38 was obtained as a 
clear oil (0.520 g, 61%), Rf = 0.17 (Hex: EtOAc 9:1).  
max/ cm-1: 3387 (-OH), 1072 (N-C); H (CDCl3, 300 MHz): 4.07 (1H, d, J = 12.0 Hz, H-1’a), 3.68 
(1H, m, CH2N), 3.59 (2H, t, J = 6.8, H-24), 3.35 (1H, d, J = 12.0 Hz, H-1’b), 3.22 – 3.10 (2H, m, 
CH2N), 3.07 – 2.85 (8H, m, CH2N), 2.75 (1H, m, CH2N), 2.44 (1H, m, H-15a), 2.36 – 2.27 (3H, m, 
CH2N, H-15b), 2.23 (1H, m, CH2N), 2.16 – 2.06 (2H, m, CH2N, H-6a), 1.87 (1H, m, H-6b), 1.67 (1H, 
m, H-13a), 1.60 – 1.34 (5H, m, H-13b; H-16; H-23), 1.32 - 1.20 (12H, m, alkylCH2); C (CDCl3, 100 
MHz): 72.8 (C-1’), 62.7 (C-24), 53.7 (C-15), [52.9, 49.3, 48.6, 48.1, 48.0 (2), 46.0, 45.1 (C-N)], 32.7 
(C-23), 29.4 (3), 29.3, 27.6, 26.2, 25.6, 25.1 (C-13), 22.4(C-6); HRMS (ESI MALDI-TOF): m/z 
Calculated for C21H45N4O (M+ H)3+ 369.3587; found, 369.3580 
 
The reaction of ammonium salt 38 (0.200 g, 0.52 mmol) in CH2Cl2 (5 mL) with NaOH (3.0 M, 50 
mL) followed by extraction, evaporation of the solvent and drying of the product yielded the free base 
compound 38a as an oil (0.169 g, 90 %). 
 
1,8-bis(10-hydroxydecyl)-1,4,8,11-tetraaza-1,11,4,8-dimethano-cyclopentadecane-1,8-
diammonium dibromide salt (39) 
 
NMR analysis of the white solid precipitate obtained from preparation of compound 38 indicated that 
the solid was the di-alkylated product 39 (0.186 g, 15%). 
Mp = 162-168 ˚C (recrystallised from CH2Cl2: MeOH – product started decomposing before it had 
completely melted) 
max/ cm-1: 3380, 3264 (-OH), 1189 (N-C); H (CD3OD, 400 MHz): 5.38 (2H, d, J = 10.0 Hz, H-1’a), 
4.45 (2H, t, J = 13.6 Hz, CH2N), 3.68 (2H, m, CH2N), 3.61 (2H, m, CH2N), 3.54 (4H, t, J = 6.8 Hz, H-
24), 3.48 (2H, d, J = 10.0 Hz, H-1’b), 3.36 – 3.18 (8H, m, CH2N; H-15), 3.05 (2H, d, J = 15.5 Hz, 
CH2N), 2.79 (2H, d, J = 15.2 Hz, CH2N), 2.60 – 2.52 (4H, m, CH2N, H-6a/13a), 1.90 - 1.71 (6H, m, 
H-6b/13b, AlkCH2), 1.57 – 1.47 (4H, m, AlkCH2), 1.47 – 1.30 (24H, m, AlkCH2); C (CD3OD, 100 
MHz): 78.7 (C-1’), 63.0 (C-24), 61.0 (C-15), [60.9, 52.7, 48.6, 48.2 (C-N)] 33.6 (C-23), 30.6, 30.5, 
30.4, 30.2, 27.6, 26.9, 22.3, 20.9(C-6/13); HRMS (ESI MALDI-TOF): m/z Calculated for C32H67N4O2 
(M + H)3+ 539.5247; found, 539.5247 






NaOH (3.0 M, 2 mL) was added to a solution of ammonium salt 39 (0.050 g, 0.08 mmol) in CH2Cl2 
(5 mL) and left stirring for 24 hrs with TLC monitoring. The phases was separated and the aqueous 
phase extracted with CH2Cl2 (2 x 10 mL). MeOH (2 mL) was added to the aqueous phase which was 
again extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts were dried, filtered and 
concentrated to yield a solid residue which was recrystallised with THF and MeOH to give the title 
compound 40 as a white solid (0.045 g, 95 %).  
max/ cm-1: 3472 (NH), 3264 (OH); Mp = 123 - 127˚C; H (CDCl3, 400 MHz): 3.60 (4H, t, J = 6.6 Hz, 
H-24), 3.10 (4H, bs, -OH/-NH), 2.70 (4H, t, J = 4.4 Hz, H-CH2N), 2.62 (4H, m, CH2N), 2.52 (4H, m, 
CH2N), 2.47 (4H, t, J = 5.4 Hz, CH2N), 2.42 (4H, t, J = 7.9 Hz, H-15), 1.74 (4H, m, H-6/13), 1.55 
(4H, qn, J = 7.0 Hz, H-23), 1.45 (2H, qn, J = 7.0 Hz, H-16), 1.37 – 1.17 (24H, m, CH2); C (CDCl3, 
100 MHz): 62.7 (C-24), 54.1 (C-15), [54.1, 53.6, 50.9, 48.1 (CH2N)], 32.8 (C-23), 29.5, 29.5, 29.4, 
29.3, (C-18-21), 27.6 (C-17), 25.7 (C-16), 25.7 (C-22) 25.6 (C-6/13); HRMS (ESI MALDI-TOF): m/z 
Calculated for C30H65N4O2+ (M + H)+ 513.5102; found, 513.5120 
 
1-[10-Hydroxydecyl]-8-[10-(2,3,4,6-O-tetrabenzoyl-β,D-glucopyranos-1-yl)decyl]-4,11-
bis(t-butoxycarbonylmethyl)- 1,4,8,11-tetraazacyclotetradecane (41) 
 
 
K2CO3 (0.156 g, 1.13 mmol) was added to a solution of cyclam 38a (0.160 g, 0.45 mmol) in MeCN 
(20 mL) and stirred for 5 min after which t-Butyl bromoacetate (0.220 g, 1.13 mmol) dissolved in 
MeCN (3 mL) was added. The reaction was stirred for 8 hrs at room temperature followed by 
filtration off of the white salt by-product. The solvent was removed under vacuum and the crude oil 
product was purified by column chromatography (CH2Cl2: MeOH 9:1) to yield an oil product as a 
mixture of two regioisomers that could not be separated (0.209 g, 79 %). This mixture was used 
directly in the next reaction. 




Bromide 3 (0.140 g, 0.17 mmol) in dry MeCN (10 mL) was added to the previously prepared cyclam 
mixed isomers (0.100 g, 0.17 mmol) and K2CO3 (0.118 g, 0.86 mmol) in dry MeCN (20 mL) and left 
stirring for 5 days at 60˚C under N2 with TLC monitoring. The white precipitate that formed was 
filtered off and the solvent evaporated under vacuum. The residue was redissolved in CH2Cl2 (10 mL) 
and H2O (10 mL) and after separating the organic layer, the aqueous phase was extracted with CH2Cl2 
(3 x 10 mL). The combined organic extracts were dried, filtered and the solvent was removed on the 
rotary evaporator. The residue was purified with column chromatography (CH2Cl2: MeOH 6:0.5) to 
give the title compound 41 as an oil (0.030 g, 14 %).  
max/ cm-1:  3413 (OH), 1725 (C=O); H (CDCl3, 400 MHz): 8.02-7.81 (8H, m, ArH), 7.55 – 7.46 (4H, 
m, ArH), 7.44 – 7.25 (8H, m, ArH),  5.89 (1H, t, J = 9.6 Hz, H-3’’), 5.66 (1H, t, J = 9.6 Hz, H-4’’), 
5.50 (1H, dd, J = 7.6, 9.6 Hz, H-2’’), 4.83 (1H, d, J = 7.6 Hz, H-1’’), 4.62 (1H, dd, J = 3.2, 12.0 Hz, 
H-6’’), 4.51 (1H, dd, J = 5.2, 12.0 Hz, H-6’’), 4.15 (1H, m, H-5’’), 3.90 (1H, dt, J = 6.4, 9.6, H-35a), 
3.63 (2H, t, J = 6.4 Hz, H-24), 3.53 (1H, dt, J = 6.8, 9.6 Hz, H-35b), 3.24 (4H, s, H-1’), 3.05 (3H, m, 
CH2N), 2.99 (4H, m, CH2N), 2.88 (1H, m, CH2N), 2.80 (1H, m, CH2N), 2.75 – 2.60 (11H, m, CH2N), 
1.78 (3H, m, CH2), 1.65 – 1.45 (9H, m, CH2Alk), 1.43 (18H, s, H-4’), 1.35 – 1.05 (24H, m, CH2Alk) ; 
C (CDCl3, 100 MHz): 170.7 (C-2’), [166.1, 165.8, 165.2, 165.1 (C=O)], [133.4, 133.2, 133.2, 133.1 
(ArC)], [129.8 (x2), 129.7 (x2), 129.4, 128.9, 128.9, 128.4 (x2), 128.3 (x2), 128.2 (ArC)], 101.3 (C-
1’’), 81.1 (C-3’), 73.0 (C-3’’), 72.2 (C-2’’), 72.0 (C-5’’), 70.4 (C-35), 69.9 (C-4’’), 63.3 (C-6’’), 62.9 
(C-24), 56.1 (C-1’) [53.9, 51.8, 51.3 (x2), 51.2 (x2), 50.7 (x2), 49.3 (x2)(C-N)], [32.7, 29.7, 29.4 (x2), 
29.4 (x2), 29.3 (x4), 29.2 (x2), 28.2, 27.2 (x2), 25.8, 25.7, 24.8, 23.7 (CH2Alk/C-4’/C-6/13]; HRMS 
(ESI MALDI-TOF): m/z Calculated for C76H110N4O15 (M)+ 1318.7967; found – could not be 




DMAP (0.002 g, 0.02 mmol) dissolved in anh. THF (1 mL) and Et3N (0.03 mL, 2.0 mmol) was added 
to a solution of Cyclam 32 (0.050 g, 0.09 mmol) in anh. THF (7 mL) followed by the drop-wise 
addition of acetyl-Cl (0.02 mL, 1.9 mmol). After stirring for 2 hrs the white salt precipitated was 
filtered off through celite and the filtrate concentrated down. The crude oil was redissolved in CH2Cl2 
(10 mL) and H2O (10 mL) and extracted with CH2Cl2 (2 x 10 mL). The organic layer was dried, 




filtered, concentrated and purified using column chromatography (CH2Cl2: MeOH 9:1). The title 
compound 42 was obtained as a clear oil (0.046 g, 87 %). 
max/ cm-1: 1725 (C=O), 1931 (C=O), 1150 (C-N); H (CDCl3, 400 MHz): 3.51-3.44 (4H, m, H-2/14), 
3.33 (2H, s, H-1’ (3.32, rotamer)),  3.22 (4H, m, H-1’), 2.79 – 2.61 (12H, m, H-3/5/7/9/10/12), 2.06 
(3H, s, H-2’’), 1.69 (2H, m, H-13), 1.57 (2H, m, H-6), 1.45 (18H, s, H-4’), 1.44 (9H, s H-4’); C 
(CDCl3, 100 MHz): 170.9 (C-2’), 170.8 (C-2’), 170.8 (C-2’), 170.4 (C-1’’), 170.3 (C-15-rotamer), 
81.0 (C-3’), 80.8 (C-3’), 80.7 (C-3’), 57.5 (57.4-rotamer)(C-1’), 56.1 (55.8-rotamer)(C-1’), 55.4 (54.7 
– rotamer)(C-1’), [53.9, 53.7, 52.3, 52.2, 51.1 (x2), 50.8, 50.7 (x2), 50.5 (x2), 50.0 (C-3/5/7/9/10/12 
and rotamers)], 48.0 (47.0 - rotamer) (C-14), 44.9 (43.6 - rotamer) (C-2), 28.3 (28.2 - rotamer) (C-4’), 
27.2 (C-13), 25.9 (C-6), 25.7 (C-13 rotamer), 25.5 (C-6 rotamer), 21.3 (C-2’’), 21.2 (C-2’’ rotamer); 





DMAP (0.003 g, 0.02 mmol) and Et3N (0.03 mL, 0.22 mmol) were added to a solution of cyclam 32 
(0.061 g, 0.11 mmol) in anh. THF (10 mL). Previously prepared acid-Cl 6a (0.10 g, 0.22 mmol) 
dissolved in anh. THF (5 mL) was added slowly to the solution. After stirring for 2 hrs, the white salt 
precipitate was filtered off through celite and the filtrate concentrated. The crude oil was redissolved 
in CH2Cl2 (10 mL) and extracted with H2O (2 x 10 mL). The organic layer was dried, filtered, 
concentrated and purified using column chromatography (CH2Cl2: MeOH 9:1). The title compound 43 
was obtained as a clear oil (0.087 g, 82 %), Rf = 0.67 (CH2Cl2: MeOH 9:1). 
H (CDCl3, 400 MHz): 7.67 (4H, m, ArH), 7.44-7.34 (6H, m, ArH), 3.64 (2H, t, J = 8.0 Hz, H-24), 
3.48 (4H, m, H-2/14), 3.34 (3.33 rotamer)(2H, s, H-1’), 3.24 (3.22 rotamer)(2H, s, H-1’), 3.22 (2H, s, 
H-1’),  2.80 – 2.60 (12H, m, H-3/5/7/9/10/12), 2.27 (2H, t, J = 8.0 Hz, H-16), 1.75-1.49 (8H, m, H-
6/13/17/23), 1.45 (27H, s, H-4’), 1.38-1.22 (10H, m, CH2Alk), 1.05 (9H, s, H-2’’); C (CDCl3, 100 
MHz): 172.9 (C=O), 170.9 (C=O), 170.8 (C=O), 170.7 (C=O),  135.6 (C-3’’’), 134.2 (C-1’’’), 129.4 
(C-4’’’), 127.5 (C-2’’’),  80.9 (C-3’), 80.8 (C-3’), 80.6 (C-3’), 64.0 (C-24), 57.5 (57.3 rotamer)(C-1’), 
56.1 (55.9 rotamer)(C-1’), 55.3 (54.6 rotamer)(C-1’), [53.9, 53.9, 52.2, 52.2, 51.1, 51.1, 50.8, 50.7, 




50.7, 50.5, 50.5, 49.9, 47.2, 46.1, 45.0, 43.6 (CH2N and rotamers)], 33.1 (33.0 rotamer)(C-16), 32.6 
(C-23), 29.6, 29.5, 29.4, (Alk-CH2), 28.2 (x3)(C-4’), 27.4, 26.9 (C-2’’), 25.9, 25.8, 25.6, 25.5 (Alk-




DMAP (0.018 g, 0.15 mmol) and Et3N (0.10 mL, 0.73 mmol) was added to a solution of cyclam 32 
(0.200 g, 0.37 mmol) in anh. THF (30 mL). Freshly prepared acid-Cl 10a (0.345 g, 0.44 mmol) was 
dissolved in anh. THF (10 mL) and slowly added to the solution. After stirring for 2 hrs, the white salt 
precipitate was filtered off through celite and the filtrate concentrated down under vacuum. The 
residue was redissolved in CH2Cl2 (20 mL) and H2O (10 mL) and extracted with CH2Cl2 (2 x 10 mL). 
The organic layer was dried, filtered, concentrated and purified using column chromatography 
(CH2Cl2: MeOH 9:1). The title compound 44 was obtained as a clear oil (0.216 g, 46 %). 
H (CDCl3, 300 MHz): 8.02-7.81 (8H, m, ArH), 7.55-7.25 (12H, m, ArH), 5.89 (1H, t, J = 9.6 Hz, H-
3’’), 5.66 (1H, t, J = 9.6 Hz, H-4’’), 5.51 (1H, dd, J = 7.8, 9.7 Hz, H-2’’), 4.83 (1H, d, J = 7.8 Hz, H-
1’’), 4.63 (1H, dd, J = 3.4, 12.1 Hz, H-6a’’), 4.50 (1H, dd, J = 5.2, 12.1 Hz, H-6b’’), 4.15 (1H, m, H-
5’’), 3.90 (1H, dt, J = 6.2, 9.7 Hz, H-24a), 3.53 (1H, dt, J = 6.2, 9.7 Hz, H-24b), 3.48-3.42 (4H, m, 
CH2N), 3.34 (3.33 rotamer)(2H, s, H-1’), 3.23 (3.22 rotamer)(2H, s, H-1’), 3.22 (2H, s, H-1’), 2.79-
2.60 (12H, m, CH2N), 2.24 (2H, t, J = 7.4 Hz, H-16), 1.70-1.46 (8H, m, H-17/23/6/13), 1.45 (9H, s, 
H-4’), 1.44 (9H, s, H-4’), 1.43 (9H, s, H-4’), 1.25-1.04 (10H, m, H-18-22); C (CDCl3, 100 MHz): 
173.0 (172.9 rotamer)(C-15), 171.0 (C-2’), 170.8 (C-2’), 170.7 (C-2’), [166.1, 165.8, 165.2, 165.0 
(C=O)], [133.3, 133.1, 133.1, 133.0, 129.8 (x2), 129.7 (x2), 129.6, 129.4, 128.9, 128.4 (x2), 128.3 
(x2), 128.2 (ArC)], 101.3 (C-1’’), [80.9, 80.7, 80.6 (C-3’)], 73.0 (C-3’’), 72.2 (C-2’’), 72.0 (C-5’’), 
70.4 (C-24), 69.9 (C-4’’), 63.3 (C-6’’), 57.5 (57.3 rotamer)(C-1’), 56.1 (55.9 rotamer)(C-1’), 55.3 
(54.6 rotamer)(C-1’), [53.8, 53.8, 52.2, 52.2, 51.1, 51.1, 50.8, 50.7, 50.7, 50.4, 50.4, 49.9, 47.2, 46.1, 
45.0, 43.6 (CH2N and rotamers)], 33.0 (32.9 rotamer)(C-16), 29.5, 29.4, 29.4, 29.2, 28.2 (x3)(C-4’), 
27.4, 25.9, 25.8, 25.7, 25.6, 25.5 (CH2Alk including C-6 and C-13) 
 




O-Benzyl-N-(10-bromodecyl) carbamate (45) 
 
Triphenylphosphine (3.45 g, 13.15 mmol) and carbon tetrabromide (4.38 g, 13.15 mmol) were added 
to a solution of carbamate 22 (2.70 g, 8.77 mmol) in dry CH2Cl2 (160 mL) under N2(g), which was 
stirred for 3 hrs. Silica was added to the solution and the crude material was then dry loaded onto a 
prepacked column and purified using automated flash column chromatography (Hexane:EtOAc 9:1, 
8.2). The title compound 45 was obtained as a white solid (2.99 g, 92%). Rf = 0.68 (Hex: EtOAc 1:1)  
Mp = 45 - 46˚C (recrystallised in CH2Cl2: Hexane); max/ cm-1: 3319 (NH), 1688 (C=O); H (CDCl3, 
300 MHz): 7.35-7.28 (5H, m, ArH), 5.09 (2H, s, H-2’), 4.75 (1H, b.s, -NH), 3.40 (2H, t, J = 6.8 Hz, 
H-10), 3.18 (2H, m, H-1), 1.84 (2H, qn, J = 6.8 Hz, H-9), 1.50-1.36 (4H, m,  H-2, H-8), 1.33-1.20 
(10H, m, Alk-CH2); C (CDCl3, 100 MHz): 156.4 (C=O), [136.7, 128.5, 128.3, 128.0 (Ar-C)], 66.5 
(C-2’), 41.1 (C-1), 33.9 (C-10), 32.8 (C-9), 29.9 (C-2), [29.3, 29.3, 29.1, 28.7, 28.1, 26.7 (AlkC)]; 
HRMS (ESI MALDI-TOF): m/z Calculated for C18H29BrNO2 (M + H)+ 370.1376; found, 370.1369 
 
1-[10-(Benzyloxycarbonylamino)decyl]-1,4,8,11-tetraaza-4,8-methano-cyclopentadecane 
ammonium bromide salt (46) 
 
Bromide 45 (1.06 g, 2.88 mmol) was added under N2(g) to a solution of bridged cyclam 36 (0.773 g, 
3.45 mmol) in anh. CH3CN (80 mL) and stirred for 72 hrs. The solvent was evaporated and the crude 
oil redissolved in CH2Cl2 (50 mL) and washed with H2O (50 mL). The aqueous layer was extracted 
with CH2Cl2 (2 x 50 mL) and the organic layers combined, dried, filtered and concentrated. The 
residue obtained was purified with column chromatography (CH2Cl2: MeOH 9:1 with few drops of 
NH4OH) to yield the title compound 46 as an oil (1.02 g, 69%). Rf = 0.56 (CH2Cl2: MeOH 9:1)  
max/ cm-1: 3446 (-NH), 1717 (C=O), 1266 (C-N); H (CDCl3, 400 MHz): 12.70 (1H, bs, NH), 9.10 
(1H, bs, NH), 7.31-7.24 (5H, m, ArH), 5.05 (2H, s, H-2’), 4.77 (1H, bs, NH), 4.05 (1H, d, J = 12.0 Hz, 
H-15a), 3.68 (1H, m, CH2N), 3.34 (1H, d, J = 12.0 Hz, H-15b), 3.20-3.10 (4H, m, CH2N, H-25), 3.05-
2.83 (8H, m, CH2N), 2.73 (1H, dt, J = 5.0, 12.0 Hz, CH2N), 2.43 (1H, m, H-16a), 2.35-2.25 (3H, m, 
H-16b, CH2N), 2.20 (1H, m, CH2N), 2.11 (2H, m, CH2N, H-6a), 1.87 (1H, m, H-6b), 1.65 (1H, m, H-




13a), 1.55 (1H, m, H-13b), 1.50-1.30 (4H, m, H-17/24), 1.28-1.20 (12H, m, CH2Alk); C (CDCl3, 100 
MHz): 156.4 (C-1’), [136.6, 128.4, 128.0, 128.0 (ArC)], 72.8 (C-15), 66.5 (C-2’), 53.7 (C-16), [52.9, 
49.3, 48.5, 48.1, 48.0, 48.0, 46.0, 45.1 (C-N)], 41.0 (C-25), 29.9 (C-17), 29.5, 29.5, 29.4, 29.1, 27.7, 
26.6, 26.3, 25.1 (C-13), 22.4 (C-6); HRMS (ESI MALDI-TOF): m/z Calculated for C29H52N5O2+ (M + 
H)+ 502.4115; found 502.4322 
 
The cyclam ammonium bromide salt 46 was dissolved in CH2Cl2 and stirred for 3 hrs with 3M NaOH 
(CH2Cl2: NaOH 1: 3). The organic phase was separated out, dried, filtered and concentrated to yield 





Acetic anhydride (0.031 g, 0.30 mmol) was added to a solution of cyclam 46a (0.050 g, 0.10 mmol), 
Et3N (0.031 g, 0.30 mmol) and DMAP (0.003 g, 0.02 mmol) in CH2Cl2 (10 mL) and the reaction was 
stirred for 3 hrs. H2O (10 mL) and sat. NaHCO3(aq) (10 mL) was added to the reaction and the organic 
layer was separated out. The aqueous phase was then extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were dried, filtered and the solvent evaporated under vacuum. The residue 
was purified with preparative TLC (CH2Cl2: MeOH: 92:8 with a few drops of NH4OH(aq)) to yield the 
title compound 47 as an oil (0.017 g, 31 %). Rf = 0.65 (CH2Cl2:MeOH 9:1 with a few drops of 
NH4OH(aq)).  
max/ cm-1: 3321 (NH), 1714 (C=O), 1626 (C=O), 1248 (C-N); H (CDCl3, 400 MHz): 7.36-7.31 (5H, 
m, ArH), 5.09 (2H, s, H-2’), 4.80 (1H, bs, NH), 3.70 (2H, m, CH2N), 3.42 (2H, m, CH2N), 3.18 (2H, 
q, J = 6.8 Hz, H-25), 2.75-2.40 (10H, m, CH2N), 2.40-2.32 (4H, m, CH2N), 2.08 (2.07 rotamer)(3H, s, 
H-2’’), 2.00 (2H, m, CH2N), 1.75-1.55 (4H, m, H-6/H-13), 1.52-1.40 (4H, m, H-17/24), 1.35-1.20 
(12H, m, CH2Alk); C (CDCl3, 100 MHz): 170.3 (C-1’’), 156.4 (C-1’), [136.6, 128.5, 128.4, 128.0 
(ArC)], 70.3 (70.7 isomer)(C-15), 66.6 (C-2’), [56.0, 55.4 (x2), 54.9, 54.6, 54.4, 54.2, 53.9, 52.7, 52.4, 
51.8, 50.9 (x2), 50.2, 47.4, 46.0 (x2), 43.7 (NCH2 and isomers)], 41.1 (40.9 isomer)(C-25), [30.0, 











DMAP (0.046 g, 0.37 mmol) and Et3N (0.190 g, 1.88 mmol) was added to a solution of cyclam 46a 
(0.460 g, 0.93 mmol) dissolved in anh. THF (35 mL). Acid chloride X (0.775 g, 1.0 mmol) dissolved 
in anh. THF (7.8 mL) was added to the solution and stirred for 1.5 hrs. The solution was filtered 
through Celite to remove triethylammonium salts followed by the removal of THF in vacuo.  The 
crude oil was redissolved in CH2Cl2 (20 mL) and extracted with H2O (2 x 20 mL). The organic layer 
was washed with 2M NaOH (20 mL) and separated and the aqueous layer extracted with CH2Cl2 (2 x 
20 mL). All organic phases were combined, dried, filtered and concentrated. The crude oil was 
purified using column chromatography (CH2Cl2: MeOH 9:1) to yield the title compound 48 as an oil 
(0.76 g, 65%). Rf = 0.45 (CH2Cl2: MeOH 9:1).  
max/ cm-1:  3018 (NH), 1733 (C=O), 1265 (N-C); H (CDCl3, 300 MHz): 8.01-7.81 (8H, m, ArH), 
7.52-7.25 (17H, m, ArH), 5.89 (1H, t, J = 9.6 Hz, 3’), 5.65 (1H, t, J = 9.6 Hz, H-4’), 5.50 (1H, dd, J = 
7.8, 9.6 Hz, H-2’), 5.08 (2H, s, H-2’’), 4.83 (1H, d, J = 7.8 Hz, H-1’), 4.80 (1H, bs, NH), 4.62 (1H, dd, 
J = 3.2, 12 Hz, H-6’a), 4.50 (1H, dd, J = 5.2, 12.0 Hz, H-6’b), 4.15 (1H, m, H-5’), 3.90 (1H, dt, J = 
6.4, 9.6 Hz, H-25a), 3.85-3.55 (3H, bm, -NCH2), 3.53 (1H, dt, J = 6.8, 9.6 Hz, H-25b), 3.41 (2H, bs, -
NCH2), 3.17 (2H, t, J = 6.8 Hz, H-35), 2.78- 2.45 (10H, bm, -NCH2), 2.39-2.30 (5H, m, H-26/-NCH2), 
2.26 (2H, m, H-17), 1.70-1.38 (12H, m, H- 18/24/27/34/6/13), 1.35-1.00 (22H, m, CH2-alk); C 
(CDCl3, 100 MHz): 172.9 (C=O), [166.1, 165.8, 165.2, 165.0 (C=O)], 156.4 (C=O), 136.7 (ArC), 
[133.4, 133.2, 133.2, 133.1 (ArC)], [129.9 (x2), 129.8 (x2), 129.6 (x2), 129.0 (x2), 128.6, 128.5 (x2), 
128.4 (x2), 128.3, 128.1 (ArC)], 101.3 (C-1’), 73.0 (C-3’),  72.1 (C-2’), 71.9 (C-5’), 70.7 (C-15), 70.3 
(C-25), 69.9 (C-4’), 66.5 (C-2’’), 63.3 (C-6’), 56.0 (C-26), [55.4 (x2), 55.0, 54.7, 54.4, 54.1, 53.9, 
52.7, 52.4, 51.9, 51.1, 50.2, 46.5, 45.1, 43.7, 41.2 (NCH2)], 41.1 (C-35), 33.4/ 33.1 (C-17), 29.9 (C-
34), [29.5 (x2), 29.4 (x3) 29.3 (x2), 29.2, 27.8, 27.6, 27.5, 26.9, 26.8, 25.7, 25.5, 21.6 (CH2-alk, C-
6/13)]; HRMS (ESI MALDI-TOF): m/z Calculated for C73H96N5O13 (M + H)+ 1250.6999; found, 
1250.6929 (including bis-aminal bridge); Calculated for C72H96N5O13 (M + H)+ 1238.6999; found, 
1238.6953 (excluding bis-aminal bridge) 
 









Potassium carbonate (0.033 g, 0.24 mmol) was added to a solution of cyclam 48 (0.100 g, 0.08 mmol) 
in anh. MeCN (15 mL) under N2(g). t-Butyl bromoacetate(0.047 g, 0.24 mmol) was dissolved in anh. 
MeCN (1 mL) and added to the solution which was then stirred for 16 hrs. The solvent was removed 
under vacuum and the residue was redissolved in H2O (20 mL) and extracted with CH2Cl2 (4 x 20 
mL). The organic extracts were dried, filtered and the solvent evaporated under vacuum. The oily 
residue was purified using column chromatography (CH2Cl2: MeOH 9.5:0.5) to yield the title 
compound 49 as an oil (0.086 g, 73%). 
max/ cm-1:  1724 (C=O), 1258 (C-N); H (CDCl3, 400 MHz): 8.02-7.81 (8H, m, ArH), 7.53-7.25 (17H, 
m, ArH), 5.89 (1H, t, J = 9.6 Hz, H-3’), 5.66 (1H, t, J = 9.6 Hz, H-4’), 5.50 (1H, dd, J = 7.8, 9.6 Hz, 
H-2’), 5.09 (2H, s, H-2’’), 4.83 (1H, d, J = 7.8 Hz, H-1’), 4.78 (1H, bs, NH), 4.63 (1H, dd, J = 3.2, 
12.0 Hz, H-6’a), 4.50 (1H, dd, J = 5.2, 12.0 Hz, H-6’b), 4.15 (1H, m, H-5’), 3.90 (1H, dt, J = 6.4, 9.6 
Hz, H-25a), 3.53 (1H, dt, J = 6.8, 9.6 Hz, H-25b), 3.45 (4H, m, NCH2), 3.25 (2H, m, H-1’’’), 3.22 
(2H, s, H-1’’’), 3.17 (2H, t, J = 6.8 Hz, H-35), 2.82- 2.62 (8H, m, H-26/NCH2), 2.46 (2H, m, NCH2), 
2.37 (4H, m, NCH2), 2.25 (2H, t, J = 6.8 Hz, H-17), 1.67 (1H, bm, CH2), 1.57 (5H, m, CH2), 1.50 
(4H, m, CH2), 1.45 (9H, s, H-4’’’), 1.43 (9H, s, H-4’’’), 1.32-1.02 (24H, m, CH2Alk); C (CDCl3, 100 
MHz): 172.9 (C-16), 170.8 (C-2’’’), [166.1, 165.8, 165.2, 165.0 (C=O)], 156.4 (C-1’’), 136.7 (ArC), 
[133.3, 133.1, 133.1, 133.0, 129.8, 129.7 (x4), 129.4, 128.9 (x2), 128.5, 128.4, 128.3 (x3), 128.2, 
128.0(ArC)], 101.3 (C-1’), 80.6 (x2)(C-3’’’), 73.0 (C-3’),  72.2 (C-2’), 72.0 (C-5’), 70.3 (C-25), 70.0 
(C-4’), 66.5 (C-2’’), 63.3 (C-6’), 57.2 (C-1’’’), 55.9, (C-1’’’), [55.0, 53.9, 52.3, 52.0, 51.3, 51.2 (x2), 
47.0, 44.9 (NCH2)], 41.1 (C-35), 33.1/ 33.0 (C-17), [30.0, 29.5, 29.4 (x3), 29.3, 29.2 (x2), 28.2 (x2), 
28.0, 27.6, 26.7 (x2), 26.5, 25.8, 25.5 (x3)(CH2Alk, C-6/13, C-4’’’)]; HRMS (ESI MALDI-TOF): m/z 












Sodium metal (0.119 g, 5.17 mmol) was reacted with anh. MeOH (5 mL) and then added to a solution 
of glucose-cyclam derivative 49 (0.640 g, 0.512 mmol) in anh MeOH (30 mL) under N2 (g) and stirred 
for 1 hr. The MeOH was evaporated in vacuo and the product redissolved in CH2Cl2 (20 mL). Water 
(20 mL) was added and the pH was adjusted to 3-4 with 1 M HCl. The organic layer was separated 
out and the aqueous phase further extracted with CH2Cl2 (3 x 40 mL). The organic layers were 
combined, dried, filtered and concentrated under vacuum. The crude oil was purified using column 
chromatography (CH2Cl2: MeOH: NH4OH, 8: 1.8: 0.2) to yield the title product 50 as an oil (0.374 g, 
92 %). Rf = 0.55 (CH2Cl2: MeOH: NH4OH, 8: 1.8: 0.2) 
max/ cm-1:  3351 (OH), 1714 (C=O), 1626 (C=O); H (CD3OD, 400 MHz): 7.34-7.23 (5H, m, ArH), 
5.06 (2H, s, H-2’’), 4.25 (1H, d, J = 7.8 Hz, H-1’), 3.91-3.84 (2H, m,  H-6’a/25a),  3.80-3.55 (2H, bm, 
-NCH2 including 3.67 (1H, m, H-6’b)), 3.60-3.40 (2H, bs, -NCH2 including 3.53 (1H, dt, J = 6.9, 9.6 
Hz, H-25b)), 3.37-3.23 (5H, m, H-3’/4’/5’/NCH2), 3.17 (1H, t, J = 7.8 Hz, H-2’), 3.10 (2H, t, J = 7.2 
Hz, H-35), 2.80- 2.50 (10H, bm, -NCH2), 2.50-2.40 (4H, m, H-26/NCH2), 2.37 (2H, t, J = 7.2 Hz, H-
17), 1.74 (2H, m), 1.61 (4H, m), 1.48 (4H, m), 1.40-1.20 (24H, m, CH2-alk); C (CD3OD, 100 MHz): 
175.6 (C=O), 158.8 (C=O), 138.5 (ArC), [129.4, 128.9, 128.7 (ArC)], 104.4 (C-1’), 78.1 (C-3’), 77.9 
(C-2’), 75.1 (C-5’), 71.7 (C-25), 71.1 (C-15), 70.9 (C-4’), 67.2 (C-2’), 62.8 (C-6’), 56.9 (C-26), [56.2, 
55.4, 55.2, 55.2, 54.6, 54.5, 54.5, 53.8, 53.1, 52.5, 51.1, 51.1, 47.9, 46.0, 45.1, 42.3 (NCH2)], 41.8 (C-
35), 34.2 /34.0 (C-17), [30.9, 30.8, 30.6, 30.6, 30.5, 30.5, 30.4, 30.4, 28.7, 28.6, 28.1, 28.0, 27.8, 27.0, 
26.8, 26.7, 22.4 (C-alk including C-6/13)]; HRMS (ESI MALDI-TOF): m/z Calculated for 
C45H80N5O9 (M + H)+ 834.5950; found, 834.5938 (including bis-aminal bridge); Calculated for 













Pd/C (0.037 g, 10%w/w) was added to a solution of glucose cyclam 50 (0.374 g, 0.45 mmol) in anh. 
MeOH (10 mL). The flask was flushed with H2 (g) and stirred overnight under a H2 (g) environment 
using a hydrogen-filled balloon. The solution was filtered though a Celite pad which was washed with 
MeOH and the filtrate concentrated under vacuum. The crude oil was then redissolved in MeOH (5 
mL) and 2M NaOH (5 mL) added to obtain the product in its free base form. The water and MeOH 
were removed under vacuum and MeOH (10 mL) again added to the flask. A white solid precipitated 
out which was then filtered off though Celite. The solvent was evaporated and the crude product dry 
loaded and purified using column chromatography (CH2Cl2: MeOH: NH4OH, 7: 2.5: 0.5). Two major 
isomers were obtained which could not be fully separated (top isomer 0.040 g, mixed isomers 0.153 g, 
bottom isomer 0.084 g, total yield = 89 %). NMR analysis indicated that the top isomer still contained 
the bis-aminal bridge (50a) whereas the bottom isomer was analysed to be the title compound 51. 
max/ cm-1:  3345 (OH/NH), 1626 (C=O); H (CD3OD, 400 MHz): 4.25 (1H, d, J = 8.0 Hz, H-1’), 3.89 
(1H, dt, J = 6.8, 9.6 Hz, H-25a), 3.86 (1H, dd, J = 2.0, 12.0 Hz, H-6’a), 3.68 (1H, dd, J = 5.6, 12.0 Hz, 
H-6’b), 3.62-3.44 (5H, m, H-2/14/25b), 3.37 (1H, t, J = 8.8 Hz, H-3’), 3.32 - 3.24 (2H, m, H-4’/5’), 
3.17 (1H, t, J = 8.0 Hz, H-2’), 2.96 (2H, m, -NCH2), 2.86- 2.76 (8H, m, H-35/-NCH2(x3)), 2.66 (2H, 
m, -NCH2), 2.55-2.33 (6H, m, H-17/26/NCH2), 1.85 (2H, m, H-6), 1.80 – 1.55 (8H, m, H-
13/18/24/34), 1.49 (2H, m, H-27), 1.42-1.28 (22H, m, CH2-alk); C (CD3OD, 100 MHz): 175.6 (C-
16), 104.4 (C-1’), 78.2 (C-3’), 77.9 (C-2’), 75.2 (C-5’), 71.8 (C-25), 70.9 (C-4’), 62.9 (C-6’), 56.0 (C-
26), [53.5, 53.4, 52.8, 52.6, 51.3 (x2), 50.5 (x2), 49.7 (x2), 48.6 (x2), 48.0 (x2), 46.4 (x2) (NCH2 and 
rotamers)], 41.4 (C-35), 34.2/33.9 (C-17 and rotamers), [30.8, 30.7, 30.6, 30.4(x4), 30.3, 28.7, 28.5, 
28.2, 27.8 (x2), 27.6 (x2), 27.4, 27.0, 26.7, 26.5 (CH2Alk including C-6/13 and rotamers)]; HRMS 











tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (52) 
 
A solution of di-tert-butyl dicarbonate (2.72 g, 12.5 mmol) in CH2Cl2 (150 mL) was added drop wise 
over 4 hrs to a solution of cyclam (1.00 g, 5.00 mmol) in CH2Cl2 (300 mL) at RT˚. The reaction was 
then stirred for another 12 hrs. All solvent was removed under vacuum and the residue redissolved in 
diethyl ether (15 mL) and CH2Cl2 (5 mL) followed by removal of the solvent again under vacuum. 
The oily residue was adsorbed onto silica and purified with flash column chromatography 
(EtOAc:MeOH 9:1, 8:2) to yield the title compound 52 as a clear oily foam (1.37 g, 55%), Rf = 0.69 
(EtOAc:MeOH 8:2). The 1H NMR spectra agreed with those reported in the literature.281  
max/ cm-1:  1678 (C=O), 1160 (C-N); H (CDCl3, 400 MHz): 3.37 (4H, m, CH2N), 3.35-3.24 (8H, m, 
CH2N), 2.76 (2H, t, J = 5.2 Hz, CH2N), 2.59 (2H, t, J = 5.2 Hz, CH2N), 1.91 (2H, bm, H-13), 1.68 
(2H, bm, H-6), 1.44 (18H, s, H-3’), 1.43 (9H, s, H-3’), C (CDCl3, 100 MHz): [156.3, 155.5, 155.5 (C-
1’)], [79.4, 79.4, 79.3 (C-2’)], [50.5, 50.0, 47.7, 46.7 (x3), 45.9, 44.1 (CH2N)], 30.6 (C-6), 29.8 (C-





Et3N (0.35 mL, 2.48 mmol) and DMAP (0.048 g, 0.33 mmol) was added to a solution of cyclam 52 
(1.30 g, 1.66 mmol) in THF (18 mL) under N2(g). Previously prepared acid chloride 10a was dissolved 
in THF (10 mL) and slowly added to the solution at 0˚C after which the reaction was left to stir for 2.5 
hrs and warm to room temperature. The solution was then filtered through celite to remove the 
triethylamine salts and the solvent removed in vacuo. The residue was redissolved in EtOAc (40 mL) 
and washed with sat. NH4Cl(aq) (40 mL). The organic phase was separated and the aq. phase extracted 
with EtOAc (3 x 25 mL). The combined organic extracts were dried, filtered and the solvent 




evaporated under vacuum to yield a crude residue that was purified with column chromatography 
(CH2Cl2: MeOH 9.5:0.5) to yield the title compound 53 as a clear foam (1.31 g, 63%) 
max/ cm-1:  1728 (C=O), 1686 (C=O), 1248 (C-N); H (CDCl3, 400 MHz): 8.02-7.81 (8H, m, ArH), 
7.55-7.25 (12H, m, ArH), 5.89 (1H, t, J = 9.6 Hz, H-3’’), 5.66 (1H, t, J = 9.6 Hz, H-4’’), 5.50 (1H, dd, 
J = 7.8, 9.6 Hz, H-2’’), 4.83 (1H, d, J = 7.8 Hz, H-1’’), 4.63 (1H, dd, J = 3.4, 12.0 Hz, H-6’’a), 4.50 
(1H, dd, J = 5.1, 12.0 Hz, H-6’’b), 4.15 (1H, m, H-5’’), 3.90 (1H, dt, J = 6.3, 9.9 Hz, H-24a), 3.55-
3.30 (17H, m, H-24b/CH2N(x8)), 2.27 (2H, m, H-16), 1.85-1.70  (6H, m, H-17/23/13), 1.62-1.45 (4H, 
m, H-6/AlkCH2), 1.45 (27H, s, H-3’), 1.20-1.05 (8H, m, AlkCH2); C (CDCl3, 100 MHz): 172.9 (C-
15), [166.1, 165.8, 165.2, 165.0 (C=O)], [156.0, 155.8, 155.4 (C-1’)], [133.3, 133.1, 133.0 (x2)], 
[129.8 (x2), 129.7 (x2), 129.4 (x2), 128.9 (x2), 128.3 (x2), 128.2 (x2)(ArC)], 101.3 (C-1’’), [80.1, 
79.9, 79.8 (C-2’)], 73.0 (C-3’’), 72.2 (C-2’’), 72.0 (C-5’’), 70.3 (C-24), 69.9 (C-4’’), 66.5 (C-2’), 63.3 
(C-6’’), [49.1, 48.5, 48.3, 47.4, 47.4, 46.8, 46.6, 46.5 (CH2N)], 33.2/32.9 (C-16 and rotamer), [29.4, 






Cyclam 53 (1.31 g, 1.05 mmol) was dissolved in CH2Cl2 (33.6 mL) and TFA (8.4 mL) was added to 
make a final solution of 20 % TFA in CH2Cl2. After stirring for 3 hrs, the flask was put on ice to cool 
and the reaction was quenched by the slow addition of sat. NaHCO3 (aq) (150 mL). Extra CH2Cl2 (50 
mL) was added and the solution stirred for 10 min. The organic phase was separated and washed 
again with sat. NaHCO3 (aq) (20 mL). The combined aq. phases were then extracted with CH2Cl2 (3 x 
50 mL). The combined organic extracts were washed with brine (50 mL) and then dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified with flash chromatography 
(CH2Cl2:MeOH 9:1 with a few drops of Et3N) to yield the title compound 54 as a clear oil (1.03 g, 
89%), Rf = 0.69 (CH2Cl2:MeOH 9:1). 
max/ cm-1:  3432 (NH), 1724 (C=O), 1677 (C=O); H (CDCl3, 400 MHz): 8.02-7.81 (8H, m, ArH), 
7.56-7.25 (12H, m, ArH), 5.89 (1H, t, J = 9.6 Hz, H-3’), 5.66 (1H, t, J = 9.6 Hz, H-4’), 5.50 (1H, dd, J 
= 7.8, 9.6 Hz, H-2’), 4.83 (1H, d, J = 7.8 Hz, H-1’), 4.62 (1H, dd, J = 3.4, 12.0 Hz, H-6’a), 4.50 (1H, 




dd, J = 5.1, 12.0 Hz, H-6’b), 4.15 (1H, m, H-5’), 3.90 (1H, dt, J = 6.3, 9.9 Hz, H-24a), 3.54 (5H, m, 
H-24b/CH2N (x2)), 3.01 (2H, m, CH2N), 2.91 (8H, m, CH2N), 2.78 (2H, m, CH2N), 2.27 (2H, t, J = 
7.6 Hz, H-16), 1.94 (2H, qn, J = 5.2 Hz, H-6), 1.77 (2H, m, H-13), 1.52 (4H, m, H-17/23), 1.24-1.05 
(10H, m, AlkCH2); C (CDCl3, 100 MHz): 174.0 (C-15), [166.1, 165.8, 165.2, 165.0 (C=O)], [133.3, 
133.1 (x2), 133.0], [129.8 (x2), 129.7 (x2), 129.6, 129.4, 128.9 (x2), 128.3 (x3), 128.2 (ArC)], 101.3 
(C-1’), 73.0 (C-3’), 72.2 (C-2’), 72.0 (C-5’), 70.4 (C-24), 70.0 (C-4’), 63.3 (C-6’), [50.5, 49.5, 49.1, 





Sodium metal (0.053 g, 2.28 mmol) was reacted with anh. MeOH (2 mL) and then added to a solution 
of cyclam 54 (0.900 g, 0.90 mmol) in anh MeOH (13 mL) under N2 (g) and stirred for 2 hr. The MeOH 
was evaporated in vacuo and the product redissolved in CH2Cl2 (25 mL) and water (25 mL). The 
solution was acidified to pH 2 with 1 M HCl and the aqueous phase was extracted with CH2Cl2 (3 x 
25 mL). The methyl benzoate by-product was extracted into the organic layer while the product 
remained in the aqueous phase. The aqueous phase was then basified to pH 10 with 2 M NaOH and 
extracted with CHCl3: EtOAc (2:1)(12 x 20 mL). The solvent was removed under vacuum to yield the 
title compound 55 as an oil (0.392 g, 80 %) that was judged to be 95% pure by NMR. 
max/ cm-1:  3309 (OH/NH), 1677 (C=O); H (D2O, 400 MHz): 4.53 (1H, d, J = 8.0 Hz, H-1’), 3.99 
(2H, m, H-24a/6’a), 3.81 (1H, dd, J = 5.6, 12.0 Hz, H-6’b), 3.75 (1H, dt, J = 6.8, 9.6 Hz, H-24b), 
3.72-3.60 (4H, m, H-2/14), 3.57 (1H, m, H-3’), 3.52 (1H, m, H-5’), 3.47 (1H, m, H-4’), 3.34 (1H, dd, 
J = 8.0, 9.2 Hz, H-2’), 3.16 (2H, m, CH2N), 3.10 (2H, m, CH2N), 3.06-2.95 (6H, m, CH2N), 2.86 (2H, 
t, J = 6.4 Hz, CH2N), 2.50 (2H, t, J = 7.6 Hz, H-16), 1.91 (4H, m, H-6/13), 1.69 (4H, m, H-17/23), 
1.48-1.38 (10H, m, AlkCH2); C (D2O, 100 MHz): 177.3 (C-15), 102.3 (C-1’), 76.0 (C-3’) 76.0 (C’5’), 
73.3 (C-2’), 70.7 (C-24), 69.8 (C-4’), 60.9 (C-6’), [48.7 (C-2/14), 48.2, 47.8, 47.3, 46.7 (C-2/14 
rotamer), 46.4, 45.8 (C-2/14), 44.7 (x2), 44.1 (C-2/14 rotamer)(CH2N)], 32.9 (C-16), [28.9 (C-23), 
28.6 (x2), 28.5 (x2), 27.8, 25.3, 25.1 (CH2Alk/ C-13)], 24.8 (C-6); HRMS (ESI MALDI-TOF): m/z 
Calculated for C26H53N4O7+ (M + H)+ 533.3908; found 533.3933 







Bromide 3 (0.590 g, 0.72 mmol) dissolved in MeCN (10 mL) and NaHCO3 (0.152 g, 1.80 mmol) was 
added to a solution of cyclam 32 (0.372 mg, 0.60 mmol) in MeCN (30 mL). The reaction was heated 
at 80˚C for 48 hrs after which K2CO3 (0.250 mg, 1.80 mmol) was added and the reaction was heated 
again at 80˚C for 48 hrs. The solvent was removed in vacuo and the residue was redissolved in DCM 
(20 mL) and water (20 mL). The organic phase was separated and the aq. phase extracted with DCM 
(2 x 20 mL). The combined organic extracts were dried, filtered and the solvent evaporated under 
vacuum to yield a crude residue that was purified with column chromatography (CH2Cl2: MeOH 
9.5:0.5) to yield the title compound 56 as an oil (0.370 g, 48%). Rf = 0.7 (CH2Cl2: MeOH: NH4OH 
8:1.9;0.1) 
H (CDCl3, 300 MHz): 8.02-7.81 (8H, m, ArH), 7.55-7.25 (12H, m, ArH), 5.89 (1H, t, J = 9.6 Hz, H-
3’’), 5.66 (1H, t, J = 9.6 Hz, H-4’’), 5.51 (1H, dd, J = 7.8, 9.7 Hz, H-2’’), 4.83 (1H, d, J = 7.8 Hz, H-
1’’), 4.63 (1H, dd, J = 3.4, 12.1 Hz, H-6a’’), 4.50 (1H, dd, J = 5.2, 12.1 Hz, H-6b’’), 4.15 (1H, m, H-
5’’), 3.90 (1H, dt, J = 6.2, 9.7 Hz, H-24a), 3.53 (1H, dt, J = 6.2, 9.7 Hz, H-24b), 3.53 (2H, m, CH2N), 
3.32-3.22 (8H, m, CH2N, 3 x H-1’), 3.12-3.06 (4H, m, H-15, CH2N), 2.72 – 2.60 (10H, m, 5 x CH2N), 
1.99 (2H, m, H-13), 1.78 (2H, m, H-16), 1.61 (2H, m, H-6), 1.52 (2H, m, H-23), 1.45 (27H, s, H-4’), 
1.30-1.05 (12H, m, CH2-alk); C (CDCl3, 100 MHz): 170.7 (C-2’), 170.5 (x2)(C-2’), [166.1, 165.8, 
165.2, 165.0 (C=O)], [133.3, 133.1, 133.1, 133.0, 129.8, 129.7 (x3), 129.6, 129.4, 128.9, 128.8, 128.3 
(x3), 128.2 (ArC)], 101.3 (C-1’’), 81.4 (x2) (C-3’), 81.0 (C-3’), 73.0 (C-3’’), 72.1 (C-2’’), 71.9 (C-
5’’), 70.3 (C-24), 69.9 (C-4’’), 63.3 (C-6’’), 55.7 (x2)(C-1’), 55.2 (C-1’), 53.2 (C-15), [52.0, 51.9, 
51.8, 51.0, 50.7, 50.2, 50.0, 49.6 (CH2N)], [29.4, 29.3, 29.2, 29.1, 29.0 (CH2-alk)], 28.2 (x3)(C-4’), 











acid ammonium trifluoroacetate salt (57) 
 
A 25 % solution of sodium methoxide (0.02 mL, 0.07 mmol) was added to a solution of cyclam 56 
(0.110 g, 0.09 mmol) in anh. MeOH (4 mL) and the solution was stirred for 1 hr. The reaction was 
quenched with 0.25 M HCl (10 mL) and extracted with diethyl ether (3 x 10 mL). The aqueous phase 
was then basified to pH 10-11 with 2 M NaOH and extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were then dried over MgSO4, filtered and concentrated under vacuum to yield an oil 
(0.050 g, 67 %) that showed only one spot on TLC and was so used directly in the next reaction.  
The oil (0.050 g, 0.058 mmol) was dissolved in DCM (2 mL) and tri-fluoro acetic (2 mL) was added 
after which the reaction was stirred overnight. The solvent was evaporated off under vacuum, the 
crude oil redissolved in H2O (5 mL) and then the aqueous phase was extracted with CHCl3 (3 x 3 
mL). The aqueous layer was concentrated under a stream of air and dried under vacuum to yield the 
title compound as a pure, glass-like, TFA salt product (0.027 g, 43 %). Rf = 0.08` (CH2Cl2: MeOH: 
NH4OH 8:1.9;0.1), Mp = glassy solid started decomposing at 180˚C. 
H (D2O, 400 MHz): 4.32 (1H, d, J = 7.8 Hz, H-1’’), 3.93 (2H, s, H-1’),  3.79 (2H, m, H-6’’a/24a), 
3.61-3.51 (6H, m, H-6’’b/24b/1’’(x2)), 3.40-3.25 (11H, m, H-3’’/4’’/5’’/NCH2(x4)), 3.16-3.08 (7H, 
H-2’’/15/ NCH2(x2)), 2.90 (4H, bm, -NCH2(x2)), 1.93 (4H, m, H-6/13), 1.59 (2H, m, H-16), 1.50 
(2H, m, H-23), 1.25-1.15 (12H, m, CH2-alk(x6)); C (D2O, 100 MHz): 173.8 (x2)(C-2’), 173.7 (C-2’), 
169.6 (TFA), 114.8 (TFA), 102.1 (C-1’’), 75.8 (C-3’’), 75.8 (C-5’’), 73.1 (C-2’’), 70.6 (C-24), 69.6 
(C-4’’), 60.7 (C-6’’), 54.6 (C-1’), 54.5 (C-1’), 54.4 (C-1’), 54.0 (C-15), [52.8, 52.5, 51.6, 51.5, 50.6, 
50.0, 49.6, 48.8 (CH2N)], [28.7, 28.4, 28.3, 28.2, 28.0, 25.6, 25.0, 22.5 (CH2-alk)], 21.6 (C-6), 21.0 














1,4,8,11-tetraazacyclotetradecane dichloropalladate(II) (58) 
 
PdCl2(COD) (0.145 g, 0.50 mmol) was dissolved in CH2Cl2 (8 mL) and added to a stirring solution of 
cyclam (0.10 g, 0.50 mmol) in CH2Cl2 (12 mL). Upon addition, the yellow colour of the PdCl2(COD) 
solution disappeared and the solution became milky. The reaction was stirred for 1 hr after which a 
white solid had precipitated onto the sides of the flask. The precipitate was filtered off and washed 
with CH2Cl2 (2 x 10 mL) after which it was recrystallised with CH2Cl2 and MeOH to yield the title 
compound 58 (0.118 g, 63 %). 
max/ cm-1: 3443, 3064, 1050; H (D2O, 300 MHz): 3.13 (4H, m, CH2N), 3.02 (4H, m, CH2N), 2.85 – 
2.65 (8H, m, CH2N), 2.22 (2H, m, H-6a/H-13a), 1.64 (2H, m, H-6b/H-13); C (D2O, 100 MHz): 52.0 
(C-N), 49.4 (C-N), 27.2 (C-6/13) 
 
Benzyl N-(3-hydroxypropyl)carbamate (59) 
 
Na2CO3 (1.76 g, 16.6 mmol) and benzyloxy chloroformate (1.42 g, 1.18 mL, 8.3 mmol) was added to 
a solution of 3-amino-propanol (0.50 g, 6.6 mmol) in CH2Cl2:H2O (1:1, 50 mL) and the solution 
stirred for 4 hrs. The organic layer was separated and aqueous layer extracted with CH2Cl2 (3 x 50 
mL). The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo to yield a 
crude white solid which was dry loaded onto a pre-packed column and purified using automated 
column chromatography (Hex:EtOAc 7:3). The title compound 59 was obtained as a white solid (1.30 
g, 94%), Rf = 0.19 (Hex: EtOAc 1:1). The 1H and 13C NMR spectra agreed with those reported in the 
literature.282  
max/ cm-1: 3321 (OH, NH), 1682 (C=O); H (CDCl3, 300 MHz): 7.35-7.32 (5H, m, ArH), 5.10 (2H, s, 
H-2’), 3.66 (2H, t, J = 5.6 Hz, H-3), 3.33 (2H, t, J = 6.4 Hz, H-1), 2.55 (1H, br, -OH), 1.73-1.65 (2H, 
m, H-2); C (CDCl3, 100 MHz): 157.2 (C-1’), 136.5, 128.5, 128.1, 128.0 (ArC), 66.8 (C-2’), 59.7 (C-
3), 37.9 (C-1), 32.5 (C-2). 







Hexamethyldisilane (0.389 g, 2.65 mmol) in CH2Cl2 (10 mL) was added to a solution of glucose 1 
(3.00 g, 4.28 mmol) in CH2Cl2 (50 mL). To this solution was added ZnI2 (0.342 g, 1.07 mmol), 
followed by I2 (0.674 g, 2.65 mmol) and stirred for 16 hrs. The reaction was quenched by addition of 
CH2Cl2 (40 mL) and an aqueous solution (100 mL) of NaHCO3 (1.44 g) and Na2S2O3 (0.96 g) and 
stirred for 10 min until the pinkish colour and milky solution had cleared. The organic phase was 
separated and washed with brine (50 mL) and the combined aqueous phases extracted with CH2Cl2 (2 
x 50 mL). The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo to 
yield a crude oil product iodide 1a which was used directly in the next reaction. 
Molecular sieves (3.00 g), ZnCl2 (0.525 g, 3.85 mmol) and carbamate 59 (0.403 g, 1.93 mmol) was 
added to the freshly prepared iodide 1a (1.36 g, 1.93 mmol) in anh. CH2Cl2 (25 mL) and the reaction 
stirred for 16 hrs. The molecular sieves were filtered off through a Celite pad and the reaction 
quenched with an aqueous solution (50 mL) of NaHCO3 (0.480 g) and Na2S2O3 (0.720 g) and stirred 
for 10 min. The organic layer was separated and the aq. phase extracted with CH2Cl2 (2 x 50 mL). The 
combined organic layers were washed with brine and aq. phase extracted once more with CH2Cl2 (50 
mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo to yield a crude oil 
product which was purified using automated column chromatography (Hex:EtOAc 9:1, 8:2, 7:3) to 
yield the title compound 60 as a white foam (0.95 g, 63%). Rf = 0.2 (Hex: EtOAc 1:1) 
[α]D= +11.0 (c =1.0 in CH2Cl2); max/ cm-1: 3055 (HN-C=O), 1734 (C=O); H (CDCl3, 300 MHz): 7.94 
-7.74 (8H, m, ArH), 7.46-7.18 (17H, m, ArH), 5.83 (1H, t, J = 9.6 Hz, H-3’), 5.59 (1H, t, J = 9.6 Hz, 
H-4’), 5.44 (1H, dd, J = 7.8, 9.6 Hz, H-2’), 4.97 (3H, s, H-2’’, -NH), 4.76 (1H, d, J = 7.8 Hz, H-1’), 
4.57 (1H, dd, J = 3.0, 12.1 Hz, H-6a’), 4.43 (1H, dd, J = 5.1, 12.3 Hz, H-6b’), 4.08 (1H, m, H-5’), 
3.89 (1H, dt, J = 6.2, 9.7 Hz, H-1a), 3.56 (1H, dt, J = 6.2, 9.7 Hz, H-1b), 3.09 (2H, m, H-3),  1.68 (2H, 
m, H-2); C (CDCl3, 100 MHz): [166.1, 165.8, 165.2, 165.1 (C=O)], 156.4 (C=O), 136.8, 133.4, 
133.3, 133.2, 133.1, 129.8 (x2), 129.7 (x2), 129.6, 129.2, 128.8 (x2), 128.4 (x2), 128.3 (x2), 128.0, 
127.9 (ArC), 101.2 (C-1’), 72.8 (C-3’), 72.4 (C-2’), 71.9 (C-5’), 69.7 (C-4’), 67.7 (C-1), 66.4 (C-2’’) 
63.0 (C-6’), 38.1 (C-3), 29.5 (C-2); HRMS (ESI MALDI-TOF): m/z Calculated for C45H42NO12 (M + 
H)+ 788.2628; found, 788.2684 
 
 






Sodium (0.130 g, 5.71 mmol) was reacted with anh. MeOH (6 mL) to form a solution of NaOMe (1M, 
5.7 mmol) which was then added to a solution of carbamate 60 (0.900 g, 1.14 mmol) in anh. MeOH 
(30 mL) under N2 (g) and stirred for 45 min. The MeOH was evaporated in vacuo and the crude white 
solid material redissolved in H2O (50 mL) with MeOH (5 mL) and 1M HCl added to pH 5 and 
extracted with CH2Cl2 (2 x 30 mL). The aqueous layer was concentrated to yield a crude product to 
which acetone was added to precipitate out the sodium salts which were filtered off through Celite. 
The mother liquor was concentrated and purified using column chromatography (CH2Cl2: MeOH, 9:1, 
8:2) to yield the title product 61 as a clear oil (0.297 g, 70%). Rf = 0.28 (CH2Cl2: MeOH 9:1)  
[α]20,D= -30.0  (c = 0.1 in MeOH); max/ cm-1: 3374 (-OH, NH), 1705 (C=O); H (CDCl3, 300 MHz): 
7.28 (5H, m, ArH), 5.69 (1H, bs, -NH), 5.03 (2H, s, H-2’), 4.30- 4.20 (5H, bs, H-1’’, -OH), 3.85- 3.78 
(3H, m, H-6’’/3a), 3.55- 3.46 (3H, m, H-3b/3’’/4’’), 3.38- 3.30 (1H, m, H-5’’), 3.25 (3H, m, H-1/2’’), 
1.72 (2H, m, H-2); C (CDCl3, 100 MHz): 157.0 (C=0), 136.6 (C-3’), [128.5, 128.3, 128.1 (ArC)], 
102.8 (C-1’’), 76.5 (C-5’’), 75.7 (C-3’’), 73.4 (C-2’’), 69.6 (C-4’’), 67.4 (C-3), 66.7 (C-2’), 61.3 (C-
6’’), 37.9 (C-1), 29.6 (C-2); HRMS (ESI MALDI-TOF): m/z Calculated for C17H26NO8 (M + H)+ 
372.1652; found, 372.1644. 
 
1-β-D-(3-Aminopropyl) glucopyranoside (62) 
 
Carbamate 61 (0.280 g, 0.75 mmol) was dissolved in anh. MeOH (5 mL) and Pd/C (10% w/w) in anh. 
MeOH (2 mL) was added to the solution. The flask was flushed with H2 (g) and the reaction stirred 
under H2 (g) for 20 hrs. The solution was filtered through a Celite pad and the MeOH removed under 
vacuum. The crude material was dry loaded and purified on a C-18 reverse phase column using H2O 
as the eluent. The title product 62 was obtained as an oil (0.135 g, 73%).   
max/ cm-1: 3254 (OH/NH); H (CD3OD, 300 MHz): 4.26 (1H, d, J = 7.8 Hz, H-1’), 3.99 (1H, dt, J = 
6.6; 9.6 Hz, H-1a), 3.87 (1H, dd, J = 1.8, 11.7 Hz, H-6’a),  3.70-3.63 (2H, m, H-6’b/1b), 3.38-3.26 
(3H, m, H-3’/4’/5’), 3.17 (1H, dd, J = 7.8, 8.4 Hz, H-2’), 2.83 (2H, dt, J = 1.5, 6.9 Hz, H-3), 1.80 (2H, 




qn, J = 6.9 Hz, H-2); C (D2O, 100 MHz): 102.3 (C-1’), 76.0 (C-3’), 75.9 (C-2’), 73.2 (C-5’), 69.8 (C-




4 Ǻ Molecular sieves (3.00 g), ZnCl2 (0.386 g, 2.83 mmol) and S-3-hydroxypropyl thioacetate (0.189 
g, 1.41 mmol) was added to a solution of freshly prepared iodide 1a (1.00 g, 1.41 mmol) in CH2Cl2 
(20 mL) and the reaction stirred for 19 hrs. The molecular sieves were filtered off through a celite pad 
and the reaction quenched with an aqueous solution (50 mL) of NaHCO3 (0.96 g) and Na2S2O3 (1.44 
g) and stirred for 10 min. The organic layer was separated and the aq. phase extracted with CH2Cl2 (3 
x 50 mL). The organic layers were washed with brine and then dried over MgSO4, filtered and 
concentrated in vacuo to yield a crude product which was purified using automated column 
chromatography (Hex:EtOAc 9:1, 8:2) to yield the title compound 63 as a clear oil (0.68 g, 68%). Rf = 
0.38 (Hex: EtOAc 7:3)  
[α]20,D = +30.5 (c =1.0 in CH2Cl2); max/ cm-1: 1734 (C=O), 1688 (C=O); H (CDCl3, 300 MHz): 8.03-
7.81 (8H, m, ArH), 7.57-7.25 (12H, m, ArH), 5.91 (1H, t, J = 9.6 Hz, H-3’’), 5.67 (1H, t, J = 9.6 Hz, 
H-4’’), 5.51 (1H, dd, J = 7.8, 9.9 Hz, H-2’’), 4.85 (1H, d, J = 7.8 Hz, H-1’’), 4.65 (1H, dd, J = 3.3, 
12.0 Hz, H-6a’’), 4.51 (1H, dd, J = 5.4, 12.3 Hz, H-6b’’), 4.17 (1H, m, H-5’’), 3.96 (1H, dt, J = 6.0, 
9.9 Hz, H-1a), 3.62 (1H, m, H-1b), 2.81 (2H, m, H-3),  2.21 (3H, s, H-2’), 1.89-1.77 (2H, m, 
AlkCH2); C (CDCl3, 100 MHz): 197.8 (C=O), [166.1, 165.8, 165.2, 165.1 (C=O)], [133.4, 133.3, 
133.2, 133.1, 129.8 (x2), 129.7 (x2), 129.6, 129.2, 128.9, 128.8, 128.4 (x2), 128.3 (x2)(ArC)], 101.2 
(C-1’’), 72.9 (C-3’’), 72.3 (C-2’’), 71.9 (C-5’’), 69.8 (C-4’’), 68.3 (C-1), 63.2 (C-6’’), 30.4 (C-2’), 
29.4 (C-3), 25.6 (C-2); HRMS (ESI MALDI-TOF): m/z Calculated for C39H38O12S (M + H2O)+ 
730.208; found, 730.232. 
 
β-D-(3-Mercaptopropyl) glucopyranoside (64) 
 
Sodium (0.101 g, 4.40 mmol) was reacted with anh. MeOH (5 mL) to form a solution of NaOMe, 
which was then added to a solution of glycoside 63 (0.627 g, 0.88 mmol) in anh. MeOH (20 mL) 




under N2(g). The solution was stirred for 30 min. The solvent was evaporated in vacuo and the residue 
was redissolved in CH2Cl2 (20 mL) and H2O (20 mL). The solution was acidified to pH 5 with 1 M 
HCl and the aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The residue was purified with 
column chromatography using CH2Cl2: MeOH (9:1; 8:2) to yield the title compound 64 as an oil 
(0.152 g, 68 %). The 1H and 13C NMR spectra agreed with those reported in the literature.283  
max/ cm-1: 3342 (OH) 
Thiol: H (D2O, 300 MHz): 4.70 (1H, d, J = 7.8 Hz, H-1’), 4.26 (1H, m, H-1a), 4.17 (1H, m, H-6’a),  
4.05-3.94 (2H, m, H-6’b/H-1b), 3.77-3.59 (3H, m, H-3’/4’/5’), 3.51 (1H, t, J = 7.8, Hz, H-2’), 2.90 
(2H, t, J = 6.9 Hz, H-3), 2.17 (2H, qn, J = 6.9 Hz, H-2); C (D2O, 100 MHz): 102.4 (C-1’), 76.0 (C-
3’), 75.9 (C-2’), 73.2 (C-5’), 69.8 (C-4’), 68.5 (C-1), 60.9 (C-6’), 32.9 (C-3), 20.3 (C-2); HRMS (ESI 
MALDI-TOF): m/z Calculated for C9H19O6S+ (M + H)+ 255.0896; found, 255.0895. 
Disulfide: H (D2O, 300 MHz): 4.70 (1H, d, J = 7.8 Hz, H-1’), 4.30-4.22 (1H, m, H-1a), 4.17 (1H, m, 
H-6’a),  4.08-3.94 (2H, m, H-6’b/H-1b), 3.77-3.59 (3H, m, H-3’/4’/5’), 3.51 (1H, t, J = 7.8 Hz, H-2’), 
3.09 (2H, t, J = 6.9 Hz, H-3), 2.29 (2H, m, H-2); C (D2O, 100 MHz): 102.4 (C-1’), 76.0 (C-3’), 75.9 




Dansyl-chloride (0.027 g, 0.01 mmol) was dissolved in acetone (8 mL) and added to a solution of 
amine 27 (0.036 g, 0.10 mmol) dissolved in 0.25 M NaHCO3 (aq) (8 mL). The reaction was stirred for 
1.5 hrs followed by removal of the acetone in vacuo. The aqueous phase was extracted with EtOAc (3 
x 10 mL) and the organic phase then dried, filtered and concentrated. The crude product was purified 
using column chromatography (CH2Cl2: MeOH 9:1) to yield the title compound 65 as a fluorescent-
green oil (0.047 g, 82%). Rf = 0.34 (CH2Cl2: MeOH 9:1) 
max/ cm-1: 3307 (-OH), 1310 (S=O), 1141 (S=O); H (CDCl3, 400 MHz): 8.52 (1H, d, J = 8.4 Hz, 
ArH), 8.32 (1H, d, J = 8.8 Hz, ArH), 8.22 (1H, dd, J = 7.2, 0.8 Hz, ArH), 7.50 (2H, m, ArH), 7.16 
(1H, d, J = 7.2 Hz, ArH),  5.14 (1H, t, J = 6.0 Hz, -NH), 4.30 (1H, d, J = 6.8 Hz, H-1’’), 3.90-3.77 
(3H, m,  H-6’’/H-10a), 3.65-3.45 (3H, m, H-3’’/4’’/10b), 3.44- 3.29 (2H, m, H-2’’/5’’), 2.87 (6H, s, 
H-5’a), 2.85 (2H, q, J = 6.4 Hz, H-1), 1.57 (2H, qn, J = 6.4 Hz, H-9), 1.57 (2H, qn, J = 6.8 Hz, H-2), 
1.30-1.05 (12H, m, H-3-8); C (CDCl3, 100 MHz): 151.7, 135.1, 130.2, 129.8, 129.7, 129.5, 128.3, 




123.2, 119.1, 115.2 (ArC), 102.8 (C-1’’), 76.4 (C-3’’), 75.5 (C-2’’), 73.5 (C-5’’), 70.4 (C-10), 69.7 
(C-4’’), 61.6 (C-6’’), 45.4 (C-5’a), 43.3 (C-1), 29.6, 29.6, 29.3, 29.3, 29.2, 28.9, 26.4, 25.8 (CH2Alk) 
HRMS (ESI MALDI-TOF): m/z Calculated for C28H45N2O8S (M + H)+ 569.2891, Found 569.2882 
7.3 Radiolabelling Studies Materials and Methods 
7.3.1 General  
All 99mTcO4- labelling reactions were carried out at either iThemba LABS in Somerset West or at 
Necsa in Pretoria. The 99mTcO4- was then obtained from Tygerberg Hospital or NTP Radioisotopes 
SOC, respectively. Cyclotron irradiated Rh foil (50 MBq, 154 mg, 12 mm diameter) was obtained 
from the Hungarian Academy of Sciences, Institute for Nuclear Research (Atomki) in Debrecen, 
Hungary. All commercial chemical reagents were purchased from Sigma Aldrich Chemical Co. Ltd or 
Merck (South Africa). The ITLC-SG strips and No. 3 Whatmann paper for TLC was purchased from 
Sigma Aldrich Chemical Co. Ltd or Merck (South Africa). The activity of the TLC strips, used for 
determining 99mTc labelling, was counted using a Capintec CRC-15 Beta Dose Calibrator while those 
used for 103Pd labelling were counted using a NaI(TI) ASA-100 MCA scintillation detector. The 
activity of the 103Pd-fractions eluted from ion-exchange chromatography was determined using a 
Canberra Germanium Detector – GC2518 (25 % efficiency).  
7.3.2 Preparation of Buffer solutions 
 
Solutions of 0.2 M Na2HPO4, 0.1 M Citric acid, 0.2 M NaH2PO4, 0.1 M KH2PO4, 0.1 M NaOH, 0.2 M 
NaHCO3 were prepared by dissolving the appropriate amount of salt in distilled water and making up 
the volume to 20 mL in a volumetric flask. Different pH buffer solutions were then prepared as 
indicated in Table 3.1. 
 
Table 3.1: Volumes of salt solutions required to prepare buffers of different pH’s 
 














5-6 3.0 mL 2.0 mL - - - -  
7.5 8.9 mL 2.2 mL - - - -  
0.252 mL - 0.048 mL - - -  
8 - - - 1.0 mL 0.68 mL -  
10 - - - - - 10.0 mL 0.10 g 
 
  




7.3.3 99mTc labelling  
7.3.3.1 General labelling procedure 
 
SnCl2 as the reducing agent: All vials and solutions used for labelling were flushed for 15 min with 
N2 (g) to remove any oxygen present. SnCl2 (10.0 mg) was dissolved in 0.1 M HCl (aq) (100 uL) and 
water (9.900 mL).  The freshly prepared SnCl2 solution (100 uL) was then added to an aqueous 
solution of cyclam 51 (5.0 mg/mL, 200 uL) and the desired buffer (100 uL). 99mTcO4- of varying 
specific activity was obtained from a Moly-generator in a saline solution and a volume of this solution 
was then added to the reaction vial. The reaction was heated at 80 ˚C for 30 min.  
 
Sn(II) tartrate as the reducing agent: A 6 x 10-4 M Sn(II) tartrate solution was prepared by dissolving 
3.0 mg in 0.01 M HCl (18.75 mL).The procedure was repeated as above, except for the addition of 
Sn(II) tartrate (100 uL) as the reducing agent.  
7.3.3.2 TLC analysis  
 
A 10 cm ITLC and Whatmann No 3 paper strip was cut and the control or reaction solution (2 uL) 
was spotted on the origin of each strip. The strips were developed, ITLC with saline and Whatmann 
No 3 with acetone, to 1 cm from the top of the strip and then cut in half. The activity of each section 
(origin or front) was counted. 
7.3.3.3 HPLC analysis  
 
A sample (10 uL) of the 99mTcO4- control or reaction solution was injected into an Agilent 1200 series 
HPLC fitted with a Phenomenex Luna 5 uM C-18(2) 100 Ǻ, 4.6 x 250 mm column and connected to a 
Raytest Gabi Star Gamma detector. The HPLC was run with a mobile phase system of A (0.1% 
trifluoroacetic acid in water) and B (CH3CN) in a gradient elution (0–3 min A:B = 90:10; 3-15 min 
A:B = 60:40; 15-20 min A:B = 20:80; 20-30 min A:B = 0:100) with a flow rate of 1mL/min. 
7.3.4 103Pd Labelling  
7.3.4.1 Dissolution of Rh target foil 
 
Dissolution of the irradiated Rh target foil (50 MBq, 154 mg, 12 mm diameter) was achieved through 
modification of the method of Lagunas-Solar et al (11). The equipment was set-up as shown in Figure 
7.1. A 220 V AC autotransformer (“VARIAC”) was connected to a copper sheet and a 10 mm 
graphite rod electrode. A VESCONITE (nylon) sleeve (internal diameter 12 mm) with liquid inlets at 
the bottom and gas discharge holes at the top was fitted over the graphite rod. The Rh foil was placed 
in the crucible which was resting on the copper plate, and centred beneath and pinned to the bottom, 
about 15 mm from the graphite electrode, by the nylon sleeve covering the electrode. The whole 
experimental setup was placed in a plastic spill tray under a local suction hood which filtered through 




a NaOH scrubber connected to the laboratory ventilation system. Once the foil was clamped beneath 
the electrode, approximately 25-30 mL of HCl (32%) was added to the crucible bringing the liquid 
level to just above the top of the nylon sleeve. The VARIAC was then switched on with the voltage 
set to zero. The current, measured with a standard commercial clamp-on type multi-meter, was slowly 
increased by adjusting the voltage. The initial current passing through the solution was 7-8 A. After 
15-20 min, the liquid level was no longer in contact with the graphite electrode and no more current 
was measured. The power was switched off and the pink-red HCl solution (20-25 mL) was then 
removed using a graduated pipette and rubber suction bulb. A fresh aliquot of HCl (25-30 mL) was 
added to the crucible and the process was repeated. A total of 5 runs were done on Day 1, after which 
the residual mass of the target foil was 100 mg. On Day 2 the electrolysis was repeated using HCl 
(25-30 mL) but with a current of 2.0-2.5 A. A total of 3 runs were done, over 5.5 hr, after which the 
Rh foil had completely disintegrated. 
 
 
Figure 7.1: Experimental set-up for the dissolution of the Rhodium foil target 
 
7.3.4.2 Ion exchange chromatography 
 
103Pd was separated from the solution of 103Rh, obtained by the dissolution process, using anion 
exchange chromatography as per the method of Chunfu et al.233 
Large scale column: An AG1X8(Cl-/100-200 mesh) anion exchange column (1.7 cm x 10 cm) was 
prepared and equilibrated using 6 M HCl. 3 aliquots (3 x ± 22 mL) containing approximately 100 mg 




of Rh from the dissolution process was loaded onto the column and 10 mL fractions collected as the 
solution ran through. After loading, the remaining rhodium chloride (pink colour) was washed off the 
column with 6M HCl (40 ML). The column was flushed with H2O (40 mL) and the 103Pd eluted from 
the column with 0.5M NH3:NH4Cl (1:1) (70 mL). A large amount of radioactivity remained on the 
column and so the column was again eluted with H2O (30 mL), 6M HCl (30 mL), H2O (30 mL) and 
0.5M NH3:NH4Cl (1:1) (30 mL). Fractions obtained from elution with 0.5M NH3:NH4Cl (1:1) were 
measured for radioactivity.  
 
2nd purification small scale column: An AG1X8(Cl-/100-200 mesh) anion exchange column (0.4 cm x 
2 cm) was prepared and equilibrated using 6 M HCl. A fraction (10 mL) of 103Pd eluted from the ion 
exchange column with 0.5M NH3:NH4Cl (1:1) was evaporated to dryness by heating under a stream 
of nitrogen gas. The103Pd(NH3)4Cl2 and NH4Cl salt in the vial was redissolved in aliquots of water (3 
x 0.4 mL)  and loaded onto the column. The column was then eluted with 6 M HCl (2 x 0.4 mL), 
water (2 x 0.4 mL), 0.1 M NH4OH (4 x 0.4 mL) and 0.5M NH3:NH4Cl (1:1) (2 x 0.4 mL) and elution 
fractions (0.4 mL) collected. The radioactivity of each fraction was measured. 
7.3.4.3 Procedure for labelling with 103Pd 
 
Labelling reaction containing excess NH4Cl: A fraction (10 mL) of 103Pd eluted from the ion 
exchange column with 0.5M NH3:NH4Cl (1:1) was evaporated to dryness by heating under a stream 
of nitrogen gas. The 103Pd(NH3)4Cl2 in the vial, containing a large amount of NH4Cl salt, was 
redissolved in water (400 uL)(approx. pH 5). Cyclam 57 (3.8 g) was dissolved in water (200 uL) and 
the pH adjusted with 5M NaOH (20 uL) to pH 10-11. The cyclam ligand solution (100 ul, ±0.9 mg) 
was added to the 103Pd(NH3)4Cl2 solution (350 uL) in a plastic epindorf vial, the pH again adjusted to 
10 with  5M NaOH (50 uL), and the vial heated at 80˚C for 30 min. The reaction solution (20 uL) was 
analysed by injection into an Agilent 1200 series HPLC-MS fitted with a Phenomenex Luna® 5 µm 
C18(2) 100 Å, 250 x 4.6 mm LC Column and a Raytest Gabi Star Gamma detector and run 
isocratically using water: acetonitrile (50:50)(1.0 mL/min). 
Control 1: 103Pd(NH3)4Cl2 solution (50 uL) containing excess NH4Cl was adjusted to pH 10 with 5M 
NaOH (20 uL). This control solution (20 uL) was then analysed by HPLC using the same conditions 
as above 
 
Labelling reaction containing minimal NH4Cl: A fraction (0.4 mL) of 103Pd eluted from the ion 
exchange column with 0.1M NH3 was evaporated to dryness by heating under a stream of nitrogen 
gas. The 103Pd(NH3)4Cl2 in the vial was redissolved in water (150 uL)(approx. pH 5) and the pH 
adjusted to 10-11 with 5M NaOH (4 uL). The cyclam ligand solution (50 ul, ±0.45 mg) was added to 
the 103Pd(NH3)4Cl2 solution (120 uL) in a plastic eppendorf vial and the vial heated at 80˚C for 30 
min. The reaction solution (20 uL) was then analysed by injection into a HPLC fitted with a 




Phenomenex Luna® 5 µm C18(2) 100 Å, 250 x 4.6 mm LC Column and a Raytest Gabi Star Gamma 
detector and run isocratically using water: acetonitrile (50:50)(1.0 mL/min). A second HPLC column 
was used for analysis (Agilent Zorbax Extend C-18 5um, 4.6 x 250mm column) with a mobile phase 
system of A: 0.01 M ammonium acetate pH 9.5, B: methanol run under a gradient elution (0 min A: B 
= 95:5; 2 min A:B = 80:20; 4 min A:B = 50:50; 10 min A:B = 0:100) with a flow rate of 0.8 mL/min 
 
Control 2: 103Pd(NH3)4Cl2 solution (20 uL) with minimal NH4Cl was adjusted to pH 10-11 with 5M 
NaOH (4 uL). This control solution (20 uL) was then analysed by radio HPLC using both Luna C-18 
and Zorbax Extend C-18 HPLC columns, under the same conditions as above. 
7.3.4.4 TLC analysis of 103Pd-labelling 
 
ITLC strips (1 cm x 12 cm) were cut and the 103Pd(NH3)4Cl2 reaction or control solutions (2 uL) were 
spotted onto a ITLC strip and run with different solvents: Acetone, Saline, Methanol and Water: 
Acetonitrile (50:50 or 20:80). The strips were allowed to dry and cut into pieces (10 x 1 cm) between 
the origin and the solvent front. Each piece was placed in a plastic vial and the activity measured.  
7.4 Nanoparticle Studies Materials and Methods 
7.4.1 General 
 
All the nanoparticle work was conducted at the Laboratory of Inorganic Chemistry (EOK-HY), 
Department of Chemistry, University of Helsinki, Finland. The γ-Fe2O3 magnetic nanoparticles were 
obtained from the Xavier University of Louisiana as very thick colloidal suspension in a mixture of 
ethyl acetate and diethylene glycol (DEG). All commercial chemical reagents were purchased from 
Sigma Aldrich Chemical Co. Ltd or Merck (South Africa). Syringe filters were obtained from GE 
Healthcare Life Sciences (Little Chalfont, United Kingdom). The TEM analysis was conducted at the 
Electron Microscope Unit at UCT and TEM images were obtained using a Zeiss EM 912 CRYO 
EFTEM at an operating voltage of 120 kV and equipped with a CCD camera for direct digital image 
acquisition.  
7.4.2 Synthesis of the glucose-Palladium nanoparticles 
7.4.2.1 Preparation of Na2PdCl4.3H2O solution 
Stock solution (0.36 M): NaCl (0.11 g, 1.88 mmol) was added to a suspension of PdCl2 (0.16 g, 0.90 
mmol) in distilled H2O (2.5 mL) and stirred for 20 hrs. 
Reaction solution (0.05 M): Na2PdCl4.3H2O stock solution (0.139 mL) was diluted to 1 mL with 
d.d.H2O 




7.4.2.2 General method for the PdNP synthesis 
All glassware and stirrer bars were washed in aqua regia and dried in a 100˚C oven before use and 
only Milli-Q water was used for solutions. 0.05 M Na2PdCl4.3H2O solution(1.0 mL) was added to an 
aqueous solution of thioglucose (2 to 5 eq.)(3.0 mL) at a specific temperature (RT, 58˚C, 95˚C) and 
stirred for 1 min before L-Ascorbic acid (2 or 3 eq.)(3.0 mL) was added. The solutions were stirred 
for a set time (15 min, 22 hrs, 44 hrs) before purification by dialysis or NP characterisation was done.  
A slight modification to the method of nanoparticle synthesis, in order to allow for potential 103Pd 
incorporation, was adjustment of the Na2PdCl4.3H2O solution to a pH of 9-10 by dilution of the stock 
solution (0.36 M) to 0.05 M using a 0.0005 M NH4OH(aq) solution. The rest of the synthesis was 
continued as normal.  
Synthesis of Pd-NP with glucose compounds 51, 27, 62 and 64 were carried out as above except that 
compounds 51, 27 and 64 had to be dissolved in a 1:1 mixture of water and methanol. 
7.4.2.3 Dialysis tube preparation 
Desired lengths of dialysis tube were cut and rinsed in d.d. H2O. The tubing was then soaked for 1-2 
min in a solution of 0.3 % Na2S at 80˚C, washed for 1 min in d.d.H2O at 60˚C, washed for 1-2 min in 
a solution of 0.2 % H2SO4 at room temperature and followed by rinsing of the tubing in warm d.H2O. 
The tubing was then stored in d.H2O. 
7.4.2.4 Dialysis of PdNP solutions 
PdNP solutions (6-7 mL) were transferred to pre-treated dialysis tubes (10-12 cm) and sealed with 
dialysis tubing clips. Each sample tube was placed in 2 L of d.d.H2O and stirred for 3-4hrs after which 
the water was discarded and replaced. The water was then changed again after 16 hrs, 8 hrs and again 
16 hrs. A sample of each water change was taken to determine the amount of ascorbic acid and 
thioglucose remaining in the Pd-NP solution. After dialysis, each Pd-NP solution was filtered through 
a non-sterile GD/X 25 Syringe filter (0.2 μm, 25 mm, nylon filtration medium) and transferred to a 
vial. 
7.4.3 Synthesis of glucose-Fe2O3 nanoparticles 
7.4.3.1 General method for surface functionalisation of γ-Fe2O3 magnetic nanoparticles  
Thioglucose (2, 2.5, 3 eq.) was dissolved in DEG (500 uL) with heating and added to γ-Fe2O3 
magnetic nanoparticles (10.0 mg) dissolved in DEG (500 uL). The solution was thoroughly mixed for 
5 min at which point a sample (200 uL) was taken for DLS analysis. The remainder of the solution 
(800 uL) was then diluted with ethyl acetate (10 mL) followed by precipitation of the particles using a 
centrifuge (10000 rpm x 10 min). The solvent supernatant was removed and the pellet was washed 
again in the same manner. After the second wash, the particles were redissolved in water (1.20 mL) 
and again sent for size analysis. 




Synthesis of Fe2O3-NP with glucose compounds 51, 27, 62 and 64 were carried out as above except 
that the compounds were dissolved in 1.50 mL DEG. 
7.4.4 Characterisation and size determination of the nanoparticles 
7.4.4.1 Dynamic Light Scattering (DLS) 
-Measurement of PdNP sizes: A sample (0.2 mL) was taken from each Pd-NP solution and d.H2O (1 
mL) added. Each sample solution was then filtered through a 0.2 or 0.45 μm filter into a cuvette and 
the sizes of the Pd-NP were then measured on a Malvern Instrument Zetasizer Nano ZS90 using a 
laser of 633 nm. The particle sizes were measured three times and the Z-average value generated was 
reported as the hydrodynamic diameter of the nanoparticles.The SOP for determining the sizes were: 
Pd-NP refractive index = 4.1; Absorption = 0.01; Dispersant = Water at 25 ˚C; RI = 1.330; viscosity = 
0.8872; Equilibration time = 2 min; Number of runs = 5  
 
-Measurement of Fe2O3 NP sizes in A) DEG: A sample (0.2 mL) was taken from each Fe2O3NP DEG 
solution and diluted with DEG (1 mL). The sample was placed directly into a cuvette and the sizes of 
the nanoparticles measured on a Malvern Zetasizer. B) Water: Nanoparticles that were precipitated 
with EtOAc and dried were redissolved in water (2 mL). From this solution 1 mL was filtered through 
a 0.45 μm filter into a cuvette and the sizes of the nanoparticles measured on a Malvern Instrument 
Zetasizer Nano ZS90 using a laser of 633 nm. The particle sizes were measured three times and the Z-
average value generated was reported as the hydrodynamic diameter of the nanoparticles. The 
standard operating procedure (SOP) for determining the sizes were:  Fe2O3 NP refractive index = 
2.42; Absorption = 0.01; Dispersant = Water at 25 ˚C; RI = 1.330; viscosity = 0.8872; Dispersant = 
DEG at 25 ˚C; RI = 1.447; viscosity = 35.7; Equilibration time = 2 min; Number of runs = 5  
7.4.4.2 Transmission Electron Microscopy  
TEM samples were prepared by placing a drop (5 uL) of the PdNP or Fe2O3NP solutions on a carbon 
coated copper grid (300 mesh x 3.05 mm) and evaporating the solvent over 10min under a light.  
7.4.4.3 IR analysis 
A sample (0.20 mL) of each PdNP solution was evaporated in vacuo to complete dryness. The 
resulting flaky, brown solid was ground up with solid KBr and compacted into a KBr disc. FTIR 
analysis of the discs was done using a Perkin Elmer Spectrum 100 FT-IR Spectrometer. 
7.5 Biological Studies Materials and Methods 
7.5.1 General 
 
Cell culture reagents were obtained from GIBCO BRL Life Technologies (Gaithersburg, MD) and all 
other chemicals and solvents were purchased from Sigma Aldrich Chemical Co. Ltd or Merck 




Biosciences (Darmstadt, Germany) unless otherwise specified. Cultured cells were viewed with an 
inverted microscope (Carl Zeiss Microimaging Inc., Germany) equipped with phase contrast optics to 
determine cell viability. Fluorescent microscopy was done using an Olympus Ix81 motorized inverted 
microscope equipped with an X-Cite 120Q light source (120W Mercury Vapor Short Arc lamp), Ix2-
UCB external power supply unit and UIS2 optical system. The images were processed using cellSens 
1.12 Dimension digital imaging software. HPLC analysis was done on an Agilent 1220 Infinity LC 
with an Agilent Zorbax Eclipse Plus C-18 (4.6 x 150 mm 5 um) column. The Phosphate Buffer Saline 
(PBS) (1 x solution) was prepared as follows: NaCl (8.00 g), KCl (0.20 g), Na2HPO4 (1.44 g) and 
KH2PO4 (0.24 g) was dissolved in 800 mL distilled water. The pH was adjusted to 7.4 with HCl and 
the volume made up to 1.0 L with distilled water. 
7.5.2 Maintenance of Cells 
7.5.2.1 Growth of WHCO-1 cells in culture 
 
Cells used in this study were WHCO-1 oesophageal cancer cell lines established from surgical 
biopsies. All work done on the cells was performed under standard sterile tissue culture conditions. 
The cells were plated in 150mm tissue culture plates and cultured at 37˚C in a humidified atmosphere 
of 5% CO2 in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% heat 
inactivated fetal calf serum, 100 U/mL penicillin and 100ug/mL streptomycin. The media was 
changed three times a week. For experiments, the cells were split or plated into a 24 well plate. 
Briefly, the DMEM was removed by aspiration and the cells were trypsinised with 0.5 % trypsin in 
PBS containing 10 mM EDTA (4 mL) for 3-5 min in the incubator at 37˚C. An equal volume of 
serum-containing DMEM was then added and the detached cells were transferred to a sterile 12 mL 
tube and centrifuged at 4 000 r.p.m for 3 min. The supernatant was removed through aspiration and 
the cell pellet was re-suspended in serum-containing DMEM. The cells were then split equally into 3 
plates or the cells were counted using a Countess® Automated Cell Counter after staining 10 uL cells 
with trypan blue (10 uL) and distributed into a 24 well plate according to the desired number of cells.  
7.5.2.2 Thawing and freezing down of cells 
 
The thawing of cells for growth was done by removing vials of cells from the liquid nitrogen tank and 
rapidly thawing them in a water bath at 37˚C. The vials were sterilised by wiping with 70 % ethanol 
and the cells were mixed with fresh DMEM followed by centrifugation at 1000 r.p.m for 4 minutes. 
The media was decanted and the cells were suspended in DMEM and transferred to a culture dish.  
 In order to freeze cells for storage, the cells were prepared as follows: The media was removed by 
aspiration from one plate of cells which was then washed with PBS (3mL) and incubated for 3-5 min 
at 37˚C with 0.5 % trypsin containing 10 mM EDTA (4 mL). The detached cells in trypsin were 
transferred to sterile 12 mL tube and complete DMEM (3mL) added. The cells were centrifuged at 4 




000 rpm for 3 min. The media was removed and the cell pellet re-suspended in freezing down media 
(70 % DMEM, 20 % FCS and 10 % DMSO) (3mL). The cells were then aliquoted into cryo vials 
(1mL/vial) and frozen at -80˚C for 48 hrs before transfer to a liquid nitrogen tank.  
7.5.3 Incubation studies  
7.5.3.1 Determination of compound uptake (Section 5.2.1.1)  
 
WHCO-1 cells were grown and prepared for plating into wells as indicated in 5.4.2.1. The cells were 
counted and 20 000 cells per well were plated in a sterile 12 well plate in 1 mL of complete DMEM. 
After 24 hrs of incubation, the cells had attached to the bottom of the plates and were ready to be 
incubated with 65. The compound (65) was dissolved in DMSO to a concentration of 10 mg/mL and 
then diluted with glucose-free DMEM to make a stock solutions of 25 uM, 50 uM and 130 uM of the 
compound with 0.1% DMSO. The media was removed from the cell wells by aspiration and 1 mL of 
the different stock solutions was added to the cells in triplicate. A row of control wells was also 
included in which only glucose free DMEM was added to the cells. The cells were incubated at 37˚C / 
5% CO2 for 1 hr and monitored by fluorescence microscopy. After 2 hrs, the media was removed, the 
cells washed once with DMEM and then new DMEM added. The cells were again examined under 
the fluorescent microscope. 
7.5.3.2 Competitive binding studies to determine mechanism of compound uptake (Section 
5.2.1.2) 
 
WHCO-1 cells were grown and prepared for plating into wells as indicated in 5.2.2. The cells were 
counted and then 20 000 cells per well plated in a sterile 12 well plate in 1 mL of complete DMEM. 
After 24 hrs of incubation, the cells had attached to the bottom of the plates and were ready to be 
incubated with 68. The compound was dissolved in DMSO to a concentration of 10 mg/mL and then 
added to glucose-free DMEM (1% FCS) to make a stock solution of 10 uM of the compound with 
0.1% DMSO. A solution of DMEM containing 1mg/mL glucose was prepared and this was then 
added along with the solution of compound 65 to glucose-free DMEM to make a dilution series of the 
compound containing 0 uM, 10 uM, 50 uM, 100 uM, 500 uM, 1000 uM and 2000 uM glucose. The 
used media was removed from the cell wells and 1 mL of the different concentrations of glucose-65 
solutions was added to the cells to create a series cells incubated with different amounts of glucose. A 
control well was also included in which only glucose-free DMEM (1%FBS) was added to the cells. 
The cells were incubated at 37˚C / 5% CO2 for 30 min and monitored by fluorescence microscopy. 
7.5.4 HPLC studies of maleimide-BSA binding reaction  
 
Control solutions of BSA and 31 were made by dissolving BSA (0.016 g, 24.0 umols) and 31 (0.001 
g, 2.4 umols) each in 1 x PBS (1 mL). 20 uL of each control solution was analysed by HPLC under a 




gradient elution with A: CH3CN (0.1 % TFA) and B: H2O (0.1 % TFA), 0 - 60 % A over 30 min. The 
control solutions were then heated at 37˚C for 24 hrs and re-analysed by HPLC using the same 
method. 
Fresh solutions of BSA (0.24 mM) and 31 (0.024 mM) were prepared as above and reacted together in 
an eppendorf vial by heating at 37˚C. After 5 min, a sample of the solution was analysed by HPLC 
using the same method as above. 
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(* indicates peaks of solvent impurities) 
 
 
Figure 9.1: 1H and 13C NMR of glycoside 3 in CDCl3 





Figure 9.2: 1H and 13C NMR of glycoside 10 in CDCl3 





Figure 9.3: 1H and 13C NMR of glycoside 31 in CD3OD 





Figure 9.4: 1H and 13C NMR of cyclam 41 in CDCl3 





Figure 9.5: 1H and 13C NMR of carbamate 45 in CDCl3 





Figure 9.6: 1H and 13C NMR of cyclam 46 in CDCl3 





Figure 9.7: 1H and 13C NMR of cyclam 48 in CDCl3 





Figure 9.8: 1H and 13C NMR of cyclam 51 in CD3OD 





Figure 9.9: 1H and 13C NMR of cyclam 55 in D2O 





Figure 9.10: 1H and 13C NMR of cyclam 57 in D2O 





Figure 9.11: 1H and 13C NMR of glycoside 65 in CDCl3 
